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ABSTRACT 
 
This thesis describes the work conducted on three projects towards the development 
of putative inhibitors of various targets involved in cancer development. 
Granzyme B (Grb) inhibitors 
GrB is an interesting target for the treatment of leukaemia, as once inhibited it could 
simultaneously prevent Graft-Versus-Host disease and promote Graft-Versus-
Leukaemia. Following the design of putative inhibitors of GrB using computational 
modelling, the synthesis of six analogues was carried out. Although these compounds 
could not be assessed in our biological assay due to lack of solubility, interesting 
synthetic routes have been developed in order to access these novel molecules. 
Liver receptor homolog-1 (LRH-1) inhibitors 
LRH-1 has recently been demonstrated as being an interesting target in the treatment 
of breast cancer, potentially overcoming the resistance and side effects associated 
with currently widely used anti-oestrogen therapies, such as Tamoxifen. Following 
the identification of resorcylate compounds as a new class of inhibitors of LRH-1, 
work has been conducted in the design and the synthesis of novel analogues. As such, 
dehydroxylated resorcylates, N-heterocyclic resorcylates or steroidal hybrids were 
synthesised and tested in cell-based assays. Although no improvement of biological 
activity was achieved, they represent interesting compounds for targeting other 
members of the nuclear receptor family. 
Fulvestrant analogue 
Fulvestrant is an approved drug in the treatment of breast cancer, however it requires 
intravenous administration due to its poor oral bioavailability. Recent development 
within our laboratory identified a triaminohydroxy side chain as greatly improving the 
bioavailability of inhibitors of CDK-7. As such, an analogue of Fulvestrant bearing a 
triaminohydroxy side chain was designed and the synthesis was initiated. After a 
failed initial synthetic route, the synthesis of an interesting novel intermediate was 
achieved, which could be used towards the synthesis of the desired analogue. 
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ABBREVIATIONS 
 
Ac  Acetyl 
AIBN  Azobisisobutyronitrile 
ALL  Acute Lymphoid Leukaemia 
AML  Acute Myeloid Leukaemia 
AMP  Adenosine monophosphate 
app.  Apparent 
Ar  Aromatic substituent 
ATP  Adenosine triphosphate 
Bax  Bcl-2-associated X protein 
Bcl-2  B-cell lymphoma 2 
Bid  BH3 interacting-domain death agonist 
Boc  t-Butoxycarbonyl 
br.   Broad 
Bu  Butyl 
calc.  Calculated 
cat.  Catalytic 
CDI  Carbonyldiimidazole 
CI  Chemical ionisation 
CML  Chronic Myeloid Leukaemia 
CNS  Central nervous system 
CTL  Cytotoxic T-Lymphocytes 
DCM  Dichloromethane 
DDQ  2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD  Diethyl azodicarboxylate 
DIPEA N,N-Diisopropylethylamine 
DMAP  4-Dimethylaminopyridine 
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DNA  Deoxyribonucleic acid 
DMF  Dimethylformamide 
EDCI  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
eq.  Equivalent 
EI  Electron impact 
ER  Oestrogen receptor 
ESI  Electrospray ionisation 
Et  Ethyl 
FADD  Fas-Associated protein with death domain 
FRET  Fluorescence resonance energy transfer 
GrB  Granzyme B 
GVHD  Graft-Versus-Host disease 
GVL  Graft-Versus-Leukaemia 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate 
HFIP  Hexafluoro-2-isopropanol 
HMDS  Bis(trimethylsilyl)amide 
HRMS  High resolution mass spectrometry 
HTS  High-throughput screening 
IEPD  Isoleucine-Glutamic acid-Proline-Aspartic acid 
IR  Infrared spectroscopy 
J  Coupling constant 
Ki  Binding affinity 
LCMS  Liquid chromatography-mass spectrometry 
L.R.  Lawesson’s reagent 
LRH-1  Liver receptor homologue-1 
M   Molar 
Me  Methyl 
MHC  Major histocompatibility complex 
MOM  Methoxymethyl 
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mp  Melting point 
MS  Mass spectrometry 
NBS  N-Bromosuccinimide 
NMR  Nuclear magnetic resonance 
P1  Part 1 
PE  Petroleum Ether 
PPi  Pyrophosphate 
pTSA  p-Toluenesulfonic acid 
R  Organic substituent 
RAR  Retinoic acid receptor 
Rf  Retention factor 
ROR  RAR-related orphan receptor 
rt  room temperature 
S1  Site 1 
SF-1  Steroidogenic factor-1 
sat.  Saturated 
SM   Starting material 
TBAF  Tetrabutylammonium fluoride 
TBAI  Tetrabutylammonium iodide 
TBME  tert-Butyl methyl ether 
TBS  tert-Butyldimethylsilyl 
TCR  T-cell receptors 
TES  Triethylsilyl 
Tf  Triflate 
TFA  Trifluoroacetic acid 
Thelp  Helper T-cell 
THF  Tetrahydrofuran 
TIPS  Triisopropylsilyl 
TLC  Thin layer chromatography 
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TMEDA Tetramethylethylenediamine 
TMS  Trimethylsilyl 
TNF  Tumor necrosis factor 
Treg  Regulatory T-cell 
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CHAPTER 1 
 
 
 
 
 
DESIGN AND SYNTHESIS OF PUTATIVE 
INHIBITORS OF GRANZYME B 
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1. INTRODUCTION 
 
1.1. Cancer 
 
In 2008, cancer accounted for the death of 7.6 million people around the world and is 
therefore a leading cause of death worldwide.1 The complexity of this disease coupled 
with the extremely large number of its variations make the discovery of a treatment 
highly challenging. The term cancer, or malignant neoplasm, encompasses a large 
number of diseases that can affect any part of the body. It is defined by the 
uncontrolled growth of a group of cells, leading to the creation of an abnormal mass 
of tissue, called a tumor. A malignant tumor has the ability to invade adjacent tissues 
and spread to other locations in the body, a process referred to as metastasis.  
Cancer results from mutations that disrupt the controls regulating normal cell growth 
and two classes of genes are particularly important in this process.2 The first are the 
tumor suppressor genes that act, in a normal cell, to restrain the rate of cell division.3 
The second are called oncogenes, whose overactivity causes cells to become 
cancerous. During the multistep progression to malignancy, cancer cells need to 
acquire different “abilities” that enable them to escape the normal regulatory cycle. 
Published in 2000, these abilities have been defined as the “hallmarks of cancer”. Six 
of which have first been identified (Figure 1): they include sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis.3 Ten 
years later, two emerging hallmarks were added to this list: reprogramming of energy 
metabolism and evading immune destruction.4 This last hallmark plays an important 
role in the case of bone marrow transplantation (See Section 1.3). 
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Figure 1:3 Hallmarks of cancer 
 
1.2. Leukaemia 
 
Leukaemia is a cancer of the blood or bone marrow. It is characterised by an 
abnormal increase in the number of white blood cells. These immature cells, which 
are not yet differentiated and therefore not fully functional, accumulate in the blood 
and within organs of the body. As a consequence, the term leukaemia has been 
derived from two Greek words: leukos, meaning “white” and aima, “blood”. The 
condition was first described in 1845 by Rudolf Virchow and John Hughes Bennett.5 
Ten years later, the bone marrow was found to be responsible for the abnormal blood 
of leukaemia patients: this is indeed where all the constituents of the blood are 
produced before they differentiate. In the year 2000, approximately 256,000 children 
and adults developed a form of leukaemia around the world and subsequently 209,000 
cases were fatal.1 This figure accounted for 3% of all cancer related deaths during the 
year. Significantly, this disease dramatically hits young patients, as leukaemia 
represents about a third of the cancers developed by children. There are four major 
Cell
58
AcquiredGSautonomywas the first of the six capabili-
ties to be clearly defined by cancer researchers, in large
part because of the prevalence of dominant oncogenes
that have been found to modulate it. Three common
molecular strategies for achieving autonomy are evi-
dent, involving alteration of extracellular growth signals,
of transcellular transducers of those signals, or of intra-
cellular circuits that translate those signals into action.
While most soluble mitogenic growth factors (GFs) are
made by one cell type in order to stimulate proliferation
of another—the process of heterotypic signaling—many
cancer cells acquire the ability to synthesize GFs to
which they are responsive, creating a positive feedback
signaling loop often termed autocrine stimulation (Fedi
et al., 1997). Clearly, themanufacture of a GFby a cancer
cell obviates dependence on GFs from other cells within
the tissue. The production of PDGF (platelet-derived
growth factor) and TGF  (tumor growth factor  ) by
glioblastomas and sarcomas, respectively, are two illus-
trative examples (Fedi et al., 1997).
The cell surface receptors that transduce growth-
stimulatory signals into the cell interior are themselves
targets of deregulation during tumor pathogenesis. GF
receptors, often carrying tyrosine kinase activities in
their cytoplasmic domains, are overexpressed in many
cancers. Receptor overexpression may enable the can-
cer cell to become hyperresponsive to ambient levelsFigure 1. Acquired Capabilities of Cancer
of GF that normally would not trigger proliferation (FediWe suggest that most if not all cancers have acquired the same set
et al., 1997). For example, the epidermal GF receptorof functional capabilities during their development, albeit through
various mechanistic strategies. (EGF-R/erbB) is upregulated in stomach, brain, and
breast tumors, while the HER2/neu receptor is overex-
pressed in stomach and mammary carcinomas (Slamon
et al., 1987; Yarden andUllrich, 1988). Additionally, grossWe describe each capability in turn below, illustrate with
overexpression of GF receptors can elicit ligand-inde-a few examples its functional importance, and indicate
pendent signaling (DiFiore et al., 1987). Ligand-indepen-strategies by which it is acquired in human cancers.
dent signaling can also be achieved through structural
alteration of receptors; for example, truncated versions
Acquired Capability: Self-Sufficiency
of the EGF receptor lacking much of its cytoplasmic
in Growth Signals domain fire constitutively (Fedi et al., 1997).
Normal cells require mitogenic growth signals (GS) be- Cancer cells can also switch the types of extracellular
fore they can move from a quiescent state into an active matrix receptors (integrins) they express, favoring ones
proliferative state. These signals are transmitted into the that transmit progrowth signals (Lukashev and Werb,
cell by transmembrane receptors that bind distinctive 1998; Giancotti andRuoslahti, 1999). These bifunctional,
classes of signaling molecules: diffusible growth fac- heterodimeric cell surface receptors physically link cells
tors, extracellular matrix components, and cell-to-cell to extracellular superstructures knownas the extracellu-
adhesion/interaction molecules. To our knowledge, no lar matrix (ECM). Successful binding to specific moieties
type of normal cell can proliferate in the absence of of the ECM enables the integrin receptors to transduce
such stimulatory signals. Many of the oncogenes in the signals into the cytoplasm that influence cell behavior,
cancer catalog act by mimicking normal growth signal- ranging from quiescence in normal tissue to motility,
ing in one way or another. resistance to apoptosis, and entrance into the active
Dependence on growth signaling is apparent when cell cycle. Conversely, the failure of integrins to forge
propagating normal cells in culture, which typically pro- these extracellular links can impair cell motility, induce
liferate only when supplied with appropriate diffusible apoptosis, or cause cell cycle arrest (Giancotti and Ru-
mitogenic factors and a proper substratum for their inte- oslahti, 1999). Both ligand-activated GF receptors and
grins. Such behavior contrasts strongly with that of tu- progrowth integrins engaged to extracellular matrix
mor cells, which invariably show a greatly reduced components can activate the SOS-Ras-Raf-MAP kinase
dependenceonexogenousgrowth stimulation. Thecon- pathway (Aplin et al., 1998; Giancotti and Ruoslahti,
clusion is that tumor cells generate many of their own 1999).
growth signals, thereby reducing their dependence on Themost complexmechanismsof acquiredGSauton-
stimulation from their normal tissue microenvironment. omy derive from alterations in components of the down-
This liberation from dependence on exogenously de- stream cytoplasmic circuitry that receives and pro-
rived signals disrupts a critically important homeostatic cesses the signals emitted by ligand-activated GF
mechanism that normally operates to ensure a proper receptors and integrins. The SOS-Ras-Raf-MAPK cas-
cade plays a central role here. In about 25% of humanbehavior of the various cell types within a tissue.
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kinds of leukaemia: their variations depend upon how they are expressed clinically 
and pathologically (Table 1).  
  Acute Chronic 
Lymphocytic ALL CLL 
Myelogenous AML CML 
Table 1: Abbreviations for commons types of leukaemia 
They are first divided according to their rate of development: acute leukaemia 
exhibits a rapid progression of the disease and requires an immediate treatment. The 
bone marrow is crowded by a vast number of immature blood cells, making it unable 
to produce the healthy components of the blood. The other type, chronic leukaemia, 
refers to a slower progression, where the blood cells, still produced excessively, 
appear to be more mature than in the acute form. This allows more time to find the 
appropriate treatment that will ensure maximum effectiveness. The second 
subdivision refers to the kind of blood cells that are affected. When the cancerous 
cells originate from marrow cells that normally go on to form lymphocytes, this 
leukaemia is called lymphocytic – or lymphoblastic. Myelogenous – or myeloid – 
leukaemia refers to cancer arising from other types of white cells, as well as red blood 
cells and platelets. 
Damage of the bone marrow, due to the high number of immature cells, leads to a 
range of specific symptoms displayed by leukaemia patients. First, this results in a 
lack of platelets and associated coagulation disorders, such as the tendency to bruise 
easily and bleed excessively. Then, the production of white blood cells can be 
compromised: on the one hand, this could result in the inability of the patient’s 
immune system to fight off simple infections, in the case that the white cells are not 
functional; on the other hand, dysfunctional cells could deviate from their initial 
purpose and cause severe damage by attacking normal cells of the body. Finally, 
another important symptom is anaemia, due to a red blood cell deficiency. This results 
in pallor and dyspnea because oxygen is not sufficiently transported through the body. 
There is no single cause that can be attributed to the development of leukaemia, and 
as with any type of cancer, it results from somatic mutations in the DNA. These 
mutations can occur spontaneously or may be caused by exposure to carcinogenic 
substances or radiation. Several viruses have been linked to some forms of leukaemia, 
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however it is not a general feature. Finally, it has been shown that a genetic 
predisposition may increase the risk of contracting the disease in some families.  
Classical treatments of leukaemia are similar to many cancers and involve 
pharmaceutical medication, but small variations are applied depending on the type of 
leukaemia. Often, the first phase of the treatment is an induction chemotherapy, which 
aims at inducing bone marrow remission. Classical drugs are prednisone, 
L-asparaginase, vincristine or imatinib (Figure 2).  
  
Figure 2: Classical anti-leukaemia drugs 
Then a consolidation phase is necessary in order to prevent the disease from spreading 
and to eliminate any remaining cancerous cells. This involves the use of other anti-
cancer drugs, such as methotrexate or 6-mercaptopurine (Figure 6). As this type of 
cancer develops in the blood, it can easily access the whole body, therefore particular 
attention is paid to the protection of the brain. This procedure is called CNS 
prophylaxis and classically includes radiation of the brain, which may be in 
combination with drugs delivered directly into the spinal cord. Finally, a maintenance 
phase is important to monitor any relapse of the disease, once remission has been 
achieved, in order to make sure that all residual cancer cells have been killed. It 
involves the additional use of anti-cancer drugs, although the doses are usually lower, 
and the treatment can continue for several months or years. 
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Unfortunately, these classical treatments are not always generally affective and cannot 
be dosed to the entire patient population. This is due to certain patient sensitivities 
that would not tolerate the treatment or have developed resistance to chemotherapy 
from earlier treatments. Moreover, relapse of the disease is not uncommon and new 
treatments are emerging to combat this aspect. Among them, allogeneic bone marrow 
transplantation (BMT) is particularly applied to three malignant diseases: chronic 
myeloid leukaemia (CML), acute myeloid leukaemia (AML) and acute lymphoid 
leukaemia (ALL).6,7  
Although this treatment appears as a very effective way to treat these diseases, it is 
often associated with a side-effect that causes the death of approximately 30% of the 
patients (See Section 1.3). Research is making great improvements in the 
understanding of the biological mechanisms of this procedure, in order to make it 
safer and more efficient, but many aspects are still not fully understood.  
 
1.3. Allogeneic Bone Marrow Transplantation 
 
The principle of this treatment is to replace the dysfunctional bone marrow of the 
patient with that from a healthy donor. The term allogeneic indicates that the graft is 
not genetically identical to the recipient’s tissue: the donor and the patient are 
therefore histoincompatible, which raises some concern about immune recognition 
and host tolerance. Prior to the transplant, the patient’s bone marrow needs to be 
ablated, by chemotherapy or irradiation, in order to eradicate the maximum amount of 
cancer tissue. This in tandem suppresses immune responses – called the 
immunosuppressive effect – and is crucial to help prevent the graft from being 
rejected by the recipient’s immune system.  
The therapeutic action of this treatment relies on the Graft-Versus-Leukaemia effect 
(GVL).8 Functional immune cells from the donor present within the graft will be able 
to detect and kill the residual cancer cells in the recipient’s body. This mechanism of 
action is responsible for the lower risk of cancer relapse post treatment of leukaemia 
with BMT. However, the beneficial effect of GVL is not always observed, and an 
additional negative reaction might occur: the Graft-Versus-Host disease (GVHD). 
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This is the major complication and inherent drawback of bone marrow 
transplantation.  
GVHD is the attack of patient’s tissues by the graft’s immune cells, because they 
recognise the body as “foreign”. This only occurs because the recipient has been 
immunocompromised and therefore cannot defend itself against the transplanted cells. 
The positive effect of GVL and negative effect of GVHD both rely on the action of 
specific immune cells, the T cells. The latter kill their targets – either the cancer cells 
or patient’s tissues – by inducing apoptosis, which is a complex process that needs to 
be understood in order to control the outcome of the bone morrow transplantation.  
 
1.4. Apoptosis 
 
Apoptosis is an important pathway that results in cell death in multi-cellular 
organisms and has an essential role in removing unwanted or damaged cells. It occurs 
as a defined series of events, regulated by a conserved machinery.2 This programmed 
cell-death can be triggered via either endogenous or exogenous agents, such as 
radiation, hormones, growth factors or viral infections.9 During apoptosis, cells 
undergo characteristic macroscopic changes, including blebbing – formation of 
irregular bulges in the plasma membrane – chromatin condensation and DNA 
fragmentation.10 This produces cell fragments that are quickly engulfed and treated by 
surrounding cells, therefore preventing an inflammatory reaction. 
Once apoptosis has been triggered by external or internal factors, a number of 
components are involved in a cascade leading to the observed macroscopic changes 
and finally the death of the cell (Figure 3). 
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Figure 3: Intrinsic apoptotic cascade 
The major components of the apoptotic cascade are caspases, a specific family of 
proteases – enzymes that degrade polypeptides. Their etymology, “cysteine-
dependent aspartate-directed protease”, describe their mechanism of action in that 
they use a cysteine residue within their catalytic mechanism and cleave polypeptides 
specifically after an aspartate unit.11 The first caspases encountered in the apoptotic 
cascade are known as “initiators”, such as caspases 3 and 8 (Figure 3a). Normally 
inactive under a pro-form, initiator caspases are activated by diverse signals and will 
then activate other components of the cascade by cleaving them. The latter can be 
other caspases or members of the Bcl-2 family.9  
Proteins of the Bcl-2 family can be pro- or anti-apoptotic. They govern mitochondrial 
outer membrane permeabilisation, a process which is responsible for the release of 
potentially toxic proteins from mitochondria into the cytosol and which represents a 
point-of-no-return in the apoptotic process.12 An important member of this family is 
Bid (Figure 3b). Once cleaved and activated by caspase 8, Bid initiates opening of the 
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outer mitochondrial membrane channel. This allows cytochrome c, normally present 
between the two membranes of mitochondria, to be released into the cytosol.9  
Cytochrome c plays a critical role in the apoptotic cascade (Figure 3c). Once released 
into the cytosol, it aggregates with other proteins to form a complex called 
apoptosome, which in turn activates another type of caspases, the “effectors”, such as 
caspases 9 and 6 (Figure 3d). These caspases are directly responsible for the cleavage 
of death substrates, which are important components of the cell when uncleaved and 
help maintain structural and regulating cell functions. Therefore cleavage leads to the 
observed structural changes and finally the cell death (Figure 3e).9  
Several pathways can be used to trigger this enzymatic cascade that terminates with 
cell death (Figure 4).  
 
Figure 4: Triggers of the apoptotic cascade 
The most important of them is initiated by p53, one of the major tumor suppressor 
genes (Figure 4a). In response to cellular stress, such as DNA damage, anoxia or 
!
"#$$!%#%&'()#!
!*)+,+(,-'!!!!!!!!!!!!!!!!!!!!!!!!!!!*)+,+(,-'!
.'-/0(1.(1#!!!!!!!!!!!!!!!!!!!!!0(1.(1#!
*)(0,+2#!!!!!!!!!!!!!!!!!!!!!30,+2#!
4+5!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!4+5!
"6,-07'-%#!0!!!!!!!!!!!!!!!!!!!!!!!3.-.,-1-%#!
899#0,-'!!!!!!!!!!!!!!!!!!!!!!!!!!!899#0,-'!
.'-/0(1.(1#!!!!!!!!!!!!!!!!!!!!0(1.(1#!
:#(,7!!!!!!!!!!!!!!!!!!!!!!!!!!;'(<%#),(,+-)!
1=&1,'(,#!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!"#$$!%#&'(!
">?!
;(1?!
;(1!
;3::!
@#'9-'+)!
A'4!
:B3!
.CD!
4(E!
)&*!
)+*!),*!
 
26 
imbalance in growth signals, p53 drives the expression of the protein Bax, another 
member of the Bcl-2 family. Analogous to Bid, it has a pro-apoptotic effect leading to 
the opening of the external mitochondrial membrane, and inducing the release of 
cytochrome c. As this cascade is initiated from within the cell, it has been termed an 
“intrinsic” apoptotic program.  
A second important route involves cell surface receptors that are activated by external 
factors, therefore called the “extrinsic” apoptotic program. This class of trans-
membrane proteins, termed death receptors, are composed of many different receptors 
that share a common cytoplasmic death domain (Figure 4b). There are as many 
ligands as death receptors, two important ones being TNF-α or FasL. Once these 
ligands bind to their specific receptors, for example FasL to Fas receptor, this induces 
the oligomerisation of the death receptor and activation of an associated protein called 
FADD in the cytoplasm. This complex is then responsible for cleavage of initiator 
procaspase 8, initiating the apoptotic cascade. 
Finally, a third pathway is used in specific situations (Figure 4c). This involves the 
action of immune cells, such as cytotoxic T lymphocytes. Once these cells come in 
contact with the target cell, they release cytotoxic granules containing two proteins: 
perforin and granzyme B. Perforin inserts itself into the target cell’s plasma 
membrane, forming a pore and allowing granzyme B to enter into the cytoplasm. 
Granzymes are another family of proteases, and are able to cleave and activate 
caspases – such as initiator caspases 3 and 8 – starting the apoptotic cascade.  
 
1.5. Immune system and T cells 
 
The immune system is responsible for recognising external pathogens, such as viruses 
or bacteria, that have entered the body and is then able to neutralise or kill them. In 
parallel it can alert the other components of the immune system and recruit them to 
the location of the attack. In order to defend the body against these aggressions, 
pathogens must be identified as “foreign”. Cells have developed a way to discriminate 
between themselves and others, via the use of antigens. By definition, an antigen is a 
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molecule capable of eliciting an immune response when introduced into the body and 
recognised by the immune system.10  
When a cell is invaded by a pathogenic agent, such as a virus, it needs to inform the 
neighbouring cells that it has been infected. The virus directs the synthesis of its own 
alien proteins, using the cellular machinery. One small portion of these newly created 
proteins is fragmented by specific proteases, and these fragments are then exposed on 
the surface of the cell by the “major histocompatibility complex” (MHC) proteins. 
These MHC proteins can be compared to arms that will present these antigens to 
immune cells that patrol around the extracellular area. The immune system is able to 
recognise foreign particles, called “non-self”, and attack infected cells presenting 
these alien fragments. Similarly, healthy cells also display some fragments of their 
normal proteins at their surface, which are recognised as “self” by the immune 
system. Therefore, these MHC-antigen complexes allow any cell of the body to 
communicate to the surroundings what is happening within its membrane.  
Among the many components of the immune system, T cells are particularly involved 
in the defence against infected cells. Their role is to recognise cells carrying 
intracellular pathogens, and kill them before the infection is spread throughout 
neighbouring cells. T cells possess “T cell receptors” (TCRs) that trigger a response 
when they bind to their specific antigen. This requires a direct contact between the T 
cell and its target. There are three different types of T cells, called helper, cytotoxic 
and regulatory. Helper T cells (Thelp) help stimulate responses of other types of T cells 
as well as other effectors of the immune system. They are therefore crucial during the 
activation step but do not directly kill targeted cells. Cytotoxic T cells, also called 
cytotoxic T lymphocytes (CTLs), are the real effectors in the defence of cells, as they 
are directly responsible for killing infected cells. Through its T cell receptor, a CTL is 
able to recognise a microbial antigen presented at the surface of an infected cell and 
binds to its target. It can then use two different mechanisms to kill the target, both 
relying on the induction of the apoptotic cascade. The first one is the release of 
granules containing perforin and granzyme B, whereas the second involves the 
binding of the Fas ligand (FasL) present at the surface of T cells to the Fas protein on 
the target cell. Finally, the third class is called regulatory T cells (Treg), because they 
are able to suppress the activity of other T cells. Their main role is to allow a “self-
tolerance” by inactivating effector T cells that recognise the body as foreign, which 
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can cause vast damages to the body if it is not carefully monitored. Regulatory T cells 
therefore help to control immune responses and prevent excessive activation of 
effector T cells. Although their mechanism of action is not fully understood, it is 
believed to involve some of the apoptotic pathways previously described.  
As they derive from normal cells of the body, cancer cells might be difficult to 
identify. Although some of them are virus-induced, they have not necessarily been 
invaded by pathogens. However, some small differences can be seen at the surface of 
tumor cells, mainly due to the antigen exposure via MHC molecules. Indeed, because 
their genetic material has been altered, they synthesise abnormal proteins, a part of 
which will be fragmented and exposed. Two mechanisms are responsible for the 
expression of these “tumor-associated” proteins. First, DNA instability of cancer cells 
due to their high replication rate can lead to alteration of some genes. These altered 
genes could then express abnormal proteins that will be previously unknown to a 
specific organism. Another indication of the cancerous state of a cell is the production 
of proteins at an incorrect location or time of development, although these proteins 
are naturally encoded by the DNA. Therefore antigen presentation at the surface of a 
cancer cell differs from a normal one. These tumor antigens can be identified by the 
immune system, more specifically by cytotoxic T cells that can induce their death in 
the same way as described with infected cells. In contrast, some tumors can also 
develop a way to evade the immune system by recruiting regulatory T cells. The latter 
will be able to protect the tumor by killing effector T cells that have identified the 
abnormal aspect of the tumor cells. 
 
1.6. Granzyme B 
 
1.6.1. Definition and catalytic triad 
 
The term “granzyme” was given to the enzymes found in cytoplasmic granules of 
CTLs.13 Among the five identified granzymes present in humans, granzyme B (GrB) 
is the most abundant.14,15 These proteins all exhibit proteolytic activity, which means 
that they cleave protein substrates by hydrolysis of one of their amide bonds, and they 
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belong to the large family of serine proteases.16 In the crystal structure, solved in 
2000,17 GrB appears as a globular protein folded into two six-stranded β-barrels, 
connected by three trans-domain segments. The active site, where the substrate 
specifically binds, reveals itself as a groove in the enzyme surface.  
 
Figure 5: Catalytic triad of serine proteases 
Serine proteases all use a common “catalytic triad” (Figure 5).18 This consists of three 
amino acid residues, in the active site of the enzyme, that are essential for the catalytic 
activity: histidine (His57), serine (Ser195) and aspartic acid (Asp102). 
When the polypeptide substrate binds to the protease, the hydroxy group of the serine 
(Ser195) undergoes a nucleophilic attack to the carbonyl carbon of the scissile peptide 
bond (Figure 5a). The histidine (His57) of the catalytic triad, located near the serine, 
acts as a specific base catalyst by accepting the hydrogen from the serine hydroxy 
group. The third residue of the triad, the aspartic acid (Asp102), makes the histidine 
lone pair more basic by accepting a hydrogen bond from this residue.  
The substrate is now covalently bound to the protease, and this results in the 
formation of a tetrahedral intermediate (Figure 5b). It then collapses by breaking the 
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nitrogen-carbon bond, releasing the N-terminus part of the polypeptide substrate. The 
latter takes the hydrogen from the previously protonated histidine residue, and a 
molecule of water replaces it in the active site (Figure 5c). The histidine accepts a 
hydrogen bond from the water, making it nucleophilic enough to attack the carbonyl 
carbon, resulting in the formation of a new tetrahedral intermediate. Finally, the bond 
created at the first step between the serine residue and the carbonyl carbon moves 
towards the hydrogen that the histidine just accepted, which liberates the C-terminus 
part of the substrate and returns the enzyme to the catalytic ground state (Figure 5d).  
 
1.6.2. Specificity 
 
The substrate specificity of an enzyme is determined by the three-dimensional 
structure and electronic nature of its binding site, in which the substrate typically 
interacts with the amino-acid residues of the protein. In the particular case where the 
substrate is a peptide, the residue situated on the N-terminal side of the scissile 
peptide bond is named P1, and then P2, P3, etc. thus designates peptide positions in 
the N-terminal direction (Figure 6).  
 
Figure 6: General structure of protease-peptide substrate complex 
On the other side of the scissile bond, residues are attributed the names of P1’, P2’, 
etc. following the C-terminal direction. Similarly, the subsites of the enzyme are 
termed S1, S2 etc. and S1’, S2’, etc. according to the substrate residue that binds into 
them.16 GrB exhibits the unique specificity among serine proteases to cleave substrate 
peptide bonds after aspartic acid residues (P1), a preference which they share only 
with caspases.16 This is an important consideration knowing that both GrB and 
caspases are involved in the apoptotic cascade induced by CTLs. Positional screening 
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of substrate combinatorial libraries were used to rigorously define the specificity of 
GrB from P1 to P4.19,20 Tetrapeptide IEPD (Figure 7) has been found to be the 
optimal amino-acid recognition sequence. These studies also showed that substrate 
residues at P3 and P4 have considerable effect on the hydrolysis rate. However, GrB 
is able to cleave macromolecules much more efficiently than tetrapeptides, indicating 
that the substrate recognition involves larger features in the active site. 
 
Figure 7: Tetrapeptide IEPD (isoleucine-glutamic acid-proline-aspartic acid) 
 
1.6.3. Co-crystal structure 
 
In 2001, a co-crystal structure of GrB has been obtained, using as a ligand the 
modified tetrapeptide Ac-IEPD-CHO, compound 1 (Figure 8).21  
 
Figure 8: 3D structure of human Granzyme B with Ac-IEPD-CHO (1) as a ligand (red) 
Subsite S1 displays a pronounced depression in which the P1 side chain of the 
substrate is projected (Figure 9). At the bottom of this pocket lies a positively charged 
arginine (Arg226), creating a strong interaction with the negatively charged P1 
aspartic acid of the optimal substrate IEPD: this explains the strong S1 Asp-
specificity of GrB (Figure 9). In S2 and S3, the tetrapeptide side chains point out of 
the protein body. S2 has a hydrophobic wall and no specific interaction is observed 
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with the substrate. In S3, the amide nitrogen and carbonyl of the protein form anti-
parallel β-structure-like hydrogen bond with the peptidic substrate. Finally, S4 
exhibits a shallow hydrophobic depression, formed by aromatic rings and the side 
chain of a leucine residue. In addition, two solvent-exposed arginines (Arg217 and 
Arg217a) compose the surface of this subsite. 
 
Figure 9: Active site of Granzyme B with Ac-IEPD-CHO (1)21 
 
1.6.4. Inhibitors 
 
Only one class of synthetic inhibitors of Granzyme B has been reported to date.22 The 
authors initiated their research with modified tetrapeptide Ac-IEPD-CHO (Figure 8), 
which was found to have a Ki of 80 nM. This potent inhibitor covalently binds to the 
protein, in which the active site serine undergoes a nucleophilic attack onto the 
inhibitor’s aldehyde moiety – therefore called “electrophilic serine trap”. 
In order to increase the binding affinity, the authors achieved a series of 
modifications: firstly the refinement of P2 and P3 into a rigidified structure, then the 
replacement of the serine trap with a triazole and finally the optimisation of P4 led to 
compounds 2 and 3, which display a Ki of 13 nM and 7 nM respectively against GrB 
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(Figure 10). Furthermore, they block CTL-mediated apoptosis with an IC50 of 6.3 µM 
and 3.1 µM. Importantly, these compounds exhibit no caspase inhibition and yet they 
are able to inhibit the induction of apoptosis, which underlines the importance of 
granzyme B in this process. 
 
Figure 10: Potent inhibitors of Granzyme B 
 
1.7. Aim of the project 
 
Working on murine models, Braun et al. showed that both perforin and FasL 
pathways are used and are required by CTLs to kill hematopoietic cells – issued from 
the bone marrow – and that these two pathways are responsible for the induction of 
GVHD.23 However, perforin- and FasL-deficient CTLs are still able to kill other types 
of cells, which suggest that there is a third pathway. It might be through the release of 
cytokines, such as TNF-α, and Cooke et al. showed that the production of an 
inflammatory response attributed to cytokines after BMT can be controlled in order to 
diminish the effects of GVHD.6 
Later, Grossman et al. demonstrated that human Treg cells control immune response 
by killing other autologous – from the same individual - immune cells in a 
perforin/granzyme dependent fashion.24 Moreover, this cytotoxicity is independent of 
the FasL pathway. Therefore, GrB-deficient Tregs lose their ability to kill autologous 
cells. 
More recently, other experiments on mice models carried out by Cao et al. showed 
that tumor cells induce granzyme B expression in Treg cells, which then use GrB to 
kill CTLs.25 The latter therefore lose their ability to eliminate cancer cells, which lead 
to the development of the tumor: GrB is used to suppress the antitumor response. 
NH
OHN
O
S N
O
O NH NH
N
N
3
NH
OHN
O
N
O
O NH NH
N
N
2
P1P2-3P5 P4P1P2-3P5 P4
 
34 
When Treg and CTL cells are issued from GrB-deficient mice, Tregs are deactivated but 
there was no influence on CTLs, which were still able to kill cancer cells. As a result 
the tumor did not develop. These results demonstrate that GrB is important for 
Treg-mediated suppression of tumor clearance.  
Finally, Cai et al. investigated the role of Treg cells in GVHD.26 They showed that 
their regulation of GVHD was independent of GrB. They used irradiated mice that 
were transfected with bone marrow from another individual. When the transplant was 
depleted of any type of T cells, the mice showed no sign of GVHD, and on the 
contrary died rapidly when the transplant contained only CTLs. When the transplant 
also contained regulatory T cells, the survival rate was increased, independently of the 
normal or GrB-deficient character of these Treg cells. This demonstrates that GrB is 
not required for Treg-mediated suppression of GVHD.  
All of these studies indicate that Treg cells use distinct mechanisms to suppress GVHD 
and the antitumor response – GVL in this case. More importantly, GrB seems to play 
a crucial role in controlling these two effects. As a consequence, by inhibiting 
granzyme B it might be possible to enhance the graft-versus-leukaemia effect of 
allogeneic BMT while suppressing the graft-versus-host response (Figure 11). 
 
Figure 11: Role of granzyme B in controlling GVHD and GVL 
The aim of this project was therefore to develop small molecule inhibitors of 
granzyme B, which are suitable as drugs and do not exhibit activity against other 
granzymes and the different types of caspases. 
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2. COMPUTATIONAL MODELLING 
 
2.1. Initial work carried out by collaborators of the project 
 
2.1.1. Virtual screening 
 
The project was started by collaborators at Emory University, Atlanta, GA, USA. The 
extensive work undertaken around the computational modelling of putative inhibitors 
of Granzyme B has been recently published.27  
Based on the published crystal structures, an initial virtual screening was conducted 
by M.-S. Kim and aimed at identifying potential commercially available inhibitors of 
granzyme B. Two types of libraries were screened: the first was a specific, protease-
targeted library from TimTec, based on structural and fragmental similarities to 
known protease inhibitors; the second, from Maybridge, displayed a high diversity of 
drug-like molecules.  
Glide (Grid-Based Ligand Docking with Energetics), a program developed by 
Schrodinger, was used to achieve the in silico screening.28,29 This software performs 
an exhaustive search of the positional, orientational and conformational space of the 
docked molecule, which makes it one of the most accurate docking programs. It has 
three different levels of screening. Each of them assigns a score to the binding poses, 
representing the relative ligand binding affinities. The first one is the High-
Throughput Virtual Screening (HTVS), which can be run on millions of compounds. 
It is used to reduce the number of ligands, which can then be processed through the 
next level, the Standard Precision Screen (SP), used to refine the selection. Finally, 
the Extra Precision Screen (XP) gives extremely accurate binding mode predictions of 
the selected ligands. Another program, Prime MM-GBSA (Molecular Mechanics 
Poisson–Boltzmann Surface Area), can then be used to refine the selected poses, by 
giving a new score, which might differ from the Glide score.30 It incorporates implicit 
solvation into the estimation of ligand-binding free energies, which might give more 
accurate predictions.  
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The two selected libraries were docked onto the published crystal structure of GrB 
bound to tetrapeptide Ac-IEPD-CHO.21 This crystal structure was chosen over the apo 
– without ligand – because it was anticipated that it would give a better idea of what 
the binding site looks like when occupied by a ligand. Indeed, some conformational 
changes are observed between the two structures: some parts open when the ligand 
enters into the site. Out of the 57,520 screened compounds (only 1,520 from the 
protease-targeted library), 249 compounds were selected after the three levels of 
calculation, and were purchased for biological testing. 
 
2.1.2. Biological evaluation 
 
Following the selection of the compounds based on the work conducted by 
computational modelling, the biological assessment was undertaken by our 
collaborators from the Department of Medicine at Imperial College. 
The first in vitro testing was the measure of the inhibition of the enzyme GrB at 
100 µM for all commercially obtained compounds. This value was compared to the 
inhibition of the enzyme by the tetrapeptide Ac-IEPD-CHO. Only molecules from the 
protease-targeted library showed some activity in this assay. Those that had an 
inhibition ≥ 40% were then tested again at different concentrations in order to 
calculate their IC50. Among them, 11 compounds had an IC50 ≤ 50 µM and were 
finally tested for selectivity against granzyme A and caspases 3 and 8. 
Most of these molecules were of high molecular weight – MW ≥ 500 g.mol-1. 
However one of them, compound 4, was more promising (Figure 12): it had an IC50 of 
35 µM, which was reasonable considering its low molecular weight (339 g.mol-1). It 
was 2-fold more active on granzyme B than on GrA and Casp-8, and showed no 
inhibition of Casp-3. In addition, this tetrazole moiety was found in several 
compounds that exhibited encouraging inhibition values, which suggests that this 
structural feature might play an important role in the binding affinity. Finally, this 
molecule has a simple core that is easy to modify. For all these reasons, compound 4 
was chosen as a starting point for the docking. 
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Figure 12: One of the hits from the initial screening 
Starting from this compound, the aim of this project was to progressively make small 
structural changes in order to improve the binding score, and therefore design a 
specific inhibitor of this protein. 
 
2.2. Starting point of the project 
 
2.2.1. Docking strategy 
 
The project therefore started with the observation of the binding pose of compound 4 
when docked into the binding site of GrB. 
The best pose for compound 4 is shown in Figure 13. The tetrazole ring occupies the 
upper part of S1, where it is hydrogen-bound to Arg226. This hydrogen bond is likely 
to enhance the affinity of the ligand for the binding site, which could explain why this 
structural feature appears in several tested molecules. In addition, some hydrophobic 
interactions in subsites S2 and S4 stabilise the molecule into the pocket. However, no 
specific interaction between the ligand and the protein can be seen in S3. 
 
Figure 13 Binding pose of compound 4 
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By comparison, it is also interesting to look at the published inhibitor (compound 3, 
Figure 10), which adopts a binding pose that is very similar to the one of tetrapeptide 
Ac-IEPD-CHO. Figure 14 below shows the superposition of published inhibitor 3 
(orange molecule) with compound 4.  
 
Figure 14: Superposition of compound 4 and published inhibitor 3 (orange) 
On the one hand, published inhibitor 3 has several advantages over compound 4. 
Firstly it goes deeper into S1, where the aspartate specificity of GrB is defined. Then 
it creates several hydrogen bonds in S3 with the backbones of the protein residues. 
Finally it has a fifth part, the benzothiophene, which creates cation-π stacking with an 
arginine residue (Arg217) and may be responsible for an increase in the affinity. 
On the other hand, compound 4 also has an important improvement over the 
published inhibitors: the tetrazole ring. It occupies a space between S1 and S2, where 
it creates a hydrogen bond, which is not the case with the published compounds. 
Therefore, an effort will be made to conserve this interaction. One last observation is 
that the S2 pocket is much deeper than what inhibitor 3 occupies, so it might be 
interesting to add a substituent that goes further into this pocket. 
 
2.2.2. Design of a potential inhibitor of GrB 
 
The strategy for the design of new inhibitors of GrB consisted in making small 
structural modifications on the core of compound 4, then docking the novel 
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compounds into the binding site of GrB and comparing the binding scores. The 
MM-GBSA score was used as a reference, as being the most accurate calculation of 
the binding affinity for a given compound. MM-GBSA scores are given as negative 
values, with lower scores representing higher binding affinities. Initial compound 4 
displayed an MM-GBSA score of –16.1. 
This docking process initially focussed on the modification of parts 1 and 2 (which 
bind respectively into subsites S1 and S2, see section 1.6.2). Several modifications 
were added (data not shown), leading to the design of compound 5 (Figure 15), with a 
MM-GBSA score of –32.3.  
 
Figure 15: Modification of P1 and P2 
The first modification that was made on compound 4 was the replacement of the 
tetrazole moiety with a triazole, allowing for the addition of a third substituent. A 
pyridine was initially used as a substituent, leading to an interesting binding pose: 
both the triazole and the pyridine nitrogen atoms were able to create hydrogen bonds 
with the same residue, Arg226. However, due to the rotation of the pyridine 
substituent, different binding poses were observed, some of which displaying the 
pyridine nitrogen oriented in the opposite direction. The pyridine was therefore 
replaced with a pyrimidine, affording a similar binding pose as shown in Figure 16. 
The second modification aimed at occupying the space in S2, and it was found that 
replacing the cyclohexyl substituent with a para-substituted phenyl ring increased the 
binding score. Furthermore, the presence of a hydroxy group created a new hydrogen 
bond at the end of subsite S2 with a tyrosine residue (Figure 16). 
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Figure 16: Binding pose of compound 5 
Although other modifications could be done to the core – such as replacing the 
hydroxyl group with a fluorine atom or the pyrimidine with a furan ring – the eastern 
part of compound 5 was taken as a model when trying to improve parts 3 and 4 
(binding respectively into S3 and S4).  
In order to further increase the binding scores, the ethylene linker of compound 5 was 
replaced with various functional group that would create interactions in the S3 and S4 
sub-pockets (data not shown). However, no dramatic improvements could be added to 
the binding scores. Interestingly, it was found that the dipeptide side chain of 
published inhibitor 3 gave interesting results. Optimisation of the binding pose was 
achieved when the dipeptide side chain was linked to the triazole core through a 
methylene group, as shown on the general structure of compound 6 below (Figure 
17).  
 
Figure 17: General structure of potential GrB inhibitors 
The R and Ar groups could be replaced with a range of aliphatic and aromatic 
substituents. Some interesting docking results are shown in Table 2, showing that the 
replacement of parts 3 and 4 with a dipeptide side chain led to an increase of the 
MM-GBSA score of around 10 units.  
N N
NNH N
N
OH
6a-f
OHN
O
Ar
R
 
41 
Entry	   Compound	   R	   Ar	   MM-­‐GBSA	  score	   MW	  (g.mol-­‐1)	   cLogP	  1	   6a	   1-­‐methylpropyl	   phenyl	   –40.7	   528	   4.26	  2	   6b	   1-­‐methylpropyl	   3-­‐benzothiophene	   –44.7	   584	   4.49	  3	   6c	   isopropyl	   phenyl	   –42.6	   514	   3.84	  4	   6d	   isopropyl	   3-­‐benzothiophene	   –47.7	   570	   4.08	  5	   6e	   1-­‐methylpropyl	   3-­‐thiophene	   –44.8	   534	   3.30	  6	   6f	   1-­‐methylpropyl	   3-­‐furan	   –44.5	   518	   2.57	  
Table 2: Docking results for potential GrB inhibitors 
By comparison, the Table 3 below shows the docking score for the two most active 
published inhibitors, compound 2 and 3 (See Figure 10), which are in the same order 
of magnitude with slightly higher molecular weights.  
Entry	   Compound	   R	   Ar	   MM-­‐GBSA	  score	   MW	  (g.mol-­‐1)	   cLogP	  7	   2	   1-­‐methylpropyl	   phenyl	   –40.4	   558	   1.81	  8	   3	   1-­‐methylpropyl	   3-­‐benzothiophene	   –42.9	   614	   2.04	  
Table 3: Docking results for published inhibitors 
The binding mode of these compounds was similar to the one of the published 
inhibitors, with hydrogen-bond interactions in S3 and S4 as well as a cation-π 
stacking in S5, which was likely to contribute in a large extent to the increase in 
binding score. Interestingly, the triazole core remained in the same binding position, 
created by previously observed hydrogen interactions with Arg226 (Figure 18). 
 
Figure 18: Binding pose for compound 6b (entry 2) 
Using CADD software, we were therefore able to design a set of compounds 
showing an interesting binding pose when docked into the GrB binding site: while the 
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western part of the molecule was inspired by published inhibitors of GrB, the eastern 
part was designed to create H-bonding interactions with the backbone of residues 
within the binding site, such as Gly216 (Figure 18). In order to validate the design of 
these putative inhibitors of Granzyme B through computational modelling, one of the 
molecules from this new set was chosen as a model compound for synthesis in the 
laboratory and subsequent biological assessment: compound 6a was an interesting 
starting point, as the substrates for the 1,2,4-triazole ring formation could be easily 
accessible from commercially available starting materials (see section 3.1). 
 
3. RESULTS AND DISCUSSION 
 
3.1. Synthesis of initial analogue 6a 
 
3.1.1. Retrosynthesis 
 
In order to access the chosen model compound 6a, a retrosynthetic analysis was 
designed as follows (Scheme 1). 
 
Scheme 1: Retrosynthesis for analogue 6a 
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The target molecule 6a would be obtained via two consecutive peptide couplings, 
with two simple building blocks – phenyl acetic acid (7), isoleucine (8) – on amine 9. 
The triazole moiety of amine 9 would be synthesised by cyclodehydration between 
acyl hydrazide 10 and thioamide 11. Finally, thioamide 11 would be accessed from 
commercially available starting materials: aniline derivative 12 and glycine (13). This 
strategy, consisting in the formation of the heterocyclic ring from two building blocks 
of similar size and complexity, would allow for variation of the triazole substituents, 
which is convenient and interesting for the further synthesis of analogues. 
 
3.1.2. Synthesis of acyl hydrazide 10 
 
It was decided to start the synthesis of acyl hydrazide 10 with the hydrolysis of 
commercially available 2-pyrimidinecarbonitrile (14) (Scheme 2). Classical 
conditions for this transformation are the use of concentrated sulphuric acid in 
water.31 Accordingly, this method was trialled. When following the reaction by TLC 
it was evident that all of the starting material was consumed, but it was not possible to 
extract the resulting acid 15 from the aqueous layer at the end of the reaction, even 
after adjusting the pH to 1. An alternative synthesis of this particular acid from nitrile 
14 has been reported, using potassium hydroxide in water.32 Using these conditions, 
the reaction was once again complete according to TLC analysis. However, after 
attempted extraction from the aqueous phase, only a 16% yield of acid 15 was 
obtained, compared with the 40% yield reported in the original paper.32 
 
Scheme 2: Hydrolysis of 2-pyrimidinecarbonitrile (14) 
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As the next step was to be formation of ester 16 via esterification of acid 15, a new 
way to synthesise ester 16 directly from nitrile 14 was considered. The use of TMS 
chloride in dry methanol and heating of the reaction mixture at 50 °C for 70 h was 
employed.33 Methyl ester 16 was obtained in a high yield. Subsequently, the methoxy 
group of the ester was displaced with hydrazine to afford the desired acyl hydrazide 
10 in quantitative yield. 
Acyl hydrazide 10 was found to be unstable at room temperature over the course of 
several days, as products of degradation were observed via TLC analysis and 1H 
NMR spectroscopy. It was found that storage of the solid at –20 °C slowed this 
process down. Due to the fact that a large amount of 10 was need to attempt the 
cyclodehydration step, the ester 16 was synthesised on a large scale, but only the 
required quantity of acyl hydrazide was synthesised each time and used directly. 
 
3.1.3. Synthesis of thioamide 11 
 
The first steps in the assembly of thioamide 11 were the protections of the two 
buildings blocks used for the peptide coupling (Scheme 3). The amine moiety of 
glycine (13) was protected with a Boc group, using classical conditions,34 to afford 
carboxylic acid 17. In parallel, the alcohol of aniline derivative 12 was protected as a 
TIPS ether to give amine 18. This reaction, usually carried out in DMF as the solvent, 
worked well also in dichloromethane, which was more convenient as regards to 
subsequent scale-up. The next step was a peptide coupling of carboxylic acid 17 with 
aniline 18 to afford amide 19 in 71% yield. 
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Scheme 3: Synthesis of thioamide 11 
The following step was the thiation of amide 19 into the corresponding thioamide 11. 
Lawesson’s reagent (20, L.R.) has been extensively described to achieve this 
transformation, and due to the low solubility of this reagent the reaction is usually 
carried out in solvents such as toluene and at high temperature.35 However, when 
these conditions were attempted for the conversion of amide 19, a degradation of the 
substrate was observed after 2 h at 120 °C. Other papers reported the alternative use 
of L.R. in THF at lower temperature.36 In the case of amide 19, although the 
conversion was not complete after 48 h under these conditions, the desired thioamide 
11 was obtained with a 63% yield after chromatography. 
 
3.1.4. Cyclodehydration 
 
The formation of tri-substituted 1,2,4-triazoles by cyclodehydration between a 
thioamide and an acyl hydrazide has been reported by Klingele and Brooker in 
2004.37 They reported that n-BuOH at reflux was the most convenient solvent for this 
reaction. The same strategy was chosen to form triazole 21 (Scheme 4). However, the 
first attempt to form triazole 21 in n-BuOH at 110 °C led only to decomposition of 
thioamide 11 (Table 4, entry 1). 
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Scheme 4: Cyclodehydration using different solvents 
Entry Solvent Temperature Results 
1 n-BuOH 110 °C Decomposition of 11 
2 t-BuOH 90 °C No reaction 
3 HFIP 65 °C No reaction 
4 t-BuOH 150 °C, µw No reaction 
5 neat 150 °C, µw No reaction 
Table 4: Cyclodehydration using different solvents 
In order to investigate this decomposition, thioamide 11 alone was heated in n-butanol 
at 110 °C for 4 h (Scheme 5). A new product was isolated, which was identified as 
aniline 18. One explanation for the formation of this product is the nucleophilic attack 
of the n-butanol on the electrophilic thiocarbonyl, leading to elimination of the amine. 
A less nucleophilic alcohol, t-butanol, was then considered as a potential solvent 
instead. In a control experiment, heating thioamide 11 at 90 °C in t-BuOH for 24 h 
did not lead to any decomposition. 
 
Scheme 5: Decomposition of 11 in n-BuOH 
The cyclodehydration was therefore attempted in refluxing t-butanol (Table 4, entry 
2), but no product formation was observed. A more acidic solvent, hexafluoro-2-
propanol (entry 3) did not work either. Finally, the activation of the reaction under 
microwave irradiation at 150 °C was trialled, both in t-butanol (entry 4) or neat (entry 
5), but again in these cases no product was observed and starting materials remained 
unreacted. 
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As mentioned previously, acyl hydrazide 10 is not indefinitely stable at room 
temperature, which suggests that it may not be stable to the reaction conditions. In 
order to verify this hypothesis, thioamide 11 was allowed to react with two different 
commercially available acyl hydrazides (Scheme 6). Using phenyl acyl hydrazide 
(22a) as a model for pyrimidine acyl hydrazide 10, the reaction was carried out in the 
same conditions as before (Table 5, entry 1) but in this case again, no reaction 
occurred. Another well-described hydrazide compound in the literature to form this 
class of triazole is formic hydrazide (22b), having only a hydrogen atom attached to 
the carbonyl group. Following a procedure using this particular reagent,38 the 
cyclodehydration was conducted at room temperature using a mercury salt as catalyst 
(entry 2). Unfortunately, no product was formed and most of thioamide 11 was 
recovered. In addition a small amount of amide 19, resulting from the hydrolysis of 
the thioamide, was found in the reaction mixture. Although these two experiments did 
not lead to the formation of the cyclisation product, they suggested that the problem 
encountered with this reaction might not originate from the acyl hydrazide. 
 
Scheme 6: Cyclodehydration with different acyl hydrazides 
Table 5: Cyclodehydration with different acyl hydrazides 
Another possible explanation for the failure of this reaction may be the lack of 
reactivity of the thioamide. In order to activate it, two strategies were considered. 
First, Klingele reported that S-alkylation of the thioamide could help such reactions to 
occur.37 Accordingly, when thioamide 11 was treated with Meerwein’s salt, thioether 
derivative 24 was obtained as a 1 : 1 mixture of two inseparable isomers (Scheme 7). 
Several by-products were also formed and the desired product required purification by 
chromatography. The very low yield of 17% could be explained by the poor stability 
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of the product during the purification step. Unfortunately, when the mixture of 
thioethers 24 was subsequently treated with acyl hydrazide 10 in refluxing t-butanol, 
no product was observed. 
 
Scheme 7: Activation of thioamide 11 by S-alkylation 
Another strategy for the formation of 1,2,4-triazoles, reported by Johansson in 2006, 
was to form an imidoyl chloride starting from an amide.39 Accordingly, amide 19 in 
dichloromethane was treated with oxalyl chloride at room temperature, with one 
equivalent of base to quench the resulting HCl (Scheme 8). Intermediate 25 was not 
isolated and, after evaporation of the solvent, was used directly in the attempted 
cyclisation step. Under the reported reaction conditions, which consisted in treating 
imidoyl chloride 25 with acyl hydrazide 10 at room temperature in dichloromethane, 
then refluxing the residue after evaporation of the solvent in a saturated aqueous 
potassium carbonate solution, only decomposition of the starting materials was 
observed. 
 
Scheme 8: Activation of amide 19 by formation of an imidoyl chloride 
Following these unsuccessful attempts to induce cyclodehydration, a third approach 
was considered. Returning to the thioamide substrate, a procedure reported in 1987 by 
Santus described this type of reaction to be successful when carried out in pyridine as 
the solvent (Scheme 9).40 Attempted cyclodehydration of thioamide 11 and hydrazide 
12 in pyridine at room temperature or at 50 °C did not result in any reaction (Table 6, 
entries 1 and 2). Conducting the reaction at 100 °C led to the formation of a small 
amount of the desired triazole 21 after 1 h (entry 3). An increased reaction time only 
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resulted in decomposition of the starting material without total consumption of the 
starting material (entry 4). These conditions could not however be improved and were 
therefore used to synthesise a sufficient amount of 1,2,4-triazole 21 in order to pursue 
the synthesis of the target compound. Depending on the scale and time of the reaction, 
the desired triazole 21 was obtained consistently with yields in the range 43–47%. 
 
Scheme 9: Cyclodehydration in pyridine 
Table 6: Cyclodehydration in pyridine 
 
3.1.5. Selective deprotection 
 
With the desired 1,2,4-triazole 21 in hand, the Boc protecting group needed to be 
cleaved selectively in the presence of the TIPS ether (Scheme 10). 
 
Scheme 10: Selective Boc deprotection 
Different conditions were employed. Attempted classical Boc-deprotection conditions 
using 10% TFA solution in dichloromethane led to the removal of both protecting 
groups, with only a small amount of the desired product 9 being detected (Table 7, 
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entry 1). The use of a saturated solution of HCl in acetonitrile has been reported as a 
selective way to cleave a Boc group in the presence of silyl ethers (entry 2).41 
However, when these conditions were applied to 21, no desired product 9 was 
observed, and several by-products were formed. Finally, conditions using TMSOTf as 
a Lewis acid and 2,6-lutidine as a proton scavenger have been reported for the 
deprotection of a N-Boc group.42 When only one equivalent of TMSOTf was used, no 
reaction occurred (entry 3), however formation of product 9 was observed when 
9 equivalents were added to the reaction mixture (entry 4). The reaction was slow and 
required an additional 9 equivalents of TMSOTf after 24 h in order to go to 
completion. When the reaction was conducted at higher concentration, the formation 
of by-products was observed, resulting in a decrease in the yield and difficult 
purification. When using the optimised concentration of 0.1 M, free amine 9 was 
obtained with a yield of 90% after purification.  
Entry Conditions Results 
1 10% TFA in CH2Cl2 Product 9 + deprotection of TIPS 
2 sat. HCl in AcOEt No product, formation of by-product 
3 TMSOTf (1 eq.), 2,6-lutidine, CH2Cl2 No reaction 
4 TMSOTf (9 eq.), 2,6-lutidine, CH2Cl2, 0.1 M Product 9 only 
Table 7: Conditions for the Boc deprotection 
 
3.1.6. End of the synthesis of analogue 6a 
 
The free amine 9 was subsequently coupled with commercially available 
Boc-isoleucine (8), using EDCI and DMAP,43 to afford amide 26 in 81% isolated 
yield (Scheme 11). Although the presence of mildly basic DMAP could be 
responsible for the epimerisation of sensitive stereogenic centres, amine 26 was 
obtained as a single diastereoisomer as observed by 1H and 13C carbon NMR. 43 Boc-
protected amine 26 required to be cleaved selectively once again, so the optimised 
conditions using TMSOTf and 2,6-lutidine were used, to afford free amine 27 with a 
yield of 62%. Amine 27 was then coupled with phenylacetic acid (7), under the same 
peptide-coupling regime, to afford compound 28 with a yield of 92%. The last step to 
obtain the first analogue was the deprotection of the TIPS protecting group, which 
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was carried out using TBAF in a solution of tetrahydrofuran buffered with acetic acid. 
This reaction proceeded only slowly, and required two subsequent additions of 
2.2 equivalents of TBAF in the course of several hours in order to go to completion. 
Finally, compound 6a was obtained after two chromatographic purifications, with a 
yield of 83%. 
 
Scheme 11: End of synthesis of analogue 6a 
 
3.1.7. Biological evaluation of 6a 
 
Compound 6a was submitted for biological evaluation to our collaborators. The assay 
was an in vitro enzyme inhibition assay. Tetrapeptide Ac-IEPD-CHO (1) (c.f. Figure 
8, Section 1.6.3) was used as a positive control. Unfortunately, compound 6a did not 
show any inhibition of Granzyme B, as can be seen on Figure 19 below: while 
positive control Ac-IEPD-CHO (1) displayed a percentage of expression close to 0%, 
the activity of Granzyme B was unaltered by the presence of analogue 6a, similarly to 
when DMSO only was present in the enzymatic reaction. 
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Figure 19: Biological assessment of initial analogue 6a in a GrB inhibition assay 
 
3.1.8. Selection of new compounds for synthesis 
  
Although these results were disappointing, there was a number of reasons that could 
explain this lack of activity, and two different strategies were developed in order to 
investigate further the set of compounds designed by computational modelling. One 
possible explanation for the lack of inhibition could be that the subsite S2 was too 
narrow to allow the hydroxyethyl substituent in P2 to bind adequately in the pocket. 
Indeed, published inhibitors 2 and 3 as well as tetrapeptide Ac-IEPD-CHO (1) bear 
much shorter substituents at this position. Moreover, it was demonstrated that narrow 
or buried binding sites could be occupied by water molecules, which could not be 
displaced upon binding of a ligand.44  
In order to investigate this hypothesis, the synthesis of new compounds with shorter 
substituents on N-4 of the triazole core was considered (Figure 20). Two examples 
displayed interesting binding poses and high scores when docked on the protein: first 
p-fluorophenyl analogue 29a was still able to create hydrogen bond at the end of the 
S2 subsite; then cyclopropyl analogue 29b, which is smaller and fully carbonated, 
seemed to fit nicely into the S2 pocket where it creates hydrophobic interactions. The 
chemistry for the synthesis of these two new analogues will be described in the 
following sections (3.2 and 3.3). 
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Figure 20: New analogues with smaller substituent in P2: 29a and 29b 
As parallel investigations, some of the compounds that were designed at the various 
intermediate steps of the docking process appeared as interesting targets, as a way to 
validate that the changes during the design of the new ligands had the desired effect of 
increasing the binding activity. The first step was to confirm that the initial hit 4 
(section 2.1.2), on which the CADD was based, showed reproducible activity. Both 
chloro and bromo analogues 4 and 30 could be accessed easily (Figure 21). 
It was then chosen to synthesise the two initial hits from the docking process (Figure 
21). The first modification that was added to the initial hit compound was the 
transformation of the tetrazole into substituted triazole 31a, occupying therefore a 
new chemical space in P1. The subsequent replacement of the pyridine substituent 
with a pyrimidine, giving compound 31b, was shown to increase the binding score, as 
the hydrogen bonding of the heterocycle became independent of the rotation of this 
substituent. The synthesis of these four new analogues will be presented in 
section 3.4. 
 
Figure 21: Intermediate compounds from the CADD 
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3.2. Synthesis of the p-fluoro analogue 29a 
 
3.2.1. Retrosynthesis 
 
For the synthesis of the new series of analogues, a slightly different retrosynthetic 
analysis was considered in order to make the synthesis more convergent and therefore 
giving access to a range of new analogues in a more efficient manner (Scheme 12). A 
first disconnection afforded two fragments of similar size: acid 32 and amine 33. This 
would limit the linear coupling and deprotection steps of the previous route and allow 
easy variations of the substituents on the western part of the molecule. As for the 
eastern part of the molecule, the synthesis of triazole 33 would be carried out with the 
same methodology previously used. 
 
Scheme 12: New route for the synthesis of the p-fluorophenyl analogue 29a 
 
3.2.2. Synthesis of the western dipeptide 32 
 
The first attempt to form the amide bond of dipeptide 32 was accomplished following 
a literature known procedure starting from carboxylic acid 7 and amine 8 (Scheme 
13).43 Although the followed procedure used DMF as the reaction solvent, the use of 
dichloromethane was preferred, as this reaction would be carried out on a large scale 
after suitable conditions were found. However, when a test reaction in 
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dichloromethane was attempted, the poor solubility of zwitterionic amino acid 8 
resulted in a really low conversion after an extended reaction time of several days. 
To avoid this solubility issue, another route was considered, which would go through 
the formation of acid chloride 35 and subsequent reaction of this activated acid with 
isoleucine dissolved in a basic aqueous solution.45 When this reaction was carried out, 
the desired amide product 32 was isolated in 56% yield. Although the yield was lower 
than what would be expected under classical coupling conditions, the product was 
isolated in high purity and a sufficient amount was produced on a large scale in order 
to pursue the synthesis. 
 
Scheme 13: Synthesis of the western dipeptide 32 
 
3.2.3. Synthesis of the p-fluorophenyl analogue 29a 
 
The synthesis of the p-fluorophenyl analogue 29a started with a peptide coupling 
between Boc-glycine (17) and p-fluoroaniline (36), to afford amide 37 with a yield of 
82% (Scheme 14). Amide 37 was then transformed into the corresponding thioamide 
34 using Lawesson’s reagent (20). The reaction was complete after 2 h and the 
desired product 34 was obtained with an 85% yield, which was higher than the 
previous substrate having a hydroxyethyl substituent on the phenyl group (compound 
11, section 3.1.3).  
 
Scheme 14: Synthesis of thioamide 34 
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The next step was the cyclodehydration, starting with the conversion of ester 16 into 
acyl hydrazide 10, which after evaporation of the solvent was directly allowed to react 
with thioamide 34 to form the desired 1,2,4-triazole 38 (Scheme 15). When using one 
equivalent of acyl hydrazide, the cyclodehydration reaction was incomplete after two 
days (Table 8, entry 1). A 27% yield of the desired product 38 was obtained and 28% 
of starting thioamide 34 was recovered. Interestingly, it was possible to convert all the 
starting material by adding one additional equivalent of acyl hydrazide 10 after one 
day (entry 2) and in this case a reasonable yield of 57% was obtained. The formation 
of several by-products as observed by TLC analysis could explain why this reaction 
was not quantitative.  
 
Scheme 15: Synthesis of final compound 29a 
Table 8: Cyclodehydration with different equivalents of 10 
Boc-amine 38 was subsequently deprotected under classical conditions using 10% 
TFA solution in DCM to afford amine 33 with a low yield of 12%. This could mainly 
be explained by the high solubility of amine 33 in water, resulting in the loss of a 
significant amount of the compound following extraction. Moreover, purification of 
the product was required but due to its high polarity, product 33 was largely retained 
on silica. Finally, the peptide coupling of amine 33 with previously synthesised 
carboxylic acid 32, using EDCI and HOBt to avoid epimerisation (thanks to the lower 
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basicity of HOBt compared to DMAP), afforded final compound 29b with a 
satisfying yield of 88% after column chromatography. 
 
3.3. Synthesis of the cyclopropyl analogue 29b 
 
3.3.1. First attempt using the initial strategy 
 
The synthesis of the cyclopropyl analogue 29b initially followed a similar route, 
starting with a peptide coupling between Boc-glycine (17) and cyclopropylamine (39) 
to afford amide 40, which was then transformed into the corresponding thioamide 41 
using Lawesson’s reagent (20) with a yield of 84% (Scheme 16). With thioamide 41 
in hand the subsequent cyclodehydration step was attempted. Although the desired 
triazole 42 was observed and isolated, it was not possible to obtain a yield higher than 
5%. When an initial attempt was conducted by adding several equivalents of acyl 
hydrazide 10 over the course of three days, 70% of unreacted starting material 41 was 
recovered (Table 9, entry 1). Increasing the concentration of the reaction did not 
improve the yield but instead more by-products were formed and only 54% of the 
starting material was recovered (entry 2). Finally, attempted activation with 
microwave irradiation resulted in the formation of numerous by-products and only 
30% of the starting thioamide was recovered with no improvement of the yield 
(entry 3). 
 
Scheme 16: Initial route towards the synthesis of cyclopropyl analogue 29b 
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Table 9: Cyclodehydration conditions 
With some material in hand, deprotection of Boc-amine 42 was attempted. 
Unfortunately, due to the high solubility of the resulting amine 43 in aqueous media, 
it was not possible to extract the desired product from the aqueous phase during the 
work-up procedure. Considering the problems encountered during the last two steps 
of the synthesis, it was decided to design a new route that would go through more 
stable intermediates and required conditions that would avoid extracting highly polar 
molecules from aqueous media. 
 
3.3.2. New strategy 
 
The new retrosynthetic analysis of cyclopropyl analogue 29b is presented in Scheme 
17 below. The same disconnection would be made in the final molecule 29b, giving 
western part 32, previously synthesised, and free amine 43. In this case however, the 
amine moiety would be accessed by reduction of azide 44. This masking group was 
chosen over the boc-protecting amine to avoid the problems encountered during the 
deprotection step. Moreover, the azide might prove to be more stable during the 
cyclisation step and would allow the use of a wider variety of conditions. Therefore, 
triazole 44 would be obtained by reaction of acyl hydrazide 10 – also previously 
synthesised – with an activated amide 45. Finally, the amide leading to 45 would be 
obtained from commercially available bromoacetyl bromide (46) and 
cyclopropylamine (39).  
Entry Conditions Yield Recovered SM 41 
1 0.1 mol.L-1 5% 70% 
2 0.5 mol.L-1 5% 54% 
3 microwave irradiation 5% 30% 
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Scheme 17: Retrosynthesis towards cyclopropyl analogue 29b 
 
3.3.3. Beginning of the synthesis 
 
The synthesis started with the displacement of the acyl bromide from bromoacetyl 
bromide (46) using cyclopropylamine (39) (Scheme 18). The reaction, carried out in 
THF at low temperature, afforded amide 47 with an 87% yield after isolation in 
sufficient purity. The next step was the displacement of the aliphatic bromide with 
sodium azide, to afford azide derivative 48. This reaction, usually carried out in DMF 
at 100 °C, yielded only 25% product because of the work-up procedure: indeed, a 
significant amount of product remained in the aqueous layer with the DMF, and 
repeated extractions caused the DMF to be extracted with the organic layer, which 
was not desirable. Fortunately, it was found that this reaction also proceeded well in 
acetonitrile at 80 °C. The reaction required monitoring by 1H NMR, as both starting 
bromide 47 and product 48 had the same Rf on TLC analysis. After 12 h, the reaction 
was complete and azide 48 was isolated in 67% yield. 
 
Scheme 18: Beginning of the synthesis 
Finally, amide 48 had to be transformed into thioamide 49 in order to achieve the 
cyclodehydration step. Although the azide functional group was reported to be stable 
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towards the use of Lawesson’s reagent (20),46,47 product 49 could not be isolated. A 
high-resolution mass spectrometry analysis of the reaction mixture showed that the 
product was present, but a TLC analysis showed many components and the ones that 
were substantial enough to be isolated after chromatography exhibited aromatic 
protons belonging to Lawesson’s reagent or its derivatives. An alternative route was 
therefore sought. 
 
3.3.4. Formation of the 1,2,4-triazole 
 
Johansson and co-workers have reported the formation of 1,2,4-triazole moiety 50, 
starting from the same building blocks as previously described, which are amide 51 
and acyl hydrazide 52 (Scheme 19).39 The activation of amide 51 could be carried out 
by transforming this functional group into the corresponding imidoyl chloride 53.  
 
Scheme 19: Triazole synthesis though imidoyl chloride formation 
This reaction had already been attempted during the synthesis of the previous 
p-fluorophenyl analogue 29a starting from amide 37, but did not give any of the 
desired product. The lack of reactivity of analogue 37 could be attributed to the 
electron-withdrawing effect of the fluorine atom on the aromatic ring.39 However, the 
electron-donating cyclopropyl substituent required for the synthesis of this new 
analogue might be a more suitable substrate with regards to this cyclisation. This 
reaction was therefore attempted for the synthesis of triazole 44 (Scheme 20). The 
synthesis of imidoyl chloride 54 was achieved by treating amide 48 with oxalyl 
chloride. Although the reaction could not be followed by TLC analysis, the formation 
of the product was inferred by the observation of gas evolution during the first five 
minutes of the reaction as well as infrared spectrometry after evaporation of the 
solvent showing the disappearance of the characteristic amide band. Freshly prepared 
acyl hydrazide 10 was then added to the reaction mixture and it was found that the 
presence of base prior to the addition of the second reactant 10 was required in order 
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to prevent the decomposition of the entities present in the reaction mixture. At this 
stage again TLC analysis could not be used to monitor the reaction. Finally, 
evaporation of the solvent followed by dissolution and refluxing of the residue in 
basic aqueous media afforded the desired 1,2,4-triazole 44 in 20% yield. 
Notwithstanding this low yield, it represented an improvement on the 5% obtained 
using the initial route. Due to the difficulties in monitoring the reaction, it was not 
possible to further improve the conditions, but this route provided a sufficient amount 
of triazole 44 in order to pursue the synthesis of the cyclopropyl target molecule 29b. 
 
Scheme 20: Synthesis of triazole 44 
 
3.3.5. Completion of the synthesis of cyclopropyl analogue 29b 
 
With triazole 44 in hand, the next step was the azide reduction to afford free amine 
43, using hydrogen and activated palladium on charcoal (Scheme 21). Under these 
conditions, no aqueous work-up was necessary, which was desirable knowing the 
affinity of amine 43 for water, and product 43 was obtained in high yield and high 
purity. Finally, amine 43 was coupled to acid 32 using EDCI and HOBt. After 
chromatography purification, the final compound 29b was obtained with a yield of 
82%, and an LCMS indicated that the product was pure. However, on both 13C and 1H 
NMRs, the product appeared to be a mixture of diastereomers (55 : 45). 
Unfortunately, it was impossible to separate them. In order to eliminate the hypothesis 
of having two rotamers, variable temperature NMRs were carried out,48 in different 
solvents, but even at 150 °C in DMSO no change in the ratio of the two species could 
be observed. Similarly, adding drops of acid or base into the NMR tube did not 
change the ratio.49,50  
The epimerisation therefore appeared to have taken place at the isoleucine α-position. 
One explanation for the epimerisation could be the formation of an azalactone, which 
can occur when the carboxylic acid moiety of a peptide chain is activated with a 
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coupling reagent.51 For this reason, peptide couplings are not usually carried out in the 
N- to C-terminus direction, although in the case of analogue 29b, this was inherent to 
the chosen synthetic route. In order to avoid this unwanted side-reaction, it would 
have been necessary to avoid the activation step, in which carboxylic acid 32 was 
reacted alone with the coupling reagent, and instead have amine 43 present in the 
reaction mixture from the beginning of the reaction. Compound 29b was therefore 
submitted for biological evaluation as a mixture of diastereomers. 
 
Scheme 21: Synthesis of the cyclopropyl analogue 29b 
 
3.4. Synthesis of intermediates from the CADD 
 
3.4.1. Synthesis of tetrazole analogues 
 
Compound 4 had been previously tested and shown to be an inhibitor of Granzyme B, 
and hence was used as the starting point of the docking studies. It was decided to 
synthesise it as well as its bromo analogue 30 (Scheme 22). Final compounds 4 and 
30 would be obtained by substitution of the bromine on phenol derivatives 55a,b with 
aromatic thiol 56. Finally, tetrazole 56 would be formed by cycloaddition between 
sodium azide and isothiocyanate 57, easily accessible via the corresponding amine.  
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Scheme 22: Retrosynthetic analysis for tetrazole analogues 
The conversion of an amine into the corresponding isothiocyanate is well 
documented. The amine is reacted with carbon disulfide in the presence of a base to 
form a dithiocarbamate salt, which is then treated with an oxidising agent such as lead 
nitrate.52 A more convenient procedure, recently developed, forms the 
triethylammonium salt 58 from amine 59, and then uses molecular iodine to obtain 
the desired product 57 (Scheme 23).53 However, no isothiocyanate 57 could be 
observed when these conditions were applied on cyclohexyl substrate 59. One 
explanation could be that a work-up is necessary between these two steps. Another 
paper reports the use of tosyl chloride to treat the dithiocarbamate in situ, which when 
applied on cyclohexylamine 59 gave the desired isothiocyanate 57 with a yield of 
80% after chromatography purification.54 Infrared spectroscopy analysis showed an 
absorption peak at 2097 cm-1, characteristic of this functionality.  
 
Scheme 23: Synthesis of tetrazole 56 
The cycloaddition step was then carried out with sodium azide following a known 
procedure.55 Isothiocyanate 57 was not soluble in water, which was initially used as 
the reaction solvent, and no product was observed when the concentration of the 
reaction was lowered to 0.1 M (Table 10, entry 1). When increasing the concentration 
to 1.0 M, the desired tetrazole 56 was formed but the yield was only 50% after one 
day at reflux (entry 2). Other procedures, such as the ones describing the synthesis of 
the Julia-Kociensky reagent, use a co-solvent to dissolve the isothiocyanate.56 By 
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using a 4 : 1 mixture of water and isopropanol, the reaction was complete after only 
1 h, affording tetrazole 56 with a yield of 77% after purification.  
Entry Solvent Concentration Reaction time Product 
1 water 0.1 M 24 h – 
2 water 1.0 M 24 h 50% 
3 water : isopropanol 1.0 M 1 h 77% 
Table 10: Cycloaddition conditions 
In order to synthesise the western part of the molecule, 1,2-dibromoethane (60) was 
reacted with the desired p-halogenophenol 61a or 61b under basic conditions 
(Scheme 24). 
 
Scheme 24: Bis-alkylation toward the final compounds 4 and 30 
In a first attempt, potassium phenoxide 61a was formed using potassium hydride in 
THF as the solvent, then an excess of dibromoethane 60 was added and the mixture 
was refluxed for two days, affording the desired ether 55a in 40% yield (Table 11, 
entry 1). The presence of side reactions due to the reactivity of 1,2-dibromoethane 
could explain this low yield, which nevertheless produced enough of the desired 
product to pursue the synthesis of the p-bromo derivative. 
However, when the reaction was carried on with p-chloro derivative 61b under the 
same conditions, only a 10% yield of product 55b was obtained after 3 days at reflux 
(entry 2). The addition of a catalytic amount of tetrabutylammonium iodide only 
increased the yield up to 25% (entry 3). Replacing potassium hydride with sodium 
hydride made the reaction even less efficient, with only 5% conversion (entry 4). 
Finally, a different set of conditions was employed: as the presence of a strong base 
could be responsible for the occurrence of side reactions, caesium carbonate was used 
instead. When, in addition to this base, sodium iodide was used to catalyse the 
reaction in refluxing acetone, the yield was increased up to 33% after 2 days (entry 5). 
1H NMR analysis of the crude reaction mixture at the end of the reaction revealed the 
presence of several by-products. Running the same reaction but without a catalyst 
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afforded the desired product 55b with an increased yield of 42% as no side reaction 
was observed (entry 6). The yield could be further improved by adding more 
equivalents of dibromoethane portionwise over the course of the reaction. During the 
scale-up, a yield of 49% was obtained after 48 h, which produced enough material to 
continue with the synthesis. 
Entry X = Base / Catalyst Solvent T° Time Yield Product 
1 Br KH THF 60 °C 48 h 40% 55a 
2 Cl KH THF 60 °C 72 h 10% 55b 
3 Cl KH, TBAI THF 60 °C 72 h 25% 55b 
4 Cl NaH DMF 80 °C 72 h 5% 55b 
5 Cl Cs2CO3, NaI Acetone 55 °C 48 h 33% 55b 
6 Cl Cs2CO3 Acetone 55 °C 48 h 42-49% 55b 
Table 11: First alkylation conditions 
Finally, the second bromine atom from intermediates 55a,b was displaced with the 
previously synthesised thiol 56, in the presence of one equivalent of 
diisopropylethylamine (Scheme 24). The reaction was complete after 30 h in both 
cases affording final compounds 4 and 30 with yields of 60% and 63% respectively. 
 
3.4.2. Synthesis of triazole analogues 
 
The last series of analogues that was selected for synthesis were triazole derivatives 
31a and 31b (Scheme 25). These compounds would be obtained by a substitution of 
the bromine atom from compound 55a previously synthesised, with aromatic thiols 
62a,b. The triazole ring of 62a,b can be formed by cyclisation between isothiocyanate 
57 and acyl hydrazides 63 or 10. The syntheses of both 10 and 57 have already been 
reported in previous sections (10: section 3.1.2; 57: section 3.4.1), starting from 
commercially available materials, and the synthesis of acyl hydrazide 63 would be 
carried out similarly to its pyrimidine analogue 10.57 
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Scheme 25: Retrosynthetic analysis for the triazole series 
Acyl hydrazides 63 and 10 could be easily accessed starting from the corresponding 
methyl esters 64 and 16 (Scheme 26).57 The synthesis of pyrimidine derivative 16 had 
been reported in a previous section (3.1.2), while the pyridine analogue 64 could be 
purchased. The substitution of the methoxy group by hydrazine in refluxing methanol 
afforded the desired acyl hydrazides with a quantitative yield. Because of their low 
stability, compounds 63 and 10 were used directly in the following step.  
 
Scheme 26: Synthesis of the triazole analogues 
The formation of 1,2,4-triazole rings containing a sulphur substituent on C-5 has been 
reported by Zamani et al. in 2009.58 The first step involves the condensation of an 
isothiocyanate with an acyl hydrazide to afford a thiosemicarbazide intermediate, 
which can then undergo an intramolecular cyclodehydration, in basic condition, to 
give the desired triazole. Refluxing a mixture of acyl hydrazide 63 or 10 and 
cyclohexyl isothiocyanate 57 in ethanol afforded thiosemicarbazides 65a and 65b 
with yields of 75 and 81% respectively (Scheme 26). Infrared spectroscopic analysis 
of these intermediates showed a strong absorption around 1250 cm-1, characteristic of 
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the C=S bond, as well as a strong peak around 1670 cm-1 attributable to the carbonyl 
group.   
Intramolecular cyclisation of thiosemicarbazides 65a,b was carried out in a refluxing 
solution of sodium hydroxide, followed by acidification to afford the desired triazoles 
62a and 62b with yields of 78 and 50% respectively. The disappearance of the 
carbonyl peak in the infrared spectrum confirmed that intermediates 65a,b reacted 
and the final alkylation step would prove that the cyclisation gave rise to triazoles 
instead of thiadiazoles, which would be formed under acidic conditions.58 
Finally, thiols 62a and 62b were used in the substitution of bromoalkane derivative 
55a, previously synthesised. The reaction had to be carried out under inert atmosphere 
due to the ability of thiols to undergo self-oxidation with the presence of traces 
impurity.59 The reaction was slow, therefore another equivalent of bromoalkane and 
DIPEA were added to the reaction mixture after one day. After four days, a 
significant amount of starting thiol 62a,b remained unreacted but the reaction was 
stopped because the formation of new components was observed by TLC analysis. 
After chromatography purification, the final compounds 31a and 31b were obtained 
with yields of 85 and 78% respectively. 
 
3.5. Semi-synthesis of Merck compound 
 
3.5.1. Aim and retrosynthesis 
 
As a positive control for the biological assay, and before the biological assessment of 
the newly synthesised analogues, it was chosen to synthesise and test the most active 
compound described in the literature by Merck in their 2002 paper.22 In order to 
synthesise compound 3, a small amount of an advanced intermediate 66 was provided 
by collaborators of the project (Scheme 27). The desired compound 3 could be 
obtained via a peptide coupling between amine 67 and the carboxylic acid issued from 
the saponification of ethyl ester 66. Triazole 67 could be made from propargyl amine 
(68) using a cycloaddition reaction to form the desired heterocycle.  
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Scheme 27: Retrosynthesis of Merck compound 3 
 
3.5.2. Synthesis of triazole 67 
 
The synthesis of triazole 67 started with the Boc-protection of commercially available 
propargylamine (68), giving carbamate 69 with a good yield of 93% after purification 
(Scheme 28). This Boc-protected intermediate was poorly stable and needed to be 
used rapidly in the next step. A subsequent cycloaddition using TMS-azide and a 
catalytic amount of copper iodide afforded triazole 70 with an excellent yield of 96% 
after purification. Finally, deprotection of the Boc protecting group gave the desired 
building block 67 as its hydrochloride salt.  
 
Scheme 28: Synthesis of triazole 67 
 
3.5.3. Hydrolysis test reaction 
 
The hydrolysis of the ester moiety from advanced intermediate 66 had to be carefully 
controlled in order to avoid the epimerisation of the centre in α to the ester group. It 
was decided to investigate this reaction on a model substrate before applying it on the 
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advanced intermediate 66. Acetyl protected amino ester 71 was chosen as a model 
substrate, as it represented a fragment of the tricyclic scaffold of Merck inhibitor 3, 
and could be easily synthesised from commercially available (S)-indoline-2-
carboxylic acid (72) (Scheme 29). 
 
Scheme 29: Fragment used for the test reactions 
The first step towards the synthesis of model compound 71 was the esterification of 
enantiopure (S)-indoline-2-carboxylic acid (72) under classical conditions to give 
compound 73 as its HCl salt (Scheme 30). After neutralisation of the salt by one 
equivalent of base, free amine 73 was then protected with an acetyl group to afford 
test compound 71 with a yield of 93% over two steps. This compound was in the form 
of two rotamers, as can be seen very clearly on 1H and 13C NMR spectra, which is not 
surprising considering the presence of the acetamide group on a cyclic scaffold.48  
 
Scheme 30: Synthesis of test compound and hydrolysis test reaction 
With test compound 71 in hand, the hydrolysis the ethyl ester into acid 74 was 
attempted. These conditions, using lithium hydroxide, were mild and known to avoid 
epimerisation.43 Carboxylic acid 74 was thus obtained with a yield of 92% and the 
optical rotation ([α]D –132°) was a good match for the literature value ([α]Dlit –133°) 
showing that no epimerisation occurred.60 
 
3.5.4. Synthesis of Merck inhibitor 
 
After having checked by NMR analyses that intermediate 66 had not degraded on 
storage, the deprotection of the ethyl ester was carried out using lithium hydroxide as 
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previously tested (Scheme 31). However, in this case the molecule was found to be 
insoluble in methanol. A mixture of THF and water (4 : 1) was used instead in order 
to efficiently solubilise ester 66. Under these conditions, the reaction was complete 
after 1 h allowing for the isolation of acid 75 in a quantitative yield after work-up. 
Unfortunately, this carboxylic acid was insoluble in all available NMR solvents, so it 
was not possible to obtain a clean 1H NMR spectrum. However, by saturating a 
solution of deuterated methanol it was possible to confirm that both signals of the 
ethyl ester group were not present anymore in the 1H NMR spectrum. 
 
Scheme 31: Synthesis of Merck inhibitor 
Finally, acid 75 was coupled with amine 67.HCl, using HATU as a coupling 
reagent.43 This particular reagent was known to avoid epimerisation, both because the 
procedure did not require an activation step and because the activated intermediate is 
more stable than when using the EDCI/DMAP procedure.61 The reaction was carried 
out in DMF as it was the only solvent trialled that would dissolve acid 75. After two 
chromatography purifications to eliminate all residual DMF, compound 3 was 
obtained with a yield of 52%. The purity was proven by NMR and LCMS and no 
diastereomers could be seen by either LCMS or NMR analyses, showing that no 
epimerisation occurred at either the hydrolysis step or peptide coupling. 
 
3.6. Biological assessment 
 
3.6.1. Biological testing by our collaborators 
 
With six new synthetic analogues in hand in addition to Merck compound 3, the 
biological assessment was carried out by our collaborators in the Biology department, 
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using the same assay as previously used in the assessment of compounds chosen by 
virtual screening, at the beginning of the project (section 2.1.2). Unfortunately, it was 
found that the results from the assay were not reproducible, as the biological testing of 
Merck compound 3, synthesised in our laboratory, showed no inhibitory activity, 
whereas it has been described in the literature as having an IC50 of 6.3 µM.22 All of 
the analytical data from this synthesised compound were matching the data obtained 
on the reference compound: it was single diastereoisomer in high purity, with NMR 
data matching exactly the one of the reference compound. Furthermore, after several 
attempts, the required inhibition was finally observed in the biological assay with the 
compound synthesised in our laboratory. This worrying observation led us to have 
doubts about the data issued from this assay, and it was then decided to further 
investigate these results by looking more closely at the biological assay, as described 
in the following section (3.6.2). 
 
3.6.2. Enzyme inhibition assay 
 
In an attempt to understand why the biological testing of our analogues gave such 
unpredictable results, it was chosen to carry on the enzyme inhibition assay in our 
laboratory. A Granzyme B enzyme inhibition assay was available for purchase from 
EnzoLife Science, and we were able to obtain a kit that would allow us to attempt one 
assay on all of our six new molecules. Unfortunately, Merck compound 3 was entirely 
used by our collaborators in trying to understand the irreproducibility of the assay, 
resulting in the impossibility of testing this compound in our assay. 
This particular assay was using substrate Ac-IEPD-pNA (76) to follow the enzymatic 
reaction in order to assess the inhibitory activity of the tested compounds (Figure 22). 
This substrate contained the Granzyme B recognition sequence, tetrapeptide IEPD, 
attached via an amide bond (blue) to an aniline derivative (purple). In the presence of 
the enzyme, the scissile amide bond of the substrate was cleaved, realising 
tetrapeptide Ac-IEPD (77) as well as a molecule of p-nitroaniline (78, pNA, yellow), 
which absorbs at 405 nm. The course of the reaction was therefore followed by UV 
spectroscopy, using a wavelength of 405 nm. If an inhibitor of Granzyme B was 
present in the solution, the active site of the enzyme would be less accessible to 
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substrate 76, therefore less substrate would be cleaved and the UV absorption would 
be lower.  
 
Figure 22: Principle of the Granzyme B inhibition assay 
 
3.6.3. Assay results 
 
This assay was performed on our six final compounds (Figure 23), as well as 
Ac-IEPD-CHO (1) as a positive control. Each compound was tested in two replicates, 
at six different concentration points. 
 
Figure 23: Final compounds tested in the assay 
The compounds were firstly dissolved in DSMO then serial dilutions were undergone 
in the buffer, as described in the experimental part (section 1) and were added in the 
different wells of the plate, followed by the addition of the enzyme and finally 
substrate 76. The plate was read by UV method every five minutes for one hour. The 
slope for each well was calculated, which was then normalised using the absorbance 
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read in the high wells (enzyme + substrate, no inhibitor) and low wells (substrate 
only, no enzyme): the resulting value represented the response, for each 
concentration. Finally, Prism® was used to analyse the data, and the logarithm of the 
concentration for each compound was plotted against the response.  
Unfortunately, the graph showed inconsistent data (Figure 24). Although the positive 
control Ac-IEPD-CHO (1) showed an inhibition similar to the literature data (Ki = 
80 nM),22 proving that the assay was working as expected, a problem occurred with 
the six new compounds. The error was important in most cases, showing no 
correlation between the results from the duplicates. In addition, the response was 
higher that 100% at many points, meaning that the absorbance in these particular 
cases was greater than the absorbance of the control experiment. This result was 
inconsistent with the principle of this assay, and therefore indicated that something 
unexpected was happening when testing the six new compounds. 
 
 
Figure 24: Results of the inhibition assay 
Visual inspection of the plate used for the serial dilutions of the tested compounds in 
the buffer revealed some precipitation in the most concentrated wells. The presence of 
precipitates could scatter the beams of light and greatly alter the resulting 
measurement of the UV absorbance.62 This would result in UV readings that are 
inconsistent with the activity of the enzyme and could be the reason why this assay 
was not working under these conditions.   
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3.6.4. Termination of the project 
 
These results were greatly disappointing, and indicated that a large amount of 
additional work would have been needed in order to solve this problem. 
Unfortunately, due to a lack of time and resource, it was chosen to terminate this 
project.  
However, if we were to continue with this project, some important points would be 
considered. Firstly, light scattering experiments62 would be carried out in order to 
prove the presence of precipitates under the assay conditions, determining the 
solubility of the compounds at various concentrations. Then, the conditions of the 
assay would be improved and optimised still using light scattering experiments in 
order to obtain complete solubility of the tested compounds on the whole range of 
concentrations needed in the assay. This would include modifying parameters such as 
the percentage of DMSO, the order of addition or the temperature both before and 
during the assay. The new set of compounds would then be assessed under optimised 
conditions. Finally, the information obtained with the biological testing would allow a 
review of the hypotheses drawn at the beginning of the project: a new set of 
compounds could be designed by docking using the observations from the first set of 
analogues, and an effort would be made in attempting to design compounds with a 
higher predicted solubility and would be followed by further synthesis and testing in 
order to validate the new hypotheses. 
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4. CONCLUSION OF CHAPTER 1 
 
Starting from the results of a virtual screening, one hit compound, molecule 4, was 
found to be an interesting starting point in order to target the inhibition of Granzyme 
B. Computational modelling and docking experiments led to the design of a new set 
of putative inhibitors of Granzyme B such as general structure 6 below (Figure 25). 
These compounds displayed interesting binding poses when docked into the binding 
site of Granzyme B, creating key hydrogen-bonding interactions at various positions 
in the pocket. 
 
Figure 25: Design of a new set of putative analogues of GrB 
Following the computational modelling process, seven new compounds, with 
increasing molecular weight and complexity, were synthesised in the laboratory 
(Figure 26). 
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Figure 26: Seven new compounds synthesised as putative inhibitors of GrB 
Unfortunately, when attempting to assess the biological activity of these new 
compounds, the results of the assay lacked reproducibility. A first trial to run the 
assay from a commercially available kit in our laboratory revealed a solubility issue 
that were not able to solve due to a lack of resources, and the project was 
subsequently discontinued. 
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CHAPTER 2 
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1. INTRODUCTION 
 
1.1. Breast cancer 
 
1.1.1. Introduction 
 
Breast cancer represents 25% of all cases of cancer in women, making it the leading 
form and resulting in more than 1.6 million cases annually and causing 522,000 
deaths in 2012.63,64 Advances in breast cancer diagnosis over the past 30 years 
revealed an increased number of cases in developing countries.65 Early detection and 
discovery of new therapies has started to trigger a decline of the mortality.65  
The link between breast cancer and the ovaries was identified over a century ago, 
which led to the discovery in the 1930s of the implication of oestrogens in the 
development of breast cancer.66 Extended research has since been carried out in order 
to evaluate the impact of oestrogen antagonists in the treatment of breast cancer.66  
 
1.1.2. Physiology of breast cancer 
 
In humans, the mammary gland consists of a fat pad, in which a system of branching 
ducts connects the lobes to the nipple (Figure 27a).66 Inside the lobes, small units 
called lobules are responsible for secreting the milk into the lumen, which is then 
transported into the ducts. In the non-cancerous breast, the ducts are composed of a 
layer of milk-synthesising epithelial cells, surrounded by a second layer of 
myoepithelial cells, and finally fibroblasts (Figure 27b). The maintenance of the 
ducts, in addition to the changes that occur during the menstrual cycles, are regulated 
by oestrogens, a group of hormones that are natural ligands of the oestrogen receptor 
(ER).67 In the case of breast cancer, a cell mass develops from the epithelial cells and 
leads to the break down of the structure of the ducts (Figure 27c). 
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The different types of breast cancer can be classified depending on the physiological 
origin of the malignant cells: the two main categories are invasive ductal carcinomas, 
representing up to 80% of all breast cancers, followed by invasive lobular carcinomas, 
accounting for 5 to 15%.68 Both types evolve following a multistep process, 
originating in the terminal lobules. The initially hyperproliferative cells then progress 
to a precancerous stage, followed by the development of in situ carcinoma, and 
finally, invasive breast cancer.  
Following gene expression profiling studies, breast cancers were classified into 
different subtypes, such as luminal, basal, HER-2 positive and normal breast-like 
subtypes. Interestingly, whereas luminal breast cancer is characterised by being ERα-
positive, the expression of ERα in the other subtypes was found to be low or even 
absent.69 
 
Figure 27:66 (a) Anatomy of the human mammary gland and (b) structure of normal and (c) malignant 
breast tissue 
 
1.1.3. The role of oestrogen 
 
Natural oestrogens are a class of steroid hormones that play a key role in postnatal 
development. They are involved in various physiological processes such as the 
function of the female reproductive organs, pregnancy, fertility, cardiovascular 
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protection and maintenance of bone density.70 The three main circulating oestrogens 
are oestrone (E1), oestradiol (E2) and oestriol (E3) (Figure 28). 
 
Figure 28: Main circulating oestrogens in mammals 
The enzyme aromatase (CYP19), member of the cytochrome P450 superfamily, is 
responsible for the synthesis of oestrogens from androgen hormones, which mainly 
takes place in the ovaries. Two oestrogen receptors, ERα and ERβ, mediate the action 
of oestrogens, ERα being the most widely studied in relation to breast cancer.66  
In a normal breast, around 15 to 25% of the epithelial cells express ERα, although 
this number varies with the menstrual cycle. Those are non-dividing cells, and have 
been shown to respond to oestrogen stimulation by triggering the proliferation of 
adjacent ERα-negative cells.71 In the case of a breast cancer tumor, ERα is expressed 
at high levels by a large proportion of the cells (70–80%). Interestingly, the growth of 
the tumor is stimulated by oestrogen, which indicates that in malignant cells the 
oestrogen-regulated pathway has been altered.72 Efforts were therefore made in order 
to identify molecules being able to block the action of oestrogen and their potential 
use as a treatment for breast cancer. 
 
1.1.4. Anti-oestrogen therapies 
 
In 1966, Tamoxifen (79) was described as the first non-steroidal agent displaying 
anti-oestrogenic properties, and was approved in the 1970s for the treatment of 
women with advanced breast cancer (Figure 29).73 For the last 30 years, Tamoxifen 
has been administered as an adjuvant therapy following surgery in order to eliminate 
potential metastatic cells, and remains today the treatment of choice for women with 
ERα-positive breast cancer.74 Interestingly, Tamoxifen is rapidly metabolised in the 
body into a principal active metabolite, 4-hydroxytamoxifen (80).75 This phenol 
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derivative exhibits high affinity for ERα, and has been shown to successfully inhibit 
the growth of oestrogen-sensitive and ERα-positive breast cancer tumors.76  
Studies carried out over several years of treatment with Tamoxifen have shown 
reduced annual recurrence rate and mortality.77 However, various dramatic side 
effects have been associated with this treatment, leading to pathologies and death 
related to endometrial and ovarian functions.77,78 Moreover, non-responsive tumors as 
well as resistance to Tamoxifen have been extensively described.66 The majority of 
patients who developed a resistance remained ERα positive, and the use of aromatase 
inhibitors was required in order to efficiently diminish the proliferation of cancer 
cells. This suggests that ERα is involved in the process towards resistance against 
endocrine treatment. The exact mechanism of resistance development remains 
however unclear.70 
Interestingly, positive side effects were also observed upon treatment with 
Tamoxifen, such as an increase of the bone density in postmenopausal women 
(although the opposite side effect had been reported in premenopausal women),79,80 
and a reduction of total cholesterol and low-density lipoproteins, resulting in a 
decrease in cardiovascular deaths following treatment.81,82 
 
Figure 29: Examples of anti-oestrogenic drugs 
Following these observations, several other anti-estrogenic compounds have been 
developed and tested, leading to the approval of new drugs such as Raloxifene (81) 
(Figure 29). A benefit of this compound over Tamoxifen was that in addition to its 
similar beneficial properties, including lipid lowering and bone-protective activities, 
no endometrial cancer was observed as a result of the treatment.83,84 Unfortunately, 
dramatic side-effects such as fatal stroke or venous thromboembolism were 
occasionally observed.85 Moreover, although Raloxifene successfully reduced the 
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incidence of breast cancer, the results of the treatment appeared to be less effective 
than those of Tamoxifen.   
The occurrence of positive and negative side effects throughout the body is an 
indication of the tissue-specific action of these synthetic agents. The term “Selective 
Estrogen Receptor Modulators” (SERMs) was therefore used to describe the 
behaviour of compounds exhibiting antagonist activities in some tissues and agonist 
activities in others.86 
More recently, a new class of steroidal derivatives, such as Fulvestrant (82) (Figure 
29) has been developed. These molecules exhibit no agonistic action, and are 
therefore classified as “pure antagonists”.87 The lack of agonistic effect could be 
explained by a different mechanism of action, in which the binding of Fulvestrant to 
the ER results in a degradation of the receptor.88 This treatment has been used for 
patients who developed resistance towards other endocrine therapies, and its potential 
is still under investigation.89  
As most breast cancers are related to the oestrogen receptor, extensive research has 
been carried out in order to understand this receptor, leading to the discovery of a 
large family of transcription factors, defined as the nuclear receptor superfamily, 
which will be discussed in the following section (1.2). 
 
1.2. Nuclear receptors  
 
1.2.1. General structure 
 
The oestrogen receptor closely resembles other transcription factors such as the 
glucocorticoid receptor, which allowed for a new family to be identified, subsequently 
named nuclear receptors (NRs). Following genome sequencing, 48 transcription 
factors were added to this superfamily.90  
Nuclear receptors are responsible for the regulation of the expression of specific 
target genes that are essential for the control of metabolism, homeostasis, 
differentiation, and development of the organism.91 Most nuclear receptors have 
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known natural ligands regulating their activity. However, some members of the NR 
family remain “orphans” as no natural ligands have yet been identified.92,93 
The NR family is characterised by an evolutionary conserved primary structure, 
composed of two main domains (Figure 30): the DNA-binding domain (DBD) and the 
ligand-binding domain (LBD) (the latter will be the subject of section 1.2.2).94 The 
DBD is highly conserved among NRs and is composed of two zinc-coordinating 
motifs. These two “zinc fingers” bind to specific DNA sequences, which are called 
hormone response elements (HRE).95 This sequence is situated upstream with respect 
to the regulated gene, and the binding of a nuclear receptor onto to HRE triggers the 
recruitment of the transcription machinery. The two main domains are linked via a 
hinge region, which is often involved in the regulation of the transcription through 
binding to the DNA minor groove.96 
On both ends of the primary structure are situated the activation functions (AFs), 
which are largely variable among the different members and play a key role in the 
transcriptional activity of the receptor. AF-1 acts independently from the interaction 
of the LBD with ligands.97 However, AF-2 represents an integral part of the 
ligand-binding domain and as such, possesses an essential regulatory activity through 
the recruitment of cofactors. Its particular structure and function will be discussed in 
the following section (1.2.2). 
 
Figure 30:98 General structure of nuclear hormone receptors 
 
1.2.2. Ligand-binding domain 
 
Although the LDB is highly variable among the different members of the NR family, 
all nuclear receptors possess a similar tertiary structure.99 The LBD consists of a 
series of around 12 α-helices that fold into a three-layer sandwich. In the lower part of 
the LBD, a large hydrophobic cavity represents the binding site for various ligands 
(Figure 31). The binding of ligands causes dramatic allosteric changes at the surface 
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of the receptor, which represent the sites of receptor-cofactor interactions, crucial for 
the activity of the nuclear receptor.100–102  
 
Figure 31:98 Three-layer α-helical sandwich common for the nuclear receptor family, as shown on 
retinoic acid receptor-γ (RARγ) bound to all-trans retinoic acid 
Interestingly the last helical segment on the C-terminal side, which is part of the AF-2 
function, undergoes significant shift in position upon binding of a ligand. This can be 
seen within the crystal structures of ERα bound to either an agonist or an antagonist 
(Figure 32a). As a consequence of the surface modification, the recruitment of 
cofactors is altered: depending on the ligand bound into the hydrophobic pocket, the 
peroxisome proliferator-activated receptor α (PPARα) is able to interact with either a 
co-activator or a co-repressor, SRC-1 and SMRT respectively (Figure 32b). 
The pool of co-regulators through the body is extremely large, with a distribution that 
differs significantly depending on the tissue type, resulting in variable behaviour of 
the transcription factors.103 These proteins interact with the nuclear receptor surface 
via small hydrophobic α-helical sequences. Typically, the presence of a LXXLL 
motif (where L represents leucine and X any amino acid) is required for the binding 
of many co-activators. An agonist will therefore modulate the surface of the receptor 
in order to enhance the interaction with a co-activator.104,105 As for the binding of an 
antagonist, it will either result in the destabilisation of H12, thus disfavouring the 
binding of co-activators, or in the modification of the surface in order to 
accommodate the interaction with a co-repressor.  
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Figure 32:94 Shift of H12 upon binding of a ligand and effect on the interaction with cofactors 
Recently, an orphan nuclear receptor, called liver receptor homolog-1 (LRH-1), has 
been shown to be involved in the development of breast cancer tumors, and could 
potentially be targeted as a new breast cancer therapy.  
 
1.3. LRH-1 in breast cancer 
 
1.3.1. Introduction on LRH-1 
 
In mammals, LRH-1 plays key roles in the expression of genes essential for the 
development, steroidogenesis, lipid and cholesterol absorption, reverse cholesterol 
transport and bile-acid homeostasis.106 The expression of this nuclear receptor is 
highly tissue-specific, taking place mainly in the liver, pancreas and intestine, as well 
as in the ovary, pre-adipocyte and in the placenta, although at lower levels.106  
LRH-1 (NR5A2) is a member of the NR5A subgroup of nuclear receptors, also called 
Ftz-F1 (in reference to the first identified member, Drosophila Fushi factor 1, 
NR5A3). This subfamily comprises four members, NR5A1–NR5A4, and several 
orthologues of LRH-1 have been identified in various species (Figure 33).106 The 
steroidogenic factor-1, SF-1 (NR5A1), is the closest mammalian homologue of 
LRH-1.107 
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Figure 33:106 Phylogenetic tree of the NR5A subfamily of nuclear receptors 
The hallmark of the NR5A subfamily is the presence of the “Ftz-F1 box”, a sequence 
of 26 amino acids situated on the C-terminus of the DNA binding domain (between 
the DBD and the hinge region).108 This sequence plays a key role in the DNA binding, 
as it targets a specific extension of the NR DNA-binding motif. A crystal structure of 
LRH-1 DBD in complex with a duplex DNA sequence revealed that the Ftz-F1 
domains folds into an α-helix that packs against the DBD and influences the 
transcriptional activity of the receptor.109 As such, the members of the NR5A 
subfamily are able to bind as monomers to the DNA consensus site. This specificity 
represents a major difference with the other nuclear receptors, which usually bind to 
the DNA as homo- or hetero-dimers.  
Another particularity of the NR5A family is that although some ligands have recently 
been identified for certain members (which will be discussed in section 1.4), these 
nuclear receptors were originally classified as orphans with no natural ligands. 
Particularly, the crystal structure of mouse LRH-1 solved in 2003 displayed a large 
(~820 Å) but empty hydrophobic pocket (Figure 34).110 The stability of apo-LRH-1 as 
a monomer suggested that LRH-1, as well as other members of the NR5A family, are 
constitutionally active and do not require any ligand for basal activity.106 
q32.11 [8,9]. In mice, in which a LRH-1 pseudogene has
been identified, LRH-1 maps to band E4 of chromosome 1
[14]. The human gene enc ding LRH-1 gives rise to two
bands on a northern blot of 3.8 and 5.2 kb, derived from the
use of two different polyadenylation signals [13]. The region
between these 30 polyadenylation signals contains a repeti-
tiveAUUUAmotif that negatively affectsmRNAstability of
the 5.2-kb transcript. The 5.2-kb transcript is the only form
observed inadult liver [1,9,10],whereasanadditional3.8-kb
transcript is expressed in the hepatoma cell line HepG2 [9].
Figure 1. Liver receptor homolog-1 (LRH-1) and the NR5A subfamily of nuclear receptor ( Rs). (a) Canonical structure of a generic NR (top) and amino acid alignment of
selected members of the NR5A NR subfamily (bottom). The location of the Ftz-F1 box between the C and DE domains and the percentage identity are indicated. Abbrevi-
ation: SF1, steroidogenic factor-1. (b) Phylogenetic tree of the NR5A subgroup of NRs. The complete amino acid sequences of NR5A family members were aligned and phy-
logenetic analyses were carried out using the CLUSTAL X program [83]. GenBank accession numbers of Ftz-F1 members are indicated between brackets: zebrafish LRH-1
(GenBank accession number AAC60274), Xenopus LRH-1 (A56543), chick LRH-1 (O42101), mouse LRH-1 (S27874), rat LRH-1 (NP068510), horse LRH-1 (AAG35649), human
LRH-1 (AAD03155), fr g SF-1 (BAA36789), turtle SF-1 (AAD01975), Taeniopygia guttata SF-1 (AAK97659), chick SF-1 (BAA22839), tammar wallaby SF-1 (AAK94918), human
SF-1 (AAH32501), rat SF-1 (P50569), mouse SF-1 (A40716), horse SF-1 (AAG35648), bovine SF-1 (Q04752), pig SF-1 (AAC64209), orange-spotter grouper ftz-f1 (AAQ72771),
zebrafish ff1b (AAF43283), African catfish ftz-f1b (AAG49005), African catfish ftz-f1a (AAG49004), goldfish ftz-f1 (AAM89250), Tilapia nilotica SF-1 (BAC75890), medaka
NR5A4 (BAA32394), sand shrimp ftz-f1 (AAD41899), yellow-fever mosquito ftz-f1 (AAF83207), fruitfly ftz-f1 (AAA28542), tobacco hornworm bftz-f1 (AAL50351), silk moth
ftz-f1 (BAA01745). Retinoid X receptor a (RXRa) from four different species was used as an outgroup and collapsed for simplification.
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Figure 34:106 Crystal structure of ligand-binding domain of mouse LRH-1 
Interestingly, this crystal structure revealed the presence of an extended rigid helix 2 
(blue), not observed on other nuclear receptors, and thus stabilising helix 12 (green) in 
an active position, which is crucial for the recruitment of cofactors as being part of the 
activation function AF-2. 
 
1.3.2. Recent finding towards breast cancer 
 
The link between LRH-1 and breast cancer was first observed when LRH-1 was 
found to be involved in the expression of aromatase in the ovary, therefore regulating 
the synthesis of oestrogens.111 In breast cancer adipose tissue, LRH-1 regulates the 
expression of aromatase through binding to additional gene promoters.112,113 
It was then found that LRH-1 was expressed in ER-α positive breast cancer cell lines 
and that treatment with oestradiol (E2) induced the expression of LRH-1. 
Furthermore, this regulation was shown to result from the binding of the oestrogen 
receptor to the LRH-1 promoter, demonstrating that LRH-1 is an oestrogen receptor 
target gene.114 
Another implication of LRH-1 in breast cancer was found when it was demonstrated 
that LRH-1 promotes the motility and cell invasion of cancerous cells. Interestingly, 
this process occurs independently of oestrogen sensitivity.115 
been unsuccessful so far, with the exception of one report
suggesting that oxysterols could activate SF-1 [31] – a
finding that could not be confirmed in most cellular
contexts [32]. However, structural and molecular studies
of the LBD of SF-1 and LRH-1 have helped to explain their
constitutive activity. The N-terminal region of the LBD,
including H1, H2 and H3, is conserved among members of
the NR5A subgroup and shares limited sequence simi-
larity with other NR subfamilies. In contrast to ligand-
activated NRs, interaction of this N-terminal region with
the remaining part of the LBD is ligand-independent in
NR5A NRs [33]. Unequivocal evidence that ligands are
dispensable for activity has come from the crystal struc-
ture of the mouse LRH-1 LBD, which shows a stable
monomer with a large, but empty, ligand-binding pocket
[34] (Figure 3). This study showed that, despite the
presence of this large hydrophobic ligand-binding pocket,
activation is probably independent of ligands because
disruption of the size and shape of the cavity by bulky side
chains does not affect LRH-1 activity.
Although these findings do not exclude the existence of
ligands for LRH-1, they do demonstrate that they are
dispensable for basal activity. How can the absence of a
ligand, a coactivator peptide or a dimeric-receptor partner
be compatible with a stabilized active conformation of the
LBD? The crystal structure of the LRH-1 LBD, which
displays features that are strikingly different from other
LBDs, might provide an explanation. The structural
differences involve the NR5A-specific N-terminal region
of the LBD, in which the extended rigid structure of H2
forms an additional fourth layer in the canonical fold of the
receptor LBD. This additional structure confers constitu-
tive activity by stabilizing indirectly (through the exten-
sion of H2) the active position of H12, which contains AF-2
(Figure 3). This was also reflected in the reduced activity
and co-regulator recruitment seen following the mutation
of the conserved arginine (R352E) in H2 of LRH-1, which
destabilized H12 [34]. This finding is consistent with the
partial loss-of-function phenotype observed previously in
an analogous human SF-1 mutant [35], and illustrates an
alternative structural strategy for the stabilization of an
active LBD.
LRH-1 contains an intact and functional AF-2 domain.
This consists of the hexameric motif LLIEML, which is
found in most NRs and is important for stabilization of
coactivator binding. Thus, an AF-2-truncated form of
LRH-1 functions as a dominant negative protein [1,16,36].
In contrast to other NRs, no ligand-independent AF-1
function has been identified in the A/B domain of LRH-1.
Interestingly in SF-1, a potential AF-1 region has been
mapped to a domain spanning the hinge and H1 of the
LBD. This region contains a mitogen-activated protein
kinase (MAPK)-phosphorylation site at S203 [37,38]. SF-1
activation by MAPK phosphorylation involves protein
stabilization [33] and stimulates the recruitment of the
transcriptional intermediary factor 2 (TIF2 or GRIP1)
co-regulator [37]. The corresponding potential MAPK-
phosphorylation site is conserved in the hinge of LRH-1
[33], although its impact on LRH-1 activity is not yet
known. The primary sequence of LRH-1 contains several
potential consensus protein kinase (PK)A- and PKC-
phosphorylation sites, but further studies are required to
determine whether LRH-1 activity is regulated by PKA- or
PKC-signaling pathways.
Co-regulators of LRH-1
Although it seems that the binding of coactivators,
through their LXXLL motif, to the LBD of SF-1 and
LRH-1 is ligand-independent in vitro, binding affinities
are generally lower compared with ligand-dependent NRs
[34,37]. LRH-1 interacts with members of the p160
coactivator family – SRC-1 [39] and SRC-3 [40] – and
Figure 3. 3D structure of the ligand-binding domain (LBD) of mouse liver receptor homolog-1 (LRH-1). Helix (H) 12, the position of which determines the active state of a
nuclear receptor, is highlighted in green. The extended NR5A-specific H2 (blue) provides an a ditional layer to the canonical LBD fold and stabilizes the active position of
H12 in the LRH-1 crystal structure. The empty ligand-binding pocket is shown in gray. Figure based on the data from Sablin et al. [34]. Views from two opposite angles (a,b)
are shown.
(a) (b)
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Finally, recent developments have shown that in breast cancer, LRH-1 regulates the 
expression of the oestrogen receptor.116 It was found that LRH-1 and ER are 
co-expressed in breast cancer cell lines and that the tumor growth is inhibited when 
LRH-1 is knock-down. Furthermore, it was demonstrated that LRH-1 directly binds to 
the ER gene promoter, thus regulating its expression. 
Taken together, these results show that in breast cancer cell lines, LRH-1 and ER 
function as a positive cross-regulatory loop, responsible for a sustained oestrogen 
supply and signalling. Considering the problems encountered with anti-oestrogen 
therapies, such as the development of resistance and the occurrence of undesirable 
side effects, LRH-1 appears to be an interesting target for the development of a new 
form of therapy for breast cancer.116  
 
1.4. Structure and regulation of human LRH-1 
 
In the last decade, the orphan character of LRH-1 had to be reconsidered. Although 
crystal structures of mouse LRH-1 revealed an empty pocket and an activating 
function (AF-2) in an active conformation, suggesting a ligand-dependent activity, 
natural ligands were found in the binding pocket of the human homologue of LRH-1 
after crystallisation.  
 
1.4.1. General structure of human LRH-1 
 
The first mention of the presence of a ligand bound to hLRH-1 was in a 2005 
publication.117 Figure 35 depicts the superposition of mouse and human LRH-1. Both 
proteins display high similarity, with the same tertiary structure composed of 12 
α-helices arranged in a 3-layer sandwich. Helix 2 (in red for hLRH-1), adding a 
fourth layer and providing stability for AF-2, displays the highest degree of variation 
among the two homologues. 
 
89 
 
Figure 35:117 Crystal structures of hLRH-1 LBD (orange) superposed with mLRH-1 (yellow) 
The striking difference with mouse LRH-1 was that additional electron density was 
found in the ligand binding pocket, which was consistent with the presence of a bound 
molecule (in blue). Further characterisation allowed for the assignment of this 
compound as a phosphatidyl glycerol (PG). 
 
1.4.2. Nature of LRH-1 ligands 
 
Simultaneously, another group reported a crystal structure of hLRH-1 bound to a 
phospholipid.118 In this case, the ligand was found to be a phosphatidylglycerol-
phosphoglycerol, with a palmitic ester (C16:0) linked to C1 of the glycerol backbone 
and palmitoleic ester (C16:1, Δ9) on C2 (Figure 36). 
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(a)  
(b)   
Figure 36:118 (a) Phospholipid bound in the hLRH-1 binding pocket. (b) Phosphatidylglycerol-
phosphoglycerol (C16:0/C16:1, Δ9) ligand 
This structure reveals that the ligand-binding domain is able to accommodate both 
side chains of the ligand, and the bend caused by the cis-alkene allows for the 
palmitoleic chain to pack around the linear palmitic ester, filling almost entirely the 
space in pocket. The binding mode is further stabilised by extensive Van de Waals 
interactions with the hydrophobic residues within the pocket, in particular with the 
AF-2 helix, thus stabilising it in an active conformation. As for the phosphate head of 
the ligand, its position is anchored through hydrogen-bond interactions with residues 
at the mouth of the pocket.  
The presence of co-purified bacterial phospholipids could however be fortuitous. MS 
analysis revealed the presence of a range of phosphatidylglycerols with various 
degrees of saturation and length between 14 and 18 carbons. Interestingly, mutations 
of residues within the pocket affected the binding of phospholipids and resulted in 
reduced transcriptional activity.119  
 
OO
O
P O
O
O- O
OH
O
O
P O
O
O- OH
OH
 
91 
1.4.3. Interaction with cofactors 
 
The ligand-regulated character of LRH-1 was further confirmed by the publication of 
a third crystal structure in the same year.120 It had previously been established that an 
atypical co-repressor, the small heterodimer partner (SHP), was able to efficiently 
repress the activity of LRH-1. As such, the crystal structure of hLRH-1 in complex 
with the SHP NR box motif was solved (Figure 37). Similarly to the previous two 
structures, it was found that various bacterial phospholipids were present within the 
ligand-binding pocket.  
 
Figure 37:120 Crystal structure of hLRH-1 LDB in complex with SHP NR box (in red) 
The binding of the SHP motif differs from that observed with other nuclear receptors, 
and explains the selectivity of LRH-1 for the cofactors SHP, DAX-1 and PGC-1α. 
Indeed, these co-factors all display a NR box that slightly differs from common 
co-factors, and they use this recognition motif to bind onto the groove created at the 
surface of LRH-1 via the activation function.121 This atypical selectivity results in a 
down-regulation of the transcriptional activity of LRH-1 in tissues where SHP and 
DAX-1 are expressed. Unfortunately, the ability to recruit the co-activator PGC-1α 
has a dramatic effect in breast cancer as it results in the expression of aromatase and 
subsequent oestrogen synthesis, responsible for maintaining the tumor growth.   
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1.4.4. Regulatory role of phospholipids 
 
These results together suggested that phospholipids may play the crucial role of 
regulating the activity of LRH-1 by affecting the recruitment of cofactors. In the 
search of potent agonists of LRH-1, dilauroyl phosphatidylcholine (DLPC) was found 
to selectively activate LRH-1-mediated transcription by increasing the recruitment of 
co-activators (Figure 38).122 As such, treatment of diabetic mice with DLPC resulted 
in a decrease of the serum lipid and blood glucose levels, and this effect was proven 
to be completely dependent on LRH-1.122 Furthermore, it was shown that the length 
of the acyl chain is important for the selectivity. Indeed, DLPC is able to displace 
phospholipids with longer chains from the LRH-1 ligand-binding pocket, whereas the 
other screened phospholipids cannot.122 
 
Figure 38: Dilauroyl phosphatidylcholine ligand 
Following these observations, the crystal structures of both apo hLRH-1 and hLRH-1 
in complex with DLPC were published in 2012.123 Organic solvents were used to 
denature phospholipid-bound LRH-1 in order to eliminate the bacterial phospholipid, 
followed by refolding to generate ligand-free LRH-1. Treatment of apo LRH-1 with 
various lipids revealed that the recruitment of cofactors is greatly dependent on the 
size of the phospholipid chains, with medium chains being activating, whereas longer 
chains are not.  
In the absence of a ligand, a large sequence of residues (397–421) appeared to be 
completely disordered, as can be seen within the crystal structure of apo LRH-1, in 
which they are represented as a dashed line (Figure 39a). Interestingly, the 
superposition of the surface of apo LRH-1 with the ribbons of DLPC-bound LRH-1 
revealed that this sequence includes helix 6 as well as both β-strands (Figure 39b). 
This new region was therefore shown to be critical for the regulation of the receptor 
andg modulated by the presence or absence of a ligand in the binding pocket. 
Moreover, the absence of ligand allows for the receptor to interact with more typical 
co-repressors such as SMRT. 
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(a) (b)  
Figure 39:123 (a) Crystal structure of apo LRH-1 and (b) molecular surface of apo LRH-1 (grey) 
superposed with residues 398–420 (pink) of DLCP-bound LRH-1 
Although following its discovery LRH-1 was thought to be an orphan receptor, 
extended research has since then been carried out, resulting in the identification of 
phospholipid-driven regulation. These results, together with the recent discovery of its 
ability to greatly modify its surface upon ligand binding, resulting in the recruitment 
of an array of cofactors, confirms the potential of LRH-1 as a therapeutic target.  
 
1.5. Synthetic ligands of LRH-1 
 
1.5.1. Whitby compounds 
 
The first synthetic agents reported to have an activity against LRH-1 were published 
in 2006.124 Compound 83 (GSK8470) was identified as a potent agonist of LRH-1, 
increasing the recruitment of co-activator TIF2 in a FRET-based assay (EC50 = 
430 nM) (Figure 40). In vivo, this agonist efficiently increased the expression of an 
LRH-1 target gene, SHP. Compound 83 also exhibited agonistic activity on SF-1 
(EC50 = 54 nM) for the recruitment of DAX-1. Interestingly, Whitby et al. showed 
that the selectivity of this bicyclic compound for LRH-1 over SF-1 could be tuned 
through modifications of the phenyl and alkyl substituents.  
The major drawback of this class of compounds, however, is their instability under 
acidic conditions. Recently, the crystal structure of compound 83 in complex with 
LRH-1 was published, revealing that the hydrophobic pocket contracts around the 
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bicyclic compound, narrowing the mouth of the pocket.125 The most flexible segments 
of the protein are helix 3 (in yellow) and the β-turn/helix 6 region (in orange), situated 
at the entrance of binding site, whereas the inner part of the pocket remains 
unchanged compared with the phospholipid-bound structure (Figure 40). 
 
Figure 40:125 1st generation of Whitby compounds and crystal structure of LRH-1 in complex with 83 
(white) superposed with phospholipid-LRH-1 complex (magenta, yellow and orange) 
Interestingly, no polar interactions with the ligand were created within the pocket, 
suggesting that the acid-labile aniline moiety could be replaced with a more stable 
functional group. Furthermore, polar residues were observed in close proximity to 
compound 83, suggesting that the incorporation of polar substituents around the 
molecular framework could act to both improve the binding affinity, and 
simultaneously decrease the hydrophobicity of the compound. Following the design 
of several classes of bicyclic compounds, molecule 84 appeared as an ideal candidate 
for further exploration of the biological target (Figure 41). Displaying an increased 
stability and solubility over the 1st generation of agonists, compound 84 possesses a 
higher affinity for both LRH-1 and SF-1 (pEC50 = 6.6 & 7.5 respectively). Selectivity 
over one of the nuclear receptors was achieved through variation of the substituents 
and/or the bicyclic skeleton. 
 
Figure 41: 2nd generation of Whitby compounds 
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1.5.2. Hodder compounds 
 
In 2008, the first synthetic inhibitors of a member of the NR5A subfamily were 
reported.126 Following a high-throughput screening in a cell-based assay, compound 
85 was found to be a potent antagonist of SF-1, with an IC50 value of 260 nM (Figure 
42). Whereas the high-throughput screening assay was using a chimeric SF-1 
construct, a second cell-based assay using full-length SF-1 displayed an even higher 
IC50 value of 16 nM. Furthermore, additional assays showed that compound 85 
presents good to excellent selectivity for SF-1 against ROR-α and LRH-1.  
In lieu of these encouraging results, a synthetic route to compound 85 was developed, 
allowing access to a library of analogues. Among them, compound 86 appeared to 
have a higher potency, with an IC50 of 200 nM in the chimeric assay, in addition to 
complete selectivity against other nuclear receptors such as ROR-α, and no cell 
toxicity. 
 
Figure 42: Examples of inhibitors of SF-1 
 
1.5.3. Griffin compounds 
 
The first mention of a molecule capable of antagonising the effect of LRH-1 was 
published in an online database of molecular library screening.127 The most active 
compound, linear scaffold 87, was found to have an IC50 of 320 nM in a reporter 
assay, with a 31-fold selectivity over SF-1 (Figure 43). This compound therefore 
represents an interesting probe in order to investigate the potential of LRH-1 as a 
therapeutic target. 
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Figure 43: Structure of the most active Griffin compound against LRH-1 
 
1.5.4. Fletterick compounds 
 
Recently, a novel class of inhibitors of LRH-1 has been published.128 A high-
throughput screening of 5.2 million compounds was carried out via molecular 
docking, using a model of the LRH-1 ligand-binding domain in an antagonised 
conformation. By comparison with the oestrogen receptor, it was observed that H12 
gets displaced upon binding of an antagonist. A similar model was therefore 
generated for LRH-1 and used for the docking experiments. Upon in silico refinement 
of the top-ranking molecules, three compounds were selected for biological 
assessment. All of them were shown to directly bind to LRH-1, shifting the melting 
temperature downwards as a result of the destabilisation of the ligand-binding pocket. 
Interestingly, compound 88 was able to decrease the interactions of LRH-1 with 
co-regulators, and as a consequence, also inhibited the transcriptional activity of 
LRH-1 in a cell-based assay (Figure 44). Moreover, high selectivity was observed 
with this compound, as it had no effect on the transactivation of other nuclear 
receptors such as SF-1.  
Following these encouraging results, analogues of initial hit 88 were screened, leading 
to the identification of compound 89. Similarly to the initial hit, this molecule 
displays a high binding affinity towards LRH-1, a good inhibition of the 
transcriptional activity in cell-based assays, as well as a large selectivity for LRH-1. 
Finally, both 88 and 89 were proven to inhibit the proliferation of LRH-1-positive 
cancer cells.  
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Figure 44: The two most active compounds published as the first inhibitors of LRH-1 
 
1.6. Recent developments at Imperial College 
 
1.6.1. Biological assays 
 
In order to investigate potential inhibitors of LRH-1, it is important to carry out 
cell-based assays, which possess the complete machinery required for gene 
expression. The expression of the target gene has to be monitored and quantified, 
which led to the development of reporter assays. The use of luciferase-based assay 
has been extensively developed: this enzyme triggers the production of light via 
bioluminescence. It works by catalysing the conversion of luciferin (90) into 
oxyluciferin (91) (Figure 45).129 The product of this reaction is released in an excited 
state, which upon emission of a photon, returns to its ground state.  
 
Figure 45: Luciferase enzymatic reaction 
The principle of a reporter assay is to attach the regulatory sequence, or upstream 
activating sequence (UAS), of the gene of interest to a reporter gene, in this case 
luciferase (blue, Figure 46).130 The transcription factor that is being studied, for 
example LRH-1 (red), will therefore bind selectively to the regulatory sequence 
through its DNA-binding domain, and trigger the expression of the reporter gene via 
recruitment of the transcription machinery (green). The presence of ligands will cause 
allosteric changes to the ligand-binding domain and alter the recruitment of cofactors, 
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and consequently impacts the transcription. The measure of the level of luciferase 
being expressed is therefore a direct indication of the effect of a ligand on the 
transcriptional activity of the nuclear receptor.  
 
Figure 46: Principle of the reporter gene assay 
As mentioned previously, a pool of cofactors exists in vivo, and also varies depending 
on the tissue type. The reporter assay works by using any cofactor available in the 
specific type of cells used for the experiment. However, it is not possible with this 
assay to observe the interaction with one particular cofactor.  
To this end, another type of cell-based assay had been developed: the mammalian 
two-hybrid assay (Figure 47).131 This assay allows the study of the interaction 
between LRH-1 and the co-activator PGC1-α, which is essential in the development 
of breast cancer. It is based on the principle that, for the regulation to take place, both 
the DNA-binding domain and the ligand-binding domain require to be in close 
proximity, however not necessarily attached to each other.132 In this case, the 
transcription faction Gal4 (orange) is used to regulate the expression of the luciferase 
reporter gene. Two hybrid constructs have been engineered: the Gal4 DNA-binding 
domain has been attached to the LRH-1 ligand-binding domain (red); and PGC1-α 
(purple) has been attached to the Gal4 activating domain (AD). The interaction 
between LRH-1 and PGC1-α is therefore required for the transcription to occur, via 
recruitment of the activation complex. As previously, the addition of a ligand of LRH-
1 will enable or disable the interaction between the two constructs, which could be 
quantified by the level of luciferase being produced. 
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Figure 47: Principle of the mammalian two-hybrid assay 
Similar assays have been reported in the literature,126,127 and the ability to carry out 
both assays in our laboratory, in order to study the biological activity of synthetic 
molecules, is an attractive feature for the project. 
 
1.6.2. Design and synthesis of novel analogues 
 
Collaborations have been made within several groups at Imperial College towards the 
discovery of new classes of LRH-1 inhibitors. Three series of compounds were 
designed through computational modelling techniques, taking known ligands or 
inhibitors of distinct nuclear receptors as molecular frameworks. The first series of 
compounds was derived from ER inhibitor Tamoxifen (79), which is known to induce 
a steric clash upon binding into the oestrogen receptor pocket, resulting in the 
displacement of helix 12. Following this principle, the core structure of Tamoxifen 
was docked into the LRH-1 ligand-binding domain, and the molecule was extended in 
the direction of helix 12.133 As such, Tamoxifen analogues 92a-c, and compound 93, 
bearing a bulkier tertiary amino side chain, were designed and synthesised (Figure 
48). Unfortunately, the tetra-substituted alkene moiety present in compounds 92a-c 
and 93 acted to destabilise this series of compounds, generally resulting in their 
isomerisation. Thus, a fifth analogue 94 was synthesised, in which the alkene moiety 
was replaced with a cyclopropane, proposed to have greater stability, yet still 
comprise of similar structural rigidity as per the originally designed analogues. 
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Regrettably, the acute low solubility of this new class of Tamoxifen derivatives in 
polar solvents rendered assessment of their biological activity impossible. 
 
Figure 48: Tamoxifen series of analogues 
The development of a second series of LRH-1 inhibitor analogues was thus 
undertaken, and initiated with the docking of a steroid derivative (MFA-1, depicted as 
the black core, Figure 49), which is a known agonist of another nuclear receptor, the 
farnesoid X receptor. Following the same principle as previously, displacement of 
helix 12 was achieved in silico through the addition of a para-substituted benzyl or 
aryl ether substituents on the A ring of the steroidal core (depicted in blue, Figure 49), 
resulting in the design and synthesis of the series of analogues 95a,b and 96a,b.134 
The binding affinity of these compounds was unfortunately not as high as predicted, 
and cell-based assays showed low inhibition of LRH-1, again rendering this series of 
compounds ineligible for further investigation.  
 
Figure 49: Steroidal series of analogues 
Finally, a third series of compounds, based on anti-oestrogen agent Raloxifene (81), 
were synthesised, which gratifyingly gave rise to more encouraging results. Docking 
experiments revealed analogue 97, possessing a side chain (depicted in blue, Figure 
50) positioned in the chemical space normally occupied by helix 12, as a potential 
LRH-1 inhibitor. Biological evaluation of Raloxifene derivative 97 demonstrated 
promising LRH-1 inhibitory activity in the low µM range. Due to the considerable 
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size of this compound, analogues of lower molecular weight (compounds 98a,b) were 
sought after. In these cases, substituents in the meta position of the southern side 
chain engendered similar steric hindrance towards helix 12 as for compound 97. 
Although this modification resulted in an overall decrease of the antagonist activity of 
compounds 98a,b, when compared to initial analogue 97, this series of compounds 
certainly represents an interesting achievement in the search of LRH-1 antagonists. 
 
Figure 50: Raloxifene series of analogues 
One further approach towards LRH-1 inhibition was to focus on the protein-protein 
interaction between LRH-1 and various cofactors. α-Helix mimetic scaffolds are 
interesting targets as they have the ability to efficiently bind onto the surface of 
LRH-1, therefore disrupting the recruitment of co-activators such as PGC-1α. As 
such, computational modelling was undertaken with the aim of identifying a chemical 
scaffold that would overlay with an α-helix (Figure 51a), and display several residues 
of the helix in the same orientation (Figure 51b).135 This led to the design and 
synthesis of bicyclic compound 99 (Figure 51c), bearing five substituents that could 
be modified in order to accommodate the desired substituents, mimicking the targeted 
α-Helix. However, no inhibition data have been reported yet. 
 
Figure 51:135 Design of a scaffold for α-helix mimetics: (a) α-helix with residues i, i+1, i+2, i+4 and 
i+5, (b) design of a scaffold (orange) that overlays with the α-helix, (c) structure of scaffold 99 
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1.6.3. Resorcylates as potential antagonists 
 
In an attempt to identify new inhibitors of LRH-1, screening of a range of molecules 
previously synthesised within our laboratory for the various other projects was 
undertaken. Interestingly, a few resorcylate derivatives exhibited some antagonist 
activity against LRH-1 (Figure 52). 
 
Figure 52: The three most active compounds of the resorcylate series 
The three most active compounds were thus further tested in both the reporter and 
mammalian-two hybrid assays (Figure 53). In these cases, BHPIII116 (100) was 
shown to be the least active compound, displaying inhibition slightly below 40% at 
25 µM concentration in both assays. This result is nonetheless highly interesting due 
to the compound’s small molecular weight. BHP170 (101) and BHP329 (102) gave 
similar profiles, with BHP329 being the most potent inhibitor, and displaying an 
inhibition of 80% at 25 µM.  
 
Figure 53: Biological assessment of the resorcylate series. Percentage of LRH-1 activity (vertical axis) 
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The resorcylate framework has been extensively developed and published within our 
laboratory (Figure 54). The resorcylate core 103 (depicted in blue) could be accessed 
via deprotection of isopropylidene 104, initially derived by cyclisation and 
aromatisation of a derivative of ketodioxinone 105. The dioxinone moiety was 
primarily used to protect β-ketoesters in the biomimetic synthesis of resorcylate 
natural products.136 Several synthetic routes have since been developed giving access 
to resorcylate derivatives with alternative substitution patterns, in particular at the C-5 
position, as in BHPIII116 (100), or at the C-6 position for the two other analogues, 
BHP170 (101) and BHP329 (102). 
 
Figure 54: Resorcylate core 103 and ketodioxinone 105 
The reported synthesis of the C-6 substituted resorcylate derivatives began with 
ketodioxinone 105, which was acylated with Weinreb amide 106 (Figure 55).137 The 
resulting diketoester 107 subsequently underwent an aromatisation-cyclisation 
sequence under basic conditions, yielding protected resorcylate core 108. Finally, 
deprotection in basic methanol afforded the desired resorcylate esters 101 and 102.  
 
Figure 55: Patel’s synthesis of C-6 resorcylates 101 and 102137 
Similarly, the published synthesis of C-5 derivative 100 began with the acylation of 
dioxinone 109 with acyl imidazole 110 (Figure 56).138 The resulting ketodioxinone 
111 was then regioselectively deprotonated and treated with ethyl formate to afford 
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enol 112. Under basic conditions, the cyclisation-aromatisation sequence afforded 
protected resorcylate 100.  
 
Figure 56: Patel’s synthesis of C-5 resorcylate 100138 
Following the encouraging biological results of compounds 100, 101 and 102, several 
analogues of the initial hit compounds were synthesised in the laboratory. However, 
small structural changes did not lead to significant alteration of their biological 
activity, thus a concrete structure-activity relationship could not be derived (data not 
shown). It was instead rationalised that the addition of more substantial substitutions 
on the core structure of the resorcylate compounds could perhaps give more definite 
results.  
 
1.7. Aim of the project 
 
The design of novel small synthetic inhibitors of LRH-1 remains therefore an 
attractive target. The aim of this project was to continue the work initiated in our 
laboratory through the exploration of resorcylate derivatives as putative inhibitors of 
LRH-1. 
Several classes of molecules were subsequently designed and synthesised. Firstly, 
small structural modifications were investigated in order to gain some information 
about the structure-activity relationship of the initial resorcylate derivatives 100-102, 
including the synthesis of dehydroxylated resorcylates (section 2.1) and analogues of 
sulfonamide 101 substituted at the C-5 position as on compound 100 (section 2.2). 
Secondly, the synthesis of larger molecules was undertaken, based on the idea of 
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obtaining hybrid molecules, designed by linking two small active compounds 
(sections 2.3 and 2.4). Finally, N-resorcylates were designed and synthesised in order 
to investigate the influence of a change in the electron density around the resorcylate 
ring (section 2.5). 
 
2. RESULTS AND DISCUSSION 
 
2.1. Dehydroxylated resorcylates 
 
2.1.1. Retrosyntheses 
 
In order to investigate the role of the hydroxy groups on the resorcylate core in the 
biological activity of resorcylate BHP170 (101), two analogues, each lacking one of 
the alcohol groups, were selected for synthesis. 4-Hydroxybenzoic acid derivative 113 
could be synthesised by bromine displacement on intermediate 114 with the desired 
sulfonamide (Scheme 32). Compound 114 could be obtained by benzylic bromination 
of commercially available 4-methoxy-2-methylbenzoic acid (115).139 
 
Scheme 32: Retrosynthesis of the 4-hydroxybenzoic acid derivative 113 
As for the synthesis of the 2-hydroxybenzoic acid analogue 116, the targeted salicylic 
acid derivative could be obtained by directed lithiation and quenching with methyl 
chloroformate starting from intermediate 117, which would derive from 
3-methoxybenzylamine (118) (Scheme 33).140 In the event that the lithiation step 
could not be performed on sulfonamide 117, then dimethylamino analogue 119 could 
be used as a substrate for the lithiation, affording intermediate 120, which could then 
be converted easily into the desired sulfonamide 116. 
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Scheme 33: Retrosynthesis of the 2-hydroxybenzoic acid derivative 116 
 
2.1.2.  4-Hydroxybenzoic acid derivative 
 
As part of the synthesis of 4-hydroxybenzoic derivative 113, sulfonamide 121 was 
obtained by reaction of methylamine with benzene sulfonylchloride (122) (Scheme 
34). The reaction was slow due to the low solubility of the amine hydrochloride salt, 
but nevertheless afforded the desired sulfonamide 121 with a yield of 87% after a 
reaction time of 48 h. 
As for the functionalisation of the 4-hydroxybenzoate core, benzoic acid derivative 
115 was esterified through the intermediacy of the acid chloride to give methyl ester 
123 (Scheme 34). Free radical bromination afforded the desired benzylic bromo 
intermediate 114 with a yield of 78%. Although all the starting material was 
consumed during the course of the reaction, traces of aromatic bromination products 
were observed by 1H NMR of the crude mixture, which could explain the moderate 
yield. Displacement of the benzylic bromine with previously synthesised sulfonamide 
121 yielded the desired functionalised core 124 after 4 h at room temperature.  
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Scheme 34: Synthesis of 4-hydroxybenzoic acid analogue 113 
The final step was the deprotection of the methyl ether, which was first attempted 
using boron tribromide.141 The reaction gave one single product, which was not the 
one expected, but lactam 125, resulting from the cleavage of the sulfonamide moiety 
and cyclisation of the amine onto the ester group. Interestingly the methyl ether 
protecting group was still in place. Piras and co-workers have reported lithium 
chloride in refluxing DMF to be efficient for the cleavage of activated alkyl aryl ether 
bearing electron-withdrawing groups in the ortho or para position.142 These 
conditions were applied for the deprotection of methyl ether 124, affording the 
desired free phenol 113 with a yield of 66%. 
 
2.1.3.  2-Hydroxybenzoic acid derivative 
 
The synthesis of directed ortho-metalation substrate 117 started with the sulfonylation 
of benzylamine 118 (Scheme 35). N-Alkylation of the resulting sulfonamide 126 
afforded methylsulfonamide intermediate 117. Ortho-lithiation was then attempted on 
substrate 117, using n-butyl lithium to selectively deprotonate the position in ortho to 
both substituents.140 However, using these conditions, only starting material was 
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recovered after the reaction was quenched by addition of methyl chloroformate and 
the formation of product 127 was not observed. Using 2 equivalents of n-BuLi instead 
of 1 equivalent resulted in the formation of by-products, which could not be isolated 
and identified. Using a different electrophile (dimethylcarbonate or deuterated 
methanol) only gave starting material. These observations indicated that intermediate 
117, bearing a sulfonamide moiety as a directing group, might not be a suitable 
substrate for directed ortho-lithiation. 
 
Scheme 35: Attempted directed ortho-metalation on substrate 117 
A better substrate for directed ortho-metalation might be benzylic dimethylamine 119, 
as reported by Rapoport and co-workers (Scheme 36).140 The dimethylamine 
functional group could potentially be converted to the desired sulfonyl group via 
chloro intermediate 128.  
Starting from 3-hydroxybenzaldehyde (129), alkylation of the hydroxy group to form 
methyl ether 130, followed by reductive amination with dimethylamine afforded 
tertiary amine 119 (Scheme 36). Directed ortho-lithiation of substrate 119 was 
attempted in the same conditions as previously described, but no product was 
observed. Deuterated methanol was used as an electrophile in a test reaction but no 
deuterium incorporation was observed. Using diethyl ether as a solvent instead of 
THF did not favour the formation of the product, neither did the use of TMEDA as a 
chelating agent. When different electrophiles were used (benzaldehyde or CO2), a 
mixture of inseparable by-products was recovered, but no desired products (cf. 120) 
were observed. 
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Scheme 36: Attempted directed ortho-metalation on substrate 119 
Following the difficulties encountered with the deprotonation of 1,3-disubtituted 
aromatic substrates, a different strategy was considered. Following the work of 
Snieckus and co-workers,143 the desired 1,2,3-substitution pattern could be obtained 
from acylation of amide 131 (Scheme 37). Amide 131 was synthesised in high yield 
from o-anisic acid (132) via the corresponding acyl chloride. Directed ortho-lithiation 
on substrate 131 using sec-butyl lithium, followed by trapping of the resulting 
lithiated species with DMF, afforded the desired aldehyde 133 with a yield of 85%. 
Diethyl amide 133 was then converted to the corresponding methyl ester 134 
following a literature procedure.144 
The next step was the conversion of the aldehyde into the required sulfonamide 
moiety. Reductive amination with sulfonamides has only been described starting from 
primary sulfonamides and using two equivalents of base because of the weakly basic 
character of this functional group.145 Reductive amination with benzenesulfonamide 
was therefore carried out on aldehyde 134 affording secondary sulfonamide 135. It 
was found, however, that intermediate 135 decomposed rapidly and yields higher than 
21% could not be obtained. Due to its low stability, reductive amination product 135 
was used directly after purification in the subsequent alkylation reaction, affording 
methyl sulfonamide 127. The last step that remained in order to access the desired 
2-hydroxybenzoic acid analogue 116 was the deprotection of the methoxy group. 
Unfortunately, this deprotection could not be achieved on substrate 127. The use of 
boron tribromide led to decomposition as previously observed on the 
4-hydroxybenzoic substrate 124. Similarly, the use of lithium chloride in DMF 
resulted in complete decomposition of the starting material 127 upon heating at 60 °C, 
whereas at lower temperatures no reaction took place. The difficulties in obtaining 
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free phenol 116 did not however have dramatic consequences. Indeed, previous 
biological results indicated that the presence of a methyl on one of the hydroxy 
groups of hit compound BHP170 (101) did not induce a dramatic change in the 
biological activity of the tested analogues (data not shown). 
 
Scheme 37: Synthesis of protected 2-hydroxybenzoic acid derivative 127 
 
2.1.4. Biological assessment 
 
Two dehydroxylated resorcylate analogues were therefore submitted for biological 
testing: free phenol 113 and methoxy derivative 127 (Figure 57). 
 
Figure 57: Dehydroxy-resorcylate series 
Compounds were tested in both reporter and mammalian two-hybrid assays (Figure 
58). Interestingly, in both assays, the tested compounds lost some inhibitory activity 
in comparison to the initial hit compound, BHP170 (101). These results suggest that 
the resorcylate core, with its two hydroxy groups, is required for maximal activity, 
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although in the second case, the presence of the methoxy might alter the binding of 
this analogue. Further work would be to test these compounds in both assays at 
various concentration points to obtain an accurate IC50, as well as in other cell-based 
assays such as tumour growth inhibition assay, which would give more information 
about the in vitro activity of these novel compounds.  
 
Figure 58: Biological assessment of the dehydroxy-resorcylate series 
 
2.2. C-5 substituted resorcylates 
 
2.2.1. Retrosynthesis 
 
Analogues 136 could be interesting molecules to test against LRH-1 (Scheme 38). 
They contain the same benzylic sulfonamide as initial hit BHP170 (101) but are 
substituted on the C-5 position, similar to the other initial hit BHP116 (100). Such 
compounds could be synthesised following the methodology developed in our 
laboratory.138 Aromatic compound 136 would result from the cyclisation and 
dehydration of intermediate 137. This intermediate would be the formylation product 
of the ketodioxinone derivative obtained by acylation between dioxinone 109 and 
carboxylic acid 138. Two analogues, with a linker of either one or two carbon atoms, 
were selected for synthesis. 
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Scheme 38: Retrosynthesis of C-5 substituted resorcylate analogues 136 
 
2.2.2. Synthesis of ketodioxinones and attempt of formylation-cyclisation 
 
The synthesis of the C-5 substituted analogues started with the sulfonylation of amino 
acids 139a,b (Scheme 39). Due to the low solubility of these zwitterionic compounds 
in organic solvents, a biphasic mixture of 1,4-dioxane and water was used as the 
solvent and the desired sulfonamides 140a,b were obtained with reasonable yields. 
The subsequent step was the methylation of the sulfonamide moiety. This could not 
be achieved selectively as the carboxylic acid was esterified at the same rate, even 
when using strictly one equivalent of alkylating agent. Therefore, it was decided that 
both functional groups would be alkylated and that the resulting ester would 
subsequently be hydrolysed. The 2-step process afforded the desired acids 138a,b 
with high yields. The resulting acids 138 were converted to the corresponding acyl 
chlorides 141a,b, then directly reacted with deprotonated dioxinone 109. The reaction 
afforded the desired ketodioxinone 142a and 142b with yields of 36 and 49% 
respectively. The low yield for 142a can be explained by the formation a gel during 
the conversion of the carboxylic acid into the corresponding acyl chloride, which 
could not be efficiently transferred by cannula and resulted in a loss of material.  
The final reaction to afford the targeted C-5 substituted resorcylates 136 was the 
formylation-aromatisation sequence developed in our laboratory.138 The first step 
consisted in reacting the dianion of ketodioxinones 142 with ethyl formate. If 
successful, this reaction would afford formylated intermediates 137. When these 
conditions were applied on analogue 142b, bearing a 2-carbon linker between the 
sulfonamide and the ketone moiety, a new component was observed by TLC analysis 
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just above the baseline, which is characteristic of the presence of the formylated 
product 137b. The 1H NMR spectrum of this intermediate displayed a complex 
mixture of products and the presence the desired formylated product could not be 
confirmed. Because of the instability of this intermediate, the crude mixture, 
following work-up, was directly used in the next step. Cyclisation of putative 
formylated dioxinone 137b was trialled under basic conditions. However, after 
isolation of the crude mixture, 1H NMR indicated the presence of a mixture of 
by-products, including some of the starting material 142b. Although HRMS of the 
crude mixture showed the presence of the desired product 136b, it was not possible to 
isolate and identify any product after column chromatography. The only significant 
fraction that could be isolated was starting material 142b. As for substrate 142a, when 
the same reaction conditions were applied, no characteristic component could be seen 
by TLC analysis, and no indication of the formation of product 136a was found by 
either 1H NMR or HRMS. As previously, only starting material 142a was isolated 
from the complex mixture of by-products isolated at the end of the reaction. 
 
Scheme 39: Attempted synthesis of C-5 substituted resorcylate analogues 136 
Increasing the reaction time (40 min between each addition and 5 h after the addition 
of ethyl formate), the number of equivalents (4.4 eq. of LDA, diethylzinc and ethyl 
formate instead of 2.2 eq.) and temperature (raised to −30 °C after the addition of 
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ethyl formate), did not result in the formation of the desired product and the 
impossibility of isolating and characterising intermediate 137 made the reaction 
difficult to monitor and understand. Furthermore, these conditions were developed on 
substrates bearing fully carbonated substituents and the presence of the sulfonamide 
moiety might alter the regioselectivity of the deprotection and/or formylation steps. It 
was therefore decided to discontinue working on these analogues, until further 
progress is made on the methodology of this reaction. 
 
2.3. C-16 steroidal resorcylates  
 
2.3.1. Rational for the design of hybrid molecules 
 
As mentioned previously, small modifications around the resorcylate hit compounds 
failed to induce a large increase in the inhibitory activity of the newly synthesised 
compounds. The fact the LRH-1 binding pocket was large, flexible, and that little 
structural data was available about this nuclear receptor, made the design of new 
molecules difficult. It was believed that in order to gain more activity, larger 
structural changes had to be made.  
The idea of hybrid molecules as ligands for biological targets has been described in 
the literature on a few occasions. Large libraries of hybrids molecules designed by 
adding the side chain of anticancer agent taxol onto biologically active molecules 
such as discodermolide or dictyostatin have been synthesised and shown to have some 
anticancer activity, such as the work of Paterson and co-workers146 or Horwitz and 
co-workers.147 Similarly, Lee and co-workers have reported the synthesis of 
conjugates of taxol with various anticancer compounds, and interestingly these 
conjugates exhibits unique antitumor activities.148 They hypothesised that this strategy 
could increase the potency of the drug and at the same time decrease the development 
of resistance relative to administration of a component drug alone. Finally, this 
strategy has been used by some companies, such as Palumed S. A., in which case the 
development of hybrid molecules was used to overcome the resistance of antimalarial 
drugs.149 The principle of this project was to link two pharmacophores interacting 
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with the same biological target, and this dual mode of action was therefore defined as 
a “double-head sword”.  
 
2.3.2. Retrosynthesis 
 
As such, it was hypothesised that it would be interesting to synthesise hybrid 
molecules comprising the resorcylate core attached to some natural ligands of most 
nuclear receptors, such as steroids. A few examples were selected for synthesis, with 
the aim of developing a methodology to access these structures, which could then be 
further developed in the event of these hybrid molecules displaying interesting 
biological activity. 
One interesting compound would be hybrid 143, derived from oestrone (144), upon 
which the resorcylate core is attached via the carbon-16 of the steroid skeleton 
(Scheme 40). The resorcylate moiety could be installed via the aromatisation 
sequence developed in our laboratory, starting from diketodioxinone derivative 145. 
This compound would be obtained by acylation of ketodioxinone 105 with an 
activated acid derived from ester 146. Finally, ester 146 would be synthesised by 
carboxylation of commercially available oestrone (144). 
 
Scheme 40: Retrosynthesis for C-16 steroidal hybrid 143 
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2.3.3. Synthesis of TES ether 155 
 
The synthesis of targeted hybrid 143 started with the protection of the hydroxy group 
of oestrone (144) to afford TBS ether 147 (Scheme 41). Unfortunately, when 
submitted to the conditions for the acylation in order to install the desired ester group 
on C-16, the TBS group was shown to be unstable and the desired product 146 was 
obtained as an inseparable mixture of by-products, such as deprotected product 148 
and starting materials 147 and 144. 
 
Scheme 41: Attempted acylation of TBS-protected substrate 147 
It was therefore decided to replace the TBS protecting group with a benzyl group, 
which was more likely to be stable under the required acylation conditions, as 
described in the literature, affording benzyl ether 149 (Scheme 42).150 
Benzyl-protected oestrone 149 was subsequently acylated to afford β-ketoester 150 as 
a mixture of diastereoisomers (ratio 7 : 3), which could not be separated by 
chromatography.  The assignment of the stereochemistry as well as the separation of 
the two isomers were not useful at this step because isomerisation had been reported 
during the subsequent hydrolysis step.150  
Prior to hydrolysis, protection of ketone 150 as the corresponding dioxolane 
derivative 151 was attempted. However, no suitable procedure was found to access 
the desired ketal 151. The different conditions that were used to attempt the protection 
of ketone 150 are summarised in Table 12. Dean-Stark conditions led to 
decomposition of starting ketone 150 (entry 1),151 whereas milder conditions such as 
using oxalic acid in acetonitrile at room temperature did not yield any product 
(entry 2).152 The use of tetrabutylammonium tribromide has been previously used to 
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protect hindered or unreactive ketones, however, no reaction was observed when 
these conditions were applied to substrate 150 (entry 3).153 Finally, the conditions 
described by Noyori using highly reactive bis(trimethylsiloxy)ethane and TMS triflate 
did not yield any product either (entry 4).154  
 
Scheme 42: Attempted protection of β-ketoester 150 
Entry Conditions Outcome 
1 HO(CH2)2OH, p-TsOH, PhMe, Δ Decomposition  
2 HO(CH2)2OH, (CO2H)2, MgSO4, MeCN, rt No reaction 
3 HO(CH2)2OH, HC(OMe)3, TBABr3, CH2Cl2, rt No reaction 
4 TMSO(CH2)2OTMS, TMSOTf, CH2Cl2, –78 °C No reaction 
Table 12: Attempted ketal protection of ketone 150 
Since the protection of ketone 150 as an acetal could not be performed, it was decided 
to reduce the carbonyl group and protect the resulting alcohol. Reduction of ketone 
150 with sodium borohydride, with complete face selectivity for the carbonyl group, 
gave a mixture of the syn and anti diastereoisomers 152a and 152b respectively, 
which were separable by column chromatography (Scheme 43). The data matched the 
literature, in which comparing the 1H NMR coupling constants for the two 
diastereoisomers with published NMR data allowed for the assignment of the 
stereochemistry.155 Protection of the alcohol was first attempted using TBSCl, but the 
large size of this protecting group and the steric hindrance of the neopentyl alcohol 
152 resulted in an extremely low reaction rate (5% conversion after 2 days). Using the 
less bulky TESCl as a reagent instead afforded the desired protected alcohols 153a 
and 153b with high yields.  
The next step was the hydrolysis of esters 153a and 153b to the corresponding 
carboxylic acids 154a,b. Initially, the syn diastereoisomer 153a was used in trial 
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reactions (Table 13). No reaction was observed when using lithium hydroxide in a 
mixture of THF and water, probably due to a lack of solubility (entry 1). Using 
methanol and water solved the solubility issue, however, under these conditions, the 
only reaction that took place was the deprotection of the TES group, with 
epimerisation of the centre α to the ester to give a mixture of alcohols 152a and 152b 
(entry 2). Potassium trimethylsilanolate has been described in the literature as a mild 
reagent for the hydrolysis of esters.156 When applied to the syn diastereoisomer 153a, 
a small amount of the acid was isolated, but some epimerisation of the centre α to the 
ester was observed (entry 3). Another reagent described to avoid epimerisation was 
trimethyltin hydroxide157 but when used on substrate 153a, formation of the desired 
acid was not observed (entry 4), even when using a large excess of the reagent 
(entry 5). Finally, since Me3SiOK was the only reagent found that was able to 
hydrolyse ester 153, and as the anti diastereoisomer was the thermodynamic product, 
these conditions were applied to the anti ester 153b. When using 1.2 equivalents of 
the reagent, a low yield of 31% was obtained, due to incomplete conversion (entry 6). 
Using 8 equivalents pushed the reaction to completion and the desired carboxylic acid 
154b was obtained with a yield of 62%, with the loss of material attributed to the low 
solubility of the carboxylic acid during the work-up procedure (entry 7). 
 
Scheme 43: Synthesis of TES-protected intermediate 153 and optimisation of hydrolysis conditions 
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Entry Substrate Conditions Product Yield 
1 153a: syn LiOH, THF / water - - 
2 153a: syn LiOH, MeOH / water 152a + 152b - 
3 153a: syn Me3SiOK (1.2 eq.), THF, rt 154b: anti 20% 
4 153a: syn Me3SnOH (1.2 eq.), DCE, 80 °C - - 
5 153a: syn Me3SnOH (10.0 eq.), DCE, 80 °C - - 
6 153b: anti Me3SiOK (1.2 eq.), THF, rt 154b: anti 31% 
7 153b: anti Me3SiOK (8.0 eq.), THF, rt 154b: anti 62% 
Table 13: Optimisation of the hydrolysis conditions of esters 153a and 153b 
The acylation-aromatisation sequence was then attempted starting from acid 154b, 
which was activated as the corresponding carbonyl imidazolide 155. The reaction, 
which was usually complete in less than 2 h on other substrates developed in our 
laboratory,158 required 12 h to go to completion. This observation indicated that steric 
hindrance on this carbonyl resulted in a slower reaction rate. Imidazole 155 was 
purified by column chromatography prior to the acylation step, in which it was 
reacted with the dianion of ketodioxinone 105. As previously, the acylation step was 
difficult to follow by TLC analysis because several components were observed. 
1H NMR of the crude mixture revealed the presence of multiple by-products or 
tautomers, but no evidence of the formation of compound 156 could be found. 
Moreover, it was found that the TES group did not survive these conditions as the 
integration for the peaks corresponding to the TES group accounted for less than half 
of the other peaks of the steroid (such as the benzyl methylene protons). As it has 
previously been shown in our laboratory that purification of the diketodioxinone at 
this stage was not required, the crude mixture was submitted to the aromatisation 
conditions. After column chromatography, multiple by-products were isolated, but the 
trace amount and low purity of these entities made all characterisation impossible, and 
there was no indication of the formation of the desired product 157. One explanation 
for the failure of this reaction could be the presence of a free hydroxy group due to the 
deprotection of the silyl ether. It was therefore decided to replace the silyl ether with a 
more stable protecting group. 
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Scheme 44: Attempted acylation-aromatisation sequence on TES-protected intermediate 155 
 
2.3.4. Synthesis of diketodioxinone 161 
 
As such, the large amount of the syn ester 153a, which was previously synthesised 
and which was not reactive towards hydrolysis, was deprotected with TBAF (Scheme 
45). Interestingly, under these conditions, all the material was epimerised to the anti 
diastereoisomer 152b. It was previously shown that the installation of a TBS group 
failed under mild conditions using TBSCl and imidazole. A more reactive TBS source 
could be produced by the use of TBSOTf and 2,6-lutidine,159 and using these 
conditions finally gave the desired TBS protected alcohol 158. Hydrolysis of the 
methyl ester with Bu3SiOK afforded the desired carboxylic acid 159, which was 
activated with carbonyldiimidazole to afford imidazolide 160. This reaction required 
18 h to go to completion, indicating that steric hindrance around this carbonyl was 
even greater than on the TES-protected analogue 154. The acylation step was carried 
out by reacting the dianion of ketodioxinone 105 with acyl imidazolide 160. In this 
case, TLC analysis revealed the presence of a major component. Surprisingly, this 
component could be purified by column chromatography, and diketodioxinone 161 
was obtained with a reasonable yield. This was an unusual observation, as it had 
previously been shown in our laboratory that purification on silica gel of 
diketodioxinones led to cyclisation to isopropylidene-protected resorcylates. 
Unfortunately, attempted cyclisation of intermediate 161 under basic conditions did 
not give any of the desired product 162, even after an extended reaction time (up to 
three days) or upon heating (up to 80 °C in a sealed tube). Instead, starting material 
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161 was recovered when the reaction was carried out at room temperature, and 
decomposition occurred at higher temperatures. Although we were able to isolate 
diketodioxinone 161, it seemed that its stability was responsible for the failure of the 
cyclisation attempt.  
 
Scheme 45: Synthesis of TBS-protected diketodioxinone 161 and attempted cyclisation 
It was considered that a way to favour the cyclisation was to open the dioxinone upon 
heating and to trap the resulting ketene with methanol (Scheme 46). This procedure 
led to the formation of triketoester 163 as expected, which was isolated. TLC analysis 
showed the presence of a single component, HRMS confirmed the presence of the 
product, and although the 1H NMR spectrum showed multiple resonances due to 
different tautomeric forms, the disappearance of the isopropylidene peak and the 
presence of methyl ester peak at δ = 3.80 ppm were consistent with the formation of 
product 163.  
Unfortunately, attempts to cyclise triketoester 163 into the desired resorcylate 164 
were unsuccessful, under all of the conditions previously developed in our laboratory 
(Table 14).136,160 Different bases were employed in order to induce the cyclisation, 
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followed by acidification, but these resulted in decomposition of the starting material 
163 (entries 1, 2 & 3): upon the treatment of triketoester 163 under basic conditions, 
TLC analysis revealed that no component was moving above the base line even in 
highly polar eluents, and subsequent acidification did not trigger the formation of new 
components. Milder conditions include the use of silica gel to induce the cyclisation 
and aromatisation of triketoesters, unfortunately no reaction occurred when applying 
these conditions on substrate 163 (entry 4). Finally, when heating a solution of 
triketoester 163 in toluene, either with molecular sieves or in Dean-Stark apparatus in 
order to remove the water produced in the aromatisation step, the starting material 
163 decomposed to a mixture of by-products. Although some new components were 
observed by TLC analysis, the 1H NMR of the crude mixture did not display any new 
aromatic protons, and it was not possible to isolate any compound after column 
chromatography.  
 
Scheme 46: Synthesis of triketoester 163 and attempted cyclisation 
Entry Conditions 
1 Et3N, CH2Cl2, rt 
2 1. KOH, MeOH, 2. HCl, MeOH 
3 1. Cs2CO3, 2. 1 N HCl 
4 Silica gel, CH2Cl2, rt or 60 ºC  
5 PhMe, 4Å MS, 110 ºC, sealed tube 
6 PhMe, 110 ºC, Dean-Stark 
Table 14: Conditions attempted for the cyclisation-aromatisation of triketoester 163 
Although the synthesis of diketoester 161 was successful, subsequent cyclisation 
could not be achieved, which was potentially a consequence of the steric hindrance 
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caused by the steroidal core. The attempted synthesis of steroidal resorcylate 143 was 
therefore discontinued.  
 
2.4. C-21 steroidal resorcylates 
 
2.4.1. General structure of C-21 steroidal resorcylates 
 
Corticosteroids are a class of steroids bearing a hydroxyacetyl side chain on carbon-
17 of the steroidal core. The hydroxy group at the end of this side chain could 
therefore represent a handle to link the steroidal core to a resorcylate moiety. A 
general structure of the compounds that could be synthesised as potential inhibitors of 
LRH-1 is shown in Figure 59. 
 
Figure 59: General structure of the targeted C-21 steroidal resorcylates 
This would represent a new class of steroidal hybrids, based on an idea similar to the 
design of the C-16 hybrids (see section 2.3.1). Furthermore, the potentially labile 
character of the ester bond used to link the two parts of the molecules could result in 
the hybrid compound acting as a prodrug. This concept has been extensively used in 
drug discovery in order to tune the properties of a given drug, such as increasing the 
bioavailability or reducing the toxicity of the active entity.161 As such, the synthesis of 
both the potentially labile ester and the amide derivatives could be interesting in order 
to study the activity of this new class of steroidal hybrids. 
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2.4.2. Synthesis of steroidal resorcylates esters via coupling reactions 
 
In a first attempt to synthesise steroidal resorcylate esters 165a,b, classical peptide 
coupling conditions were used starting from either corticosterone (166a) or 
hydrocortisone (166b) and coupling them with resorcylic acid derivative 167 (Scheme 
47). However, no product was observed under these conditions. The steric hindrance 
around carboxylic acid 167 could explain the lack of reactivity, and it was therefore 
decided to firstly activate acid 167 as an acyl chloride, and subsequently react it with 
steroidal alcohols 166a and 166b. Unfortunately, in this case again no product was 
formed and decomposition occurred.  
 
Scheme 47: Attempted synthesis of steroidal resorcylates 165a,b 
A Mitsunobu reaction was next considered to form ester 165a,b (Scheme 48). Using 
one equivalent of triphenylphosphine and diethyl azodicarboxylate afforded the 
desired products 165a,b in low to reasonable yields. In an attempt to improve the 
yield, an excess of reagent was used, however it only resulted in the formation of 
more by-products and the use of a stoichiometric amount of reagents appeared to be 
the best alternative. The deprotection of both methoxy groups was then attempted in 
order to obtain the fully deprotected resorcylate 168a,b. Unfortunately, 
decomposition was observed using either boron tribromide or lithium chloride in 
DMF, as previously described (see Section 2.1.3). Resorcylates 166a and 166b were 
therefore submitted for testing as di-methoxy derivatives. 
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Scheme 48: Synthesis of steroidal resorcylates 165a,b and attempted deprotection 
 
2.4.3. Synthesis of steroidal resorcylates esters via ketene-trapping 
 
Another approach was considered to synthesise fully deprotected resorcylate ester 
168b, based on methodology developed in our laboratory (Scheme 49). Resorcylate 
ester 168b would be obtained via opening of diketodioxinone 169 and trapping of the 
resulting ketene with hydrocortisone (166b).162 Recent developments in our 
laboratory showed that diketodioxinone 169 could be accessed in high yield and 
purity from benzyl ester 170, via a regioselective acylation and subsequent 
hydrogenolysis-decarboxylation sequence. Finally, ketoester 170 could be synthesised 
starting from dioxinone 109, which could be acylated with the acid derived from 
Meldrum’s acid (171). 
 
Scheme 49: Retrosynthesis for C-21 steroidal resorcylate 168b 
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The synthesis towards steroidal resorcylate 168b started with Meldrum’s acid (171), 
which was treated with benzyl alcohol in refluxing toluene, to afford carboxylic acid 
172 (Scheme 50). Acid 172 was then converted to the corresponding acid chloride 
173 and directly reacted with deprotonated dioxinone 109, to afford ketoester 170. 
Acylation with acetyl chloride, using pyridine and magnesium chloride selectively 
afforded regioisomer 174.163 The advantage of this route compared to the previously 
reported route162 was the possibility of obtaining intermediate 174 in high yield and 
purity, as it was stable towards chromatography. Hydrogenolysis of the benzyl group 
lead to in situ decarboxylation affording the desired diketodioxinone 169, with 
sufficient purity after filtration through celite. The ketene trapping reaction was then 
attempted under classical conditions, which require heating both starting materials in 
toluene to generate the ketene. However, hydrocortisone was not soluble in toluene, 
and as soon as the solvent reached its boiling point, a precipitate formed in the 
reaction mixture. After collection of the precipitate, 1H NMR showed multiple by-
products but the presence of the desired triketoester 175 could not be confirmed. The 
following step was the cyclisation-aromatisation sequence, which required treatment 
of residue 175 under basic conditions followed by acidification, but no traces of the 
desired cyclised product 168b could be found, using either 1H NMR or HRMS. TLC 
analysis revealed the presence of both starting materials in solution in the reaction 
solvent after filtration of the precipitate. However further heating of the filtrate 
mixture followed by subjection to the same cyclisation and aromatisation conditions, 
did not result in the formation of the desired product 168b. 
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Scheme 50: Attempted ketene trapping with hydrocortisone (166b) 
One important factor for ketene trapping reactions is the solubility of the nucleophile, 
and the fact that the starting alcohol 166b was not soluble under the trialled 
conditions might be an issue. Different solvents were therefore considered, such as 
acetonitrile or ethyl acetate. In both cases, hydrocortisone (166b) was soluble and the 
ketene trapping reaction was carried out in a sealed tube at 110 ºC for 1 h. 
Unfortunately, a precipitate formed after 5 min, as previously observed in toluene, 
exhibiting a similar 1H NMR and no cyclised product could be observed. 
Following the failed attempt of ketene trapping using hydrocortisone (166b), it was 
thought that the presence of the tertiary alcohol might be responsible for the 
occurrence of side-reactions. It was therefore decided to use corticosterone (166a) as 
a nucleophile instead (Scheme 51). As previously, diketodioxinone 169 was 
synthesised from benzylic ester 174 and used directly in the ketene opening-trapping 
step. The reaction did not go to completion, as it seemed that at high temperatures, 
part of the starting steroid 166a decomposed and the presence of triketoester 176 
could not be proved. Following evaporation of the solvent, and subsequent treatment 
with base and finally acidification, a main component could be observed by TLC 
analysis. The desired resorcylate ester 168a was isolated in low yield after column 
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chromatography. This low yield could be explained by the presence of multiple 
by products, the necessity to carry out two consecutive chromatography purifications 
due to the presence of impurities with similar polarities, and the low solubility of the 
product in organic solvents such as diethyl ether or dichloromethane, resulting in the 
loss of material during the extraction and purification procedures.  
 
Scheme 51: Ketene trapping with corticosterone (166a) 
 
2.4.4. Synthesis of analogues of BHP170 and BHP329 via ketene-
trapping 
 
Two additional molecules 177a and 177b were selected for synthesis using the 
ketene-trapping methodology: these would be analogues of BHP170 (101) and 
BHP329 (102), bearing a methylene-sulfonamide substituent at the C-6 position of the 
resorcylate core (Scheme 52).   
The synthesis started with the sulfonylation of sarcosine (178) with aromatic sulfonyl 
chlorides under aqueous basic conditions, to afford sulfonamides 179a and 179b. The 
resulting carboxylic acids were then activated as the corresponding acid chlorides 
180a,b and used directly in the acylation step. Following a previously described 
procedure, ketoester 170 was deprotonated regioselectively using pyridine and 
magnesium chloride, and subsequently reacted with acid chlorides 180a or 180b. 
When the reaction was previously carried out using acetyl chloride as the electrophile 
(see Section 2.4.3), all of the starting material was consumed and the product could be 
purified by column chromatography to separate it from minor impurities. However in 
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this case, the reaction did not go to completion and a significant amount of 
by-products were formed in both cases. High-resolution mass spectrometry indicated 
that enols 181a and 181b might have been formed. 1H NMR analysis was complex 
because of the presence of both keto and enol forms, as well as potential rotamers. 
Variable temperature 1H NMR showed slight difference in shifts, however on the 
available temperature range – a temperature higher than 50 °C would lead to the 
opening of the ketene – no significant merging of the peaks happened, which would 
have been required in order to fully characterise intermediates 181a and 181b. 
Unfortunately, chromatographic purification of these intermediates could not be 
undertaken due to streaking on silica, resulting in loss of material and decomposition. 
No product was recovered after column in both cases. The only entity that could be 
isolated in significant amounts was an impure fraction containing the protected 
resorcylate resulting from the cyclisation of compound 181a or 181b, as could be 
seen by 1H NMR and HRMS. 
It was then decided to use intermediate 181 directly in the next step without 
purification. Hydrogenolysis and in situ decarboxylation was carried out on both 181a 
and 181b, but at this stage again it was not possible to characterise diketodioxinones 
182a and 182b by 1H NMR, although a single component was observed when 
following the reaction by TLC analysis. The crude ketodioxinones 182 were then 
reacted with hydrocortisone (166a) in refluxing toluene. This step created multiple 
by-products, as could be observed by TLC analysis. When treated under basic 
conditions, most components on TLC remained unchanged, whereas the desired 
triketoester 183 should have moved down to the baseline at this stage. After 
acidification, it was difficult to see whether a new entity had formed, and several 
attempts of chromatographic purifications were not successful in isolating any 
product with new aromatic protons corresponding to 177a and 177b. 
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Scheme 52: Attempted synthesis of steroidal resorcylates 177a,b 
 
Although this methodology has been proven to be reproducible on substrates bearing 
fully carbonated substituents, the presence of the sulfonamide moiety in addition to 
the poor stability of the steroidal nucleophile have a dramatic effect on the course of 
reaction and the formation of the desired products could not be observed. The 
presence of multiple by-products and the impossibility to purify the intermediates of a 
three-step sequence resulted in difficulties for the understanding and optimisation of 
this reaction.  
 
2.4.5. Synthesis of steroidal resorcylate amide 
 
Finally, due to the fact that an ester bond might be labile under the assay conditions, it 
was decided to synthesise an amide derivative of the C-21 esters series. Amide 184, 
on which the primary hydroxy group of hydrocortisone (166b) was replaced with an 
amine, was therefore selected for synthesis (Scheme 53). 
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The synthesis of target amide 184 started with the selective formation of primary 
mesylate 185, which was displaced with sodium azide to afford azide derivative 186 
in good yields. Reduction of azide 186 has been reported with zinc powder and 
ammonium chloride,164 and using these conditions afforded the desired amine 187. 
This α-amino ketone was not stable after a couple of hours, and was therefore used 
directly in the subsequent step. Peptide coupling with 2,4-dimethoxy-6-methylbenzoic 
acid (167) afforded amide 188. Deprotection with boron tribromide in an attempt to 
obtain deprotected resorcylate 184 led to decomposition, therefore amide 188 was 
submitted for biological assessment as its di-methoxy derivative. 
 
Scheme 53: Synthesis of steroidal resorcylate amide 188 
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2.4.6. Biological assessment 
 
Ultimately, four steroid-resorcylate hybrid compounds were synthesised (Figure 60). 
 
Figure 60: Structures of synthesised C-21 steroidal resorcylate analogues 
These compounds were tested in both cell-based assays developed in the laboratory 
(Figure 61). In each assay, BHP329 (102) is routinely used as a positive control. In 
addition, because of the potential labile character of the ester bond, both parts of the 
hybrid compounds, the steroid and the resorcylic acid, were tested in the assay (data 
not shown). Interestingly, neither of them showed any activity on LRH-1. 
The reporter assay indicated some agonistic activity of compounds 165a, 165b and 
168a, with the expression of luciferase being increased up to 300% at a 25 µM 
concentration for analogue 165a. However, this activating behaviour was not 
observed in the mammalian two-hybrid assay, where no activity was found, apart 
from compound 168a, which shows a slight inhibition.  
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Figure 61: Biological assessment of the C-21 steroidal resorcylate series 
The dual behaviour of the series of compounds in the two different assays is once 
again an indication that the mechanism of regulation of LRH-1 is more complex than 
expected. Although the design of a potent inhibitor of LRH-1 was not achieved with 
this series, these hybrid compounds remain interesting analogues and will be tested in 
various biological assays on LRH-1 as well as on other nuclear receptor targets.  
 
2.5. N-Resorcylates 
 
2.5.1. Retrosynthesis for N-resorcylates derivatives 
 
It would be interesting to modulate the electron density of the resorcylate ring by 
introducing heteroatoms in the ring. As such, three N-resorcylate derivatives were 
considered: pyridines 189a and 189b as well as pyrimidine 189c (Scheme 54). A few 
syntheses for these types of heteroaromatic systems, bearing an alkyl substituent on 
C-6, have been described in the literature. The first analogue, 3-N-resorcylate 189a, 
could be obtained via cyclisation of cyanoacetamide (190) with β-ketoester 191.165 As 
for the 3-N-resorcylate 189b, it could be synthesised by reaction of activated malonate 
192 (Ar = 2,4,6-trichlorophenyl) with enamine 193.166 The same enamine could be 
0%	  50%	  
100%	  150%	  
200%	  250%	  
300%	  350%	  
reporter	  LRH-­‐1	  Luc	  
0%	  20%	  
40%	  60%	  
80%	  100%	  
120%	  140%	  
160%	   M2H	  LRH-­‐1/PGC1-­‐a	  
0.1µM	  1µM	  10µM	  25µM	  
 
134 
treated with methyl isocyanatoformate (194) to access the third analogue, pyrimidine 
189c.167 Finally, enamine 193, used for the synthesis of both N-resorcylates 189b and 
189c, could be derived from the same β-ketoester 191 used in the synthesis of 
N-resorcylate 189a, upon treatment with ammonium acetate. 
 
Scheme 54: Retrosynthesis for N-resorcylate derivatives, X = N(Me)SO2Ar, N3 
 
2.5.2. Synthesis of β-ketoester 191 
In order to access these three analogues, the synthesis of β-ketoester 191 was 
attempted (Scheme 55). The first step was to synthesise methylsulfonamide 191a 
(X = N(Me)SO2Ar) from sulfonylation of methylamine. The required sulfonyl 
chloride was available from several chemical suppliers, but it was found that this 
starting material was extremely reactive and got rapidly hydrolysed to sulfonic acid 
195. Sulfonic acid 195 was therefore treated with oxalyl chloride in order to 
synthesise the desired sulfonyl chloride in situ, and subsequent reaction with 
methylamine in solution in methanol afforded the desired sulfonamide 196 in high 
yields. The next step was the alkylation of sulfonamide 196 with commercially 
available methyl 4-chloroacetoacetate (197). Several conditions were trialled and are 
summarised in Table 15 (entries 1 to 4). Sulfonamide 196 was however not 
nucleophilic enough in order to react with chloro derivative 197, and in every case the 
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sulfonamide was recovered at the end of the reaction. As for β-ketoester 197, its high 
reactivity led to decomposition, as can by seen by TLC analysis with the formation of 
fluorescent components, and the impossibility to isolate these entities after 
purification by chromatography. 
 
Scheme 55: Attempted synthesis of β-ketoester 191a via N-alkylation 
Entry Conditions 
1 NaH, THF or DMF 
2 THF or DMF, rt or heating 
3 NaI, DMF, rt or heating 
4 Cs2CO3, NaI, DMF, rt or heating 
Table 15: Attempt of alkylation of sulfonamide 196 
In order to overcome the stability issue of chloro derivative 197, it was chosen to 
follow the methodology developed by Carreira and co-workers, in which Birch 
reduction product 198 could be used as a masking group for β-ketoester 191a, which 
could then be revealed by ozonolysis after functionalisation into the required 
sulfonamide (Scheme 56).168  
 
Scheme 56: Retrosynthesis for the masking of β-ketoester 191a as unconjugated diene 198 
The extended literature on the Birch reduction indicates that a benzylic substituent is 
likely to be reduced before the aromatic system. However, one paper reported this 
reaction on a methylenedioxyphenyl derivative, giving 70% of the desired diene – the 
doubly reduced product being isolated in 15%.169 A Birch reduction was therefore 
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attempted on 3-methoxybenzyl alcohol (199) under the conditions described in the 
literature, using a large excess of sodium (Scheme 57). However, the product that was 
isolated in high yield after this reaction was not the expected benzylic alcohol 198, 
but diene 200, on which over reduction of the benzylic alcohol occurred. With diene 
200 in hand, radical halogenation was attempted to investigate whether the 
regioselectivity of this reaction would allow for the functionalisation of the methyl 
substituent through bromide derivative 201. Unfortunately, this reaction led to a 
mixture of multiple by-products and substrate 200 could therefore not be used in the 
synthesis of targeted β-ketoester 191a. 
 
Scheme 57: Birch reduction of 3-methoxybenzyl alcohol (199) 
In an attempt to understand why this reaction was successful on the substrate 
described in the literature, it was thought that the presence of a protected hydroxy 
group in para of the benzylic alcohol was making the benzylic position more 
electron-rich and consequently less reactive than the aromatic ring towards a Birch 
reduction. As such, a new substrate was designed for the Birch reduction to afford a 
masked ketoester: carboxylic acid 202 was reduced to the corresponding alcohol to 
afford new substrate 203 (Scheme 58). The Birch reduction was carried out under 
milder conditions, using lithium instead of sodium and in lower amount 
(1.5 equivalents instead of 6). However, the reaction was not selective towards the 
formation of the desired diene 204. Instead, a mixture of products, which mainly 
contained the dehydroxylated product, could be seen by 1H NMR after a short 
reaction time of 5 min, indicating that on this substrate as well the dehydroxylation 
was faster than reduction of the aromatic system.  
 
Scheme 58: Attempted Birch reduction of benzyl alcohol 203 
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It was therefore decided to employ a different strategy to access the desired diene 
moiety. Symmetrical diene 205 could be an interesting compound, masking two 
molecules of β-ketoesters (Scheme 59). Following the esterification of succinic acid 
(206) under acidic conditions170 to afford dimethyl succinate (207), a double 
condensation gave dihydroxy derivative 208 as described by Christoffers and 
co workers.171 The di-methylation of diol 208 could not be undertaken due to poor 
stability of the desired product 205 (Table 16): indeed, no product could be isolated 
upon treatment of diol 208 with either sodium hydride or caesium carbonate 
(entries 1 & 2), and in the case of potassium tert-butoxide, a white solid was isolated 
at the end of the reaction but no characterisation could be conducted as the solid 
rapidly decomposed into a black residue.  
 
Scheme 59: Attempted synthesis of protected 1,4-cyclohexadiene 205 
Entry Conditions Outcome 
1 NaH, MeI, THF, 0 ºC  No product isolated 
2 Cs2CO3, MeI, THF, rt No product isolated 
3 t-BuOK, Me2SO4, DMSO, 0 ºC to rt 
Decomposition of product after 
isolation 
Table 16: Attempted methylation of diol 208 
Following the failed attempts in synthesising unconjugated dienes, a new strategy was 
considered: dioxinone derivative 209 could be used as a masking group for 
β-ketoester 191a (Scheme 60). Following a literature procedure,172 allylic 
bromination of dioxinone 109 afforded bromo derivative 210. The bromine atom was 
subsequently displaced with previously synthesised N-methylsulfonamide 196 to 
afford substituted dioxinone 209. Finally, treatment of dioxinone 209 with methanol 
in refluxing toluene revealed β-ketoester 191a with an overall yield of 45%. With the 
desired β-ketoester 191a in hand, the cyclisation with cyanoacetamide (190) in order 
to obtain lactam 211 was attempted following a procedure described in the literature 
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on a substrate lacking the sulfonamide moiety.166 Unfortunately, when compound 
191a was treated under basic, decomposition of starting β-ketoester 191a was 
observed: the reaction mixture turned into a dark slurry and TLC analysis revealed 
that all of the β-ketoester was converted into components that were retained on the 
baseline after a short reaction time of 10 min. 
 
Scheme 60: Synthesis of β-ketoester 191a and attempted cyclisation 
In order to trial the cyclisation on a slightly different system, azide derivative 191b 
(X = N3) was synthesised from 4-chloroacetoacetate (197) (Scheme 61). The result of 
the attempted cyclisation into lactam 212 was similar to the previous case when using 
sulfonamide 191a: no material was isolated at the end of the reaction, and the 
decomposition appeared to be faster than with the sulfonamide substrate: azide 191b 
decomposed into an insoluble residue after 5 min, which could therefore not be 
characterised.  
 
Scheme 61: Synthesis of β-ketoester 191b and attempted cyclisation 
 
2.5.3. Synthesis and reactivity of 3-N-resorcylate 
 
The presence of an electron-withdrawing group α to the carbonyl could explain the 
poor stability of both β-ketoester 191a and 191b under basic conditions and indicate 
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methyl-substituted pyridine derivative 213 was carried out following a reported 
procedure starting from methyl acetoacetate (214) and cyanoacetamide (190).166 
NMR analysis as well as infrared spectroscopy were consistent with the presence of 
the amide form of compound 213.  
 
Scheme 62: Synthesis of pyridine 213 
A few reactions were attempted on unprotected lactam 213 (Scheme 63). Radical 
bromination in order to functionalise the methyl substituent to afford bromide 
derivative 215 only led to decomposition, which was likely due to the lack of 
solubility of lactam 213. In parallel, as the nitrile group would have to be converted 
into the corresponding methyl ester, another approach was to carry out the required 
functional group manipulation at this stage. Firstly, attempt to hydrolyse nitrile 213 
into the corresponding carboxylic acid 216 was carried out using aqueous sulfuric 
acid, but afforded an inseparable mixture of the desired acid 216 and the 
decarboxylated compound. Direct conversion of nitrile 213 into methyl ether 217 was 
also attempted using a 6 M HCl solution in methanol, but none of the desired product 
217 could be isolated, once again likely due to solubility issues.  
It was therefore decided to protect both hydroxy groups of diol 213, as this would 
likely increase the solubility of the substrate and favour its reactivity toward the 
subsequent reactions. It was firstly decided to protect lactam 213 as di-triethylsilyl 
ether 218, but this reaction proved to be difficult. After several attempts giving 
extremely low yields, it was found that di-ether 218 could be synthesised but was not 
stable: 2-D TLC experiments showed decomposition of the product, and after an 
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decomposition process was lowered with the absence of light, it was still not possible 
to fully characterise compound 218. Considering the fact that the protecting groups 
would be retained for the subsequent steps, an alternative strategy that will render this 
molecule more stable was therefore required. 
 
Scheme 63: Attempted reactions on pyridine 213 
In the literature, there was only one example of protection of diphenol 213, into the 
corresponding bis-methylether.173 Interestingly, this compound was used for its 
particularly reactive alkene between the cyano group and the methyl ether: due the 
presence of both electron-withdrawing and electron-donating groups on both sides of 
the alkene, the latter becomes extremely reactive towards [2+2] photocycloaddition in 
the presence of UV light. Although the authors reacted this methylated compound 
with another alkene, they noticed the poor stability of the substrate due to 
dimerisation. This finding could give an explanation for our observations on di-TES 
ether 218: a silyl ether group could act as an electron-donating substituent and 
activate the alkene towards cycloaddition, which was increased by the presence of 
light. The formation of an insoluble residue and the fact that the solution was 
becoming bright red under the trialled conditions could be explained by the 
dimerisation followed by decomposition of the putative product 218.  
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carried out in an amber flask, as some decomposition was observed with light over 
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NMR spectra, both acetate groups displayed similar chemical shifts, and IR 
spectroscopy showed a broad band at 1775 cm-1, which was consistent with the 
presence of two ester groups.  
Finally, due to the necessity to functionalise the benzylic position in the subsequent 
steps, an acetyl protecting group would not be compatible with the required reaction 
conditions. It was therefore decided to synthesise pivaloyl 219b instead. With the 
addition of a more hindered group, the yield for the formation of pivaloyl 219b was 
even lower than with the acetate group, but could not be increased by varying the 
reaction conditions, such as using more reactive pivaloyl chloride, decreasing the 
concentration in order to increase the amount of solubilised starting material (from 
0.10 to 0.01 M) or replacing the solvent with THF or acetonitrile. 
 
Scheme 64: Protection of pyridine 213 as a diester 
With protected N-resorcylate 219b in hand, conversion of the nitrile group into the 
required carboxylic acid derivative was attempted (Scheme 65). Multiple conditions 
were trialled in order to access a variety of acyl derivatives and are summarised in 
Table 17 below. Unfortunately, the conversion into any of these derivatives was 
unsuccessful.  
 
Scheme 65: Attempted conversions of aromatic nitrile 219b into carboxylic acid derivative 220 
Acidic conditions (entries 1 to 3) led to the deprotection of the pivaloyl groups, even 
when a stoichiometric amount of HCl was generated in situ from TMSCl (entry 3).33 
Strongly basic conditions led to decomposition of the starting material (entry 4). As 
for milder basic conditions using hydrogen peroxide, no reaction was observed 
(entry 5).174  
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Entry Conditions 
Expected product 
Ar-COX (220) 
Result 
A
ci
di
c 1 HCl (sat.), MeOH 
Ar-CO2Me 
 
2 HCl (6 M), MeOH Piv deprotection 
3 TMSCl (1 eq.), MeOH  
B
as
ic
 4 KOH, MeOH Ar-CO2H Decomposition 
5 30% H2O2, K2CO3, DMSO Ar-CONH2 No reaction 
N
eu
tra
l 6 Na2O2, water, 50 °C Ar-CO2H Polymerisation 
7 1. Me3OBF4, DCM,        2. water, 50 °C Ar-CONHMe Decomposition 
En
zy
m
at
ic
 8 
Nitrilase, phosphate 
buffer pH 7.3, MeOH, 
water, 37 °C 
Ar-CO2H No reaction 
9 
Nitrilase, phosphate 
buffer pH 7.3, toluene, 
water, 37 °C 
R
ad
ic
al
 10 (4-BrPh)3N⋅
+SbCl6–, 
DCM Ar-CONH2 
No reaction 
11 (4-BrPh)3N⋅
+SbCl6–, 
styrene, DCM Ar-CONHCH(Me)Ph 
Le
w
is
 a
ci
d 
ca
ta
ly
se
d 12 
TBSOTf (2 eq.), MeOH 
(2 eq.), 2,6-lutidine         
(2 eq.), DCM 
Ar-CO2Me 
Piv deprotection 
13 
1.  Ph3CBF4 (1 eq.), DCM 
2. 2,6-lutidine (1 eq.),          
3. MeOH 
TrOMe isolated 
14 
1.  TBSOTf (1 eq.), DCM 
2. 2,6-lutidine (1 eq.),          
3. MeOH 
Protecting group 
interconversion 
Table 17: Attempted conversion of nitrile 219b into carboxylic acid derivative 220 
In the search of neutral and mild conditions, two different sets of conditions were 
found in the literature. The first method consisted in using sodium peroxide in hot 
water, which has been reported as converting the starting material, initially insoluble 
in water, into the corresponding soluble carboxylic acid by slow addition of the 
reagent (entry 6).175 Unexpectedly, these conditions led to the formation of a greasy 
by-product, insoluble in organic solvents or water and which could not be 
characterised. The second neutral set of conditions consisted of the alkylation of the 
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nitrile group using Meerwein’s salt, followed by hydrolysis of the activated 
ammonium salt in hot water to afford the corresponding methyl amide (entry 7). 
However, a competition with the pyridine nitrogen could take place, and no product 
could be isolated when nitrile 219b was submitted to these conditions.  
Enzymatic hydrolysis was also considered: nitrilase is a commercially available 
enzyme that converts nitriles into carboxylic acids. Classical conditions consisted in 
using a mixture of water and methanol as the reaction solvent, but even at high 
dilution, the starting nitrile precipitated when added to the reaction mixture (entry 8). 
Biphasic conditions were therefore considered, using toluene to solubilise the starting 
nitrile (entry 9). However, in both cases the starting material remained unreacted even 
after prolonged reaction time and increased amount of enzyme were used.  
A slightly less common set of conditions was considered using a stable commercially 
available radical cation reagent. Two approaches were thus considered. The first one 
was to investigate whether, when nitrile 219b was treated with 
tris(4-bromophenyl)ammoniumyl salt, the radical cation would be able to abstract an 
electron from the nitrile lone pair, activating it towards subsequent hydrolysis with 
water to afford the corresponding amide, but the starting material 219b remained 
unreacted under these conditions (entry 10). In the second experiment, styrene would 
be present in the reaction mixture and would react with the ammoniumyl salt to form 
a radical cation, which would then undergo electrophilic attack onto the nitrile 
(entry 11). Unfortunately, the nitrile did not react under these conditions and 
polymerisation of the styrene was observed instead.  
Finally, the last attempt was to investigate the use of Lewis acids to activate the nitrile 
towards hydrolysis. In order to prevent the formation of traces of Brønsted acid, a 
stoichiometric amount of base was added to each experiment. TMSOTf and methanol 
have been reported for the hydrolysis of nitriles, in which case two equivalents of 
methanol and Lewis acid were added simultaneously (entry 12).176 However, when 
applied to substrate 219b, these conditions led to the deprotection of one or both of 
the pivaloyl groups but did not favour the hydrolysis of the nitrile group. It was 
therefore thought that for the hydrolysis to take place, it was necessary to initially 
activate the nitrile group with one equivalent of Lewis acid, followed by the addition 
of the base and finally one equivalent of methanol. Two Lewis acids were selected for 
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this experiment, and in both cases most of the starting material remained unreacted, 
but interestingly new components could be seen by TLC analysis (entries 13 & 14). 
After purification, however, none of the desired product 220 (X = OMe) could be 
isolated. In the first case, using trityl cation, the only isolated product was methyl 
triphenylmethyl ether (entry 13). Using TMSOTf, three new spots were observed, but 
only one of these products was stable and could be isolated (entry 14): compound 221 
resulted from the interconversion of protecting groups on the phenol in the position 
para to the nitrile (Scheme 66). The instability of the other regioisomer had 
previously been demonstrated, due to the activation of the double bond between the 
nitrile and the silyl ether. 
 
Scheme 66: Protecting group interconversion with the use of TBSOTf 
Following the failed attempts in the hydrolysis the nitrile moiety, and the lack of 
stability of the pivaloyl groups, two new protecting groups were considered (Scheme 
67). Firstly, as seen previously, dimethyl derivative 219c could be an alternative.173 
Although it has been reported as not being stable to light, the protection of lactam 213 
using silver carbonate in the absence of light afforded the desired dimethoxy 
derivative 219c. Manipulation of the product resulted in a decrease in yield, as even 
slight exposure to light triggered the decomposition of the product. Secondly, another 
interesting protecting group that was considered was a triflate. As such, di-triflate 
derivative 219d was synthesised under biphasic conditions following a reported 
methodology.177 
 
Scheme 67: New protecting groups on N-resorcylate 213 
With two new protected pyrimidines in hand, the investigation of the stability of the 
new protecting groups was undertaken (Scheme 68). Firstly, the compounds were 
submitted to an alkaline hydrolysis, however in both cases these conditions led to 
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decomposition of the starting materials 219c and 219d, and no hydrolysis product 222 
was formed. In a second experiment, the compounds were treated with dilute HCl in 
methanol in order to access methyl ester 223, but in the case of the dimethyl 
derivative 219c, deprotection of the methyl ethers took place. Interestingly, triflate 
derivative 219d was stable to acid as no reaction was observed and all the starting 
material could be recovered at the end of the reaction. This was an advantage over the 
pivaloyl-protected analogue 219b and suggested that some of the conditions 
previously screened for the hydrolysis of the nitrile group should be trialled on this di-
triflate derivative 219d. However, due to time constraints the subsequent steps could 
not be undertaken. 
 
Scheme 68: Attempted hydrolysis of protected N-resorcylates 219c and 219d 
 
2.5.4. Synthesis and reactivity of 5-N-resorcylate 
 
In order to access the other two N-resorcylate derivatives, the synthesis of enamine 
193 was required (Scheme 69). Unfortunately, when using either sulfonamide 191a or 
azide 191b as the starting β-ketoester, treatment with aqueous ammonia led to the 
formation of a mixture of inseparable by-products. This observation indicated that the 
presence of an electron-withdrawing group on the position α to the carbonyl was not 
compatible with the reaction conditions, as it might be responsible for the formation 
of a mixture regio- as well as stereoisomers. 
 
Scheme 69: Attempted formation of enamine 193 from β-ketoester 191 
As previously observed, the functionalisation of the C-6 position of the N-resorcylate 
derivatives required to be undertaken subsequently to the cyclisation. As such, methyl 
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acetoacetate (214) was treated with aqueous ammonia to obtain enamine 224 in high 
yield. Treatment of enamine 224 with diaryl malonate (Ar = 2,4,6-trichlorophenyl, 
192) in diglyme at 100 °C following a literature procedure166 afforded the desired 
lactam 225. As previously, in order to increase the solubility of substrate 225, both 
hydroxy groups were protected with as pivaloyl esters to afford diester 226. In this 
case the higher solubility of amide 225 compared to the precedent analogue led to an 
increase in yield. The difference in solubility could be explained by the presence of 
the methyl ester, making the compound less flat compared to the nitrile group of the 
previous analogue 213.  
Radical bromination was then attempted on protected pyridine 226 in order to 
functionalise the benzylic position. However, benzylic bromide 227 could not be 
isolated as the reaction resulted in the formation of multiple by-products. It was clear 
that new products were formed from the 1H NMR of the crude mixture, however they 
could not be separated by chromatography purification as it resulted in decomposition 
of the components on silica.  
 
Scheme 70: Synthesis of lactam 225 and attempted functionalisation of the C-6 benzylic position 
Following these preliminary results, the functionalisation of the C-6 position of these 
N-resorcylate derivatives appeared to be more difficult than expected. Due to a lack of 
time, it was chosen to investigate the synthesis of the third N-resorcylate derivative 
before spending more efforts attempting to functionalise the C-6 position. 
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2.5.5. Synthesis and reactivity of pyrimidine derivative 
 
The synthesis of the targeted pyrimidine ring 189c has been reported in a Chinese 
patent.167 When applying the conditions described in the literature, treatment of 
enamine 224 with isocyanate 194 in ether afforded a mixture of two products, which 
were later found to be the products of either a conjugate addition (compound 228a) or 
a direct addition (compound 228b) of enamine 224 onto the isocyanate group of 194 
(Scheme 71). The ratio of these two products changed with the concentration of the 
reaction: a concentration of 0.25 M gave mainly product 228b (3 : 1), whereas 
increasing the concentration to 0.50 M inverted the ratio in favour of product 228a 
(1.5 : 1), which was the highest concentration that would allow appropriate stirring of 
the reaction mixture. These intermediates were not stable enough to be separated, so 
the mixture was used direct into the subsequent step, which was the cyclisation under 
basic biphasic conditions. Two products were formed as could be seen by TLC 
analysis. Following chromatographic purification, two pyrimidines 229a and 229b 
were isolated, corresponding to intermediates 228a and 228b respectively. 
Interestingly, the ratio between the two species was conserved during this second 
step.  
 
Scheme 71: Synthesis of pyrimidines 229a and 229b 
With the desired pyrimidine 229a in hand, subsequent reactions were trialled. 
Attempted protection of pyrimidine 229a as a di-pivaloyl ester 230 was unsuccessful 
due to the lack of solubility of substrate 229a. Other polar solvents, such as methanol 
or acetonitrile, did not result in an increase of solubility. Subsequently, radical 
bromination of the benzylic position was attempted in order to form benzylic bromide 
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231 but when submitted to these conditions, pyrimidine 229a rapidly decomposed 
into an insoluble precipitate. It appeared that this resorcylate analogue, bearing two 
nitrogen atoms in the aromatic ring, displayed an even lower solubility compared to 
both pyridine derivatives, and functionalisation and/or protection of pyrimidine 
derivative 229a could not be achieved. 
 
Scheme 72: Attempted reactions on pyrimidine 229a 
 
2.6. Conclusion on the N-resorcylate series 
 
The syntheses of three N-resorcylates bearing a methyl substituent on the C-6 position 
were achieved. Unfortunately, the functionalisation in order to install a sulfonamide 
group similar to initial hit BHP329 (102) prove to be difficult: a functionalisation 
prior to cyclisation was responsible for a lack of regioselectivity leading to 
decomposition; as for a latter-stage functionalisation, the low solubility of the newly 
created aromatic rings, in addition to the lack of reactivity of the various groups 
around the pyridine and pyrimidine rings, made the realisation of the subsequent steps 
impossible. Considering the difficulties encountered with the synthesis of these three 
analogues, and due time constraints, it was therefore decided to discontinue working 
on this series. 
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3. CONCLUSION OF CHAPTER 2 
 
 
Starting from initial resorcylate hits, such as BHP329 (102), the aim of the project 
was to design and synthesise analogues that would antagonise the activity of LRH-1. 
Several syntheses could not be completed, due to the non-reactivity of various 
advanced intermediates. As such, ketodioxinone 142a,b, diketodioxinone 161 and 
N-resorcylates 213, 225 and 229a were synthesised, but could not be converted into 
the desired target molecules, 136a,b, 143 and 189a,b,c respectively (Figure 62). 
 
Figure 62: Summary of attempted syntheses of analogues for LRH-1 
 
Nevertheless, two series of molecules were successfully synthesised and are 
summarised in Figure 63 below. Dehydroxylated resorcylates 113 and 127 were 
designed in order to investigate the importance of the phenols on the resorcylate core. 
Although only minor alterations in the biological activity of these compounds were 
observed, it gives an indication that both hydroxy groups of the resorcylate core are 
required for a maximum inhibitory activity. Finally, four steroidal derivatives 168a, 
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165a,b and 188 were synthesised and assessed in two cell-based assays. Although a 
strong inhibitory activity was not achieved, a dual response was observed in the two 
separate assays, indicating a complex mechanism for the regulation of LRH-1. These 
novel compounds represent interesting ligands for the member of the nuclear receptor 
family and their potential as ligands will be subjected to further investigation.  
 
Figure 63: Summary of synthesised compounds as analogues for LRH-1  
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CHAPTER 3 
 
 
 
 
 
 
INCREASING THE BIOAVAILABILITY OF 
FULVESTRANT IN THE TREATMENT OF 
BREAST CANCER 
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1. INTRODUCTION 
 
1.1. Fulvestrant 
 
Hormone therapies represent an important treatment for hormone-sensitive breast 
cancer.89,178 17β-Oestradiol (232), the dominant circulating oestrogen and natural 
substrate of the oestrogen receptor (ER), plays a critical role in the development of 
breast carcinomas, which thus led to the development of molecules able to block 
oestrogen-mediated cell signalling (Figure 64).179 For the last thirty years, the most 
widely used drug as a hormonal therapy has been Tamoxifen (79) (‘Novaldex™’), 
which acts as a selective oestrogen receptor modulator (SERM).180 The selective 
character of this class of drug implies that not only the molecule acts as an antagonist 
in the breast tissues, which is required to effectively treat patients, but it additionally 
acts as an agonist in other tissues.181 This undesirable effect could lead to an increased 
risk of carcinomas in other parts of the body, as well as being responsible for the 
development of resistance towards the primary treatment.180 These opposing 
properties thus represent an inherent need for the development of new drug molecules 
that would lack this unwanted side effect. 
 
Figure 64: Examples of modulators of the oestrogen receptor (ER) 
Fulvestrant (82) (‘Faslodex™’), developed in 1987, is the first in class of a new type 
of hormonal therapy: it acts as a ‘pure’ oestrogen antagonist and therefore possesses 
no agonist effect.87 Although Tamoxifen is still currently widely used, Fulvestrant has 
been demonstrated to be effective in the treatment of patients with ER+ breast cancer 
who have shown resistance to other endocrine therapies.182,183 In addition, it may 
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potentially be used in combination with other agents, in order to enhance its 
efficacy.184  
A crucial drawback of Fulvestrant is its low oral bioavailability. This requires the 
drug to be administrated intramuscularly, resulting in pain for the patient and potential 
risk of inflammation at the site of injection. As such, the development of orally active 
pure oestrogen receptor antagonists would be an attractive target. Efforts have been 
made to modify the alkyl side chain of Fulvestrant, which has resulted in the synthesis 
and biological assessment of compounds such as CH4893237 (233)185 and ZK-703 
(234),186 for which research is still on-going (Figure 65).187 
 
Figure 65: Development of orally active analogues of Fulvestrant (82) 
 
1.2. BS-194 side chain 
 
The issue of oral bioavailability has previously been investigated in our laboratory 
when working on a different cancer research project. Our collaborators were 
interested in developing a selective cyclin-dependent kinase inhibitor.188 A first 
analogue, BS-181 (235), showed interesting inhibitory activity when screened against 
a range of different kinases (Figure 66). A key development upon this substrate 
included the substitution of the aminoalkyl moiety with a trihydroxy side chain, 
affording compound BS-194 (236). This led to a significant increase in the oral 
bioavailability while retaining a similar inhibitory activity.189  
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Figure 66: Inhibitors of cyclin-dependent kinases 
These findings were therefore used in the design of a new analogue of Fulvestrant, on 
which the same trihydroxyamino side chain was substituted onto the steroidal core of 
Fulvestrant (compound 237, Figure 67). It was seen as beneficial that the C-7 alkyl 
side chain remained intact, and to instead attach the bioavailability enhancing 
trihydroxyamino side chain via an ethylene linker on C-11 of the steroidal core. Some 
prior modifications of the C-11 position of oestrogen derivatives have been reported 
in the literature,190 but no compound bearing both a C-11 and C-7 substituents has 
ever been described. Accordingly, with the discussed inherent benefits that it could 
offer, the synthesis of Fulvestrant analogue 237 clearly represents an interesting 
synthetic challenge. 
 
Figure 67: Design of a new analogue of Fulvestrant 
 
1.3. Previous work 
 
The synthesis of analogue 237 has been previously attempted in our laboratory.191 The 
first synthetic route involved initial functionalisation of the C-11 position, in order to 
install an allyl group, affording compounds 238a,b after a five-step sequence (Figure 
68). Unfortunately, the oxidation of the C-6 position of substrates 238a or 238b, 
required for the introduction of the alkyl side chain, was unsuccessful when submitted 
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to the tBuOK/LDA-mediated oxidation conditions, and synthesis of alcohol 239 was 
not achieved. 
 
Figure 68: First attempted route towards the synthesis of Fulvestrant analogue 237 
An alternative approach towards the synthesis of target molecule 237 was 
subsequently undertaken, this time involving early stage installation of the alkyl chain 
(Figure 69).191 As such, intermediate 240 was synthesised in three steps. However, the 
attempted alkylation reaction using iodide 241 in order to obtain compound 242 was 
unsuccessful using either TBS- or benzyl-protected substrates 240a,b. Under all of the 
screened conditions (strong or weak base, Lewis acid), only decomposition of starting 
material 240 was observed and the desired product 242 was not obtained in any 
appreciable yield. 
 
Figure 69: Second attempted route towards the synthesis of Fulvestrant analogue 237 
With these observations in hand, a new route towards the synthesis of Fulvestrant 
analogue 237, bearing the desired trihydroxy side chain was designed and will be 
discussed in Section 2.  
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2. RESULTS AND DISCUSSION 
 
2.1. Retrosynthesis 
 
The newly designed retrosynthesis of Fulvestrant derivative 237 is shown in Scheme 
73. Analogue 237 would be obtained by displacement of tosylate 243 with the 
required thiol, generated in situ from thiouronium salt 244. The protected 
trihydroxyamino side chain on tosylate 243 would be attached via an alkene handle on 
derivative 245 after oxidation and reductive amination on this functional group. This 
amino side chain would be accessed through hydrogenolysis of azide 246, synthesised 
following a reported procedure starting from a derivative of tartaric acid.189 The 
northern alkene handle would be installed starting from internal alkene 247, following 
a series of known reactions described on steroid derivatives lacking the southern alkyl 
side chain.190 Two subsequent oxidations would allow to access alkene 247 from 
enone 248a. The southern alkyl side chain would be installed following a 1,6-addition 
described for the synthesis of Fulvestrant (82), starting from dienone 249 and bromo 
alkyl derivative 250.192 Finally, dienone 249 would be accessed from commercially 
available 19-nortestosterone (251). However, due to the large amount of required 
starting material, it was chosen to synthesise 19-nortestosterone (251) from 
significantly less expensive β-oestradiol (232).  
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Scheme 73: Retrosynthesis of Fulvestrant analogue 237 
 
2.2. Synthesis of the side chains 
 
2.2.1.  Synthesis of (S)-4-((S)-1-azido-2-(methoxymethoxy)ethyl)-2,2-
dimethyl-1,3-dioxolane (246) 
 
The synthesis of the protected trihydroxyamino side chain had been reported by our 
collaborators in five steps starting from enantiopure (−)-diethyl tartrate (252).189 
When following this five-step procedure, yields similar to the literature were obtained 
and 1.8 g of azide precursor 246 were synthesised as described in Scheme 74. The 
first step was the formation of cyclic sulfite 253 from diethyl tartrate (252), followed 
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by opening of the sulfite with sodium azide to afford azido alcohol 254, as a single 
diastereoisomer. Subsequent reduction of the ester groups with in situ generated 
lithium borohydride193 afforded triol 255, which due to its high polarity was protected 
without purification as the corresponding acetonide 256. Finally, protection of the 
remaining hydroxy group as a MOM ether afforded protected azido precursor 246. 
Due to the potential instability of alkyl amines, this side chain was conserved as azido 
precursor 246 and the hydrogenolysis to reveal the desired amine would be carried out 
just prior to the attachment onto the main core. 
 
Scheme 74: Synthesis of the trihydroxyamino side chain 
 
2.2.2. Synthesis of (9-bromononyloxy)(tert-butyl)dimethylsilane (250) 
 
The synthesis of bromo alkyl side chain 250 started with nonane-1,9-diol (257), 
which was selectively mono-brominated using a literature procedure developed to 
limit the amount of dibrominated side products (Scheme 75).194 Classical conditions 
were then used to protect the remaining alcohol 258 as a TBS ether, affording 20 g of 
the desired side chain 250.195 
 
Scheme 75: Synthesis of the alkyl side chain 
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2.2.3.  Synthesis of 2-(4,4,5,5,5-pentafluoropentyl)isothiouronium 4-
methylbenzenesulfonate (244) 
 
In order to synthesise thiol precursor 244, commercially available 4,4,5,5,5-
pentafluoropentan-1-ol (259) was tosylated and the resulting tosylate 260 was 
displaced with thiourea to afford thiouronium salt 244, which was stored as a salt 
awaiting attachment to the main core (Scheme 76).196 
 
Scheme 76: Synthesis of the fluorinated side chain 
 
2.3. Synthesis of the steroidal core 
 
2.3.1. Synthesis of 19-nortestosterone (251) 
 
Due to the high price of 19-nortestosterone (251), it was decided that the synthesis of 
251 from β-oestradiol (232) would be more economical. The first step was the 
protection of oestradiol 232 as the corresponding methyl ether 261 and was carried 
out on 25 g (Scheme 77).197 Subsequent Birch reduction to afford unconjugated diene 
262 was carried out in three batches. A first attempt on 5 g following a literature 
procedure yielded 91% of the desired product 262.198 Optimisation of the conditions 
by decreasing the concentration allowed for the reaction to proceed quantitatively and 
a 99% yield was subsequently obtained on two 10-gram batches. Finally, enol ether 
262 has been reported to smoothly rearrange into conjugated enone 251 when 
deprotected using dilute methanolic hydrochloric acid.199 When carried out on 
substrate 262 in three batches, yields between 92 and 94% were obtained, affording 
21 g of 19-nortestosterone (251). 
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Scheme 77: Synthesis of 19-nortestosterone (251) 
 
2.3.2. Installation of the southern side chain 
 
The conversion of enone 251 into dienone 249 has been described by Bastien et al.200 
They reported that the treatment of enone 251 with acetyl chloride and acetic 
anhydride in pyridine upon heating afforded diacetate 263 in one high-yielding step. 
However it was found in our laboratory that when these conditions were applied on a 
5-gram scale, the selectivity of the reaction towards the formation of the desired 
product 263 was greatly altered: after two purifications by column chromatography, 
around 5% of impurities remained in the product and the yield decreased to 63%. 
Alternatively, better results were obtained by firstly protecting alcohol 251 as the 
corresponding acetate 264 under milder conditions, followed by treatment under the 
conditions described in the literature200 to afford the desired diacetate 263 (Scheme 
78). Lastly, treatment of extended enol ether 263 with NBS followed by addition of 
base led to the formation of dienone 249, required for the installation of the C-7 alkyl 
side chain. 
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Scheme 78: Synthesis of dienone 249 
The alkyl southern side chain was installed via a 1,6-addition of the previously 
synthesised alkyl bromide 250 to dienone 249 following a literature procedure 
(Scheme 79).192 As expected, the reaction led to the formation of two 
diastereoisomers, 248a and 248b, which could be separated by column 
chromatography.  
 
Scheme 79: 1,6-Addition of bromoalkyl 250 to dienone 249 
The assignment of stereochemistry had been described in the literature, using the 
β-isomer 248b (Figure 70). A first NOE experiments starting from the alkene proton 
H-4 led to the identification of the equatorial proton on C-6 (dd, J = 4, 15 Hz), 
followed by a second NOE on this proton in order to identify the geminal axial proton 
on C-6. The coupling pattern of this proton was a double doublet, with coupling 
constants of 10 and 15 Hz. While the 15 Hz constant represents the coupling with the 
geminal proton on C-6, the 10 Hz constant is characteristic of an axial-axial 
interaction, indicating that the proton on C-7 is in the axial position.192 This 
compound was therefore assigned as the β-isomer 248b, with the alkyl side chain 
being in the equatorial position. 
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Figure 70: Assignment of the stereochemistry of 248b by NOE experiments 
The β-isomer 248b was the most polar compound, hence the desired α-isomer 248a 
was least polar molecule. Although the desired product was obtained with a low yield, 
varying between 23 and 27% depending on the scale of the reaction (from 200 mg to 
4.5 g), this finding was consistent with the literature (lit: 32% yield on a 15-gram 
scale)192 and enough material was synthesised in order to continue with the synthesis. 
With the desired alkyl side chain in place, the following step involved the 
replacement of the TBS protecting group on 248a with an acetate, as the silyl ether 
moiety would not be stable during the subsequent aromatisation step (Scheme 80).192 
The replacement of this protecting group was carried out in a two-step sequence by 
treatment of TBS ether 248a under acidic conditions, followed by mild protection 
with acetic anhydride in pyridine as the solvent to afford diacetate 265. Finally, enone 
265 was oxidised into phenol 266, following a known procedure using copper(I) 
bromide and lithium bromide.192 In a first attempt, a slight excess of both copper 
bromide and lithium bromide were used, but the 55% yield resulting from these 
conditions was lower than the reported literature (Table 18, entry 1). In this 
publication, both reagents were used in a slight substoichiometric amount, and when 
these conditions were applied on substrate 265, the yield increased to 68% (entry 2), 
which was consistent with the literature.192 This could indicate that an excess of 
reagent would react with the resulting product 266 and lead to decomposition. 
Therefore, a strict stoichiometric amount of both copper bromide and lithium bromide 
were used, resulting in an improvement of the literature yield up to 81% (entry 3). 
 
Scheme 80: Synthesis of substrate 266 
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Entry Substrate (eq.) CuBr2 (eq.) LiBr (eq.) Yield 
1 1 2.20 1.10 55% 
2 1 1.95 0.97 68% 
3 1 2.00 1.00 81% 
Table 18: Optimisation of the oxidation of enone 265 into phenol 266 
With substrate 266 in hand, the next step would be the oxidation using DDQ in order 
to install an alkene between C-9 and C-11 (compound 247, Scheme 73). 
 
2.4. Attempt of installation of the northern side chain 
 
2.4.1. Study of the DDQ oxidation 
 
The DDQ oxidation of steroid skeletons has been described in select literature 
examples, such as the oxidation of oestrone (144) shown in Scheme 81, which installs 
an alkene between the carbons 9 and 11.201 The reaction on free phenol 144 was 
carried out in methanol upon heating at 45 °C to obtain alkene 267 (Scheme 81). 
Alternatively, other papers reported the same reaction on benzyl protected phenols, in 
a range of aprotic solvents such as dioxane, THF or acetonitrile.202 In order to 
investigate this reaction, the same conditions as described in the literature were 
applied on oestrone (144), using 1.7 equivalents of DDQ (Table 19, entry 1). 
However, under these conditions, decomposition of either starting material 144 or 
product 267 was observed, as no material could be recovered at the end of the 
reaction, after 1 h. It was thought that the excess of DDQ could be responsible for the 
decomposition; therefore a stoichiometric amount of DDQ was used (entry 2). Under 
these conditions, the reaction was stopped after 1 h. The only component that was 
seen when monitoring the reaction by TLC analysis was running at the same height as 
the starting material. However, while the starting material 144 was not UV active, 
TLC analysis at the end of the reaction revealed a UV active entity, which could be an 
indication that the starting material and product co-elute with the same Rf. 1H NMR 
confirmed the presence of product 267, with a characteristic alkene peak at 6.1 ppm. 
However, the reaction did not go to completion as some starting material 144 
remained in the reaction mixture. Finally, the optimal conditions were found when 
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using 1.3 equivalents of DDQ and the desired alkene 267 was isolated in high purity 
and quantitative yield after 30 min (entry 3). 
These observations indicated that the amount of DDQ used in this reaction has to be 
precisely calculated, and the reaction should be monitored by 1H NMR in order to 
observe the complete consumption of the starting material. Furthermore, it was found 
that the colour of the reaction mixture was a good indication of the progress of the 
oxidation: when DDQ was added to the reaction, the dark green colour of the reaction 
mixture was characteristic of the SET complex formed between DDQ and the phenol 
ring.203 When using 1.3 or less equivalents of DDQ, the colour rapidly faded after 
5 min into a colourless solution, indicating the all the DDQ had been consumed.  
 
Scheme 81: Study of DDQ oxidation on oestrone (144) 
Entry Eq. of DDQ Results Conversion 
1 1.7 Decomposition – 
2 1.0 SM 144 + product 267 80% 
3 1.3 Product 267 100% 
Table 19: Optimisation of the DDQ oxidation of oestrone (144) 
With these results in hand, the DDQ oxidation of Fulvestrant derivative 266 was 
attempted (Scheme 82). Using the conditions optimised on model substrate 144, it 
was found that starting material 266 was consumed, but the only observable product 
by 1H NMR was the triol resulting from the deprotection of both acetate groups on 
266 (Table 20, entry 1). This result was confirmed by HRMS, but the product could 
not be isolated due to its high polarity. In addition, 1H NMR of the crude mixture 
indicated the presence of several products showing that side reactions or 
decomposition took place, and no peak was seen around δ = 6 ppm, which would 
have indicated the formation of the desired alkene 268. When running the reaction 
again but at room temperature instead of 45 °C, only starting material 266 was 
observed (entry 2). It was thought that using isopropanol or a mixture of isopropanol 
and dichloromethane instead of methanol might slow down the deprotection process. 
Unfortunately, no reaction was observed in both cases at room temperature (entries 3 
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and 4), and upon heating some decomposition was observed by 1H NMR and most of 
the starting material 266 remained (entries 5 and 6). Finally, using aprotic solvents 
such as benzene (entry 7) or 1,4-dioxane (entry 8) gave results similar to when protic 
solvents were used. In all these experiments, no new peak at ca. δ = 6 ppm was 
observed by 1H NMR, which indicated that either the product did not form, or that it 
would decompose rapidly after being formed. 
 
Scheme 82: Attempt of DDQ oxidation on Fulvestrant substrate 266 
Entry Solvent Temperature Results 
1 MeOH 45 °C acetate deprotection 
2 MeOH 20 °C SM only 
3 iPrOH 20 °C SM only 
4 CH2Cl2, iPrOH 20 °C SM only 
5 iPrOH 45 °C SM + decomposition 
6 CH2Cl2, iPrOH 45 °C SM + decomposition 
7 benzene 45 °C SM + decomposition 
8 1,4-dioxane 45 °C SM + decomposition 
Table 20: Attempt of DDQ oxidation on substrate 266 
A final attempt employed 3 equivalents of DDQ. In this case, all the starting material 
266 was consumed but no material was recovered by extraction at the end of the 
reaction and no component were seen above the baseline by TLC analysis. This was 
an indication that an excess of DDQ led to complete decomposition of the entities 
present in the reaction mixture.  
 
2.4.2. Protecting group replacement 
 
Following the previous failure in the oxidation of steroidal derivative 266 and the 
observation of protecting group lability under the reaction condition, it was therefore 
decided to replace both acetate protecting groups on substrate 266 with TBS ethers 
(Scheme 83). A first attempt was to carry out a saponification of both acetates to 
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afford triol 269. Although 1H NMR analysis showed the disappearance of both 
acetates and the mass of the desired product was observed by HRMS, triol 269 could 
not be isolated and purified due to its high polarity. When the crude mixture from the 
saponification was used in a subsequent TBS protection, it was not possible to isolate 
the desired tri-silyl ether 270. Another approach was then preferred, which consisted 
of firstly protecting free phenol 266 as the corresponding benzyl ether 271, followed 
by saponification of both acetate groups to afford diol 272. This compound being less 
polar than the previous triol 269, purification could be achieved prior to protection as 
the corresponding di-TBS ether 273. 
With new substrate 273 in hand, the DDQ oxidation was investigated, and screening 
of the same conditions that were previously described on diacetate 266 was 
undertaken. Unfortunately, similar results were obtained: TBS deprotection took place 
in methanol at 45 °C, mono-TBS deprotection was observed even at room 
temperature in protic solvents, and decomposition occurred upon heating in various 
protic and aprotic solvents. No product formation was ever observed under any of 
these conditions. 
 
Scheme 83: Protecting group replacement and attempted DDQ oxidation 
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2.4.3. Possible explanation for the lack of reactivity of substrate 266 
 
The observed lack of reactivity led us to consider the mechanism of the oxidation. 
The main difference between model substrate 144 and Fulvestrant substrate 266 was 
the presence of the C-7 side chain. A DDQ oxidation has not previously been reported 
in the literature when a substituent is present at this position. The axial position of the 
C-7 side chain imparts a steric hindrance to the α-face of the steroid (Figure 71). This 
could have a dramatic effect when the hydroquinone radical anion has to approach the 
benzyl ring from the α-face in order to abstract the hydrogen atom: the chloro or 
cyano substituents of DDQ are then likely to clash with the protons on the first 
methylene group of the side chain. 
 
Figure 71: Supposed mechanism for the hydrogen abstraction 
Although this observation does not indicate that the oxidation cannot take place, it 
would argue in favour of the fact that this is a slow reaction (Scheme 84). 
Unfortunately, we observed on model substrate 144 that over-oxidation of the 
oxidation product 267 was likely to be happening when an excess of reagent was 
present. In the case of Fulvestrant substrate 266, if some of the product 268 were 
formed, then further oxidation by DDQ into diene 275 would be faster because the 
new substrate 268 would be less hindered toward deprotonation. Such oxidation has 
been described in the literature and was shown to lead to side reactions and 
decomposition.202 
 
Scheme 84: Possible side reaction leading to decomposition of oxidation product 268 
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This would explain why no product was observed during the various attempts in 
carrying out an oxidation using DDQ on Fulvestrant substrate 266 or 273, and it was 
therefore decided to investigate a new route. 
 
2.5. New route to a fulvestrant analogue 
 
2.5.1. Design of a new key intermediate 
 
The problem that occurred in the previous route towards the synthesis of an analogue 
of Fulvestrant was the presence of the axial side chain on C-7 blocking the access of 
the reagents that were intended to functionalise the C-9 position. Interestingly, it was 
thought that the presence of this axial side chain could be used to direct the 
functionalisation of the required positions: ether 276 was therefore designed as a key 
intermediate in the synthesis of Fulvestrant analogues (Scheme 85). Ether 276 was 
interesting as it could potentially be accessed from alcohol 277 through oxidation 
with lead tetraacetate: this reagent had been described as leading to the formation of 
5-membered cyclic ethers when reacted with acyclic monohydric alcohols.204 
Substrate 277 was known in the literature and could be accessed in five steps from 
previously synthesised dienone 249.205  
 
Scheme 85: Design of a new key intermediate 276 
 
2.5.2. Synthesis of substrate 277 
 
The first step towards the synthesis of substrate 277 was the hydrocyanation of 
dienone 249 to afford cyano derivative 278 (Scheme 86). The conjugate hydrocyanation 
of various ketones has been extensively studied by Nagata and co-workers.206 In 
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particular, 249 had been reported to yield nitrile 278 as a single diastereoisomer upon 
treatment with diethylaluminium cyanide. When these conditions were used, nitrile 
278 was obtained in 87% yield after chromatography purification. Aromatisation of 
enone 278 into phenol 279 was carried out using previously described conditions 
(Section 2.3.2), followed by treatment with DIBAL-H resulting in the reduction of the 
nitrile functionality as well as deprotection of the secondary alcohol, affording 
aldehyde 280. The next step was the protection of both hydroxy groups as ester 
derivatives. However, neither pivaloyl nor benzoyl protecting groups could be used 
for the protection of diol 280, as no product was observed when diol 280 was treated 
with the corresponding anhydride in pyridine at room temperature, even with addition 
of DMAP to catalyse the reaction. Upon heating the reaction mixture, side reactions at 
the position α to the aldehyde were observed by 1H NMR, indicating that both 
protecting groups were too bulky to be smoothly attached onto diol 280. Nevertheless, 
the protection of diol 280 under the same conditions using acetic anhydride afforded 
diacetate 281 in high purity after 18 h at room temperature. Finally, sodium 
borohydride reduction of aldehyde 281 afforded the desired alcohol substrate 277, in 
an overall sequence of five relatively high-yielding steps from dienone 249. 
 
Scheme 86: Synthesis of substrate 277 
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2.5.3. Lead tetraacetate oxidation 
 
With substrate 277 in hand, it was decided to investigate the lead tetraacetate 
oxidation of this steroid derivative. According to the literature, monohydric alcohols 
have been reported to form 5-membered cyclic ethers when treated with lead 
tetraacetate.204 If this reaction were to be carried out on alcohol 277, two cyclic ethers 
276 and 282 could potentially be obtained (Scheme 87).  
 
Scheme 87: Study of the oxidation of substrate 277 with lead tetraacetate 
Several conditions were therefore screened starting from alcohol 277 (Table 21). In a 
first attempt, alcohol 277 was reacted with lead tetraacetate only, in refluxing 
benzene, following the initially reported conditions for the use this reagent 
(entry 1).207 Unfortunately, no reaction was observed using these conditions and most 
of the starting material 277 was recovered. Iodine has been described in the literature 
as a catalyst for oxidation reactions when coupled with lead tetraacetate.208 When 
using the same conditions as previously trialled and adding iodine to the reaction 
mixture, new entities were observed when monitoring the reaction by TLC analysis 
after 1 h (entry 2). However, the reaction did not go to completion, even after an 
extended reaction time of 5 h and after the addition of one additional equivalent of 
lead tetraacetate. The use of an inorganic base such as calcium carbonate in addition 
to iodine had been reported in order to improve the oxidation reaction.209 When 
applied to substrate 277, these conditions led to observations similar to the conditions 
without the addition of a base: numerous products were formed and a significant 
amount of starting material 277 was recovered (entry 3). Interestingly, one entity 
seems to be more significant than the other by-products by TLC analysis and it was 
present in both reactions using iodine, with or without base. Unfortunately, it was not 
possible to isolate this product in sufficient amount and purity to be fully 
characterised and identified. 
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When looking at the literature, different solvents were used for this transformation, 
such as carbon disulfide.208 Benzene and carbon disulfide both belong to a class of 
solvents that have been shown to greatly improve the regioselectivity of radical 
reactions.210 The explanation for an increased selectivity is the formation of a 
complex between the radical species and the solvent: a π-complex in the case of 
benzene, and a δ-complex with carbon disulfide, both of which would lesser the 
energy of the free radical and therefore result in a higher selectivity.211 Interestingly, 
when substrate 277 was treated with lead tetraacetate in carbon disulfide at room 
temperature, all the starting material was converted after 1 h into one single entity, as 
could be observed by TLC analysis, and confirmed by 1H NMR. After isolation and 
purification, full characterisation demonstrated that the product of the reaction was 
the desired cyclic ether 276: HMBC NMR displayed a correlation between the newly 
created quaternary carbon of the ether ring and the aromatic proton on C-1 of the 
steroidal core. This reaction was reproducible on a slightly larger scale and afforded 
the desired ether 276 in 77% yield (67 mg). 
Entry Reagent Conditions Results 
1 Pb(OAc)4 benzene, ∆, 16 h no reaction 
2 Pb(OAc)4, I2 benzene, ∆, 16 h new spots + SM 227 
3 Pb(OAc)4, I2, CaCO3 benzene, ∆, 16 h new spots + SM 277 
4 Pb(OAc)4, I2 CS2, 20 °C, 1 h single product 
Table 21: Screened conditions for the oxidation of alcohol 277 with lead tetraacetate 
 
2.5.4. Future work 
 
Due to time constraints, the manipulation of ether 276 could not be undertaken. 
Nevertheless, the synthesis of this intermediate was an interesting achievement, as 
several potential reactions could be investigated from this point. 
For example, ring opening of tetrahydrofurans had been reported in the literature 
using Lewis acid as a catalyst in the presence of allylsilanes to create a new carbon-
carbon bond.212 Such reaction on ether 276 could lead to the formation of quaternary 
centre 283 (Scheme 88). This compound would bear the desired allyl handle onto a 
different carbon compared to the initially designed Fulvestrant analogue, but would 
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be nevertheless an interesting structure and could be transformed into an analogue 
bearing both the southern alkyl and the northern trihydroxy side chains. 
 
Scheme 88: Possible functionalisation of C9 position 
Alternatively, ether 276 could be oxidised into the corresponding lactone 284 
(Scheme 89).208 Various transformations could be attempted from this point, such as 
opening of the lactone with a Lewis acid and electrophilic attack of an allylsilane, 
creating a new quaternary carbon similar to structure 283 above.213 Another route 
could be the reduction of lactone 284 into tetraol 285, which following appropriate 
protections and mesylation could undergo an elimination reaction in order to install a 
C9-C11 double bond, affording an intermediate similar to the first route towards the 
synthesis of Fulvestrant analogue. 
 
Scheme 89: Possible route to install C9-C11 alkene 
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3. CONCLUSION OF CHAPTER 3 
 
 
Following the previous attempts to synthesise Fulvestrant analogue 237, a new route 
was designed, and the synthesis of key intermediate 266 was undertaken in 9 steps 
from β-oestradiol (232) (Scheme 90). Unfortunately, the DDQ oxidation of this 
substrate in order to install an alkene at the C9-C11 position failed, possibly due to a 
lack of reactivity of substrate 266 and the instability of product 268 under the reaction 
conditions. 
 
Scheme 90: Summary of first route to Fulvestrant analogue 237 
A new route was therefore designed by taking advantage of the axial position of the 
southern side chain (Scheme 91). Intermediate 277 was synthesised in five steps from 
previously obtained dienone 249, and oxidation of alcohol 277 in the presence of lead 
tetraacetate and iodine afforded an interesting, novel and potentially versatile 
intermediate 276. Potential further transformations of ether 276 have been suggested. 
 
Scheme 91: Summary of second route towards Fulvestrant analogues 
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EXPERIMENTAL PART 
 
 
1. Biological assay 
 
• Composition of the assay 
- Granzyme B: 100 U/µl in storage buffer. One U=1 pmol/min@30°C, 200 µM 
IEPD-pNA. 
- Buffer composition: 50 mM HEPES (286), pH 7.4, 100 mM NaCl, 0.1% CHAPS 
(287), 1mM EDTA (288), 10% glycerol (289) (Figure 72). 
 
Figure 72: Components of the assay buffer 
 
• Layout of the assay 96-well plate 
Compounds were dispensed on the assay plate as shown below (Figure 73): each 
section (a) to (f) represents one tested compound, and section (g) represents the 
positive control Ac-IEPD-CHO (1). Compounds were tested in two replicates (dark 
and light colour) over 6 points and three-fold serial dilution, from 100 µM to 400 nM. 
A similar serial dilution was applied to Ac-IEDP-CHO (1), with lower concentrations: 
from 10 µM to 40 nM. Concentrations for each point of the tested compounds are 
shown in Table 22 below. Finally, two reference wells were needed in order to 
normalise the response: a high well in section (h) contains the enzyme and the 
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substrate (showing the cleavage of the substrate in the absence of an inhibitor), and a 
low well in section (i) contains only the substrate (in the absence of enzyme, the 
substrate will not be cleaved and the reading of this well would be a baseline for the 
absorbance). 
  1 2 3 4 5 6 7 8 9 10 11 12 
A a      e      
B             
C b      f      
D             
E c      g      
F             
G d      h      
H       i      
Figure 73: Assay plate distribution 
Dilution point Tested compounds Positive control 1 
1 0.1000 0.01000 
2 0.0333 0.00333 
3 0.0111 0.00111 
4 0.0037 0.00037 
5 0.0012 0.00012 
6 0.0004 0.00004 
Table 22: Concentration of the 6 dilutions point for the GrB assay (mM) 
 
• Procedure for the assay 
- Another clear well plate was used for the serial dilution: 300 µL of a 1 mM DMSO 
solution of each compounds were added in column 1, from row A to F respectively. 
300 µL of a 0.1 mM DMSO solution of Ac-IEPD-CHO (1) were added in column 1, 
row G.  
-  200 µL of a 10% DMSO solution in the buffer was added into columns 2 to 6. 
- 100 µL from column 1 was added into column 2, mixed, and the process was 
repeated down up to column 6. 
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- 10 µL of the serial dilutions was taken from the dilution plate and added into the 
assay plate as shown above. The same amount of DMSO in buffer was added to the 
high (h) and low (j) wells. 
- 50 µL of the enzyme solution was diluted in 4000 µL of buffer, and 40 µL of this 
solution were added to each well containing a tested compound, section (a) to (f), as 
well as to the high wells (h). The same amount of buffer was added to the low well 
(i). 
- The plate was shaken at room temperature for 10 min to allow equilibration. 
- 1 mL of the substrate solution was diluted in 4 mL of buffer, and 50 µL of this 
solution were added to each well. 
- The plate was read on a microplate reader with a filter for absorption at 405 nm, 
every 5 min for 1 h. 
 
 
2. General procedures 
 
1H NMR spectra were recorded on a Bruker DRX-400 spectrometer at 400 MHz. 13C 
NMR spectra were recorded on a Bruker DRX-400 spectrometer at 100 MHz. 
Chemical shifts (δ) are quoted in parts per million (ppm) downfield from 
tetramethylsilane and are referenced against a residual solvent peak, CDCl3 (δH: 7.26, 
δC: 77.16), MeOD-d6 (δH: 3.31, δC: 49.00), DMSO-d6 (δH: 2.50, δC: 39.52). 2D NMR 
spectra (COSY, HSQC, HMQC) were recorded on a Bruker DRX-400 operating at 
400 MHz. Coupling constants (J) are quoted in Hertz (Hz). The signal multiplicity is 
quoted as follow: singlet (s), doublet (d), triplet (t), quadruplet (q), broad singlet (br. 
s), multiplet (m). NMR experiments were carried out by the Imperial College London 
Department of Chemistry NMR Service. 
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Low and high resolution mass spectrometry (EI, CI, ESI) were recorded by the 
Imperial College London Department of Chemistry Mass Spectrometry Service using 
a Micromass Platform II and Micromass AutoSpec-Q spectrometer. 
Melting points were obtained on a Reichert-Thermovar melting point apparatus and 
were not corrected. 
Infrared spectra were recorded on a Unicam FTIR spectrometer with automated 
background subtraction. Samples were prepared as thin films on sodium chloride 
plates. 
Specific rotation [α]D was recorded on a Perkin-Elmer 214 polarimeter at 589 nm (Na 
D-line) with a path length of 0.5 dm. Concentrations (c) are quoted in g/100 mL and 
specific rotations are quoted in units of deg.dm-1cm3g-1 at the indicated temperature 
(in °C). 
All manipulations of air or moisture sensitive materials were carried out in oven-dried 
glassware under an inert atmosphere of nitrogen or argon. Syringes, which were used 
to transfer reagents and solvents, were purged with nitrogen or argon prior to use. 
Reaction solvents were distilled from CaH2 (dichloromethane, toluene), Na/Ph2CO 
(tetrahydrofuran, diethyl ether) or obtained as dry or anhydrous from Sigma Aldrich 
(N,N-dimethylformamide, triethylamine, benzene) or VWR (ethanol). 
All flash column chromatographies were carried out on VWR silica gel 60, particle 
size 0.040–0.063 mm. Thin layer chromatographies (TLC) were performed on pre-
coated aluminium backed or glass backed plates (Merck Kieselgel 60 F254) and 
visualised with ultraviolet light (366 nm and 254 nm) or potassium permanganate 
(KMnO4), vanillin or phosphomolybdic acid (PMA) stains as deemed appropriate.  
Compounds names were created with Beilstein AutoNom Ver. 4.0 according to 
Beilstein nomenclature. Atoms numbering serves exclusively for the assignment of 
NMR spectra and does not correspond to the compounds nomenclature. 
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3. Synthesis 
 
3.1. Chapter 1 
 
Pyrimidine-2-carboxylic acid (15)32 
  
To a suspension of 2-pyrimidinecarbonitrile (14) (105 mg, 1.00 mmol, 1.0 eq.) in 
water (2.5 mL) was added KOH (109 mg, 1.9 eq.) and the mixture was refluxed for 
2 h. The mixture was acidified with aqueous HCl solution (1 M) until pH 3 and the 
solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2, filtered 
through cotton wool and the filtrate was evaporated in vacuo to afford carboxylic acid 
15 (20 mg, 16% yield) as a white solid. 
mp > 105 °C (decomp.) (CH2Cl2); IR (thin film) 2941 (br.), 2865, 1601, 1507, 
1139 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.00 (d, J = 4.9 Hz, 2H, 2 × Ar-H), 7.60 (t, 
J = 4.9 Hz, 1H, Ar-H); MS (EI+) 124 [M]+•; HRMS (EI+) calcd for C5H4N2O2 
124.0274, found 124.0273. The analytical data are consistent with the reported data in 
the literature.32 
 
Methyl pyrimidine-2-carboxylate (16)214 
  
Following a literature procedure,33 TMS-Cl (372 µL, 4.0 eq.) was added dropwise to a 
solution of 2-pyrimidinecarbonitrile (14) (105 mg, 1.00 mmol, 1.0 eq.) in dry MeOH 
(1 mL) and the reaction mixture was heated at 50 °C for 12 h. The mixture was cooled 
to 0 °C and a saturated aqueous NaHCO3 solution (15 mL) was added dropwise. The 
organic layer was extracted with CH2Cl2 (3 × 25 mL), dried over Na2SO4 and 
N
N
OH
O
N
N
OMe
O
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evaporated in vacuo to afford ester 16 (103 mg, 94% yield) as a white solid. Further 
purification was not necessary because of the purity of the product. 
mp 104–106 °C (Et2O); IR (thin film) 1731, 1562, 1322, 705 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.95 (d, J = 4.9 Hz, 2H, 2 × Ar-H), 7.50 (t, J = 4.9 Hz, 1H, Ar-
H), 4.08 (s, 3H, O-CH3); 13C NMR (100 MHz, CDCl3) δ 163.7, 157.9, 156.4, 123.2, 
53.6; MS (ESI+) 139 [M+H]+; HRMS (ESI+) calcd for C6H7N2O2 139.0508, found 
139.0501. The analytical data are consistent with the reported data in the literature.214 
 
Pyrimidine-2-carbohydrazide (10) 
  
Following a literature procedure,57 hydrazine monohydrate (49 µL, 1.2 eq.) was added 
dropwise to a solution of ester 16 (110 mg, 0.80 mmol, 1.0 eq.) in MeOH (2 mL) and 
the solution was refluxed for 4 h. The solvent was evaporated in vacuo, the residue 
was re-dissolved in MeOH (10 mL) and the solvent was evaporated in vacuo to afford 
acyl hydrazide 10 (110 mg, 99% yield) as white needles. 
mp 136–138 °C (CH2Cl2); IR (thin film) 3369 (br.), 3292, 3209, 3065, 1671, 1564, 
1417, 970 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.03 (br. s, 1H, NH-NH2), 8.88 (d, J = 
4.9 Hz, 2H, 2 × Ar-H), 7.46 (t, J = 4.9 Hz, 1H, Ar-H), 4.18 (br. s, 2H, NH-NH2); 13C 
NMR (100 MHz, CDCl3) δ 163.7, 159.2, 158.6, 124.7; MS (ESI+) 139 [M+H]+; 
HRMS (ESI+) calcd for C5H7N4O 139.0620, found 139.0617. 
 
2-(tert-Butoxycarbonylamino)acetic acid (17)215  
  
Following a literature procedure,34 NaOH (400 mg, 1.0 eq.) was added to a solution of 
glycine (13) (750 mg, 10.0 mmol, 1.0 eq.) in a mixture of dioxane and water (2:1) 
(30 mL). The mixture was cooled to 0 °C. Boc2O (2.40 g, 1.1 eq.) was added and the 
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reaction mixture was stirred at room temperature for 24 h. The mixture was diluted 
with water (100 mL) and washed with CH2Cl2 (2 × 100 mL). The aqueous layer was 
acidified with aqueous HCl solution (1 M) until pH 3–4 and extracted with CH2Cl2 
(2 × 200 mL). The combined organic layers were dried over Na2SO4 and evaporated 
in vacuo to afford the protected amino acid 17 (1.43 g, 81% yield) as a white solid. 
Further purification was not necessary because of the purity of the product. NMR 
analyses showed the presence of two rotamers (2:1). 
mp 78–80 °C (Et2O); 1H NMR (400 MHz, CDCl3) δ 10.28 (br. s, 1H, CO2H), 6.77 
and 5.01 (2 × s, 1H, minor and major, NH), 3.97 and 3.91 (2 × s, 2H, major and 
minor, CH2), 1.46 (s, 9H, C(CH3)3); 13C NMR (100 MHz, CDCl3) δ 174.8 , 157.1 and 
155.9 (minor and major), 81.7 and 80.4 (minor and major), 43.4 and 42.2 (minor and 
major), 28.3; MS (ESI–) 174 [M-H]–; HRMS (ESI–) calcd for C7H12NO4 174.0766, 
found 174.0767. The analytical data are consistent with the reported data in the 
literature.215 
 
4-(2-(Triisopropylsilyloxy)ethyl)aniline (18) 
  
To a solution of 4-aminophenethyl alcohol (12) (137 mg, 1.00 mmol, 1.0 eq.) in 
anhydrous DMF (3 mL) was added imidazole (136 mg, 2.0 eq.). The mixture was 
stirred at room temperature for 30 min and TIPSCl (216 µL, 1.1 eq.) was added 
dropwise. The mixture was stirred at room temperature for 4 h. The reaction mixture 
was diluted with CH2Cl2 (15 mL) and washed with saturated aqueous NaHCO3 
solution (2 × 15 mL) and brine (15 mL). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (PE : AcOEt, 90 : 10) to afford silyl ether 18 (230 mg, 78% yield) as 
an orange oil. 
Rf 0.18 (PE : EtOAc, 90 : 10); IR (thin film) 3369 (br.), 2941, 2864, 1516, 1096 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.00 (d, J = 8.3 Hz, 2H, 2 × Ar-H), 6.62 (d, J = 8.3 Hz, 
2H, 2 × Ar-H), 3.80 (t, J = 7.8 Hz, 2H, Ar-CH2-CH2-O), 3.55 (br. s, 2H, Ar-NH2), 
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2.75 (t, J = 7.8 Hz, 2H, Ar-CH2-CH2-O), 1.03–1.01 (m, 21H, Si(CH(CH3)2)3); 13C 
NMR (100 MHz, CDCl3) δ 144.6, 130.0, 129.3, 115.3, 65.4, 38.1, 18.0, 12.0; MS 
(ESI+) 294 [M+H]+; HRMS (ESI+) calcd for C17H32NOSi 294.2247, found 294.2253. 
 
tert-Butyl 2-oxo-2-(4-(2-(triisopropylsilyloxy)ethyl)phenylamino)ethylcarbamate 
(19) 
  
A solution of carboxylic acid 17 (90 mg, 0.50 mmol, 1.0 eq.), EDCI (115 mg, 1.2 eq.) 
and DMAP (6 mg, 0.1 eq.) in dry CH2Cl2 (6 mL) was cooled to 0 °C and stirred for 
20 min. A solution of amine 18 (147 mg, 1.0 eq.) in dry CH2Cl2 (4 mL) was added 
slowly and the mixture was stirred at room temperature for 20 h. The reaction mixture 
was diluted with CH2Cl2 and washed with cold aqueous HCl solution (1 M, 20 mL), 
cold water (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4 and 
evaporated in vacuo. The residue was purified by flash column chromatography (PE : 
AcOEt, 90 : 10 ! 80 : 20) to afford amide 19 (160 mg, 71% yield) as a white solid. 
Rf 0.24 (PE : EtOAc, 80 : 20); mp 87–89 °C (PE : AcOEt, 70 : 30); IR (thin film) 
3309 (br.), 2941, 2865, 1671, 1514, 1099 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.03 
(br. s, 1H, Ar-NH), 7.41 (d, J = 8.3 Hz, 2H, 2 × Ar-H), 7.17 (d, J = 8.3 Hz, 2H, 2 × 
Ar-H), 5.24 (br. s, 1H, NH-CH2), 3.91 (d, J = 5.8 Hz, 2H, NH-CH2), 3.84 (t, J = 
6.5 Hz, 2H, Ar-CH2-CH2-O), 2.81 (t, J = 6.5 Hz, 2H, Ar-CH2-CH2-O), 1.48 (s, 9H, 
C(CH3)3), 1.04–1.00 (m, 21H, Si(CH(CH3)2)3); 13C NMR (100 MHz, CDCl3) δ 168.1, 
156.5, 135.7, 135.1, 129.3, 119.8, 79.9, 64.6, 44.7, 39.0, 28.1, 17.8, 11.8; MS (ESI+) 
451 [M+H]+; HRMS (ESI+) calcd for C24H43N2O4Si 451.2992, found 451.2990. 
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tert-Butyl 2-thioxo-2-(4-(2-(triisopropylsilyloxy)ethyl)phenylamino)- 
ethylcarbamate (11) 
 
To a solution of amide 19 (20 mg, 0.05 mmol, 1.0 eq.) in THF (1 mL) was added 
Lawesson’s reagent (10 mg, 0.5 eq.) and the mixture was refluxed for 30 h. The 
reaction mixture was diluted with CH2Cl2 (10 mL) and washed with saturated 
aqueous solution NaHCO3 (10 mL). The aqueous layer was extracted with CH2Cl2 
(2 × 10 mL). The combined organic layers were dried over Na2SO4 and evaporated in 
vacuo. The residue was purified by flash column chromatography (PE : AcOEt, 85 : 
15) to afford thioamide 11 (15 mg, 64% yield) as a pale yellow oil. 
Rf 0.38 (PE : EtOAc, 80 : 20); IR (thin film) 3340 (br.), 2980, 1680, 1509, 1500, 
1161 cm-1 1H NMR (400 MHz, CDCl3) δ 7.99 (br. s, 1H, Ar-NH), 7.65 (d, J = 8.3, 
2H, 2 × Ar-H), 7.25 (d, J = 8.3 Hz, 2H, 2 × Ar-H), 5.39 (br. s, 1H, NH-CH2), 4.28 (d, 
J = 6.4 Hz, 2H, NH-CH2), 3.87 (t, J = 6.8 Hz, 2H, Ar-CH2-CH2-O), 2.85 (t, J = 
6.8 Hz, 2H, Ar-CH2-CH2-O), 1.48 (s, 9H, C(CH3)3), 1.07–1.00 (m, 21H, 
Si(CH(CH3)2)3); 13C NMR (100 MHz, CDCl3) δ 198.2, 156.9, 138.1, 136.6, 129.5, 
123.2, 80.8, 64.5, 47.4, 39.2, 28.3, 18.0, 12.0; MS (ESI+) 467 [M+H]+; HRMS (ESI+) 
calcd for C24H43N2O3SSi 467.2764, found 467.2752. 
 
tert-Butyl (5-(pyrimidin-2-yl)-4-(4-(2-(triisopropylsilyloxy)ethyl)phenyl)-4H-
1,2,4-triazol-3-yl)methylcarbamate (21) 
  
Following a literature procedure,37 thioamide 11 (466 mg, 1.00 mmol, 1.0 eq.) was 
dissolved in dry pyridine (4 mL) and freshly prepared acyl hydrazide 10 (206 mg, 
HN
OTIPS
BocHN
S
N N
N
BocHN
N
N
OTIPS
 
183 
1.5 eq.) was added to the solution and the resulting mixture was heated at 100 °C for 
6 h. The reaction mixture was cooled to 0 °C, diluted with CH2Cl2 (50 mL) and 
washed with aqueous HCl solution (1 M, 150 mL). The aqueous layer was extracted 
with CH2Cl2 (2 × 50 mL) and the combined organic layers were washed with brine 
(150 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by 
flash column chromatography (CH2Cl2 : MeOH : NH4OH, 95 : 5 : 0.25) to afford 
1,2,4-triazole 21 (240 mg, 43% yield) as a pale yellow oil. 
Rf 0.25 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 3311 (br.), 2945, 2868, 1706, 1511, 
1101 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.66 (d, J = 4.9 Hz, 2H, 2 × Pyrim-H), 7.31 
(d, J = 8.2 Hz, 2H, 2 × Ar-H), 7.22 (t, J = 4.9 Hz, 1H, Pyrim-H), 7.15 (d, J = 8.2 Hz, 
2H, 2 × Ar-H), 5.54 (br. s, 1H, NH-CH2), 4.31 (d, J = 5.3 Hz, 2H, NH-CH2), 3.93 (t, 
J = 6.8 Hz, 2H, Ar-CH2-CH2-O), 2.90 (t, J = 6.8 Hz, 2H, Ar-CH2-CH2-O), 1.41 (s, 
9H, C(CH3)3), 1.06 (sept, J = 5.7 Hz, 3H, Si(CH(CH3)2)3), 1.03 (d, J = 5.7, 18H, 
Si(CH(CH3)2)3); 13C NMR (100 MHz, CDCl3) δ 157.1, 155.8, 155.2, 154.0, 152.6, 
141.1, 132.3, 130.1, 126.6, 120.6 , 79.7, 64.0, 39.1, 36.2, 28.1, 17.9, 11.8; MS (ESI+) 
553 [M+H]+; HRMS (ESI+) calcd for C29H45N6O3Si 553.3322, found 553.3320. 
 
(5-(Pyrimidin-2-yl)-4-(4-(2-(triisopropylsilyloxy)ethyl)phenyl)-4H-1,2,4-triazol-3-
yl)methanamine (9) 
  
To a solution of protected amine 21 (240 mg, 0.43 mmol, 1.0 eq.) and 2,6-lutidine 
(0.9 mL, 18.0 eq.) in dry CH2Cl2 (4.5 mL) at 0 °C was added slowly TMSOTf 
(0.7 mL, 9.0 eq.) and the resulting solution was allowed to reach room temperature. 
After 6 h, additional 2,6-lutidine (18.0 eq.) and TMSOTf (9.0 eq.) were added at 0°C 
and the mixture was stirred at room temperature for 18 h. The solution was diluted 
with CH2Cl2 (20 mL), washed with saturated aqueous NaHCO3 solution (100 mL), 
brine (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was 
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purified by flash column chromatography (CH2Cl2 : MeOH : NH4OH, 95 : 5 : 0.25) to 
afford primary amine 9 (180 mg, 90% yield) as a pale orange oil. 
Rf 0.14 (CH2Cl2 : MeOH : NH4OH, 95 : 5 : 0.25); IR (thin film) 2942 (br.), 2864, 
1562, 1455, 1100 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 4.9 Hz, 2H, 2 × 
Pyrim-H), 7.31 (d, J = 8.4 Hz, 2H, 2 × Ar-H), 7.20 (t, J = 4.9 Hz, 1H, Pyrim-H), 7.16 
(d, J = 8.4 Hz, 2H, 2 × Ar-H), 3.93 (t, J = 6.4 Hz, 2H, Ar-CH2-CH2-O), 3.84 (br. s, 
2H, NH2-CH2), 2.89 (t, J = 6.4 Hz, 2H, Ar-CH2-CH2-O), 1.70 (br. s, 2H, NH2-CH2), 
1.11–0.96 (sept, J = 5.9 Hz, 3H, Si(CH(CH3)2)3), 1.00 (d, J = 5.9 Hz, 18H, 
Si(CH(CH3)2)3); 13C NMR (100 MHz, CDCl3) δ 158.0, 157.3, 156.1, 152.6, 141.4, 
132.9, 130.3, 126.8, 120.6, 64.1, 39.2, 73.1, 18.0, 11.9; MS (ESI+) 453 [M+H]+; 
HRMS (ESI+) calcd for C24H37N6OSi 453.2798, found 453.2786. 
 
tert-Butyl (2S,3S)-3-methyl-1-oxo-1-((5-(pyrimidin-2-yl)-4-(4-(2-(triisopropyl-
silyloxy)ethyl)phenyl)-4H-1,2,4-triazol-3-yl)methylamino)pentan-2-ylcarbamate 
(26) 
  
A solution of N-Boc-isoleucine (8) (99 mg, 1.1 eq.), EDCI (90 mg, 1.2 eq.) and 
DMAP (5 mg, 0.1 eq.) in dry CH2Cl2 (6 mL) was cooled to 0 °C and stirred for 
20 min. A solution of amine 9 (180 mg) in dry CH2Cl2 (2 mL) was added slowly and 
the mixture was stirred at room temperature for 25 h. The reaction mixture was 
diluted with CH2Cl2 and washed with cold aqueous HCl solution (1 M, 20 mL), cold 
water (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4 and 
evaporated in vacuo and the residue was purified by flash column chromatography 
(CH2Cl2 : MeOH, 95 : 5) to afford amide 26 (210 mg, 81% yield) as a colourless oil. 
Rf 0.34 (CH2Cl2 : MeOH, 95 : 5); [α]D20 –128 (c 1.00, CHCl3); IR (thin film) 
3294 (br.), 2941, 2866, 1673, 1563, 1515, 1171 cm-1; 1H NMR (400 MHz, CDCl3) δ 
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8.61 (d, J = 4.9 Hz, 2H, 2 × Pyrim-H), 7.52 (br. s, 1H, NH-CH2), 7.29 (d, J = 8.3 Hz, 
2H, 2 × Ar-H), 7.18 (t, J = 4.9 Hz, 1H, Pyrim-H), 7.17 (d, J = 8.3 Hz, 2H, 2 × Ar-H), 
5.21 (d, J = 8.9 Hz, 1H, NH), 4.42 (dd, J = 16.5, 5.0 Hz, 1H, NH-CHaHb), 4.36 (dd, J 
= 16.5, 5.0 Hz, 1H, NH-CHaHb), 4.14–4.01 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 3.90 
(t, J = 6.8 Hz, 2H, Ar-CH2-CH2-O), 2.88 (t, J = 6.8 Hz, 2H, Ar-CH2-CH2-O), 1.97–
1.79 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 1.49–1.40 (m, 1H, CH-CH(CH3)-CHaHb-
CH3), 1.38 (s, 9H, C(CH3)3), 1.11–0.97 (m, 4H, CH-CH(CH3)-CHaHb-CH3 + 
Si(CH(CH3)2)3), 1.00 (d, J = 5.7 Hz, 18H, Si(CH(CH3)2)3), 0.87 (d, J = 6.8 Hz, 3H, 
CH-CH(CH3)-CHaHb-CH3), 0.84 (t, J = 7.4 Hz, 3H, CH-CH(CH3)-CHaHb-CH3); 13C 
NMR (100 MHz, CDCl3) δ 171.5, 156.9, 155.6, 155.4, 153.6, 152.3, 140.9, 132.1, 
129.9, 126.6, 120.4, 79.2, 63.9, 58.9, 39.0, 37.3, 34.5, 28.1, 24.2, 17.7, 15.4, 11.6, 
11.3; MS (ESI+) 666 [M+H]+; HRMS (ESI+) calcd for C35H56N7O4Si 666.4163, found 
666.4171. 
 
(2S,3S)-2-Amino-3-methyl-N-((5-(pyrimidin-2-yl)-4-(4-(2-(triisopropylsilyl-
oxy)ethyl)phenyl)-4H-1,2,4-triazol-3-yl)methyl)pentanamide (27) 
  
To a solution of protected amine 26 (200 mg, 0.30 mmol, 1.0 eq.) and 2,6-lutidine 
(625 µL, 18.0 eq.) in dry CH2Cl2 (5 mL) at 0 °C was added slowly TMSOTf (480 µL, 
9.0 eq.). The resulting solution was allowed to reach room temperature and stirred for 
5 h. The solution was diluted with CH2Cl2 (20 mL), washed with saturated aqueous 
NaHCO3 solution (100 mL), brine (100 mL), dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by flash column chromatography (CH2Cl2 : MeOH : 
NH4OH, 95 : 5 : 0.25) to afford primary amine 27 (87 mg, 62% yield) as a yellow oil. 
Rf 0.08 (CH2Cl2 : MeOH : NH4OH, 95 : 5 : 0.25); [α]D20 –101 (c 1.00, CHCl3); IR 
(thin film) 3297 (br.), 2941, 2866, 1674, 1512, 1100 cm-1; 1H NMR (400 MHz, 
N N
N
NH
O
H2N
N
N
OTIPS
 
186 
CDCl3) δ 8.68 (d, J = 4.9 Hz, 2H, 2 × Pyrim-H), 8.19 (s, 1H, NH-CH2), 7.34 (d, J = 
8.3 Hz, 2H, 2 × Ar-H), 7.29 (t, J = 4.9 Hz, 1H, Pyrim-H), 7.19 (d, J = 8.3 Hz, 2H, 2 × 
Ar-H), 4.48 (dd, J = 16.6, 5.4 Hz, 1H, NH-CHaHb), 4.44 (dd, J = 16.6, 5.1 Hz, 1H, 
NH-CHaHb), 3.95 (t, J = 6.7 Hz, 2H, Ar-CH2-CH2-O), 3.33-3.29 (m, 1H, CH-
CH(CH3)-CHaHb-CH3), 2.93 (t, J = 6.7 Hz, 2H, Ar-CH2-CH2-O), 2.05–1.94 (m, 1H, 
CH-CH(CH3)-CHaHb-CH3), 1.68 (br. s, 2H, NH2), 1.45–1.31 (m, 1H, CH-CH(CH3)-
CHaHb-CH3), 1.17–1.02 (m, 4H, CH-CH(CH3)-CHaHb-CH3 + Si(CH(CH3)2)3), 1.05 
(d, J = 5.8 Hz, 18H, Si(CH(CH3)2)3), 0.97 (d, J = 7.1 Hz, 3H, CH-CH(CH3)-CHaHb-
CH3), 0.91 (t, J = 7.3 Hz, 3H, CH-CH(CH3)-CHaHb-CH3); 13C NMR (100 MHz, 
CDCl3) δ 174.9, 157.2, 155.9, 153.9, 152.6, 141.3, 132.4, 130.2, 126.7, 120.7, 64.1, 
59.9, 39.2, 38.0, 34.7, 23.7, 18.0, 16.1, 11.9, 11.8; MS (ESI+) 566 [M+H]+; HRMS 
(ESI+) calcd for C30H48N7O2Si 566.3639, found 566.3660. 
 
(2S,3S)-3-Methyl-2-(2-phenylacetamido)-N-((5-(pyrimidin-2-yl)-4-(4-(2-(triiso-
propylsilyloxy)ethyl)phenyl)-4H-1,2,4-triazol-3-yl)methyl)pentanamide (28) 
  
A solution of phenylacetic acid (7) (7 mg, 1.1 eq.), EDCI (12 mg, 1.2 eq.) and DMAP 
(1 mg, 0.1 eq.) in dry CH2Cl2 (0.5 mL) was cooled to 0 °C and stirred for 20 min. A 
solution of amine 27 (20 mg, 0.04 mmol, 1.0 eq.) in dry CH2Cl2 (0.5 mL) was added 
slowly and the mixture was stirred at room temperature for 26 h. The reaction mixture 
was diluted with CH2Cl2 and washed with cold aqueous HCl solution (1 M, 20 mL), 
cold water (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4 and 
evaporated in vacuo. The residue was purified by flash column chromatography 
(CH2Cl2 : MeOH, 95 : 5) to afford amide 28 (26 mg, 95% yield) as a yellow oil. 
Rf 0.29 (CH2Cl2 : MeOH, 95 : 5); [α]D20 –95 (c 1.00, CHCl3); IR (thin film) 
3270 (br.), 2939, 2865, 1640, 1563, 1514, 1099 cm-1; 1H NMR (400 MHz, CDCl3) δ 
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8.64 (d, J = 4.9 Hz, 2H, 2 × Pyrim-H), 7.68 (t, J = 5.0 Hz, 1H, NH-CH2), 7.28–7.20 
(m, 8H, 5 × Ph-H + 2 × Ar-H + Pyrim-H), 7.16 (d, J = 8.3 Hz, 2H, 2 × Ar-H), 6.39 (d, 
J = 8.8 Hz, 1H, NH), 4.42 (dd, J = 8.8, 6.1 Hz, 1H, CH-CH(CH3)-CHaHb-CH3), 4.37 
(d, J = 5.0 Hz, 2H, NH-CH2), 3.92 (t, J = 6.7 Hz, 2H, Ar-CH2-CH2-O), 3.58 (s, 2H, 
Ph-CH2), 2.89 (t, J = 6.7 Hz, 2H, Ar-CH2-CH2-O), 1.91–1.74 (m, 1H, CH-CH(CH3)-
CHaHb-CH3), 1.37–1.26 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 1.12–1.00 (m, 3H, 
Si(CH(CH3)2)3), 1.02 (d, J = 5.6 Hz, 18H, Si(CH(CH3)2)3), 0.98-0.84 (m, 1H, CH-
CH(CH3)-CHaHb-CH3), 0.79 (d, J = 6.9 Hz, 3H, CH-CH(CH3)-CHaHb-CH3), 0.78 (t, 
J = 7.3 Hz, 3H, CH-CH(CH3)-CHaHb-CH3); 13C NMR (100 MHz, CDCl3) δ 171.3, 
171.0, 157.2, 155.8, 153.7, 152.6, 141.3, 134.9, 132.1, 130.2, 129.3, 128.8, 127.1, 
126.7, 120.7, 64.1, 57.6, 43.6, 39.22, 37.1, 34.8, 24.5, 17.9, 15.5, 11.9, 11.3; MS 
(ESI+) 684 [M+H]+; HRMS (ESI+) calcd for C38H54N7O3Si 684.4057, found 
684.4084. 
 
(2S,3S)-N-((4-(4-(2-Hydroxyethyl)phenyl)-5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-
yl)methyl)-3-methyl-2-(2-phenylacetamido)pentanamide (6a) 
  
To a solution of silyl ether 28 (15 mg, 22.0 µmol, 1.0 eq.) in THF at 0 °C were added 
concentrated AcOH (6 µL, 4.0 eq.) and TBAF (1.0 M in THF, 48 µL, 2.2 eq.). The 
resulting solution was stirred at room temperature for 4 h. Further AcOH (12 µL, 
8.0 eq.) and TBAF (4.4 eq.) were added in two portions at 0 °C and the mixture was 
stirred for 35 h. The mixture was diluted with AcOEt (10 mL), washed with saturated 
aqueous NaHCO3 solution (10 mL) and brine (10 mL), dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(CH2Cl2 : Acetone : MeOH, 5 : 4 : 1), purified a second time (CH2Cl2: MeOH, 92.5 : 
7.5) to afford alcool 6a (10 mg, 83% yield) as a white solid. 
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Rf 0.16 (CH2Cl2 : MeOH, 95 : 5); mp 192–194 °C (CH2Cl2 : petroleum ether, 50 : 50); 
[α]D20 –72 (c 1.00, CHCl3); IR (thin film) 3281 (br.), 3058, 2962, 2929, 1646, 1563, 
1514 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 4.8 Hz, 2H, 2 × Pyrim-H), 8.05 
(br. s, 1H, NH-CH2), 7.33 (d, J = 8.5 Hz, 2H, 2 × Ar-H), 7.25–7.19 (m, 5H, 4 × Ph-H 
+ Pyrim-H), 7.19–7.08 (m, 3H, Ph-H + 2 × Ar-H), 6.82 (d, J = 9.1 Hz, 1H, NHCH), 
4.60 (dd, J = 15.8, 6.3 Hz, 1H, NH-CHaHb), 4.43 (dd, J = 15.8, 4.8 Hz, 1H, NH-
CHaHb), 4.32 (dd, J = 9.1, 6.2 Hz, 1H, CH-CH(CH3)-CHaHb-CH3), 3.91 (t, J = 6.0 Hz, 
2H, Ar-CH2-CH2-O), 3.60 (d, J = 3.9 Hz, 2H, Ph-CH2), 2.91 (t, J = 6.0 Hz, 2H, Ar-
CH2-CH2-O), 2.71 (br. s, 1H, OH), 1.90–1.73 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 
1.32–1.27 (m, 1H, CH-CH(CH3)-CHaHb-CH), 1.04–0.84 (m, 1H, CH-CH(CH3)-
CHaHb-CH3), 0.79 (d, J = 6.8 Hz, 3H, CH-CH(CH3)-CHaHb-CH3), 0.75 (t, J = 7.4 Hz, 
3H, CH-CH(CH3)-CHaHb-CH3); 13C NMR (125 MHz, CDCl3) δ 171.4, 171.2, 157.3, 
155.6, 154.2, 152.4, 141.2, 135.2, 132.3, 130.5, 129.2, 128.7, 127.1, 127.0, 121.0, 
63.2, 57.9, 43.5, 39.0, 37.1, 34.0, 24.6, 15.6, 11.3; MS (ESI+) 528 [M+H]+; HRMS 
(ESI+) calcd for C29H34N7O3 528.2723, found 528.2706. 
 
(2S,3S)-3-Methyl-2-(2-phenylacetamido)pentanoic acid (32)45 
 
Following a literature procedure,45 (L)-isoleucine (8) (650 mg, 7.50 mmol, 1.0 eq.) 
was dissolved in a aqueous solution of NaOH (4 M, 4 mL), phenylacetyl chloride (35) 
(990 µL, 1.5 eq.) was added and the mixture was stirred at room temperature for 
45 min. The product was precipitated by addition of aqueous HCl solution (6 M, 
10 mL) and the resulting mixture was cooled to 0 °C. The crystals were collected, 
washed with cold water and dried in vacuo. The crystals were suspended in a mixture 
of dichloroethane / petroleum ether (1:1) and stirred for 5 min, collected and dried in 
vacuo, to afford amide 32 (700 mg, 56% yield) as pure white solid. 
mp 110–112 °C (dichloroethane : petroleum ether, 50 : 50); [α]D20 –1 (c 1.00, 
MeOH); IR (thin film) 3341 (br.), 2962, 2876, 1697, 1617, 1543, 1235 cm-1; 1H NMR 
(400 MHz, MeOD) δ 7.34–7.12 (m, 5H, 5 × Ph-H), 4.90 (s, 1H, NH), 4.38 (d, J = 
OH
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5.7 Hz, 1H, CH-CH(CH3)-CHaHb-CH3), 3.59 (d, J = 2.9 Hz, 2H, Ph-CH2), 2.03–1.80 
(m, 1H, CH-CH(CH3)-CHaHb-CH3), 1.40–1.60 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 
1.33–1.14 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 0.96–0.85 (m, 6H, CH-CH(CH3)-
CHaHb-CH3); 13C NMR (100 MHz, MeOD) δ 174.8, 174.0, 137.0, 130.2, 129.5, 
127.9, 58.2, 43.4, 38.4, 26.2, 16.0, 11.8; MS (ESI+) 250 [M+H]+; HRMS (ESI+) calcd 
for C14H20NO3 250.1432, found 250.1443. 
 
tert-Butyl 2-(4-fluorophenylamino)-2-oxoethylcarbamate (37) 
 
A solution of N-Boc-glycine (17) (348 mg, 2.00 mmol, 1.0 eq.), EDCI (460 mg, 
1.2 eq.) and DMAP (24 mg, 0.1 eq.) in dry CH2Cl2 (15 mL) was cooled to 0 °C and 
stirred for 15 min. A solution of 4-fluoroaniline (36) (189 µL, 1.0 eq.) in dry CH2Cl2 
(5 mL) was added slowly and the mixture was stirred at room temperature for 72 h. 
The reaction mixture was diluted with CH2Cl2 and washed with cold aqueous HCl 
solution (1 M, 60 mL), cold water (60 mL) and brine (60 mL). The organic layer was 
dried over Na2SO4 and evaporated in vacuo. The residue was purified by flash column 
chromatography (petroleum ether : AcOEt, 70 : 30) to afford amide 37 (304 mg, 60% 
yield) as a white solid. 
Rf 0.16 (petroleum ether : AcOEt, 70 : 30); mp 140–143 °C (petroleum ether : AcOEt, 
70 : 30); IR (thin film) 3310 (br.), 1685, 1510, 1163 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.16 (br. s, 1H, NH-Ar), 7.47 (dd, J = 8.9, 4.8 Hz, 2H, 2 × Ar-H), 7.02 (dd, 
J = 8.9, 8.5 Hz, 2H, 2 × Ar-H), 5.22 (br. s, 1H, NH-CH2), 3.92 (d, J = 5.9 Hz, 2H, 
NH-CH2), 1.48 (s, 9H, C(CH3)3); 13C NMR (125 MHz, MeOD) δ 170.5, 160.7 (d, J = 
246 Hz), 158.6, 135.7, 123.2 (d, J = 7 Hz), 116.3 (d, J = 22 Hz), 80.8, 45.0, 28.7; MS 
(CI+) 269 [M+H]+; HRMS (CI+) calcd for C13H18FN2O3 269.1305, found 269.1301. 
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tert-Butyl 2-(4-fluorophenylamino)-2-thioxoethylcarbamate (34) 
 
To a solution of amide 37 (327 mg, 1.22 mmol, 1.0 eq.) in THF (12 mL) was added 
Lawesson’s reagent (247 mg, 0.5 eq.) and the mixture was refluxed for 2 h. The 
reaction mixture was diluted with CH2Cl2 (50 mL) and washed with saturated 
aqueous NaHCO3 solution (50 mL). The aqueous layer was extracted with CH2Cl2 
(2 × 30 mL). The combined organic layers were dried over Na2SO4 and evaporated in 
vacuo. The residue was purified by flash column chromatography (petroleum ether : 
AcOEt, 70 : 30) to afford thioamide 34 (295 mg, 85% yield) as a white solid. 
Rf 0.24 (petroleum ether : AcOEt, 70 : 30); mp 90–95 °C (petroleum ether : AcOEt, 
70 : 30); IR (thin film) 3340 (br.), 3160, 2980, 1698, 1500, 1161 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 10.29 (br. s, 1H, NH-Ar), 7.67 (dd, J = 9.0, 4.8 Hz, 2H, 2 × Ar-
H), 7.06 (dd, J = 9.0, 8.4 Hz, 2H, 2 × Ar-H), 5.69 (br. s, 1H, NH-CH2), 4.28 (d, J = 
5.6 Hz, 2H, NH-CH2), 1.45 (s, 9H, C(CH3)3); 13C NMR (100 MHz, CDCl3) δ 198.8, 
160.5 (d, J = 243 Hz), 156.7, 134.2, 125.4 (d, J = 8 Hz), 115.5 (d, J = 24 Hz), 80.8, 
52.8, 28.0; MS (ESI+) 285 [M+H]+; HRMS (ESI+) calcd for C13H18FN2O2S 285.1064, 
found 285.1073. 
 
tert-Butyl (4-(4-fluorophenyl)-5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)methyl-
carbamate (38) 
 
Following a literature procedure,37 thioamide 34 (287 mg, 1.01 mmol, 1.0 eq.) was 
dissolved in dry pyridine (10 mL), freshly prepared acyl hydrazide 10 (210 mg, 
1.5 eq.) was added to the solution and the resulting mixture was heated at 100 °C for 
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14 h. Additional acyl hydrazide 10 (140 mg, 1.0 eq) was added and the mixture was 
stirred at 100 °C for 25 h. The reaction mixture was cooled to 0 °C, diluted with 
CH2Cl2 (50 mL) and washed with aqueous HCl solution (1 M, 150 mL). The aqueous 
layer was extracted with CH2Cl2 (2 × 50 mL) and the combined organic layers were 
washed with brine (150 mL), dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (CH2Cl2 : MeOH, 95 : 5) to 
afford 1,2,4-triazole 38 (230 mg, 57% yield) as a pale yellow solid. 
Rf 0.18 (CH2Cl2 : MeOH, 95 : 5); mp > 182 °C (decomp.) (CH2Cl2 : MeOH, 95 : 5); 
IR (thin film) 2968 (br.), 2499, 2674, 1512, 1158 cm-1; 1H NMR (400 MHz, CDCl3) δ 
8.64 (d, J = 4.9 Hz, 2H, 2 × Pyrim-H), 7.29 (dd, J = 8.8, 4.7 Hz, 2H, 2 × Ar-H), 7.22 
(t, J = 4.9 Hz, 1H, Pyrim-H), 7.14 (dd, J = 8.8, 8.4 Hz, 2H, 2 × Ar-H), 5.59 (br. s, 1H, 
NH-CH2), 4.34 (d, J = 5.5 Hz, 2H, NH-CH2), 1.37 (s, 9H, C(CH3)3); 13C NMR 
(100 MHz, CDCl3) δ 162.9 (d, J = 249 Hz), 157.2, 155.6, 155.2, 154.2, 152.6, 130.5, 
129.1 (d, J = 8 Hz), 120.8, 116.5 (d, J = 21 Hz), 79.9, 35.9, 28.2; MS (ESI+) 371 
[M+H]+; HRMS (ESI+) calcd for C18H20FN6O2 371.1626, found 371.1632. 
 
(4-(4-Fluorophenyl)-5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)methanamine (33) 
 
To a solution of protected amine 38 (200 mg, 0.54 mmol, 1.0 eq.) in dry CH2Cl2 
(5 mL) at 0 °C was added dropwise TFA (500 µL) and the mixture was stirred at 
room temperature for 1 h. The reaction mixture was diluted with CH2Cl2 (50 mL) and 
washed with saturated aqueous NaHCO3 solution (50 mL). The aqueous layer was 
extracted with CH2Cl2 (2 × 30 mL) and the combined organic layers were dried over 
Na2SO4 and evaporated in vacuo. The residue was purified by flash column 
chromatography (CH2Cl2 : MeOH, 95 : 5) to afford primary amine 33 (18 mg, 12% 
yield) as a white solid. 
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Rf 0.30 (CH2Cl2 : MeOH : NH4OH, 90 : 10 : 0.25); mp 92–94 °C (CH2Cl2 : MeOH, 
95 : 5); IR (thin film) 3378 (br.), 1563, 1509, 1402 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 8.63 (d, J = 4.9 Hz, 2H, 2 × Pyrim-H), 7.28 (dd, J = 8.9, 4.4 Hz, 2H, 2 × Ar-H), 7.21 
(t, J = 4.9 Hz, 1H, Pyrim-H), 7.15 (dd, J = 8.9, 8.4 Hz, 2H, 2 × Ar-H), 3.83 (s, 2H, 
NH2-CH2), 1.83 (br. s, 2H, NH2-CH2); 13C NMR (100 MHz, CDCl3) δ 162.8 (d, J = 
250 Hz), 157.7, 157.2, 155.8, 152.4, 130.9, 129.2 (d, J = 9 Hz), 120.7, 116.4 (d, J = 
23 Hz), 37.0; MS (ESI+) 271 [M+H]+; HRMS (ESI+) calcd for C13H12FN6 271.1102, 
found 271.1107. 
 
(2S,3S)-N-((4-(4-Fluorophenyl)-5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)methyl)-
3-methyl-2-(2-phenylacetamido)pentanamide (29a) 
 
A solution of carboxylic acid 32 (18 mg, 0.07 mmol, 1.0 eq.), EDCI (16 mg, 1.1 eq.) 
and HOBt (11 mg, 1.2 eq.) in dry CH2Cl2 (1 mL) was stirred for 15 min. Amine 33 
(17 mg, 1.0 eq.) and Et3N (12 µL, 1.2 eq.) were added and the resulting mixture was 
stirred at room temperature for 24 h. The reaction mixture was diluted with CH2Cl2, 
washed with cold aqueous HCl solution (1 M, 60 mL), cold water (60 mL) and brine 
(60 mL). The organic layer was dried over Na2SO4 and evaporated in vacuo. The 
residue was purified by flash column chromatography (CH2Cl2 : MeOH, 95 : 5) to 
afford amide 29a (33 mg, 88% yield) as a white solid. 
Rf 0.28 (CH2Cl2 : MeOH, 95 : 5); mp 172–175 °C (CH2Cl2); [α]D20 –13 (c 1.00, 
MeOH); IR (thin film) 3227 (br.), 1636, 1562, 1510 cm-1; 1H NMR (400 MHz, 
MeOD) δ 8.70 (d, J = 4.5 Hz, 2H, 2 × Pyrim-H), 7.41 (t, J = 4.5 Hz, 1H, Pyrim-H), 
7.38–7.08 (m, 9H, 5 × Ph-H + 4 × Ar-H), 4.50–4.42 (m, 1H, NHCHaHb), 4.42–4.32 
(m, 1H, NHCHaHb), 4.14 (d, J = 7.6 Hz, 1H, CH-CH(CH3)-CHaHb-CH3), 3.54 (d, J = 
4.8 Hz, 2H, Ph-CH2), 1.84–1.70 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 1.49–1.33 (m, 
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1H, CH-CH(CH3)-CHaHb-CH3), 1.17–0.98 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 0.89–
0.75 (m, 6H, CH-CH(CH3)-CHaHb-CH3); 13C NMR (125 MHz, MeOD) δ 173.8, 
173.5, 164.6 (d, J = 248 Hz), 158.8, 156.4, 155.5, 153.9, 136.9, 131.7, 130.9 (d, J = 
9 Hz), 130.2, 129.6, 127.9, 122.8, 117.4 (d, J = 23 Hz), 59.0, 43.7, 38.2, 35.0, 25.8, 
15.9, 11.3; MS (ESI+) 502 [M+H]+; HRMS (ESI+) calcd for C27H29FN7O2 502.2358, 
found 502.2367. 
 
tert-Butyl 2-(cyclopropylamino)-2-oxoethylcarbamate (40) 
 
A solution of N-Boc-glycine (17) (440 mg, 2.50 mmol, 1.0 eq.), EDCI (573 mg, 
1.2 eq.) and DMAP (26 mg, 0.1 eq.) in dry CH2Cl2 (20 mL) was cooled to 0 °C and 
stirred for 15 min. A solution of cyclopropylamine (39) (173 µL, 1.0 eq.) in dry 
CH2Cl2 (5 mL) was added slowly and the mixture was stirred at room temperature for 
72 h. The reaction mixture was diluted with CH2Cl2 and washed with cold aqueous 
HCl solution (1 M, 60 mL), cold water (60 mL) and brine (60 mL). The organic layer 
was dried over Na2SO4 and evaporated in vacuo. The residue was purified by flash 
column chromatography (CH2Cl2 : MeOH, 95 : 5) to afford amide 40 (434 mg, 81% 
yield) as a colourless oil. NMR analyses showed the presence of two rotamers (7:1). 
Rf 0.36 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 3299 (br.), 2978, 1673, 1525, 
1168 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.37 and 5.90 (2 × br. s, 1H, major and 
minor, NHCH), 5.41 and 5.22 (2 × br. s, 1H, minor and major, NH-CH2), 4.10 and 
3.73 (2 × d, J = 5.7 Hz, 2H, minor and major, NH-CH2), 2.80–2.64 and 2.60–2.50 
(2 × m, 1H, major and minor, CH), 1.44 (s, 9H, C(CH3)3), 0.89–0.80 and 0.82–0.71 
(2 × m, 2H, minor and major, 2 × CHaHb), 0.65–0.58 and 0.50–0.45 (2 × m, 2H, 
minor and major, 2 × CHaHb); 13C NMR (100 MHz, CDCl3) δ 170.9, 156.1, 80.0, 44.1 
and 42.3 (major and minor), 28.2, 22.7 and 22.3 (minor and major), 7.9 and 6.3 
(minor and major); MS (ESI+) 237 [M+H]+; HRMS (ESI+) calcd for C10H19N2O3 
237.1208, found 237.1215. 
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tert-Butyl 2-(cyclopropylamino)-2-thioxoethylcarbamate (41) 
 
To a solution of amide 40 (280 mg, 1.30 mmol, 1.0 eq.) in THF (13 mL) was added 
Lawesson’s reagent (263 mg, 0.5 eq.) and the mixture was refluxed for 2 h. The 
reaction mixture was diluted with CH2Cl2 (50 mL) and washed with saturated 
aqueous NaHCO3 solution (50 mL). The aqueous layer was extracted with CH2Cl2 
(2 × 30 mL). The combined organic layers were dried over Na2SO4 and evaporated in 
vacuo. The residue was purified by flash column chromatography (CH2Cl2 : MeOH, 
95 : 5) to afford thioamide 41 (261 mg, 84% yield) as a white solid. NMR analyses 
showed the presence of two rotamers (6:1). 
Rf 0.58 (CH2Cl2 : MeOH, 95 : 5); mp 75–80 °C (CH2Cl2 : MeOH, 95 : 5); IR (thin 
film) 3350 (br.), 3264, 2981, 1693, 1678, 1437 cm-1; 1H NMR (400 MHz, CDCl3) δ 
8.57 (br. s, 1H, CSNH), 5.86 and 5.68 (2 × br. s, 1H, minor and major, NH-CH2), 4.19 
and 4.05 (2 × d, J = 5.2 Hz, 2H, minor and major, NH-CH2), 3.29–3.15 and 2.78–2.70 
(2 × m, 1H, major and minor, CH), 1.40 (s, 9H, C(CH3)3), 0.97–0.82 (m, 2H, 2 × 
CHaHb), 0.72–0.54 (m, 2H, 2 × CHaHb); 13C NMR (100 MHz, CDCl3) δ 201.0, 156.4, 
80.5, 51.5, 28.4 and 28.3 (major and minor), 28.2, 7.7 and 6.8 (minor and major); MS 
(CI+) 231 [M+H]+; HRMS (CI+) calcd for C10H19N2O2S 231.1171, found 231.1167. 
 
tert-Butyl (4-cyclopropyl-5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)methylcarba-
mate (42) 
 
Following a literature procedure,37 thioamide 41 (160 mg, 0.70 mmol, 1.0 eq.) was 
dissolved in dry pyridine (8 mL), freshly prepared acyl hydrazide 10 (144 mg, 1.5 eq.) 
was added to the solution and the resulting mixture was heated at 100 °C for 14 h. 
Additional acyl hydrazide 10 (96 mg, 1.0 eq.) was added and the mixture was stirred 
at 100 °C for 25 h. The reaction mixture was cooled to 0 °C, diluted with CH2Cl2 
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(50 mL) and washed with aqueous HCl solution (1 M, 150 mL). The aqueous layer 
was extracted with CH2Cl2 (2 × 50 mL) and the combined organic layers were washed 
with brine (150 mL), dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by flash column chromatography (CH2Cl2 : MeOH, 99 : 1 ! 95 : 5) to afford 
1,2,4-triazole 42 (10 mg, 4.5% yield) as a pale yellow solid. 
Rf 0.11 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 3276 (br.), 2923, 1700, 1562, 1400, 
1160 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.90 (d, J = 4.9 Hz, 2H, 2 × Pyrim-H), 7.37 
(t, J = 4.9 Hz, 1H, Pyrim-H), 5.57 (br. s, 1H, NH-CH2), 4.65 (d, J = 5.4 Hz, 2H, NH-
CH2), 3.59–3.41 (m, 1H, CH), 1.44 (s, 9H, C(CH3)3), 1.14–1.00 (m, 2H, 2 × CHaHb), 
0.81–0.64 (m, 2H, 2 × CHaHb); 13C NMR (100 MHz, CDCl3) δ 157.3, 156.4, 155.6, 
155.0, 154.0, 120.7, 80.0, 36.3, 28.3, 26.9, 8.6; MS (ESI+) 317 [M+H]+; HRMS 
(ESI+) calcd for C15H21N6O2 317.1718, found 317.1726. 
 
2-Bromo-N-cyclopropylacetamide (47)216 
 
Following a literature procedure,217 bromoacteyl bromide (46) (1.74 mL, 20.0 mmol, 
1.0 eq.) and sodium bicarbonate (3.36 g, 2.0 eq.) were dissolved in THF (150 mL) and 
the solution was cooled to –78 °C. Cyclopropylamine (39) (2.08 mL, 1.2 eq.) was 
added to the solution and the resulting mixture was stirred at –78 °C for 10 min. The 
mixture allowed to reach room temperature over 1 h and stirred for an additional 2 h. 
The reaction mixture was diluted with AcOEt (200 mL) and washed with saturated 
aqueous NaHCO3 solution (200 mL), brine (150 mL), dried over Na2SO4 and 
concentrated in vacuo to afford amide 47 (3.11 g, 87% yield) as a pale yellow solid. 
Further purification was not necessary due to the purity of the product. 
Rf 0.52 (CH2Cl2 : MeOH, 95 : 5); mp 48–50°C (Et2O); IR (thin film) 3269 (br.), 3060, 
2855, 1642, 1542, 826 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.53 (br. s, 1H, CONH), 
3.85 (s, 2H, Br-CH2), 2.78–2.70 (m, 1H, CH), 0.91–0.76 (m, 2H, 2 × CHaHb), 0.60–
0.54 (m, 2H, 2 × CHaHb); 13C NMR (125 MHz, CDCl3) δ 163.1, 29.0, 23.2, 6.5; MS 
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(ESI+) 178, 180 [M+H]+; HRMS (ESI+) calcd for C5H979BrNO 177.9868, found 
177.9874. The analytical data are consistent with the reported data in the literature.216  
 
2-Azido-N-cyclopropylacetamide (48) 
 
Following a literature procedure,218 aliphatic bromide 47 (3.00 g, 16.9 mmol, 1.0 eq.) 
and sodium azide (3.29 g, 3.0 eq.) were dissolved in dry MeCN (150 mL) and the 
reaction mixture was refluxed at –80 °C for 10 h. The solvent was evaporated in 
vacuo and the residue was partitioned between CH2Cl2 (150 mL) and water (150 mL) 
and extracted with CH2Cl2 (2 × 100 mL). The combined organic layers were washed 
with brine (150 mL), dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash column chromatography (CH2Cl2 : MeOH, 99 : 1) to afford azide 48 
(1.80 g, 76% yield) as a white solid. 
Rf 0.50 (CH2Cl2 : MeOH, 95 : 5); mp 28 °C (Et2O); IR (thin film) 3253 (br.), 3063, 
2098, 1649, 1448, 1253 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.37 (br. s, 1H, CONH), 
3.97 (s, 2H, N3-CH2), 2.76–2.67 (m, 1H, CH), 0.84–0.76 (m, 2H, 2 × CHaHb), 0.60–
0.51 (m, 2H, 2 × CHaHb); 13C NMR (125 MHz, CDCl3) δ 168.0, 52.6, 22.5, 6.4; MS 
(CI+) 141 [M+H]+; HRMS (CI+) calcd for C5H9N4O 141.0776, found 141.0772.  
 
2-(5-(Azidomethyl)-4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyrimidine (54) 
 
Following a literature procedure,39 amide 48 (200 mg, 1.43 mmol, 1.0 eq.) and 
2,6-lutidine (168 µL, 1.0 eq.) were dissolved in dry CH2Cl2 (4 mL) at 0 °C, oxalyl 
chloride (124 µL, 1.0 eq.) was added dropwise and the mixture was stirred at 0 °C for 
5 min until no gas evolution was observed. Freshly prepared acyl hydrazide 10 
(200 mg, 1.0 eq.) was added and the reaction mixture was stirred at room temperature 
N3
H
N
O
N N
N
N
N
N3
 
197 
for 12 h. The solvent was evaporated in vacuo and the residue was suspended in 
saturated aqueous NaHCO3 solution (4 mL) and refluxed at 100 °C for 8 h. The 
reaction mixture was diluted with water (50 mL) and extracted with CH2Cl2 (3 × 
50 mL). The combined organic layers were washed with brine (100 mL), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (CH2Cl2 : MeOH, 99 : 1 ! 97 : 3) to afford 1,2,4-triazole 54 (58 mg, 
17% yield) as a white solid. 
Rf 0.30 (CH2Cl2 : MeOH, 95 : 5); mp 120–122 °C (CH2Cl2); IR (thin film) 2091, 
1562, 1398, 723 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.92 (d, J = 4.9 Hz, 2H, 2 × 
Pyrim-H), 7.34 (t, J = 4.9 Hz, 1H, Pyrim-H), 4.69 (s, 2H, N3-CH2), 3.62–3.54 (m, 1H, 
CH), 1.15–1.08 (m, 2H, 2 × CHaHb), 0.82–0.74 (m, 2H, 2 × CHaHb); 13C NMR 
(125 MHz, CDCl3) δ 157.4, 156.3, 154.5, 152.8, 120.9, 44.9, 27.4, 8.4; MS (ESI+) 
243 [M+H]+; HRMS (ESI+) calcd for C10H11N8 243.1107, found 243.1101.  
 
(4-Cyclopropyl-5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)methanamine (43) 
 
To a suspension of Pd/C (10 wt%, 57 mg, 0.1 eq.) in MeOH (1 mL) under 1 atm of H2 
was added azide 54 (57 mg, 0.34 mmol, 1.00 eq) in MeOH (1 mL) and the reaction 
mixture was stirred at room temperature for 2 h. The mixture was filtered through 
celite, washed with MeOH (40 mL) and evaporated in vacuo. The residue was 
purified by flash column chromatography (CH2Cl2 : MeOH : NH4OH, 95 : 5 : 0.25 ! 
90 : 10 : 0.25) to afford amine 43 (48 mg, 92% yield) as a white gum. 
Rf 0.20 (CH2Cl2 : MeOH : NH4OH, 90 : 10 : 0.25); IR (thin film) 3366 (br.), 3287, 
1562, 1399, 634 cm-1; 1H NMR (400 MHz, MeOD) δ 8.91 (d, J = 4.9 Hz, 2H, 2 × 
Pyrim-H), 7.37 (t, J = 4.9 Hz, 1H, Pyrim-H), 4.17 (s, 2H, NH2-CH2), 3.56–3.47 (m, 
1H, CH), 1.14–1.03 (m, 2H, 2 × CHaHb), 0.75–0.69 (m, 2H, 2 × CHaHb); 13C NMR 
(125 MHz, MeOD) δ 158.7, 157.4, 156.6, 153.9, 120.6, 37.8, 29.2, 8.8; MS (ESI+) 
217 [M+H]+; HRMS (ESI+) calcd for C10H13N6 217.1202, found 217.1193.  
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(2S,3S)-N-((4-Cyclopropyl-5-(pyrimidin-2-yl)-4H-1,2,4-triazol-3-yl)methyl)-3-
methyl-2-(2-phenylacetamido)pentanamide (29b) 
 
A solution of carboxylic acid 32 (55 mg, 0.22 mmol, 1.0 eq.), EDCI (46 mg, 1.1 eq.) 
and HOBt (35 mg, 1.2 eq.) in dry CH2Cl2 (6 mL) was stirred for 15 min. Amine 43 
(47 mg, 1.0 eq.) and Et3N (61 µL, 2.0 eq.) were added and the resulting mixture was 
stirred at room temperature for 24 h. The reaction mixture was diluted with CH2Cl2 
and washed with cold aqueous HCl solution (1 M, 60 mL), cold water (60 mL) and 
brine (60 mL). The organic layer was dried over MgSO4 and evaporated in vacuo. 
The residue was purified by flash column chromatography (CH2Cl2 : MeOH, 95 : 5) 
to afford amide 29b (50 mg, 51% yield) as a white solid. NMR analyses showed the 
presence of two diastereoisomers (3 : 2). 
Rf 0.32 (CH2Cl2 : MeOH, 95 : 5); mp 84–85 °C (CH2Cl2); [α]D20 +1 (c 1.00, CHCl3); 
IR (thin film) 3266 (br.), 2961, 2939, 1638, 1540, 695 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.98 (d, J = 4.7 Hz, 2H, 2 × Pyrim-H) 7.88 (br. s, 1H, CONH), 7.37 (t, J = 
4.7 Hz, 1H, Pyrim-H), 7.31–7.18 (m, 5H, 5 × Ph-H), 6.69 (br. s, 1H, CONH), 4.74 
and 4.72 (2 × d, J = 5.1 Hz, 2H, minor and major, NH-CH2), 4.63 and 4.48 (2 × dd, 
J = 4.8, 9.0 Hz, minor, J = 6.5, 8.5 Hz, major, 1H, CH-CH(CH3)-CHaHb-CH3), 3.58 
and 3.57 (2 × s, minor and major, 2H, Ph-CH2), 3.51–3.45 (m, 1H, CH), 2.02–1.93 
and 1.93–1.95 (2 × m, minor and major, 1H, CH-CH(CH3)-CHaHb-CH3), 1.43–1.33 
and 1.33–1.23 (2 × m, major and minor, 1H, CH-CH(CH3)-CHaHb-CH3), 1.12–1.04 
(m, 2H, 2 × CHa’Hb’), 1.06–1.02 and 1.02–0.94 (2 × m, minor and major, 1H, CH-
CH(CH3)-CHaHb-CH3), 0.86–0.88 (m, 8H, CH-CH(CH3)-CHaHb-CH3 + 2 × 
CHa’Hb’); 13C NMR (100 MHz, CDCl3) δ 172.0 and 171.7’ (minor and major), 171.5 
and 171.3 (minor and major), 157.4, 156.2, 154.8, 153.9, 135.0, 129.2, 128.8, 127.1, 
120.8, 57.9 and 56.6 (major and minor), 43.5, 37.2 and 37.1 (minor and major), 34.8, 
27.2, 26.4 and 24.7 (minor and major), 15.6 and 14.4 (major and minor), 11.6 and 
11.2 (minor and major), 8.7 and 8.6 (minor and major); MS (ESI+) 448 [M+H]+; 
HRMS (ESI+) calcd for C24H30N7O2 448.2461, found 448.2451. 
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Isothiocyanatocyclohexane (57)54 
 
Following a literature procedure,54 cyclohexylamine (59) (115 µL, 1.00 mmol, 
1.0 eq.) was dissolved in THF (1 mL), triethylamine (446 µL, 3.2 eq.) was added and 
the reaction mixture was cooled to 0 °C. Carbon disulfide (60 µL, 1.0 eq.) was added 
dropwise and the reaction mixture was allowed to reach room temperature and was 
stirred for an additional 30 min. The mixture was cooled to 0 °C, tosyl chloride 
(209 mg, 1.1 eq.) was added and the reaction mixture was stirred at room temperature 
for 1 h. The mixture was diluted with CH2Cl2 (50 mL), washed with aqueous HCl 
solution (1 M, 50 mL), dried over MgSO4 and evaporated in vacuo. The residue was 
purified by flash column chromatography (hexane) to afford isothiocyanate 57 
(130 mg, 92% yield) as pale yellow oil. 
Rf 0.28 (hexane); IR (thin film) 2935, 2174, 2098, 2059, 1044, 664 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 3.74–3.65 (m, 1H, CH), 1.97–1.85 (m, 2H, 2 × CHeHa), 1.79–
1.59 (m, 4H, 2 × CHeHa + 2 × CHeHa), 1.55–1.45 (m, 1H, CHeHa), 1.45–1.32 (m, 3H, 
2 × CHeHa + CHeHa); 13C NMR (100 MHz, CDCl3) δ 129.5, 55.3, 33.1, 24.9, 23.1; 
MS (EI+) 141 [M]+•; HRMS (EI+) calcd for C7H11NS 141.0612, found 141.0605. The 
analytical data are consistent with the reported data in the literature.54 
 
1-Cyclohexyl-1H-tetrazole-5-thiol (56)55 
 
Following a literature procedure,55 isothiocyanate 57 (1.42 mL, 10.0 mmol, 1.0 eq.) in 
isopropanol (2 mL) was added dropwise to a solution of NaN3 (715 mg, 1.0 eq.) in 
water (8 mL) and the reaction mixture was refluxed at 100 °C for 1 h. The solution 
was cooled to 0 °C and concentrated HCl was added dropwise until pH 1. The crystals 
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were collected, washed with cold water until pH 7 and dried in vacuo to afford 
tetrazole 56 (1.43 g, 77% yield) as a white solid.  
Rf 0.34 (CH2Cl2 : MeOH, 95 : 5); mp 88–90 °C (Et2O); IR (thin film) 3054 (br.), 
2940, 2922, 2857, 2771, 2748, 2555, 1509, 1338 cm-1; 1H NMR (400 MHz, CDCl3) δ 
12.69 (br. s, 1H, Ar-SH), 4.61 (tt, J = 4.0, 12.0 Hz, 1H, CH), 2.14–2.04 (m, 2H, 2 × 
CHeHa), 2.00–1.90 (m, 2H, 2 × CHeHa), 1.89–1.79 (m, 2H, 2 × CHeHa), 1.80–1.74 (m, 
1H, CHeHa), 1.54–1.42 (m, 2H, 2 × CHeHa), 1.36–1.26 (m, 1H, CHeHa); 13C NMR 
(125 MHz, CDCl3) δ 163.6, 57.3, 31.3, 25.1, 24.9; MS (ESI–) 183 [M-H]–; HRMS 
(ESI–) calcd for C7H11N4S 183.0704, found 183.07045.  
 
1-(2-Bromoethoxy)-4-chlorobenzene (55a)219 
 
To a solution of 4-chlorophenol (61a) (1.73 g, 10.0 mmol, 1.0 eq.) in dry acetone 
(10 mL) were added caesium carbonate (4.98 g, 1.5 eq.) and 1,2-dibromoethane (60) 
(3.46 mL, 4.0 eq.) and the reaction mixture was refluxed for 78 h. The mixture was 
poured into water (50 mL), extracted with CH2Cl2 (3 × 30 mL), washed with brine 
(30 mL), dried with MgSO4 and dried in vacuo. The residue was purified by flash 
column chromatography (PE : AcOEt, 97 : 3) to afford ether 55a (1,16 g, 49% yield) 
as a colorless oil. 
Rf 0.26 (PE : AcOEt, 99: 1); IR (thin film) 1489, 1238, 821 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.28 (d, J = 9.1 Hz, 2H, Ar-H), 6.88 (d, J = 9.1 Hz, 2H, Ar-H), 4.29 (t, J = 
6.3 Hz, 2H, OCH2CH2Br), 3.66 (t, J = 6.3 Hz, 2H, OCH2CH2Br); 13C NMR 
(100 MHz, CDCl3) δ 156.7, 129.5, 126.3, 116.1, 68.1, 28.8; MS (EI+) 233, 235, 237 
[M]+•; HRMS (EI+) calcd for C8H879Br35ClO 233.9447, found 233.9441. 
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1-Bromo-4-(2-bromoethoxy)benzene (55b)220 
 
Potassium hydride (200 mg, 30 wt% dispersion in mineral oil, 1.5 eq.) was washed 
with hexanes (3 × 10 mL) and suspended in THF (1 mL). 4-Bromophenol (61b) 
(173 mg, 1.00 mmol, 1.0 eq.) in THF (0.4 mL) was added dropwise and the resulting 
mixture was stirred at room temperature for 20 min. TBAI (2 mg, 0.01 eq.) and 
1,2-dibromoethane (60) (346 µL, 4.0 eq.) were added and the reaction mixture was 
refluxed for 48 h. The solvent was evaporated in vacuo and the residue was 
partitioned between CH2Cl2 (30 mL) and water (30 mL). The organic layer was 
washed with brine (30 mL), dried with MgSO4 and the solvent was evaporated in 
vacuo. The residue was purified by flash column chromatography (PE : AcOEt, 97 : 
3) to afford ether 55b (112 mg, 40% yield) as a colorless oil. 
Rf 0.27 (PE : AcOEt, 99 : 1); IR (thin film) 1486, 1244, 815 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.39 (d, J = 8.9 Hz, 2H, Ar-H), 6.80 (d, J = 8.9 Hz, 2H, Ar-H), 
4.26 (t, J = 6.3 Hz, 2H, OCH2CH2Br), 3.63 (t, J = 6.3 Hz, 2H, OCH2CH2Br); 13C 
NMR (100 MHz, CDCl3) δ 135.1, 132.4, 116.6, 113.7, 68.1, 28.8 (CH2Br); MS (EI+) 
277, 279, 281 [M]+•; HRMS (EI+) calcd for C8H8O79Br2 277.8942, found 277.8954. 
 
5-(2-(4-Chlorophenoxy)ethylthio)-1-cyclohexyl-1H-tetrazole (4) 
 
To a solution of aliphatic bromide 55a (100 mg, 0.42 mmol, 1.0 eq.) and thiol 56 
(78 mg, 1.0 eq.) in THF (0.6 mL) was added DIPEA (81 µL, 1.1 eq.) and the reaction 
mixture was stirred at room temperature for 7 h. The mixture was partitioned between 
water (10 mL) and CH2Cl2 (3 × 10 mL), washed with brine (10 mL), dried with 
MgSO4 and dried in vacuo. The residue was purified by flash column chromatography 
(PE : AcOEt, 90 : 10) to afford thioether 4 (86 mg, 60% yield) as a white solid. 
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Rf 0.54 (PE : AcOEt, 70 : 30); mp 160–162 °C (PE : AcOEt, 70 : 30); IR (thin film) 
2944, 2859, 1491, 1237 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 9.1 Hz, 2H, 
Ar-H), 6.85 (d, J = 9.1 Hz, 2H, Ar-H), 4.34 (t, J = 6.0 Hz, 2H, OCH2CH2Br), 4.18–
4.10 (m, 1H, CH), 3.72 (t, J = 6.0 Hz, 2H, OCH2CH2S), 2.06–2.00 (m, 2H, 2 × 
CHeHa), 2.00–1.89 (m, 4H, 2 × CHeHa + 2 × CHeHa), 1.79–1.72 (m, 1H, CHeHa), 
1.47–1.25 (m, 3H, 2 × CHeHa + CHeHa); 13C NMR (100 MHz, CDCl3) δ 156.7, 152.2, 
129.4, 126.2, 115.9, 66.2, 58.3, 32.2, 32.0, 25.1, 24.8; MS (ESI+) 339, 341 [M+H]+; 
HRMS (ESI+) calcd for C15H2035ClN4OS 339.1046, found 339.1041.  
 
5-(2-(4-Bromophenoxy)ethylthio)-1-cyclohexyl-1H-tetrazole (30) 
 
To a solution of aliphatic bromide 55b (80 mg, 0.29 mmol, 1.0 eq.) and thiol 56 
(54 mg, 1.0 eq.) in THF (0.5 mL) was added DIPEA (56 µL, 1.1 eq.) and the reaction 
mixture was stirred at room temperature for 30 h. The mixture was partitioned 
between water (10 mL) and CH2Cl2 (3 × 10 mL), washed with brine (10 mL), dried 
with MgSO4 and dried in vacuo. The residue was purified by flash column 
chromatography (PE : AcOEt, 90 : 10) to afford thioether 30 (70 mg, 63% yield) as a 
white solid. 
Rf 0.42 (PE : AcOEt, 70 : 30); mp 90–92 °C (PE : AcOEt, 70 : 30); IR (thin film) 
2940, 2856, 1489, 1236, 820 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.9 Hz, 
2H, Ar-H), 6.79 (d, J = 8.9 Hz, 2H, Ar-H), 4.33 (t, J = 6.0 Hz, 2H, OCH2CH2Br), 
4.18–4.08 (m, 1H, CH), 3.72 (t, J = 6.0 Hz, 2H, OCH2CH2S), 2.08–1.87 (m, 6H, 2 × 
CHeHa + 2 × CHeHa + 2 × CHeHa), 1.79–1.70 (m, 1H, CHeHa), 1.48–1.22 (m, 3H, 2 × 
CHeHa + CHeHa); 13C NMR (100 MHz, CDCl3) δ 157.3, 152.2, 132.4, 116.4, 113.6, 
66.2, 58.4, 32.2, 32.0, 25.1, 24.8; MS (ESI+) 383, 385 [M+H]+; HRMS (ESI+) calcd 
for C15H2079BrN4OS 383.0541, found 383.0546.  
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Picolinohydrazide (63)37 
 
Following a literature procedure,57 hydrazine monohydrate (582 µL, 1.2 eq.) was 
added dropwise to a solution of ether 64 (1.20 mL, 10.0 mmol, 1.0 eq.) in MeOH 
(20 mL) and the solution was refluxed for 4 h. The solvent was evaporated in vacuo 
and the residue was dissolved in MeOH (10 mL). The solvent was evaporated again to 
afford acyl hydrazide 64 (1.36 g, 99% yield) as white needles. 
Rf 0.32 (CH2Cl2 : MeOH, 95 : 5); mp 78–80 °C (MeOH); IR (thin film) 3289 (br.), 
3210, 1672, 1646, 1518, 973 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.00 (br. s, 1H, NH-
NH2), 8.56–8.52 (m, 1H, Py-H), 8.17–8.13 (m, 1H, Py-H), 7.88–7.82 (m, 1H, Py-H), 
7.47–7.41 (m, 1H, Py-H), 4.09 (br. s, 2H, NH-NH2); 13C NMR (100 MHz, CDCl3) δ 
164.7, 149.0, 148.4, 137.3, 126.5, 122.2; MS (ESI+) 138 [M+H]+; HRMS (ESI+) calcd 
for C6H8N3O 138.0667, found 138.0662. 
 
N-Cyclohexyl-2-picolinoylhydrazinecarbothioamide (65a) 
 
Following a literature procedure,58 freshly prepared acyl hydrazide 63 (1.37 g, 
10.0 mmol, 1.0 eq.) was dissolved in EtOH (50 mL), isothiocyanate 57 (1.42 mL, 
1.0 eq.) was added and the reaction mixture was refluxed for 6 h. The mixture was 
cooled to room temperature and the precipitate was collected, washed with cold EtOH 
and dried in vacuo to afford thiosemicarbazide 65a (2.07 g, 75% yield) as a white 
solid. 
Rf 0.63 (CH2Cl2: MeOH : NH4OH, 95 : 5 : 0.25); mp 140–142 °C (EtOH); IR (thin 
film) 3295 (br.), 3241 (br.), 2928, 2850, 1652, 1543, 1428, 1243 cm-1; 1H NMR 
(400 MHz, d6-DMSO) δ 10.48 (br. s, 1H, NH), 9.31 (br. s, 1H, NH), 8.69–8.65 (m, 
1H, Py–H), 8.05–7.98 (m, 2H, 2 × Py-H), 7.70–7.60 (m, 2H, Py-H + NH), 4.16–4.02 
N
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(m, 1H, CH), 1.86–1.50 (m, 5H, 5 × CHeHa), 1.32–1.16 (m, 4H, 4 × CHeHa), 1.13–
1.00 (m, 1H, CHeHa); 13C NMR (125 MHz, d6-DMSO) δ 180.1, 162.9, 149.2, 148.5, 
137.7, 126.9, 122.4, 52.8, 31.8, 25.1, 24.8; MS (ESI+) 279 [M+H]+; HRMS (ESI+) 
calcd for C13H19N4OS 279.1280, found 279.1274. 
 
N-Cyclohexyl-2-(pyrimidine-2-carbonyl)hydrazinecarbothioamide (65b)  
 
Following a literature procedure,58 freshly prepared acyl hydrizde 10 (753 mg, 
5.45 mmol, 1.0 eq.) was dissolved in EtOH (25 mL), isothiocyanate 57 (773 µL, 
1.0 eq.) was added and the reaction mixture was refluxed for 12 h. The mixture was 
cooled to room temperature and the precipitate was collected, washed with cold EtOH 
and dried in vacuo to afford thiosemicarbazide 65b (1.23 g, 81% yield) as a white 
solid. 
Rf 0.15 (CH2Cl2: MeOH, 95 : 5); mp 160–162 °C (EtOH); IR (thin film) 3276 (br.), 
2925 (br.), 2853, 1668, 1546, 1247 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 10.61 (br. 
s, 1H, NH), 9.37 (br. s, 1H, NH), 8.99 (d, J = 4.8 Hz, 2H, 2 × Pyrim-H), 7.72 (t, J = 
4.8 Hz, 1H, Pyrim-H), 7.66 (br. s, 1H, NH), 4.16–4.02 (m, 1H, CH), 1.86–1.52 (m, 
5H, 5 × CHeHa), 1.32–1.16 (m, 5H, 5 × CHeHa); 13C NMR (100 MHz, d6-DMSO) δ 
179.6, 161.0, 157.3, 156.7, 123.0, 52.6, 31.5, 24.8, 24.5; MS (ESI+) 280 [M+H]+; 
HRMS (ESI+) calcd for C12H18N5OS 280.1232, found 280.1227.  
 
4-Cyclohexyl-5-(pyridin-2-yl)-4H-1,2,4-triazole-3-thiol (62a) 
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Following a literature procedure,58 thiosemicarbazide 61a (2.00 g, 7.20 mmol, 1.0 eq.) 
was added portionwise into aqueous NaOH solution (2 M, 70 mL) at 80 °C and the 
reaction mixture was refluxed for 16 h. The mixture was cooled to room temperature 
and aqueous HCl solution (2 M) was added slowly until pH 1. The precipitate was 
collected, washed with water and dried in vacuo to afford 1,2,4-triazole 62a (1.23 g, 
78% yield) as a white solid. 
Rf 0.46 (CH2Cl2 : MeOH : NH4OH, 90 : 10 : 0.1); mp 152–154 °C (Et2O); IR (thin 
film) 3089 (br.), 2931, 2852, 1499, 1298, 791 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 
14.03 (s, 1H, Ar-SH), 8.79–8.75 (m, 1H, Py-H), 8.05–7.99 (m, 1H, Py-H), 7.86–7.81 
(m, 1H, Py-H), 7.63–7.58 (m, 1H, Py-H), 4.86–4.75 (m, 1H, CH), 2.42–2.19 (m, 2H, 
2 × CHeHa), 1.81–1.62 (m, 4H, 2 × CHeHa + 2 × CHeHa), 1.63–1.53 (m, 1H, CHeHa), 
1.32–1.16 (m, 2H, 2 × CHeHa), 1.11–0.96 (m, 1H, CHeHa); 13C NMR (125 MHz, d6-
DMSO) δ 167.2, 150.1, 149.2, 146.5, 137.8, 125.3, 124.8, 56.9, 28.9, 25.5, 24.6; MS 
(ESI+) 261 [M+H]+; HRMS (ESI+) calcd for C13H17N4S 261.1174, found 261.1184.  
 
4-Cyclohexyl-5-(pyrimidin-2-yl)-4H-1,2,4-triazole-3-thiol (62b) 
 
Following a literature procedure,58 thiosemicarbazide 61b (1.22 g, 4.30 mmol, 
1.0 eq.) was added portionwise into aqueous NaOH solution (2 M, 40 mL) at 80 °C 
and the reaction mixture was refluxed for 16 h. The mixture was cooled to room 
temperature and aqueous HCl solution (2 M) was added slowly until pH 1. The 
precipitate was collected, washed with water and dried in vacuo to afford 
1,2,4-triazole 62b (1.23 g, 50% yield) as a white solid. 
Rf 0.49 (CH2Cl2 : MeOH : NH4OH, 90 : 10 : 0.1); mp 118–120 °C (Et2O); IR (thin 
film) 3380 (br.), 3153, 2920, 2855, 1565, 1445, 809 cm-1; 1H NMR (400 MHz, d6-
DMSO) δ 14.12 (s, 1H, Ar-SH), 9.05 (d, J = 5.0 Hz, 2H, 2 × Pyrim-H), 7.74 (t, J = 
5.0 Hz, 1H, Pyrim-H), 4.71–4.67 (m, 1H, CH), 2.21–2.02 (m, 2H, 2 × CHeHa), 1.80–
1.65 (m, 4H, 2 × CHeHa + 2 × CHeHa), 1.62–1.54 (m, 1H, CHeHa), 1.33–1.18 (m, 2H, 
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2 × CHeHa), 1.07–0.94 (m, 1H, CHeHa); 13C NMR (125 MHz, d6-DMSO) δ 167.0, 
158.0, 155.3, 149.0, 122.4, 57.0, 29.1, 25.4, 24.6; MS (ESI+) 262 [M+H]+; HRMS 
(ESI+) calcd for C12H16N5S 262.1126, found 262.1115. 
 
2-(5-(2-(4-Chlorophenoxy)ethylthio)-4-cyclohexyl-4H-1,2,4-triazol-3-yl) 
pyridine (31a) 
 
To a solution of aliphatic bromide 55a (364 mg, 2.0 eq.) and thiol 62a (200 mg, 
0.77 mmol, 1.0 eq.) in THF (0.8 mL) was added DIPEA (148 µL, 1.1 eq.) and the 
reaction mixture was stirred at room temperature for 96 h. The mixture was 
partitioned between water (10 mL) and CH2Cl2 (3 × 10 mL), washed with brine 
(10 mL), dried with MgSO4 and dried in vacuo. The residue was purified by flash 
column chromatography (PE : AcOEt, 90 : 10) to afford thioether 31a (170 mg, 85% 
yield) as a white solid. 
Rf 0.26 (PE : AcOEt, 50 : 50); mp 108–110 °C (PE : AcOEt, 50 : 50); IR (thin film) 
2938, 1585, 1489, 1227 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.68–8.63 (m, 1H, Py-
H), 8.13–8.09 (m, 1H, Py-H), 7.85–7.79 (m, 1H, Py-H), 7.37–7.32 (m, 1H, Py-H), 
7.28–7.20 (m, 2H, 2 × Ar-H), 6.92–6.86 (m, 2H, 2 × Ar-H), 5.22–5.12 (m, 1H, CH), 
4.38 (t, J = 6.2 Hz, 2H, OCH2CH2S), 3.72 (t, J = 6.2 Hz, 2H, OCH2CH2S), 2.30–5.17 
(m, 2H, 2 × CHeHa), 1.92–1.82 (m, 4H, 2 × CHeHa + 2 × CHeHa), 1.73–1.75 (m, 1H, 
CHeHa), 1.41–1.17 (m, 3H, 2 × CHeHa + CHeHa); 13C NMR (125 MHz, CDCl3) δ 
157.1, 154.1, 151.2, 148.8, 148.3, 136.9, 129.3, 125.9, 124.6, 123.9, 116.0, 66.8, 57.0, 
32.3, 30.8, 26.0, 25.0; MS (ESI+) 415, 417 [M+H]+; HRMS (ESI+) calcd for 
C21H2435ClN4OS 415.1359, found 415.1338. 
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2-(5-(2-(4-Chlorophenoxy)ethylthio)-4-cyclohexyl-4H-1,2,4-triazol-3-yl) 
pyrimidine (31b) 
 
To a solution of aliphatic bromide 55a (384 mg, 2.0 eq.) and thiol 62b (200 mg, 
0.77 mmol, 1.0 eq.) in THF (0.8 mL) was added DIPEA (148 µL, 1.1 eq.) and the 
reaction mixture was stirred at room temperature for 96 h. The mixture was 
partitioned between water (10 mL) and CH2Cl2 (3 × 10 mL), washed with brine 
(10 mL), dried with MgSO4 and dried in vacuo. The residue was purified by flash 
column chromatography (AcOEt : MeOH, 99 : 1 → 95 : 5) to afford thioether 31b 
(251 mg, 78% yield) as a white solid. 
Rf 0.24 (AcOEt : MeOH, 99 : 1 → 95 : 5); mp 118–120 °C (AcOEt : MeOH, 95 : 5); 
IR (thin film) 2944, 1559, 1492, 1232 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.90 (d, 
J = 4.9 Hz, 2H, 2 × Pyrim-H), 7.35 (t, J = 4.9 Hz, 1H, Pyrim-H), 7.26–7.20 (m, 2H, 2 
× Ar-H), 6.93–6.88 (m, 2H, 2 × Ar-H), 5.08–4.98 (m, 1H, CH), 4.37 (t, J = 6.1 Hz, 
2H, OCH2CH2S), 3.72 (t, J = 6.1 Hz, 2H, OCH2CH2S), 2.30–5.20 (m, 2H, 2 × 
CHeHa), 1.91–1.83 (m, 4H, 2 × CHeHa + 2 × CHeHa), 1.72–1.67 (m, 1H, CHeHa), 
1.40–1.16 (m, 3H, 2 × CHeHa + CHeHa); 13C NMR (125 MHz, CDCl3) δ 157.5, 157.0, 
157.0, 153.1, 151.5, 129.3, 125.8, 120.7, 116.0, 66.6, 57.3, 32.2, 30.7, 26.0, 24.9; MS 
(ESI+) 416, 418 [M+H]+; HRMS (ESI+) calcd for C20H2335ClN5OS 416.1312, found 
416.1295. 
 
tert-Butyl prop-2-ynylcarbamate (69)221 
 
Following a literature procedure,221 propargyl amine (68) (64 µL, 1.00 mmol, 1.0 eq.) 
was dissolved in dry CH2Cl2 at 0 °C and Boc2O (219 mg, 1.0 eq.) was added and the 
reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated 
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in vacuo to afford protected amine 69 (91 mg, 58% yield) as a white solid. Further 
purification was not necessary due to the purity of the product. 
Rf 0.26 (PE : AcOEt, 95 : 5); mp 24–26°C (PE); IR (thin film) 3305 (br.), 3280, 2981, 
1674, 1530, 1157, 652 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.72 (br. s, 1H, NHBoc), 
3.91 (br. s, 2H, NHCH2), 2.21 (t, J = 2.5 Hz, 1H, C≡CH), 1.45 (s, 9H, C(CH3)3); 13C 
NMR (100 MHz, CDCl3) δ 155.2, 80.1, 77.2, 71.2, 30.4, 28.3; MS (CI+) 173 
[M+NH4]+; HRMS (CI+) calcd for C8H17N2O2 173.1290, found 173.1289. The 
analytical data are consistent with the reported data in the literature.221  
 
tert-Butyl (1H-1,2,3-triazol-4-yl)methylcarbamate (70)222 
 
To a solution of terminal alkyne 69 (85 mg, 0.55 mmol, 1.0 eq.) in a mixture of 
MeOH : DMF (1 : 9) were added copper iodide (6 mg, 0.1 eq.) and TMS azide 
(109 µL, 1.5 eq.) and the reaction mixture was heated at 95 °C in a sealed tube for 
13 h. The solvent was evaporated in vacuo and the residue was purified by flash 
column chromatography (CH2Cl2 : MeOH, 99 : 1 ! 95 : 5) to afford triazole 70 
(50 mg, 51% yield) as a colorless oil. 
Rf 0.30 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 3149 (br.), 2977, 2932, 1678, 1518, 
1162 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H, C=CH), 5.30 (br. s, 1H, 
NHBoc), 4.44 (d, J = 6.0 Hz, 2H, NHCH2), 1.45 (s, 9H, C(CH3)3); 13C NMR 
(125 MHz, CDCl3) δ 156.2, 144.5, 130.5 (br. s), 80.1, 35.6, 28.4; MS (ESI+) 221 
[M+Na]+; HRMS (ESI+) calcd for C8H14N4O2Na 221.1014, found 221.1002.  
 
(1H-1,2,3-Triazol-4-yl)methanamine hydrochloride (67.HCl) 
 
BocHN
N
H
N
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Protected amine 70 (89 mg, 0.45 mmol, 1.0 eq.) was dissolved in an HCl solution in 
dioxane (4 M, 2 mL) and the reaction mixture was stirred for 30 min at room 
temperature. The solvent was evaporated in vacuo and the precipitate was triturated 
with MeCN, collected, washed with MeCN and dried in vacuo to afford the HCl salt 
of primary amine 67 (38 mg, 63% yield) as a white solid. Further purification was not 
necessary due to the purity of the product. 
mp > 150 °C (decomp.) (MeCN); IR (thin film) 3136 (br.), 2819, 2590, 1486, 883 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.48 (br. s, 3H, NH3Cl), 7.98 (s, 1H, C=CH), 
4.17–4.09 (m, 1H, NHCH2); 13C NMR (100 MHz, DMSO-d6) δ 139.8, 128.9, 33.7; 
MS (EI+) 98 [M]+•; HRMS (EI+) calcd for C3H6N4 98.0592, found 98.0583.  
 
(S)-Ethyl indoline-2-carboxylate hydrochloride (73.HCl) 
 
Following a literature procedure,223 (S)-indoline-2-carboxylic acid (72) (163 mg, 
1.00 mmol, 1.0 eq.) was suspended in dry MeOH (2 mL) at 0 °C, thionyl chloride 
(159 µL, 1.5 eq.) was added dropwise and the reaction mixture was stirred at room 
temperature for 1 h. The solvent was evaporated in vacuo to afford the HCl salt of 
indoline 73 (227 mg, 99% yield) as a pale brown solid. The product is used crude in 
the next reaction.  
1H NMR (400 MHz, MeOD) δ 7.53–7.38 (m, 4H, 4 × Ar-H), 5.07 (app. t, J = 8.3 Hz, 
1H, CHCO2Et), 4.33 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 3.69 (dd, J = 9.5, 16.5 Hz, 1H, 
Ar-CHaHb), 3.49 (dd, J = 7.3, 16.5 Hz, 1H, Ar-CHaHb), 1.32 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3); MS (ESI+) 192 [M+H]+; HRMS (ESI+) calcd for C11H14NO2 192.1025, 
found 192.1019.  
 
 
ClH.HN
CO2Et
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(S)-Ethyl 1-acetylindoline-2-carboxylate (71) 
 
To a suspension of indoline 73.HCl (276 mg, 0.99 mmol, 1.0 eq.) in dry CH2Cl2 
(2 mL) was added dropwise triethylamine (289 µL, 2.0 eq.) and the mixture was 
stirred for 5 min. Acyl chloride (71 µL, 1.0 eq.) was added dropwise and the reaction 
mixture was stirred at room temperature for 2 h. The solvent was evaporated in vacuo 
and the residue was purified by flash column chromatography (CH2Cl2 : MeOH, 99 : 
1) to afford amide 71 (218 mg, 93% yield) as a white solid. NMR analyses showed 
the presence of two rotamers (3 : 2). 
Rf 0.46 (CH2Cl2 : MeOH, 99 : 1); mp 72–74 °C (Et2O); IR (thin film) 2984, 1723, 
1662, 1204, 752 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.25–8.19 (m, 0.6H, Ar-H), 
7.29–7.11 (m, 2.4H, Ar-H), 7.06–7.00 (m, 1H, Ar-H), 5.14 and 4.89 (2 × d, J = 
9.6 Hz, 1H, minor and major, CHCO2Et), 4.29–4.16 (m, 2H, CO2CH2CH3), 3.62 and 
3.49 (2 × dd, J = 16.1, 11.4 Hz, 1H, major and minor, Ar-CHaHb), 3.26 and 3.09 (2 × 
d, J = 16.1 Hz, 1H, major and minor, Ar-CHaHb), 2.49 and 2.18 (2 × s, 3H, COCH3), 
1.27 (t, J = 7.1 Hz, 3H, CO2CH2CH3); 13C NMR (125 MHz, CDCl3) δ 171.3, 168.9 
and 168.4 (major and minor), 142.7 and 141.4 (major and minor), 130.9 and 128.4 
(minor and major), 127.9 and 127.8 (major and minor), 125.7 and 124.2 (minor and 
major), 124.0 and 123.4 (major and minor), 117.3 and 113.7 (major and minor), 62.0 
and 61.4 (major and minor), 61.4 and 60.3 (major and minor), 33.6 and 31.5 (major 
and minor), 24.5 and 23.7 (minor and major), 14.1; MS (ESI+) 234 [M+H]+; HRMS 
(ESI+) calcd for C13H16NO3 234.1130, found 234.1124.  
 
(S)-1-Acetylindoline-2-carboxylic acid (74)60 
 
AcN
CO2Et
AcN
CO2H
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To a solution of ester 71 (50 mg, 0.20 mmol, 1.0 eq.) in dry MeOH (2 mL) was added 
lithium hydroxide (24 mg, 5.0 eq.) and the reaction mixture was stirred at room 
temperature for 12 h. Aqueous HCl solution (1 M, 3 mL) was added dropwise until 
pH 1 and the resulting mixture was extracted with CH2Cl2 (3 × 20 mL). The 
combined organic layers were washed with brine (50 mL), dried over MgSO4 and 
concentrated in vacuo to afford carboxylic acid 74 (18 mg, 43% yield) as a white 
solid. NMR analyses showed the presence of two rotamers (3 : 1). 
mp > 140 °C (decomp.) (CH2Cl2); [α]D20 –132° (c 1.17, EtOH); lit60 [α]D –133 (c 1.17, 
EtOH); IR (thin film) 2852 (br.), 2489, 1718, 1613, 1209, 754 cm-1; 1H NMR (400 
MHz, MeOD) δ 8.13–8.07 (m, 0.75H, Ar-H), 7.34–7.15 (m, 3.25H, Ar-H), 7.08–7.01 
(m, 1H, Ar-H), 5.12 (dd, J = 10.8, 2.1 Hz, 1H, CHCO2H), 3.65 and 3.54 (2 × dd, J = 
16.4, 10.8 Hz, 1H, major and minor, Ar-CHaHb), 3.29 and 3.11 (2 × br. d, J = 
16.4 Hz, 1H, major and minor, Ar-CHaHb), 2.48 and 2.19 (2 × s, 3H, minor and 
major, COCH3); 13C NMR (125 MHz, MeOD) δ 157.7, 172.1, 143.8, 130.9, 128.9 and 
128.5 (major and minor), 126.7 and 125.5 (minor and major), 125.3 and 124.9 (major 
and minor), 118.1 and 115.4 (major and minor), 62.7 and 61.7 (major and minor), 
34.3 and 32.5 (major and minor), 24.5 and 23.6 (minor and major); MS (ESI+) 206 
[M+H]+; HRMS (ESI+) calcd for C11H12NO3 206.0817, found 206.0813. The 
analytical data are consistent with the reported data in the literature.60  
 
(3S,6S)-3-((2S,3S)-2-(2-(Benzo[b]thiophen-3-yl)acetamido)-3-methylpentanami-
do)-4-oxo-1,2,3,4,6,7-hexahydroazepino[3,2,1-hi]indole-6-carboxylic acid (75) 
 
To a solution of ester 66 (11 mg, 0.02 mmol, 1.0 eq.) in a mixture of THF and water 
(4 : 1, 0.5 mL) was added lithium hydroxide (24 mg, 5.0 eq.) and the reaction mixture 
was stirred at room temperature for 1 h. Aqueous HCl solution (1 M, 3 drops) was 
added dropwise until pH 1 and the resulting mixture was extracted with CH2Cl2 (3 × 
10 mL). The combined organic layers were washed with brine (20 mL), dried over 
N
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MgSO4 and concentrated in vacuo to afford carboxylic acid 75 (10 mg, 99% yield) as 
a white solid. The product was used crude in the next reaction. 
MS (ESI+) 534 [M+H]+; HRMS (ESI+) calcd for C23H32N3O5S 534.2056, found 
534.2063.  
 
(3S,6S)-N-((1H-1,2,3-Triazol-4-yl)methyl)-3-((2S,3S)-2-(2-(benzo[b]thiophen-3-
yl)acetamido)-3-methylpentanamido)-4-oxo-1,2,3,4,6,7-hexahydroazepino[3,2,1-
hi]indole-6-carboxamide (3)22 
 
To a solution of carboxylic acid 75 (10 mg, 0.02 mmol, 1.0 eq.) and amine salt 
67.HCl (4 mg, 1.2 eq.) in dry DMF (0.5 mL) were added HATU (8 mg, 1.0 eq.) and 
DIPEA (7 µL, 2.2 eq.) and the reaction mixture was stirred at room temperature for 
2.5 h. The reaction mixture was diluted with CH2Cl2 (10 mL) and washed with 
aqueous HCl solution (1 M, 10 mL) and brine (10 mL). The organic layer was dried 
over MgSO4 and evaporated in vacuo. The residue was purified by flash column 
chromatography (CH2Cl2 : MeOH, 95 : 5) to afford amide 3 (6 mg, 52% yield) as a 
white solid. 
Rf 0.12 (CH2Cl2 : MeOH, 95 : 5); mp 148–150 °C (CH2Cl2); [α]D20 –26 (c 0.50, 
MeOH); IR (thin film) 3279 (br.), 2928, 1634, 1536, 1455, 760 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δ 8.48 (t, J = 5.7 Hz, 1H, CONH), 8.32 (d, J = 6.8 Hz, 1H, 
CONH), 8.25 (d, J = 9.3 Hz, 1H, CONH), 7.96–7.93 (m, 1H, triazole-H), 7.87–7.84 
(m, 1H, Ar-H), 7.61 (br. s, 1H, N(Ar)-H), 7.51 (s, 1H, Ar-H), 7.37–7.34 (m, 2H, 2 × 
Ar-H), 7.09 (d, J = 7.2 Hz, 1H, Ar-H), 7.05 (d, J = 7.5 Hz, 1H, Ar-H), 6.97 (dd, J = 
7.2, 7.5 Hz, 1H, Ar-H), 5.04 (dd, J = 15.1, 3.0 Hz, 1H, Ar-CHaHb-CH), 4.40–4.34 (m, 
1H, CH-CH(CH3)-CHaHb-CH3), 4.32 (dd, J = 7.1, 5.9 Hz, 2H, CH2-triazole), 4.29–
4.24 (m, 1H, Ar-CH2-CH2-CH), 3.79 (dd, J = 42.7, 15.1 Hz, 2H, Ar-CH2-CO), 3.45 
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(dd, J = 16.8, 11.5 Hz, 1H, Ar-CHaHb-CH), 3.09–3.03 (m, 2H, Ar-CH2-CH2-CH), 
2.92 (dd, J = 17.0, 2.7 Hz, 1H, Ar-CHaHb-CH), 2.10–1.97 (m, 2H, Ar-CH2-CH2-CH), 
1.82–1.73 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 1.50–1.41 (m, 1H, CH-CH(CH3)-
CHaHb-CH3), 1.17–1.07 (m, 1H, CH-CH(CH3)-CHaHb-CH3), 0.87 (d, J = 6.7 Hz, 3H, 
CH-CH(CH3)-CHaHb-CH3), 0.79 (t, J = 7.4 Hz, 3H, CH-CH(CH3)-CHaHb-CH3); 13C 
NMR (125 MHz, DMSO-d6) δ 170.7, 170.4, 169.1, 168.9, 139.4, 138.8, 138.7, 132.4, 
131.6, 130.8, 129.3, 128.6 (br. s), 125.4, 124.2, 124.2, 123.9, 123.5, 122.9, 122.7, 
122.2, 60.7, 56.9, 52.6, 36.7, 35.2, 31.9, 30.9, 30.7, 28.4, 24.3, 15.4, 11.0; MS (ESI+) 
614 [M+H]+; HRMS (ESI+) calcd for C32H36N7O4S 614.2549, found 614.2543. 
 
 
3.2. Chapter 2 
 
N-Methylbenzenesulfonamide (121)224 
 
To a solution of methylamine hydrochloride (655 mg, 9.70 mmol, 1.0 eq.) in CH2Cl2 
(50 mL) were added triethylamine (1.23 mL, 2.1 eq.) and benzenesulfonyl chloride 
(122) (2.84 mL, 1.0 eq.) and the reaction mixture was stirred at room temperature for 
48 h. The mixture was washed with water (50 mL), extracted with CH2Cl2 (3 × 
30 mL), dried with Na2SO4 and evaporated in vacuo. The residue was purified by 
flash column chromatography (CH2Cl2 : MeOH, 95 : 5) to afford sulfonamide 121 as 
a colourless oil (1.44 g, 87% yield). 
Rf 0.23 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 3288 (br.), 1447, 1309, 1155 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.89–7.85 (m, 2H, 2 × Ar-H), 7.65–7.57 (m, 1H, Ar-H), 
7.56–7.50 (m, 2H, 2 × Ar-H), 4.62–4.54 (m, 1H, NH), 2.66 (d, J = 5.5 Hz, 3H, 
NCH3); 13C NMR (100 MHz, CDCl3) δ 138.8, 132.8, 129.2, 127.2, 29.4; MS (CI+) 
189 [M+NH4]+; HRMS (CI+) calcd for C7H13N2O2S 189.0698, found 189.0694. 
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Methyl 4-methoxy-2-methylbenzoate (123)225 
 
To a solution of 4-methoxy-2-methylbenzoic acid (115) (500 mg, 3.01 mmol, 1.0 eq.) 
in methanol was added thionyl chloride (219 µL, 1.0 eq.) and the reaction mixture 
was refluxed for 4 h. The solvent was evaporated in vacuo and the residue was 
partitioned between CH2Cl2 (20 mL) and water (20 mL) and extracted with CH2Cl2 
(20 mL). The combined organic extracts were dried with MgSO4 and evaporated in 
vacuo to afford methyl ester 123 (531 mg, 98% yield) as a colourless oil. 
Rf 0.62 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 1713, 1603, 1434, 1239, 1131 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.95–7.90 (m, 1H, Ar-H), 6.77–6.71 (m, 2H, 2 × Ar-
H), 3.85 (s, 3H, CO2CH3), 3.83 (s, 3H, Ar-OCH3), 2.60 (s, 3H, Ar-CH3); 13C NMR 
(100 MHz, CDCl3) δ 167.6, 162.3, 143.2, 133.0, 121.7, 116.9, 110.9, 55.3, 51.6, 22.4; 
MS (CI+) 198 [M+NH4]+; HRMS (CI+) calcd for C10H16NO3 198.1130, found 
198.1142. 
 
Methyl 2-(bromomethyl)-4-methoxybenzoate (114)226 
 
To a solution of toluene derivative 123 (514 mg, 2.85 mmol, 1.0 eq.) in carbon 
tetrachloride (6 mL) was added N-bromosuccinimide (508 mg, 1.0 eq.) and benzoyl 
peroxide (1.4 mg, 0.02 eq.) and the reaction mixture was refluxed for 3 h. The 
mixture was filtered through celite and washed with chloroform (10 mL). The solvent 
was evaporated in vacuo, the residue was partitioned between CH2Cl2 (20 mL) and 
water (20 mL) and the organic layer was washed with brine, dried with MgSO4 and 
evaporated in vacuo. The residue was purified by flash column chromatography (PE : 
OMe
O
MeO
OMe
O
MeO
Br
 
215 
AcOEt, 90 : 10 → 80 : 20) to afford benzylic bromide 114 (579 mg, 78% yield) as a 
white solid. 
Rf 0.50 (PE : AcOEt, 70 : 30); mp 40–42 °C (PE : AcOEt, 70 : 30); IR (thin film) 
2951, 1706, 1604, 1430, 1252 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.00–7.96 (m, 1H, 
Ar-H), 6.97–6.95 (m, 1H, Ar-H), 6.87–6.83 (m, 1H, Ar-H), 4.96 (s, 2H, Ar-CH2Br), 
3.90 (s, 3H, Ar-OCH3), 3.86 (s, 3H, CO2CH3); 13C NMR (100 MHz, CDCl3) δ 166.5, 
162.6, 141.8, 133.7, 120.9, 117.1, 113.6, 55.5, 52.0, 31.9; Exact mass couldn’t be 
found by HRMS. 
 
Methyl 4-methoxy-2-((N-methylphenylsulfonamido)methyl)benzoate (124) 
 
To a solution of benzylic bromide 114 (200 mg, 0.77 mmol, 1.0 eq.) and sulfonamide 
121 (132 mg, 1.0 eq.) in acetone (8 mL) was added Cs2CO3 (251 mg, 1.0 eq.) and the 
reaction mixture was stirred at room temperature for 4 h. The mixture was partitioned 
between AcOEt (20 mL) and aqueous HCl solution (1 M, 20 mL), extracted with 
AcOEt (2 × 20 mL) and the combined organic extracts were washed with brine 
(20 mL), dried with MgSO4 and evaporated in vacuo. The residue was purified by 
flash column chromatography (PE : AcOEt, 90 : 10 → 70 : 30) to afford sulfonamide 
124 (228 mg, 85% yield) as a white solid. 
Rf 0.25 (PE : AcOEt, 70 : 30); mp 42–44 °C (PE : AcOEt, 70 : 30); IR (thin film) 
1701, 1609, 1571, 1335, 1259, 1082 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.97–7.93 
(m, 1H, Ar-H), 7.90–7.85 (m, 2H, 2 × Ph-H), 7.65–7.51 (m, 3H, 3 × Ph-H), 2.29–7.25 
(m, 1H, Ar-H), 6.85–6.81 (m, 1H, Ar-H), 4.68 (s, 3H, Ar-CH2), 3.88 (s, 3H, 
CO2CH3), 3.81 (s, 3H, Ar-OCH3), 2.72 (m, 3H, NCH3); 13C NMR (100 MHz, CDCl3) 
δ 167.1, 163.3, 141.3, 137.7, 133.3, 132.7, 129.3, 127.4, 120.7, 113.5, 112.7, 55.5, 
52.1, 51.8, 35.6; MS (ESI+) 372 [M+Na]+; HRMS (ESI+) calcd for C17H19NO5NaS 
372.0882 , found 372.0874. 
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5-Methoxy-2-methylisoindolin-1-one (125)226 
 
To a solution of methyl ether 124 (100 mg, 0.29 mmol, 1.0 eq.) in CH2Cl2 (3 mL) at  
–78 °C was added boron tribromide in CH2Cl2 (1.0 M, 0.63 mL, 2.2 eq.) and the 
temperature was allowed to reach room temperature over 5 h. Water (2 drops) and 
methanol (10 mL) were added and the mixture was concentrated in vacuo and this 
operation was repeated twice. The residue was purified by flash column 
chromatography (PE : AcOEt, 90 : 10 → 70 : 30) to afford unexpected product 125 
(26 mg, 51% yield) as a white solid. 
Rf 0.07 (PE : AcOEt, 70 : 30); mp 106–108 °C (PE : AcOEt, 70 : 30); IR (thin film) 
2908, 2831, 1667, 1611 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.4 Hz, 1H, 
Ar-H), 6.97 (dd, J = 8.4, 2.3 Hz, 1H, Ar-H), 6.92 (d, J = 2.3 Hz, 1H, Ar-H), 4.32 (s, 
2H, CH2), 3.87 (s, 3H, OCH3), 3.17 (s, 3H, NCH3); 13C NMR (100 MHz, CDCl3) δ 
168.6, 162.5, 143.2, 125.6, 124.8, 114.4, 107.7, 55.6, 51.8, 29.4; MS (CI+) 177 [M]+•; 
HRMS (CI+) calcd for C10H11NO2 177.0790, found 177.0793. 
 
Methyl 4-hydroxy-2-((N-methylphenylsulfonamido)methyl)benzoate (113) 
 
To a solution of methyl ether 124 (25 mg, 0.07 mmol, 1.0 eq.) in DMF (1 mL) was 
added lithium chloride (9 mg, 3.0 eq.) and the mixture was refluxed for 48 h. Aqueous 
sodium hydroxide (10% w/v, 3 mL) was added and the mixture was washed with 
Et2O (3 × 2.5 mL). The aqueous layer was acidified with aqueous HCl solution (1 M, 
5 mL), extracted with Et2O (3 × 5 mL) and the combined organic extracts were 
washed with brine (10 mL), dried with MgSO4, and concentrated in vacuo. The 
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residue was purified by flash column chromatography (CH2Cl2 : MeOH, 99 : 1 → 97 : 
3) to afford phenol 113 (15 mg, 66% yield) as a white solid. 
Rf 0.31 (CH2Cl2 : MeOH, 95 : 5); mp 108–110 °C (CH2Cl2 : MeOH, 95 : 5); IR (thin 
film) 2960 (br.), 1684, 1566, 1273 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 
8.7 Hz, 1H, Ar-H), 7.90–7.84 (m, 2H, 2 × Ph-H), 7.65–7.52 (m, 3H, 3 × Ph-H), 7.29 
(d, J = 2.5 Hz, 1H, Ar-H), 6.86 (dd, J = 8.7, 2.4 Hz, 1H, Ar-H), 4.73 (s, 2H, Ar-CH2), 
3.89 (s, 3H, OCH3), 2.75 (s, 3H, NCH3) ; 13C NMR (100 MHz, CDCl3) δ 171.5, 
164.1, 142.4, 137.9, 134.5, 132.9, 129.4, 127.5, 119.7, 113.7, 112.8, 55.7, 52.4, 35.7; 
MS (ESI+) 336 [M+H]+; HRMS (ESI+) calcd for C16H18NO5S 336.0906, found 
336.0920. 
 
N-(3-Methoxybenzyl)benzenesulfonamide (126) 
 
To a solution of 3-methoxybenzylamine (118) (233 µL, 1.82 mmol, 1.0 eq.) in 
CH2Cl2 (9 mL) at 0 °C were added triethylamine (254 µL, 1.0 eq.) and benzene 
sulfonylchloride (232 µL, 1.0 eq.) and the temperature was allowed to reach room 
temperature over 1 h. The reaction mixture was washed with water (20 mL) and 
extracted with CH2Cl2 (3 × 15 mL), dried with MgSO4 and evaporated in vacuo. The 
residue was purified by flash column chromatography (CH2Cl2) to afford sulfonamide 
126 (382 mg, 75% yield) as a colourless amorphous solid. 
Rf 0.20 (CH2Cl2); IR (thin film) 3239 (br.), 2852, 1604, 1451, 1150 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.90–7.84 (m, 2H, 2 × Ph-H), 7.61–7.55 (m, 1H, Ph-H), 7.55–
7.48 (m, 2H, 2 × Ph-H), 7.17 (t, J = 8.0 Hz, 1H, Ar-H), 6.80–6.70 (m, 3H, 3 × Ar-H), 
4.85 (t, J = 6.1 Hz, 1H, NH), 4.12 (d, J = 6.1 Hz, 2H, CH2), 3.73 (s, 3H, OCH3); 13C 
NMR (100 MHz, CDCl3) δ 160.0, 140.0, 137.8, 132.9, 129.9, 129.3, 127.2, 120.1, 
113.8, 113.2, 55.3, 47.4; MS (CI+) 295 [M+NH4]+; HRMS (CI+) calcd for 
C14H19N2O3S 295.1116, found 295.1105. 
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N-(3-Methoxybenzyl)-N-methylbenzenesulfonamide (117) 
 
To a solution of sulfonamide 126 (361 µL, 1.30 mmol, 1.0 eq.) in DMF (9 mL) at 
0 °C was added portionwise sodium hydride (63 mg, 1.2 eq.) and the reaction mixture 
was stirred at room temperature for 20 min. The mixture was cooled to 0 °C, methyl 
iodide (122 µL, 1.5 eq.) was added dropwise and the temperature was allowed to 
reach room temperature over 1.5 h. The reaction mixture was washed with aqueous 
saturated NaHCO3 (30 mL), extracted with Et2O (3 × 30 mL), washed with brine 
(20 mL), dried with MgSO4 and evaporated in vacuo. The residue was purified by 
flash column chromatography (PE : Et2O, 80 : 20 → 20 : 80) to afford tertiary 
sulfonamide 117 (336 mg, 89% yield) as a colourless amorphous solid. 
Rf 0.85 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 2964, 1605, 1446, 1149 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.91–7.85 (m, 2H, 2 × Ph-H), 7.69–7.55 (m, 3H, 3 × Ph-
H), 7.30–7.24 (m, 1H, Ar-H), 6.92–6.84 (m, 3H, 3 × Ar-H), 4.15 (s, 2H, CH2), 3.82 
(s, 3H, OCH3), 2.64 (s, 3H, NCH3); 13C NMR (100 MHz, CDCl3) δ 159.9, 137.3, 
137.1, 132.7, 129.6, 129.1, 127.4, 120.6, 113.7, 113.5, 55.2, 54.1, 34.3 ; MS (CI+) 309 
[M+NH4]+; HRMS (CI+) calcd for C15H21N2O3S 309.1273, found 309.1280. 
 
3-Methoxybenzaldehyde (130)140 
 
To a solution of 3-hydroxybenzaldehyde (129) (500 mg, 4.09 mmol, 1.0 eq.) in 
acetone (9 mL) was added Cs2CO3 (1.47 g, 1.1 eq.) and methyl iodide (765 µL, 
3.0 eq.) and the reaction mixture was stirred at room temperature for 16 h. The 
mixture was partitioned between CH2Cl2 (30 mL) and aqueous HCl solution (1 M, 
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20 mL), extracted with CH2Cl2 (3 × 20 mL) and the combined organic extracts were 
washed with brine (20 mL), dried with MgSO4 and evaporated in vacuo. The residue 
was purified by flash column chromatography (CH2Cl2) to afford methyl ester 130 
(545 mg, 98% yield) as a colourless oil. 
Rf 0.45 (CH2Cl2); IR (thin film) 2831, 1684, 1583, 1290 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 9.98 (s, 1H, CHO), 7.48–7.42 (m, 2H, 2 × Ar-H), 7.41–7.38 (m, 1H, Ar-H), 
7.21–7.15 (m, 1H, Ar-H), 3.87 (s, 3H, OCH3); 13C NMR (100 MHz, CDCl3) δ 192.2, 
160.1, 137.8, 130.0, 123.6, 121.6, 112.0, 55.5; MS (EI+) 136 [M]+•; HRMS (EI+) 
calcd for C8H8O2 136.0524, found 136.0520. 
 
1-(3-Methoxyphenyl)-N,N-dimethylmethanamine (119)140 
 
To a solution of aldehyde 130 (159 mg, 1.16 mmol, 1.0 eq.) in THF (5 mL) were 
added dimethylamine (2.0 M in THF, 584 µL, 1.0 eq.) and acetic acid (1 drop, 
0.01 eq.) and the reaction mixture was stirred at room temperature for 5 min. Sodium 
triacetoxyborohydride (344 mg, 1.5 eq.) was added and the mixture was stirred for 
1.5 h. Aqueous NaOH solution (1 M, 10 mL) was added and the mixture was stirred 
for 30 min, extracted with CH2Cl2 (2 × 10 mL), washed with brine (20 mL), dried 
with MgSO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (CH2Cl2 : MeOH/NH3, 98 : 2 → 95 : 5) to afford tertiary 
amine 119 (151 mg, 79% yield) as a pale orange oil. 
Rf 0.30 (CH2Cl2 : MeOH/NH3, 95 : 5); IR (thin film) 2928, 1723, 1602, 1268 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.26–7.20 (m, 2H, 2 × Ar-H), 6.91–6.87 (m, 1H, Ar-H), 
6.83–6.78 (m, 1H, Ar-H), 3.81 (s, 3H, OCH3), 3.40 (s, 2H, CH2), 2.24 (s, 3H, 2 × 
NCH3); 13C NMR (100 MHz, CDCl3) δ 159.6, 140.6, 129.1, 121.4, 114.2, 112.7, 64.4, 
55.2, 45.4; MS (CI+) 166 [M+H]+; HRMS (CI+) calcd for C10H16NO 166.1232, found 
166.1240. 
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N,N-Diethyl-2-methoxybenzamide (131)143 
 
Following a literature procedure,143 to a solution of o-anisic acid (132) (1.00 g, 
6.50 mmol, 1.0 eq.) in thionyl chloride (6.8 mL) was added DMF (120 µL, 0.2 eq.) 
dropwise and the reaction mixture was stirred at room temperature for 30 min, after 
which no more gas evolution could be seen. The mixture was concentrated in vacuo, 
dissolved in toluene and concentrated (3 × 10 mL). The resulting orange oil was 
dissolved in THF (7.5 mL) at 0 °C and diethylamine (2.5 mL, 3.7 eq.) was added 
dropwise. The precipitate was dissolved in CH2Cl2 (20 mL), washed with water 
(20 mL), brine (20 mL), dried with MgSO4 and concentrated in vacuo. The residue 
was purified by flash column chromatography (PE : AcOEt, 50 : 50) to afford amide 
131 (1.13 g, 85% yield) as a pale yellow oil. 
Rf 0.14 (PE : AcOEt, 70 : 30); IR (thin film) 2971, 2936, 1625, 1600, 1243 cm-1; 1H 
NMR (400 MHz, CDCl3) 7.34–7.28 (m, 1H, Ar-H), 7.22–7.14 (m, 1H, Ar-H), 7.00–
6.93 (m, 1H, Ar-H), 6.92–6.86 (m, 1H, Ar-H), 3.81 (s, 3H, OCH3), 3.64–3.50 (m, 2H, 
trans-CH2-CH3), 3.13 (q, J = 7.1 Hz, 2H, cis-CH2-CH3), 1.23 (t, J = 7.2 Hz, 3H, 
trans-CH2-CH3), 1.02 (t, J = 7.2 Hz, 3H, cis-CH2-CH3); 13C NMR (100 MHz, CDCl3) 
δ 168.7, 155.1, 129.8, 127.4, 126.9, 120.7, 110.9, 55.4, 42.7, 38.7, 13.9, 12.9; MS 
(EI+) 207 [M]+•; HRMS (EI+) calcd for C12H17NO2 207.1259, found 207.1262. 
 
Methyl 2-formyl-6-methoxybenzoate (133)143 
 
Following a literature procedure,143 sec-BuLi (1.4 M in THF, 5 mL, 1.3 eq.) was 
added dropwise to a solution of TMEDA (1.05 mL, 1.3 eq.) in THF (22.5 mL) at         
–78 °C. A solution of amide 131 (1.12 g, 5.40 mmol, 1.0 eq.) in THF (4.5 mL) was 
added dropwise and the mixture was stirred at –78 °C for 1 h. DMF (0.50 mL, 1.2 eq.) 
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was added dropwise over 5 min, the reaction mixture was allowed to reach room 
temperature and was stirred for 16 h. Aqueous HCl solution (6 M, 10 mL) was added 
until pH 4, and the reaction mixture was extracted with AcOEt (3 × 30 mL). The 
combined organic extracts were washed with water (20 mL), brine (20 mL), dried 
with MgSO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (CH2Cl2 : MeOH, 99: 1 → 98 : 2) to afford aldehyde 133 
(1.08 g, 85% yield) as a pale yellow oil.  
Rf 0.10 (PE : AcOEt, 70 : 30); IR (thin film) 2978, 2939, 1706, 1619, 1263 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 9.99 (s, 1H, CHO), 7.52 (d, J = 7.3 Hz, 1H, Ar-H), 7.46 
(app. t, J = 7.9 Hz, 1H, Ar-H), 7.16 (d, J = 8.0, 1H, Ar-H), 3.86 (s, 3H, OCH3), 3.72 
(dq, J = 14.2, 7.1 Hz, 1H, trans-CHaHb-CH3), 3.53 (dq, J = 14.2, 7.1 Hz, 1H, trans-
CHaHb-CH3), 3.10 (q, J = 7.2 Hz, 2H, cis-CH2-CH3), 1.29 (t, J = 7.1 Hz, 3H, trans-
CHaHb-CH3), 1.01 (t, J = 7.2 Hz, 3H cis-CH2-CH3); 13C NMR (100 MHz, CDCl3) δ 
190.6, 165.8, 155.6, 133.6, 129.9, 129.1, 121.2, 116.4, 56.0, 42.8, 38.9, 13.7, 12.6; 
MS (ESI+) 236 [M+H]+; HRMS (ESI+) calcd for C13H18NO3 236.1287, found 
236.1302. 
 
N-(3-Methoxybenzyl)-N-methylbenzenesulfonamide (134)144 
 
Following a literature procedure,144 aqueous HCl solution (10% w/v, 2.7 mL) was 
added to amide 133 (128 mg, 0.54 mmol, 1.0 eq.) and the reaction mixture was 
refluxed for 6 h. The mixture was cooled to room temperature and the white 
precipitate was collected and wash with cold water (5 mL) and dried in vacuo. 1H 
NMR of the crude solid confirmed the presence of the carboxylic acid under the 
corresponding hemiacetal form. (1H NMR (400 MHz, CDCl3) δ 7.67 (t, J = 7.9 Hz, 
1H, Ar-H), 7.18 (d, J = 7.5 Hz, 1H, Ar-H), 7.01 (d, J = 8.3 Hz, 1H, Ar-H), 6.53 (d, 
J = 7.9 Hz, 1H, CHOH), 3.99 (s, 3H, OCH3), 3.94 (d, J = 7.9 Hz, 1H, CHOH)). The 
crude solid was dissolved in acetone (1 mL), Cs2CO3 (138 mg, 3.0 eq.) and methyl 
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iodide (25 µL, 1.2 eq.) were added and the reaction was refluxed for 4 h. The mixture 
was partitioned between CH2Cl2 (10 mL) and water (10 mL), extracted with CH2Cl2 
(2 × 10 mL) and the combined organic extracts were washed with brine (20 mL), 
dried with MgSO4 and evaporated in vacuo. The residue was purified by flash column 
chromatography (CH2Cl2 : MeOH, 99 : 1) to afford methyl ester 134 (73 mg, 70% 
yield) as a colourless amorphous solid. 
Rf 0.72 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 2957, 2877, 1733, 1689, 1258 cm-1; 
1H NMR (400 MHz, CDCl3) δ 9.96 (s, 1H, CHO), 7.55 (app. t, J = 8.0 Hz, 1H, Ar-H), 
7.45 (d, J = 7.4 Hz, 1H, Ar-H), 7.21 (d, J = 8.3 Hz, 1H, Ar-H), 3.97 (s, 3H, OCH3), 
3.88 (s, 3H, CO2CH3); 13C NMR (100 MHz, CDCl3) δ 190.3, 167.2, 156.6, 134.2, 
131.0, 123.4, 123.2, 116.9, 56.3, 52.8; MS (ESI+) 195 [M+H]+; HRMS (ESI+) calcd 
for C10H11O4 195.0657, found 195.0656. 
 
Methyl 2-methoxy-6-((N-methylphenylsulfonamido)methyl)benzoate (127) 
 
To a solution of aldehyde 135 (98 mg, 0.50 mmol, 1.0 eq.) and benzenesulfonamide 
(118 mg, 1.5 eq.) in THF (1 mL) were added triethylamine (209 µL, 3.0 eq.) and 
sodium triacetateborohydride (148 mg, 1.4 eq.) and the mixture was stirred at room 
temperature for 12 h. Acetic acid (100 µL, 3.5 eq.) was added and the mixture was 
stirred for 12 h. Water (10 mL) was added and the aqueous layer was extracted with 
CH2Cl2 (3 × 10 mL). The combined organic extracts were washed with brine (20 mL), 
dried with MgSO4 and evaporated in vacuo. The residue was purified twice by flash 
column chromatography (CH2Cl2 : MeOH, 95 : 5 → 99 : 1) to afford secondary 
sulfonamide 135 (32 mg, 21% yield). The unstable intermediate was suspended in 
acetone (0.5 mL), caesium carbonate (68 mg, 2.2 eq.) and methyl iodide (24 µL, 
4.0 eq.) were added and the reaction mixture was heated at 60 °C for 30 min. Water 
(10 mL) was added and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). 
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The combined organic extracts were washed with brine (20 mL), dried with MgSO4 
and evaporated in vacuo. The residue was purified by flash column chromatography 
(CH2Cl2 : MeOH, 95 : 5 → 99 : 1) to afford methyl sulfonamide 127 (32 mg, 99% 
yield) as a colourless oil.  
Rf 0.79 (PE : AcOEt, 50 : 50); IR (thin film) 2929, 1727, 1333, 1268 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.82 (dd, J = 7.1, 1.7 Hz, 2H, 2 × Ph-H), 7.66–7.51 (m, 3H, 3 × 
Ph-H), 7.37–7.30 (m, 1H, Ar-H), 7.01 (d, J = 7.8 Hz, 1H, Ar-H), 6.88 (d, J = 8.2 Hz, 
1H, Ar-H), 4.11 (s, 2H, Ar-CH2), 3.88 (s, 3H, CO2CH3), 3.83 (s, 3H, Ar-OCH3), 2.54 
(s, 3H, NCH3); 13C NMR (100 MHz, CDCl3) δ 167.7, 156.6, 136.7, 134.2, 132.8, 
130.8, 129.1, 127.5, 123.4, 121.2, 110.7, 56.0, 52.4, 51.6, 34.4; MS (ESI+) 350 
[M+H]+; HRMS (ESI+) calcd for C17H20NO5S 350.1062, found 350.1065. 
 
3-(N-Methylphenylsulfonamido)propanoic acid (140a) 
 
To a solution of β-alanine (139a) (864 mg, 9.7 mmol, 1.0 eq.) in a mixture of 
1,4-dioxane and water (1 : 3, 33 mL) were added Na2CO3 (3.08 g, 3.0 eq.) and 
benzene sulfonylchloride (1.23 mL, 1.0 eq.) and the reaction mixture was stirred at 
room temperature for 14 h. The mixture was acidified with aqueous HCl solution 
(1 M) until pH 1–2 and was extracted with AcOEt (3 × 30 mL). The combined organic 
extracts were washed with water (50 mL), brine (50 mL), dried with MgSO4 and 
evaporated in vacuo to afford sulfonamide 140a (1.72 g, 78% yield) as a white solid. 
Rf 0.16 (CH2Cl2 : MeOH, 95 : 5); mp 84–86 °C (CH2Cl2 : MeOH, 95 : 5); IR (thin 
film) 3282 (br.), 2932 (br.), 1705, 1449, 1321, 1156 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 10.36 (br. s, 1H, CO2H), 7.90–7.85 (m, 2H, 2 × Ph-H), 7.63–7.57 (m, 1H, 
Ph-H), 7.57–7.50 (m, 2H, 2 × Ph-H), 6.06–5.99 (m, 1H, NH), 3.45–3.18 (m, 2H, 
NCH2CH2CO), 2.68–2.61 (m, 2H, NCH2CH2CO); 13C NMR (100 MHz, CDCl3) δ 
176.2, 139.8, 132.9, 129.3, 127.0, 38.3, 34.0; MS (ESI–) 228 [M–H]–; HRMS (ESI–) 
calcd for C9H10NO4S 228.0331, found 228.0328. 
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4-(Phenylsulfonamido)butanoic acid (140b) 
 
To a solution of γ-aminobutyric acid (139b) (1.00 g, 9.70 mmol, 1.0 eq.) in a mixture 
of 1,4-dioxane and water (1 : 3, 33 mL) were added Na2CO3 (3.08 g, 3.0 eq.) and 
benzene sulfonylchloride (1.23 mL, 1.0 eq.) and the reaction mixture was stirred at 
room temperature for 14 h. The mixture was acidified with aqueous HCl solution 
(1 M) until pH 1–2 and was extracted with AcOEt (3 × 30 mL). The combined organic 
extracts were washed with water (50 mL), brine (50 mL), dried with MgSO4 and 
evaporated in vacuo to afford sulfonamide 140b (2.00 g, 91% yield) as a colourless 
oil. 
Rf 0.22 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 3274 (br.), 2936 (br.), 1706, 1428, 
1251, 1152 cm-1; 1H NMR (400 MHz, CDCl3) δ 10.39 (br. s, 1H, CO2H), 7.88–7.82 
(m, 2H, 2 × Ph-H), 7.61–7.55 (m, 1H, Ph-H), 7.55–7.48 (m, 2H, 2 × Ph-H), 5.14–4.98 
(m, 1H, NH), 3.07–2.98 (m, 2H, NCH2CH2CH2CO), 2.45–2.38 (m, 2H, 
NCH2CH2CH2CO), 1.86–1.76 (m, 2H, NCH2CH2CH2CO); 13C NMR (100 MHz, 
CDCl3) δ 178.3, 139.7, 132.8, 129.2, 127.0, 42.4, 30.8, 24.5; MS (ESI–) 242 [M–H]–; 
HRMS (ESI–) calcd for C10H12NO4S 242.0487, found 242.0500. 
 
3-(N-Methylphenylsulfonamido)propanoic acid (138a) 
 
To a solution of sulfonamide 140a (1.47 g, 6.30 mmol, 1.0 eq.) in acetone (12 mL) 
were added Cs2CO3 (4.10 g, 2.1 eq.) and methyl iodide (1.97 mL, 5.0 eq.) and the 
reaction was stirred at room temperature for 16 h. The mixture was partitioned 
between AcOEt (50 mL) and aqueous HCl solution (1 M, 20 mL) and extracted with 
AcOEt (3 × 30 mL). The combined organic extracts were washed with brine, dried 
with MgSO4 and evaporated in vacuo. 1H NMR of the residue confirmed the presence 
of the bis-methylated product. The crude intermediate was dissolved in methanol 
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(30 mL), lithium hydroxide (779 mg, 5.0 eq.) was added and the reaction mixture was 
stirred at room temperature for 26 h. Water (20 mL) was added and the mixture was 
concentrated in vacuo. The mixture was acidified with aqueous HCl solution (1 M) 
until pH 1–2 and extracted with AcOEt (3 × 30 mL). The combined organic extracts 
were washed with water (50 mL), brine (50 mL), dried with MgSO4 and evaporated in 
vacuo to afford tertiary sulfonamide 138a (1.56 g, 94% yield) as a white solid. 
Rf 0.28 (CH2Cl2 : MeOH, 95 : 5); mp 74–76 °C (CH2Cl2 : MeOH, 95 : 5); IR (thin 
film) 2898 (br.), 1702, 1448, 1334, 1158 cm-1; 1H NMR (400 MHz, CDCl3) δ 10.9 
(br. s, 1H, CO2H), 7.83–7.78 (m, 2H, 2 × Ph-H), 7.65–7.59 (m, 1H, Ph-H), 7.58–7.51 
(m, 2H, 2 × Ph-H), 3.34 (t, J = 7.0 Hz, 2H, NCH2CH2CO), 2.80 (s, 3H, NCH3), 2.70 
(t, J = 7.0 Hz, 2H, NCH2CH2CO); 13C NMR (100 MHz, CDCl3) δ 177.2, 137.2, 
132.9, 129.3, 127.4, 45.8, 35.8, 33.6; MS (ESI–) 242 [M–H]–; HRMS (ESI–) calcd for 
C10H12NO4S 242.0487, found 242.0485. 
 
4-(N-Methylphenylsulfonamido)butanoic acid (138b) 
 
To a solution of sulfonamide 140a (2.00 g, 8.20 mmol, 1.0 eq.) in acetone (16 mL) 
were added Cs2CO3 (5.60 g, 2.1 eq.) and methyl iodide (2.56 mL, 5.0 eq.) and the 
reaction was stirred at room temperature for 16 h. The mixture was partitioned 
between AcOEt (50 mL) and aqueous HCl solution (1 M, 20 mL), extracted with 
AcOEt (3 × 30 mL) and the combined organic extracts were washed with brine, dried 
with MgSO4 and evaporated in vacuo. 1H NMR of the residue confirmed the presence 
of the bis-methylated product. The crude intermediate was dissolved in methanol 
(40 mL), lithium hydroxide (982 mg, 5.0 eq.) was added and the reaction mixture was 
stirred at room temperature for 26 h. Water (30 mL) was added and the mixture was 
concentrated in vacuo. The mixture was acidified with aqueous HCl solution (1 M) 
until pH 1–2 and extracted with AcOEt (3 × 40 mL). The combined organic extracts 
were washed with water (50 mL), brine (50 mL), dried with MgSO4 and evaporated in 
vacuo to afford tertiary sulfonamide 138b (1.72 g, 82% yield) as an off-white solid. 
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Rf 0.34 (CH2Cl2 : MeOH, 95 : 5); mp 62–64 °C (CH2Cl2 : MeOH, 95 : 5); IR (thin 
film) 2920 (br.), 1705, 1445, 1335, 1154 cm-1; 1H NMR (400 MHz, CDCl3) δ 11.2 
(br. s, 1H, CO2H), 7.80–7.75 (m, 2H, 2 × Ph-H), 7.62–7.56 (m, 1H, Ph-H), 7.56–7.50 
(m, 2H, 2 × Ph-H), 3.10–3.02 (m, 2H, NCH2CH2CH2CO), 2.74 (s, 3H, NCH3), 2.52–
2.44 (m, 2H, NCH2CH2CH2CO), 1.92–1.82 (m, 2H, NCH2CH2CH2CO); 13C NMR 
(100 MHz, CDCl3) δ 179.0, 137.4, 132.7, 129.2, 127.4, 49.3, 34.8, 30.7, 22.5; MS 
(ESI–) 256 [M–H]–; HRMS (ESI–) calcd for C10H11N5NaS 256.0633, found 256.0638. 
 
N-(4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-oxobutyl)-N-
methylbenzenesulfonamide (142a) 
 
To a solution of hexamethyldisilazane in hexanes (4.5 M, 1.70 mL, 2.6 eq.) in THF 
(20 mL) at –78 °C was added n-butyllithium (2.5 M in hexanes, 3.10 mL, 2.6 eq.) and 
the mixture was stirred for 20 min. Dioxinone 109 (95% purity, filtered through silica 
prior to the reaction, 1.07 g, 2.6 eq.) was added dropwise and the mixture was stirred 
for 40 min. In a second flask, to a solution of carboxylic acid 138a (730 mg, 
3.00 mmol, 1.0 eq.) in THF (4 mL) were added oxalyl chloride (0.26 mL, 1.0 eq.) and 
DMF (1 drop, cat.), the mixture was stirred for 20 min and transferred dropwise via a 
cannula into the first flask. The mixture was stirred for 3 h and the temperature was 
allowed to reach –40 °C. Aqueous HCl solution (1 M, 25 mL) was added and the 
aqueous layer was extracted with AcOEt (3 × 30 mL). The combined organic extracts 
were dried with MgSO4 and evaporated in vacuo. The residue was purified by flash 
column chromatography (Et2O : PE, 50 : 50 → 100 : 0) to afford ketodioxinone 142a 
(412 mg, 36% yield) as a yellow oil. 
Rf 0.20 (Et2O); IR (thin film) 1718, 1636, 1375, 1158 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.81–7.75 (m, 2H, 2 × Ph-H), 7.65–7.59 (m, 1H, Ph-H), 7.59–7.52 (m, 2H, 
2 × Ph-H), 5.36 (s, 1H, C=CH), 3.39 (s, 2H, COCH2), 3.27 (t, J = 7.0 Hz, 2H, 
NCH2CH2CO), 2.89 (t, J = 7.0 Hz, 2H, NCH2CH2CO), 2.78 (s, 3H, NCH3), 1.72 (s, 
6H, C(CH3)2); 13C NMR (100 MHz, CDCl3) δ 201.5, 164.1, 160.6, 136.8, 132.9, 
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129.2, 127.4, 107.3, 96.9, 47.2, 45.1, 42.4, 36.3, 25.0; MS (ESI+) 390 [M+Na]+; 
HRMS (ESI+) calcd for C17H21NO6NaS 390.0987, found 390.0979. 
 
N-(5-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-4-oxopentyl)-N-
methylbenzenesulfonamide (142b) 
 
To a solution of hexamethyldisilazane in hexanes (4.5 M, 1.70 mL, 2.6 eq.) in THF 
(20 mL) at –78 °C was added n-butyllithium (2.5 M in hexanes, 3.10 mL, 2.6 eq.) and 
the mixture was stirred for 20 min. Dioxinone 109 (95% purity, filtered through silica 
prior to the reaction, 1.07 g, 2.6 eq.) was added dropwise and the mixture was stirred 
for 40 min. In a second, to a solution of carboxylic acid 138a (771 mg, 3.00 mmol, 
1.0 eq.) in THF (4 mL) were added oxalyl chloride (0.26 mL, 1.0 eq.) and DMF 
(1 drop, cat.), the mixture was stirred for 20 min and transferred dropwise via a 
cannula into the first flask. The mixture was stirred for 3 h and the temperature was 
allowed to reach –40 °C. Aqueous HCl solution (1 M, 25 mL) was added and the 
aqueous layer was extracted with AcOEt (3 × 30 mL). The combined organic extracts 
were dried with MgSO4 and evaporated in vacuo. The residue was purified by flash 
column chromatography (Et2O : PE, 50 : 50 → 100 : 0) to afford ketodioxinone 142b 
(542 mg, 49% yield) as a colourless oil. 
Rf 0.27 (Et2O); IR (thin film) 1718, 1635, 1374, 1158 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.77–7.72 (m, 2H, 2 × Ph-H), 7.62–7.57 (m, 1H, Ph-H), 7.56–7.50 (m, 2H, 
2 × Ph-H), 5.40 (s, 1H, C=CH), 3.44 (s, 2H, COCH2), 3.01–2.96 (m, 2H, 
NCH2CH2CH2CO), 2.71–2.66 (m, 2H, NCH2CH2CH2CO), 2.68 (s, 3H, NCH3), 1.88–
1.81 (m, 2H, NCH2CH2CH2CO), 1.73 (s, 6H, C(CH3)2); 13C NMR (100 MHz, CDCl3) 
δ 202.9, 164.6, 160.8, 137.2, 132.7, 129.2, 127.2, 107.1, 96.7, 49.1, 47.4, 39.2, 34.7, 
25.0, 20.8; MS (ESI+) 404 [M+Na]+; HRMS (ESI+) calcd for C18H23NO6NaS 
404.1144, found 404.1136. 
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(8R,9S,13S,14S)-3-(tert-Butyldimethylsilyloxy)-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one (147)227 
 
To a solution of oestrone (144) (2.50 g, 9.20 mmol, 1.0 eq.) in CH2Cl2 (92 mL) were 
added imidazole (688 mg, 1.1 eq.) and TBSCl (1.54 g, 1.1 eq.) and the reaction 
mixture was stirred at room temperature for 16 h. The mixture was diluted with 
CH2Cl2 (50 mL) and washed with a saturated aqueous solution of NH4Cl (50 mL) and 
brine (50 mL). The combined organic layers were dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash column chromatography on silica (PE : 
AcOEt, 70 : 30) to afford TBS ether 147 (230 mg, 78% yield) as a white foam. 
Rf 0.70 (PE : AcOEt, 70 : 30); IR (thin film) 2932, 2859, 1730, 1257 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.12 (d, J = 8.5 Hz, 1H, Ar-H), 6.63 (dd, J = 8.5, 2.7 Hz, 1H, 
Ar-H), 6.57 (d, J = 2.6 Hz, 1H, Ar-H), 2.93–2.77 (m, 2H, CH2), 2.50 (dd, J = 18.8, 
8.6 Hz, 1H, CH), 2.42–2.34 (m, 1H, CH), 2.30–2.20 (m, 1H, CH), 2.20–1.90 (m, 4H, 
2 × CH2), 1.69–1.35 (m, 6H, 3 × CH2), 0.98 (s, 9H, SiC(CH3)3), 0.91 (s, 3H, CH3), 
0.19 (s, 6H, Si(CH3)3); 13C NMR (100 MHz, CDCl3) δ 221.0, 153.5, 137.6, 132.4, 
126.1, 120.0, 117.3, 50.4, 48.0, 44.0, 38.3, 35.9, 31.6, 29.5, 26.5, 25.8, 25.7, 21.6, 
18.2, 13.9, –4.4; MS (CI+) 402 [M+NH4]+; HRMS (CI+) calcd for C24H40NO2Si 
402.2828, found 402.2816. 
 
(8R,9S,13S,14S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]phenanthren-17(14H)-one (149)150 
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To a solution of oestrone (144) (2.50 g, 9.2 mmol, 1.0 eq.) in CH2Cl2 (92 mL) were 
added K2CO3 (1.40 g, 1.1 eq.) and benzyl bromide (1.20 mL, 1.1 eq.) and the reaction 
mixture was stirred at room temperature for 32 h. The mixture was diluted with 
CH2Cl2 (50 mL) and washed with a saturated aqueous solution of NH4Cl (50 mL) and 
brine (50 mL). The combined organic layers were dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash column chromatography on silica (PE : 
AcOEt, 90 : 10 → 50 : 50) to afford benzyl ether 149 (2.89 mg, 86% yield) as a white 
solid. 
Rf 0.59 (PE : AcOEt, 70 : 30); mp 104–106 °C (CH2Cl2 : MeOH, 95 : 5); [α]D22 +122 
(c 1.00, CHCl3); IR (thin film) 2925, 2856, 1731, 1603, 1228 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.47–7.37 (m, 4H, 4 × Ph-H), 7.36–7.31 (m, 1H, Ph-H), 7.22 (d, 
J = 8.6 Hz, 1H, Ar-H), 6.81 (dd, J = 8.6, 2.7 Hz, 1H, Ar-H), 6.75 (d, J = 2.7 Hz, 1H, 
Ar-H), 5.05 (s, 2H, CH2Ph), 2.95–2.86 (m, 2H, CH2), 2.57–2.46 (dd, J = 18.8, 8.6 Hz, 
1H, CH), 2.45–2.37 (m, 1H, CH), 2.33–2.22 (m, 1H, CH), 2.22–1.92 (m, 4H, 2 × 
CH2), 1.69–1.39 (m, 6H, 3 × CH2), 0.92 (s, 3H, CH3).; 13C NMR (100 MHz, CDCl3) δ 
220.9, 156.9, 137.8, 137.3, 132.4, 128.6, 127.9, 127.5, 126.4, 114.9, 112.4, 70.0, 50.4, 
48.0, 44.0, 38.4, 35.9, 31.6, 29.7, 26.6, 25.9, 21.6, 13.9; MS (CI+) 378 [M+NH4]+; 
HRMS (CI+) calcd for C25H32NO2 378.2433, found 378.2441.  
 
(8R,9S,13S,14S)-Methyl 3-(benzyloxy)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16, 
17-decahydro-6H-cyclopenta[a]phenanthrene-16-carboxylate (150)150 
 
Following a literature procedure,150 a solution of ketone 149 (2.83 g, 7.85 mmol, 
1.0 eq.) THF (6 mL) was added dropwise to a solution of sodium hydride (60% in 
mineral oil, 3.0 eq.) and dimethylcarbonate (1.65 mL, 2.5 eq.) in THF (20 mL) at 
reflux. After 8 h, the reaction mixture was cooled to room temperature and aqueous 
acetic acid (3 M, 26 mL) was added slowly. Brine (30 mL) was added and the reaction 
mixture was extracted with CH2Cl2 (3 × 50 mL), dried over MgSO4 and concentrated 
H
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in vacuo. The residue was purified by flash column chromatography on silica (PE : 
AcOEt, 90 : 10 → 70 : 30) to afford ketoester 150 (2.30 mg, 70% yield) as a pale 
yellow solid. NMR analysis showed the presence of two diastereoisomers (7 : 3). 
Rf 0.57 (PE : AcOEt, 70 : 30); mp 136–136 °C (CH2Cl2 : MeOH, 95 : 5); [α]D22 +96 
(c 1.00, CHCl3); IR (thin film) 2939, 2863, 1748, 1718, 1226 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.46–7.35 (m, 4H, 4 × Ph-H), 7.35–7.28 (m, 1H, Ph-H), 7.20 (d, 
J = 8.6 Hz, 1H, Ar-H), 6.79 (dd, J = 8.7, 2.8 Hz, 1H, Ar-H), 6.74 (d, J = 2.7 Hz, 1H, 
Ar-H), 5.04 (s, 2H, CH2Ph), 3.76 (s, 3H, CO2CH3), 3.63–3.53 (m, 0.3H, CHCO2Me, 
minor), 3.21 (dd, J = 10.0, 8.4 Hz, 0.67H, CHCO2Me, major), 2.97–2.81 (m, 2H, 
CH2), 2.52–2.21 (m, 3H, CH2 + CH), 2.21–1.90 (m, 3H, CHaHb + CHa’Hb’ + 
CHa’’Hb’’), 1.69–1.34 (m, 5H, CHaHb + CHa’Hb’ + CHa’’Hb’’ + 2 × CH), 0.98 (s, 
2.1H, CH3, major), 0.96 (s, 0.9H, CH3, minor); 13C NMR (100 MHz, CDCl3) δ 212.5 
and 212.1 (minor and major), 170.4 and 169.8 (minor and major), 156.9, 137.7, 137.2, 
132.1 and 131.9 (minor and major), 128.5, 127.9, 127.4, 126.3, 114.8, 112.4, 69.9, 
54.0, 52.6 (major), 51.5, 48.9 (minor), 48.7, 48.6 and 47.9 (minor and major), 43.9 
and 43.7 (major and minor), 38.3 and 37.9 (minor and major), 31.9 and 31.7 (major 
and minor), 29.5, 26.5 (major), 26.2 (minor), 25.7, 14.3 and 13.3 (minor and major); 
MS (CI+) 436 [M+NH4]+; HRMS (CI+) calcd for C27H34NO4 436.2488, found 
436.2460. 
 
(8R,9S,13S,14S,16S,17S)-Methyl 3-(benzyloxy)-17-hydroxy-13-methyl-7,8,9,11, 
12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16-carboxylate 
(152a) and  (8R,9S,13S,14S,16R,17S)-Methyl 3-(benzyloxy)-17-hydroxy-13-
methyl-7,8,9, 11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16-
carboxylate (152b)150 
  
152a                                                     152b 
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Following a literature procedure,150 to a solution of ketone 150 (3.25 g, 7.77 mmol, 
1.0 eq.) in a mixture of THF and water (7 : 1, 80 mL) at 0 °C was added sodium 
borohydride (0.29 g, 1.0 eq.) and the reaction mixture was allowed to reach room 
temperature over 10 min. The mixture was acidified with aqueous HCl solution (2 M, 
100 mL), extracted with CH2Cl2 (2 × 100 mL) and the combined organic extracts 
were washed with brine (200 mL), dried over MgSO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (CHCl3 : AcOEt, 95 : 5 → 90 : 
10) to afford two separable diastereoisomers, alcohol 152a (1.91 g, 59% yield) as a 
beige solid and alcohol 152b (0.71 g, 22% yield) as a beige oil. 
152a: Rf 0.48 (CHCl3 : AcOEt, 90 : 10); [α]D22 +30 (c 1.00, CHCl3); IR (thin film) 
3542 (br.), 2921, 2961, 1705, 1499, 1204 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.46–
7.41 (m, 2H, 2 × Ph-H), 7.41–7.35 (m, 2H, 2 × Ph-H), 7.35–7.28 (m, 1H, Ph-H), 7.21 
(d, J = 8.7 Hz, 1H, Ar-H), 6.79 (dd, J = 8.7, 2.8 Hz, 1H, Ar-H), 6.72 (d, J = 2.8 Hz, 
1H, Ar-H), 5.04 (s, 2H, CH2Ph), 3.89 (dd, J = 10.1, 7.9 Hz, 1H, CHOH), 3.72 (s, 3H, 
CO2CH3), 3.35 (d, J = 8.0 Hz, 1H, CHOH), 3.18–3.10 (m, 1H, CHCO2Me), 2.92–2.80 
(m, 2H, CH2), 2.36–2.28 (m, 1H, CHa1Hb1), 2.27–2.19 (m, 1H, CH), 2.13–2.05 (m, 
1H, CHa2Hb2), 2.05–1.99 (m, 1H, CHa3Hb3), 1.94–1.86 (m, 1H, CHa4Hb4), 1.79–1.70 
(m, 1H, CHa2Hb2), 1.58–1.45 (m, 2H, CH + CHa1Hb1), 1.42–1.29 (m, 2H, CHa3Hb3 + 
CHa4Hb4), 1.23–1.14 (m, 1H, CH), 0.84 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3) 
δ 175.6, 156.7, 137.8, 137.2, 132.6, 128.5, 127.8, 127.4, 126.4, 114.8, 112.3, 81.8, 
69.9, 51.9, 48.6, 44.2, 44.0, 43.9, 38.2, 37.2, 29.7, 29.3, 27.3, 26.2, 11.3; MS (ESI+) 
421 [M+H]+; HRMS (ESI+) calcd for C27H33O4 421.2379, found 421.2367. 
152b: Rf 0.29 (CHCl3 : AcOEt, 90 : 10); [α]D22 +34 (c 1.00, CHCl3); IR (thin film) 
3525 (br.), 2910, 2881, 1739, 1500, 1202 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.45–
7.41 (m, 2H, 2 × Ph-H), 7.41–7.35 (m, 2H, 2 × Ph-H), 7.35–7.29 (m, 1H, Ph-H), 7.21 
(d, J = 8.7 Hz, 1H, Ar-H), 6.79 (dd, J = 8.7, 2.8 Hz, 1H, Ar-H), 6.72 (d, J = 2.8 Hz, 
1H, Ar-H), 5.03 (s, 2H, CH2Ph), 3.89 (d, J = 7.4 Hz, 1H, CHOH), 3.75 (s, 3H, 
CO2CH3), 2.91–2.82 (m, 2H, CH2), 2.82–2.73 (m, 1H, CHCO2Me), 2.38–2.28 (m, 
1H, CHa1Hb1), 2.27–2.19 (m, 1H, CH), 2.14–2.02 (m, 2H, OH + CHa2Hb2), 2.01–1.92 
(m, 1H, CHa3Hb3), 1.91–1.83 (m, 1H, CHa4Hb4), 1.78–1.66 (m, 1H, CHa2Hb2), 1.58–
1.42 (m, 2H, CH + CHa1Hb1), 1.42–1.31 (m, 3H, CH + CHa3Hb3 + CHa4Hb4), 0.84 (s, 
3H, CH3); 13C NMR (125 MHz, CDCl3) δ 176.6, 156.7, 137.9, 137.3, 132.6, 128.5, 
127.8, 127.4, 126.3, 114.8, 112.3, 84.3, 69.9, 52.0, 48.9, 48.9, 44.1, 43.8, 38.4, 36.4, 
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29.7, 27.5, 27.1, 26.1, 11.4; MS (ESI+) 421 [M+H]+; HRMS (ESI+) calcd for 
C27H33O4 421.2379, found 421.2379. 
 
(8R,9S,13S,14S,16S,17S)-Methyl 3-(benzyloxy)-13-methyl-17-(triethylsilyloxy)-7, 
8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16-
carboxylate (153a) 
 
To a solution of alcohol 152a (1.86 g, 4.40 mmol, 1.0 eq.) in DMF (24 mL) were 
added imidazole (327 mg, 1.1 eq.) and TESCl (805 µL, 1.1 eq.) and the reaction 
mixture was stirred at room temperature for 20 h. Saturated aqueous solution of 
NH4Cl (200 mL) was added and the mixture was extracted with CH2Cl2 (3 × 
300 mL). The combined organic extracts were washed with brine (200 mL), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (PE : AcOEt, 90 : 10) to afford silyl ether 153a (2.23 g, 95% yield) 
as a white amorphous solid. 
Rf 0.85 (CHCl3 : AcOEt, 90 : 10); [α]D22 +32 (c 1.00, CHCl3); IR (thin film) 2937, 
2874, 1741, 1498, 1157 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.47–7.35 (m, 4H, 4 × 
Ph-H), 7.35–7.29 (m, 1H, Ph-H), 7.20 (d, J = 8.5 Hz, 1H, Ar-H), 6.78 (dd, J = 8.5, 
2.7 Hz, 1H, Ar-H), 6.72 (d, J = 2.7 Hz, 1H, Ar-H), 5.04 (s, 2H, CH2Ph), 3.94 (d, J = 
10.4 Hz, 1H, CHOTES), 3.66 (s, 3H, CO2CH3), 3.15–3.04 (m, 1H, CHCO2Me), 2.94–
2.78 (m, 2H, CH2), 2.35–2.24 (m, 1H, CHaHb), 2.24–2.14 (m, 1H, CH), 2.01–1.80 (m, 
4H, CH2 + CHa’Hb’ + CHa’’Hb’’), 1.63–1.42 (m, 2H, CHaHb + CH), 1.43–1.29 (m, 
1H, CHa’Hb’), 1.29–1.18 (m, 1H, CHa’’Hb’’), 1.18–1.08 (m, 1H, CH), 0.98 (t, J = 
7.9 Hz, 9H, Si(CH2CH3)3), 0.88 (s, 3H, CH3), 0.61 (q, J = 7.9 Hz, 6H, Si(CH2CH3)3); 
13C NMR (125 MHz, CDCl3) δ 174.0, 156.7, 138.0, 137.3, 132.8, 128.5, 127.8, 127.4, 
126.3, 114.8, 112.3, 82.8, 69.9, 51.3, 49.0, 47.4, 44.6, 43.9, 38.3, 37.8, 29.8, 28.5, 
27.3, 26.4, 11.5, 6.9, 4.9; MS (ESI+) 535 [M+H]+; HRMS (ESI+) calcd for C33H47O4Si 
535.3244, found 535.3243. 
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(8R,9S,13S,14S,16R,17S)-Methyl 3-(benzyloxy)-13-methyl-17-(triethylsilyloxy)-7, 
8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16-
carboxylate (153b) 
 
To a solution of alcohol 152b (665 mg, 1.60 mmol, 1.0 eq.) in DMF (3 mL) was 
added imidazole (119 mg, 1.1 eq.) and TESCl (292 µL, 1.1 eq.) and the reaction 
mixture was stirred at room temperature for 20 h. Saturated aqueous solution of 
NH4Cl (100 mL) was added and the mixture was extracted with CH2Cl2 (3 × 
150 mL). The combined organic extracts were washed with brine (100 mL), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (PE : AcOEt, 90 : 10) to afford silyl ether 153b (799 mg, 97% yield) 
as a colourless oil. 
Rf 0.85 (CHCl3 : AcOEt, 90 : 10); [α]D22 +8 (c 1.00, CHCl3); IR (thin film) 2950, 
2912, 2875, 1731, 1499, 1174 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.45–7.36 (m, 4H, 
4 × Ph-H), 7.33–7.29 (m, 1H, Ph-H), 7.21 (d, J = 8.7 Hz, 1H, Ar-H), 6.79 (dd, J = 8.6, 
2.8 Hz, 1H, Ar-H), 6.72 (d, J = 2.8 Hz, 1H, Ar-H), 5.04 (s, 2H, CH2Ph), 4.00 (d, J = 
7.3 Hz, 1H, CHOTES), 3.71 (s, 3H, CO2CH3), 2.91–2.79 (m, 2H, CH2), 2.79–2.68 (m, 
1H, CHCO2Me), 2.36–2.28 (m, 1H, CHaHb), 2.27–2.17 (m, 1H, CH), 1.95–1.76 (m, 
4H, CH2 + CHa’Hb’ + CHa’’Hb’’), 1.57–1.22 (m, 5H, CHaHb + CHa’Hb’ + CHa’’Hb’’ 
+ 2 × CH), 0.97 (t, J = 7.8 Hz, 9H, Si(CH2CH3)3), 0.80 (s, 3H, CH3), 0.59 (q, J = 
7.8 Hz, 6H, Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δ 177.5, 156.7, 137.9, 137.3, 
132.7, 128.5, 127.8, 127.4, 126.3, 114.8, 112.3, 84.8, 69.9, 51.6, 49.3, 48.6, 44.7, 
43.8, 38.7, 36.9, 29.7, 29.3, 27.0, 26.3, 11.9, 6.8, 4.9; MS 535 (ESI+) [M+H]+; HRMS 
(ESI+) calcd for C33H47O4Si 535.3244, found 535.3242. 
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(8R,9S,13S,14S,16R,17S)-3-(Benzyloxy)-13-methyl-17-(triethylsilyloxy)-7,8,9,11, 
12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16-carboxylic acid 
(154b) 
 
Following a literature procedure,156 to a solution of ester 153b (600 mg, 1.12 mmol, 
1.0 eq.) in THF (11 mL) was added Me3SiOK (1.15 g, 8.0 eq.) and the mixture was 
stirred at room temperature for 25 h. Aqueous HCl solution (1 M, 50 mL) was added 
and the mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic 
extracts were washed with brine (50 mL), dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash column chromatography (PE : AcOEt, 80 : 
20 → 70 : 30) to afford carboxylic acid 154b (355 mg, 62% yield) as a white foam. 
Rf 0.53 (PE : AcOEt, 70 : 30); [α]D20 +36 (c 1.00, CHCl3); IR (thin film) 2913 (br.), 
2875, 1700, 1498, 1232 cm-1; 1H NMR (400 MHz, CDCl3) δ 11.78 (br. s, 1H, CO2H), 
7.49–7.37 (m, 4H, , 4 × Ph-H), 7.37–7.29 (m, 1H, Ph-H), 7.22 (d, J = 8.7 Hz, 1H, Ar-
H), 6.81 (dd, J = 8.6, 2.5 Hz, 1H, Ar-H), 6.74 (d, J = 2.5 Hz, 1H, Ar-H), 5.05 (s, 2H, 
CH2Ph), 4.05 (d, J = 7.5 Hz, 1H, CHOTES), 2.95–2.73 (m, 3H, CH2 + CHCO2H), 
2.40–2.29 (m, 1H, CHa1Hb1), 2.29–2.20 (m, 1H, CH), 2.02–1.75 (m, 4H, CH2 + 
CHa2Hb2 + CHa3Hb3), 1.61–1.23 (m, 5H, 2 × CH + CHa1Hb1 + CHa2Hb2 + CHa3Hb3), 
0.98 (d, J = 7.9 Hz, 9H, Si(CH2CH3)3), 0.83 (s, 3H, CH3), 0.63 (q, J = 7.9 Hz, 6H, 
Si(CH2CH3)3); 13C NMR (100 MHz, CDCl3) δ 183.5, 156.8, 138.0, 137.3, 132.7, 
128.6, 127.9, 127.5, 126.4, 114.9, 112.4, 84.6, 70.0, 49.4, 48.8, 44.9, 43.9, 38.7, 36.9, 
29.8, 29.5, 27.1, 26.3, 11.9, 6.9, 5.0; MS (ESI–) [M-H+HCO2H]–; HRMS (ESI–) calcd 
for C33H45O6Si 565.2985, found 565.3044. 
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((8R,9S,13S,14S,16R,17S)-3-(Benzyloxy)-13-methyl-17-(triethylsilyloxy)-7,8,9,11, 
12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)(1H-imidazol-
1-yl)methanone (155) 
 
To a solution of acid 154b (147 mg, 0.38 mmol, 1.0 eq.) in THF (0.8 mL) at 0 °C was 
added CDI (129 mg, 2.1 eq.) and the reaction mixture was allowed to reach room 
temperature over 1 h and stirred for 12 h. Water (20 mL) was added and the mixture 
was extracted with CH2Cl2 (3 × 30 mL). The combined organic extracts were washed 
with brine (20 mL), dried over MgSO4 and concentrated in vacuo to afford acyl 
imidazole 155 (165 mg, 99% yield) as a white foam. The residue was used directly in 
the next step without further purification, as NMR analysis showed sufficient purity. 
Rf 0.29 (PE : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H, Im-H), 7.52 
(s, 1H, Im-H), 7.45–7.35 (m, 4H, 4 × Ph-H), 7.35–7.29 (m, 1H, Ph-H), 7.20 (d, J = 
8.7 Hz, 1H, Ar-H), 7.12 (s, 1H, Im-H), 6.79 (dd, J = 8.7, 2.8 Hz, 1H, Ar-H), 6.71 (d, 
J = 2.8 Hz, 1H, Ar-H), 5.03 (s, 2H, Ph-CH2), 4.22 (d, J = 7.1 Hz, 1H, CHOTES), 
3.38–3.27 (m, 1H, CHCO2Im), 2.91–2.78 (m, 2H), 2.41–2.30 (m, 1H), 2.32–2.17 (m, 
1H), 2.03–1.87 (m, 3H), 1.87–1.74 (m, 1H), 1.59–1.52 (m, 1H), 1.52–1.45 (m, 2H), 
1.45–1.31 (m, 2H), 0.85 (d, J = 8.0 Hz, 9H, Si(CH2CH3)3), 0.50 (q, J = 8.0 Hz, 6H, 
Si(CH2CH3)3); MS (ESI+) 571 [M+H]+; HRMS (ESI+) calcd for C35H47N2O3Si 
571.3356, found 571.3364. 
 
(8R,9S,13S,14S,16R,17S)-Methyl 3-(benzyloxy)-17-(tert-butyldimethylsilyloxy)-
13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-
16-carboxylate (158) 
 
H
H H
BnO
OTES
O
N
N
H
H H
BnO
OTBS
O
OMe
 
236 
To a solution of alcohol 152b (707 mg, 1.68 mmol, 1.0 eq.) in CH2Cl2 (16 mL) at 
0 °C were added 2,6-lutidine (428 µL, 2.2 eq.) and TBSOTf (670 µL, 2.2 eq.) and the 
reaction mixture was allowed to reach room temperature over 1 h. Water (50 mL) was 
added and the mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic 
extracts were washed with brine (100 mL), dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash column chromatography (PE : AcOEt, 90 : 
10) to afford silyl ether 158 (827 mg, 92% yield) as a white foam. 
Rf 0.73 (PE : AcOEt, 70 : 30); [α]D20 +20 (c 1.00, CHCl3); IR (thin film) 2927, 2855, 
2731, 1249, 1174 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.46–7.35 (m, 4H, 4 × Ph-H), 
7.35–7.29 (m, 1H, Ph-H), 7.20 (d, J = 8.6 Hz, 1H, Ar-H), 6.78 (dd, J = 8.6, 2.6 Hz, 
1H, Ar-H), 6.71 (d, J = 2.6 Hz, 1H, Ar-H), 5.03 (s, 2H, Ph-CH2), 3.94 (d, J = 7.3 Hz, 
1H, CHOTBS), 3.70 (s, 3H, CO2CH3), 2.90–2.77 (m, 2H, CH2), 2.77–2.67 (m, 1H, 
CHCO2Me), 2.36–2.26 (m, 1H, CHa1Hb1), 2.26–2.17 (m, 1H, CH), 1.92–1.67 (m, 4H, 
CHa2Hb2 + CHa3Hb3 + CH2), 1.52–1.21 (m, 5H, 2 × CH + CHa1Hb1 + CHa2Hb2 + 
CHa3Hb3), 0.87 (s, 9H, Si (C(CH3)3)), 0.78 (s, 3H, CH3), 0.05 (s, 3H, Si(CH3)(CH3)),  
–0.02 (s, 3H, Si(CH3)(CH3)); 13C NMR (100 MHz, CDCl3) δ 177.4, 156.7, 137.8, 
137.3, 132.6, 128.4, 127.7, 127.3, 126.2, 114.8, 112.2, 85.0, 69.8, 51.4, 49.2, 48.6, 
44.6, 43.7, 38.6, 36.8, 29.6, 29.2, 27.0, 26.2, 25.7, 17.9, 11.8, –4.7, –4.9; MS (ESI+) 
535 [M+H]+; HRMS (ESI+) calcd for C33H47O4Si 535.3244, found 535.3267. 
 
(8R,9S,13S,14S,16R,17S)-3-(Benzyloxy)-17-(tert-butyldimethylsilyloxy)-13-
methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16-
carboxylic acid (159) 
 
Following a literature procedure,156 to a solution of ester 158 (820 mg, 1.53 mmol, 
1.0 eq.) in THF (15 mL) was added Me3SiOK (1.97 g, 10.0 eq.) and the mixture was 
stirred at room temperature for 25 h. Aqueous HCl solution (1 M, 50 mL) was added 
and the mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic 
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extracts were washed with brine (50 mL), dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash column chromatography (PE : AcOEt, 90 : 
10 → 70 : 30) to afford carboxylic acid 159 (551 mg, 72% yield) as a white foam. 
Rf 0.50 (PE : AcOEt, 70 : 30); [α]D20 +24 (c 1.00, CHCl3); IR (thin film) 2933 (br.), 
2857, 1698, 1234, 835 cm-1; 1H NMR (400 MHz, CDCl3) δ 10.67 (br. s, 1H, CO2H), 
7.47–7.35 (m, 4H, 4 × Ph-H), 7.35–7.28 (m, 1H, Ph-H), 7.20 (d, J = 8.7 Hz, 1H, Ar-
H), 6.78 (dd, J = 8.7, 2.7 Hz, 1H, Ar-H), 6.72 (d, J = 2.7 Hz, 1H, Ar-H), 5.03 (s, 2H, 
CH2Ph), 3.98 (d, J = 7.3 Hz, 1H, CHOTBS), 2.90–2.80 (m, 2H, CH2), 2.80–2.70 (m, 
1H, CH), 2.35–2.26 (m, 1H, CHa1Hb1), 2.26–2.15 (m, 1H, CH), 1.98–1.72 (m, 4H, 
CHa2Hb2 + CHa3Hb3 + CH2), 1.57–1.22 (m, 5H, 2 × CH + CHa1Hb1 + CHa2Hb2 + 
CHa3Hb3), 0.90 (s, 9H, Si(C(CH3)3)), 0.80 (s, 3H, CH3), 0.07 (s, 3H, Si(CH3)(CH3)), 
0.03 (s, 3H, Si(CH3)(CH3)); 13C NMR (125 MHz, CDCl3) δ 183.0, 156.8, 137.9, 
137.3, 132.7, 128.5, 127.8, 127.4, 126.3, 114.8, 112.3, 84.9, 69.9, 49.2, 48.7, 44.8, 
43.8, 38.6, 36.9, 29.7, 29.4, 27.1, 26.3, 25.8, 18.0, 11.9, –4.6, –4.6; MS (ESI+) 521 
[M+H]+; HRMS (ESI+) calcd for C32H45O4Si 521.3087, found 521.3093. 
 
((8R,9S,13S,14S,16R,17S)-3-(Benzyloxy)-17-(tert-butyldimethylsilyloxy)-13-
methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-
yl)(1H-imidazol-1-yl)methanone (160) 
 
To a solution of acid 159 (551 mg, 1.06 mmol, 1.0 eq.) in THF (10 mL) at 0 °C was 
added CDI (189 mg, 1.1 eq.) and the reaction mixture was allowed to reach room 
temperature over 1 h and was stirred for 18 h. Water (100 mL) was added and the 
mixture was extracted with CH2Cl2 (3 × 100 mL). The combined organic extracts 
were washed with brine (100 mL), dried over MgSO4 and concentrated in vacuo to 
afford imidazole 160 as a white foam (507 mg, 83% yield). The residue was used 
directly in the next step without further purification, as NMR analysis showed 
sufficient purity. 
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Rf 0.30 (PE : AcOEt, 70 : 30); [α]D20 +2 (c 1.00, CHCl3); IR (thin film) 2929, 2861, 
1750, 1234, 836 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H, Im-H), 7.55 (s, 1H, 
Im-H), 7.48–7.37 (m, 4H, 4 × Ph-H), 7.37–7.31 (m, 1H, Ph-H), 7.22 (d, J = 8.5 Hz, 
1H, Ar-H), 7.15 (s, 1H, Im-H), 6.81 (dd, J = 8.5, 2.7 Hz, 1H, Ar-H), 6.74 (d, J = 
2.7 Hz, 1H, Ar-H), 5.06 (s, 2H, CH2Ph), 4.21 (d, J = 7.2 Hz, 1H, CHOTBS), 3.39–
3.29 (m, 1H, CHCO2Im), 2.92–2.80 (m, 2H, CH2), 2.43–2.32 (m, 1H, CHa1Hb1), 
2.32–2.21 (m, 1H, CH), 2.02–1.90 (m, 3H, CH2 + CHa2Hb2), 1.90–1.78 (m, 1H, 
CHa3Hb3), 1.61–1.47 (m, 3H, CH + CHa1Hb1 + CHa2Hb2), 1.47–1.32 (m, 2H, CH + 
CHa3Hb3), 0.92 (s, 3H, CH3), 0.87 (s, 9H, Si(C(CH3)3)), 0.09 (s, 3H, Si(CH3)(CH3)),   
–0.25 (s, 3H, Si(CH3)(CH3)); 13C NMR (100 MHz, CDCl3) δ 173.4, 156.8, 137.8, 
137.2, 136.5, 132.4, 131.2, 128.5, 127.8, 127.4, 126.3, 116.3, 114.8, 112.4, 84.4, 69.9, 
49.7, 48.8, 45.0, 43.7, 38.6, 36.8, 30.3, 29.6, 27.0, 26.2, 25.7, 17.9, 12.0, –4.6, –5.2; 
MS (ESI+) 571 [M+H]+; HRMS (ESI+) calcd for C35H47N2O3Si 571.3356, found 
571.3354. 
 
6-((Z)-4-((8R,9S,13S,14S,16R,17S)-3-(Benzyloxy)-17-(tert-butyldimethylsilyloxy)-
13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-
16-yl)-2-hydroxy-4-oxobut-2-enyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (161) 
 
Following a literature procedure,137 n-butyllithium (2.25 M in hexanes, 0.66 mL, 
4.2 eq.) was added to a solution of diisopropylamine (0.21 mL, 4.2 eq.) in THF 
(6 mL) at –78 °C. A solution of ketodioxinone 105 (129 mg, 2.0 eq.) in THF (1.5 mL) 
was added dropwise and the mixture was stirred for 20 min. Diethylzinc (1.0 M in 
hexanes, 1.47 mL, 4.2 eq.) was added slowly and the reaction mixture was stirred for 
20 min. A solution of imidazole 160 (200 g, 0.35 mmol, 1.0 eq.) in THF (1.5 mL) was 
added and the mixture was stirred at –78 °C for 3 h. Saturated aqueous solution of 
NH4Cl (50 mL) was added and the pH was adjusted to pH 1–2 with aqueous HCl 
solution (1 M). The aqueous layer was extracted with CH2Cl2 (5 × 50 mL) and the 
combined organic extracts were dried over MgSO4 and concentrated in vacuo. The 
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residue was purified by flash column chromatography (PE : AcOEt, 80 : 20 → 70 : 
30) to afford product 161 (170 mg, 71% yield) as a yellow oil.  
Rf 0.62 (PE : AcOEt, 70 : 30); [α]D20 +16 (c 1.00, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 15.28 (s, 1H, C=COH), 7.47–7.36 (m, 4H, 4 × Ph-H), 7.36–7.30 (m, 1H, 
Ph-H), 7.22 (d, J = 8.6 Hz, 1H, Ar-H), 6.80 (dd, J = 8.6, 2.7 Hz, 1H, Ar-H), 6.73 (d, 
J = 2.7 Hz, 1H, Ar-H), 5.61 (s, 1H, C=CH), 5.42 (s, 1H, C=CH), 5.05 (s, 2H, Ph-
CH2), 3.96 (d, J = 7.4 Hz, 1H, CHOTBS), 3.24 (s, 2H, CH2), 2.90–2.81 (m, 2H), 2.63 
(ddd, J = 11.3, 7.4, 3.8 Hz, 1H, CHCO), 2.39–2.29 (m, 1H), 2.29–2.20 (m, 1H), 1.93–
1.80 (m, 3H), 1.72 (s, 6H, C(CH3)2), 1.59–1.21 (m, 6H), 0.90 (s, 9H, SiC(CH3)3), 0.83 
(s, 3H, CCH3), 0.05 (s, 3H, SiCH3), –0.06 (s, 3H, SiCH3); Mass of the product could 
not be found by HRMS. 
 
2-((8S,9S,10R,11S,13S,14S,17S)-11-Hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10, 
11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-
ethyl 2,4-dimethoxy-6-methylbenzoate (165a) 
 
To a solution of corticosterone (166a) (50 mg, 0.14 mmol, 1.0 eq.), 2,4-dimethoxy-6-
methylbenzoic acid (167) (28 mg, 1.0 eq.) and triphenylphosphine (39 mg, 1.1 eq.) in 
THF (1.4 mL) was added DEAD (24 µL, 1.1 eq.) and the mixture was stirred at room 
temperature for 18 h. Aqueous HCl solution (1 M, 10 mL) was added, the aqueous 
layer was extracted with CH2Cl2 (3 × 20 mL) and the combined organic extracts were 
washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (Et2O) to afford ester 165a 
(56 mg, 76% yield) as a white solid. 
Rf 0.52 (CH2Cl2 : MeOH, 95 : 5); mp 200–202 °C (Et2O); [α]D20 +138 (c 1.00, 
CHCl3); IR (thin film) 3422 (br.), 2930, 1715, 1648, 1604, 1202, 1158 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 6.33 (d, J = 2.2 Hz, 1H, Ar-H), 6.30 (d, J = 2.2 Hz, 1H, Ar-H), 
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5.66 (d, J = 1.4 Hz, 1H, C=CH), 4.90 (d, J = 16.6 Hz, 1H, CHaHbO), 4.67 (d, J = 
16.6 Hz, 1H, CHaHbO), 4.40–4.31 (m, 1H, CHOH), 3.79 (s, 3H, Ar-OCH3), 3.78 (s, 
3H, Ar-OCH3), 2.56–2.39 (m, 6H, CH + CHa1Hb1 + CHa2Hb2 + Ar-CH3), 2.39–2.11 
(m, 6H, CHa1Hb1 + CHa2Hb2 + CHa3Hb3 + CHa4Hb4 + CHa5Hb5 + CHOH), 2.09–1.93 
(m, 2H, CHa6Hb6 + CH), 1.90–1.65 (m, 3H, CHa4Hb4 + CHa5Hb5 + CHa7Hb7), 1.65–
1.57 (m, 1H, CHa3Hb3), 1.51–1.33 (m, 4H, CHa7Hb7 + CH3), 1.20–1.00 (m, 2H, CH + 
CHa6Hb6), 0.96 (m, 4H, CH3 + CH); 13C NMR (100 MHz, CDCl3) δ 203.3, 199.5, 
172.0, 167.3, 161.6, 158.4, 139.4, 122.3, 115.1, 106.8, 96.1, 69.4, 67.9, 59.4, 57.6, 
56.3, 55.9, 55.3, 47.8, 43.7, 39.2, 34.9, 33.8, 32.5, 31.9, 31.3, 24.4, 22.5, 20.8, 20.2, 
15.7; MS (ESI+) 525 [M+H]+; HRMS (ESI+) calcd for C31H41O7 525.2852, found 
525.2861. 
 
2-((8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8, 
9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-
oxoethyl 2,4-dimethoxy-6-methylbenzoate (165b) 
 
 
To a solution of hydrocortisone (166b) (51 mg, 0.14 mmol, 1.0 eq.), 2,4-dimethoxy-6-
methylbenzoic acid (167) (28 mg, 1.0 eq.) and triphenylphosphine (39 mg, 1.1 eq.) in 
THF (1.4 mL) was added DEAD (24 µL, 1.1 eq.) and the mixture was stirred at room 
temperature for 18 h. Aqueous HCl solution (1 M, 10 mL) was added, the aqueous 
layer was extracted with CH2Cl2 (3 × 20 mL) and the combined organic extracts were 
washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography (Et2O) to afford ester 165b 
(26 mg, 34% yield) as a white solid. 
Rf 0.44 (CH2Cl2 : MeOH, 95 : 5); mp 180–182 °C (Et2O); [α]D28 +119 (c 1.00, 
CHCl3); IR (thin film) 3470 (br.), 2930, 1719, 1655, 1604, 1268, 1158 cm-1; 1H NMR 
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(400 MHz, CDCl3) δ 6.34 (d, J = 2.1 Hz, 1H, Ar-H), 6.31 (d, J = 2.2 Hz, 1H, Ar-H), 
5.68 (s, 1H, C=CH), 5.18 (d, J = 17.3 Hz, 1H, CHaHbO), 5.07 (d, J = 17.3 Hz, 1H, 
CHaHbO), 4.49–4.41 (m, 1H, CHOH), 3.80 (s, 3H, Ar-OCH3), 3.79 (s, 3H, Ar-OCH3), 
2.85–2.71 (m, 1H, CHa1Hb1), 2.58–2.40 (m, 5H, CHa2Hb2 + CHa3Hb3 + Ar-CH3), 2.40–
1.91 (m, 6H, CHa2Hb2 + CHa3Hb3 + CHa4Hb4 + CHa5Hb5 + CHa6Hb6 + CH), 1.87–1.61 
(m, 4H, CHa4Hb4 + CHa5Hb5 + CHa7Hb7 + CH), 1.54–1.36 (m, 5H, CHa5Hb5 + CHa7Hb7 
+ CH3), 1.29 (br. s, 1H, CHOH), 1.15–1.04 (m, 1H, CHa6Hb6), 1.04–0.96 (m, 4H, CH 
+ CH3); 13C NMR (100 MHz, CDCl3) δ 204.7, 199.7, 172.3, 167.7, 161.6, 158.5, 
139.5, 122.3, 115.1, 106.9, 96.2, 89.9, 68.3, 68.2, 56.0, 55.3, 52.0, 47.6, 39.8, 39.2, 
34.9, 34.6, 33.8, 32.7, 32.0, 31.8, 31.4, 23.6, 20.9, 20.2, 17.1; MS (ESI+) 541 [M+H]+; 
HRMS (ESI+) calcd for C31H41O8 541.2797, found 541.2748. 
 
3-(Benzyloxy)-3-oxopropanoic acid (172)228 
 
To a solution of Meldrum’s acid (171) (10.0 g, 6.90 mmol, 1.1 eq.) in toluene 
(70 mL) was added benzyl alcohol (7.59 mL, 1.1 eq.) and the mixture was heated at 
reflux for 3 h. The solvent was evaporated in vacuo and the residue was partitioned 
between Et2O (300 mL) and aqueous saturated NaHCO3 (500 mL). The aqueous layer 
was washed with Et2O (300 mL), acidified with aqueous HCl solution (1 M, 700 mL), 
extracted with CH2Cl2 (3 × 500 mL), washed with brine (300 mL), dried over MgSO4 
and concentrated in vacuo to afford carboxylic acid 172 (12.9 g, 97% yield) as a white 
solid. The residue was used directly in the next step without further purification, as 
NMR analysis showed sufficient purity.  
Rf 0.20 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 10.50 (br. s, 1H, 
CO2H), 7.47–7.32 (m, 5H, 5 × Ph-H), 5.21 (s, 2H, CH2Ph), 3.49 (s, 2H, CH2); 13C 
NMR (100 MHz, CDCl3) δ 171.6, 166.5, 134.9, 128.6, 128.5, 128.3, 67.6, 40.8; MS 
(ESI–) [M–H]–; HRMS (ESI–) calcd for C10H9O4 193.0501, found 193.0513. The 
analytical data are consistent with the data reported in the literature.228 
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Benzyl 4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-oxobutanoate (170) 
 
To a solution of acid 172 (1.00 g, 5.00 mmol, 1.0 eq.) in CH2Cl2 (10 mL) at 0 °C was 
added (COCl)2 (470 µL, 1.1 eq.) and DMF (1 drop) and the reaction mixture was 
allowed to reach room temperature over 1 h and was stirred for 3 h until no more gas 
evolution could be seen. The solvent was evaporated in vacuo and the crude acid 
chloride was used directly into the next step. To a solution of HMDS (3.33 mL, 
3.0 eq.) in THF (30 mL) at 0 °C was added dropwise n-BuLi (2.26 M in hexanes, 
7.52 mL, 3.4 eq.) and the mixture was stirred at 0 °C for 1 h. Freshly distilled 
dioxinone 109 (2.13 mg, 3.0 eq.) was added dropwise at –78 °C and stirred for 1 h. A 
solution of the crude acid chloride in THF (10 mL) was added dropwise and the 
reaction mixture was stirred at –78 °C for 3 h. Saturated aqueous solution of NH4Cl 
(5 mL) was added and the mixture was allowed to reach room temperature, acidified 
with aqueous HCl solution (1 M, 100 mL) until pH 1 and extracted with CH2Cl2 (3 × 
300 mL). The combined organic extracts were washed with brine (200 mL), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (PE : AcOEt, 70 : 30) to afford ketoester 170 (987 mg, 63% yield) as 
a yellow oil. NMR analyses showed the presence of a mixture of keto and enol 
tautomers (4 : 1). 
Rf 0.19 (PE : AcOEt, 70 : 30); IR (thin film) 2999, 1718, 1637, 1375, 1200 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 12.03 (s, 0.2H, OH, enol), 7.46–7.32 (m, 5H, 5 × Ph-H, 
keto + enol), 5.42 (s, 0.2H, C=CH, enol), 5.34 (s, 0.8H, C=CH, keto), 5.22 (s, 0.4H, 
CH2Ph, enol), 5.21 (s, 1.6H, CH2Ph, keto), 5.17 (s, 0.2H, C=CH, enol), 3.58 (s, 1.6H 
CH2, keto), 3.48 (s, 1.6H, CH2, keto), 3.13 (s, 0.4H, CH2, enol), 1.71 (s, 6H, C(CH3)3, 
keto + enol); 13C NMR (100 MHz, CDCl3) δ 195.4, 166.1, 163.4, 160.4, 134.9, 128.7, 
128.5, 128.3, 107.4, 97.1, 95.9 (enol), 91.9 (enol), 67.6, 66.2 (enol), 49.1, 47.0, 39.4 
(enol), 25.0; MS (ESI–) 317 [M–H]–; HRMS (ESI–) calcd for C17H17O6 317.1025, 
found 317.1029. 
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(E)-Benzyl 2-(2-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)acetyl)-3-hydroxybut-2-
enoate (174) 
 
To a solution of ketoester 170 (900 mg, 2.83 mmol, 1.0 eq.) in CH2Cl2 (4.5 mL) at 
0 °C was added pyridine (570 µL, 2.5 eq.) and MgCl2 (269 mg, 1.0 eq.) and the 
mixture was stirred at 0 °C for 15 min. AcCl (261 µL, 1.3 eq.) was added and the 
reaction mixture was stirred at 0 °C for 1 h. Saturated aqueous solution of NH4Cl 
(2 mL) was added, and aqueous HCl solution (1 M, 30 mL) until pH 1 and the mixture 
was extracted with CH2Cl2 (3 × 30 mL). The combined organic extracts were washed 
with brine (20 mL), dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash column chromatography (PE : AcOEt, 90 : 10 → 70 : 30) to afford 
enol 174 (887 mg, 87% yield) as a yellow oil.  
Rf 0.36 (PE : AcOEt, 70 : 30); IR (thin film) 1727, 1708, 1638, 1561, 1373 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 17.66 (s, 1H, OH), 7.38 (m, 5H, 5 × Ph-H), 5.29 (s, 1H, 
C=CH), 5.25 (s, 2H, CH2Ph), 3.70 (s, 2H, CH2), 2.38 (s, 3H, CH3), 1.67 (s, 6H, 
C(CH3)2); 13C NMR (100 MHz, CDCl3) δ 196.1, 193.7, 166.1, 165.0, 160.7, 135.1, 
128.8, 128.7, 128.7, 108.2, 107.2, 96.5, 67.1, 43.2, 25.7, 24.9; MS (ESI–) 359 [M–H]-; 
HRMS (ESI–) calcd for C19H19O7 359.1131, found 359.1139. 
 
1-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)pentane-2,4-dione (169)160 
 
Palladium on charcoal (10 mol%, 10 mg) was loaded into a flask and flushed with 
argon. MeOH (3 mL) was added and hydrogen was bubbled through the solution for 
2 min. Enol 174 (108 mg, 0.3 mmol, 1.0 eq.) in MeOH (1.5 mL) was added and the 
reaction mixture was stirred under a hydrogen atmosphere for 30 min. The mixture 
was filtered thought celite, washed with MeOH (30 mL) and the filtrate was 
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evaporated in vacuo to afford diketodioxinone 169 (69 mg, 99% yield) as an orange 
oil. NMR analyses showed sufficient purity and the product was used directly in the 
next reaction. 
Rf 0.18 (PE : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 15.07 (s, 1H, OH), 5.57 
(s, 1H, C=CH), 5.40 (s, 1H, C=CH), 3.22 (s, 2H, CH2), 2.10 (s, 3H, CH3), 1.71 (s, 6H, 
C(CH3)2); MS (ESI+) 227 [M+H]+; HRMS (ESI+) calcd for C11H15O5 227.0919, found 
227.0889. 
 
2-((8S,9S,10R,11S,13S,14S,17S)-11-Hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10, 
11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-
ethyl 2,4-dihydroxy-6-methylbenzoate (168a) 
 
Following a literature procedure,162 to a solution of diketodioxinone 169 (165 mg, 
1.5 eq.) in toluene (3.6 mL) was added corticosterone (166a) (125 mg, 0.36 mmol, 
1.0 eq.) and the reaction mixture was refluxed for 3 h in a sealed tube. The solvent 
was evaporated in vacuo and the residue was dissolved in methanol (6 mL). Caesium 
carbonate (703 mg, 6 eq.) was added and the mixture was stirred at room temperature 
for 2 h. The pH was adjusted to 1–2 with aqueous HCl solution (1 M) and the mixture 
was stirred at room temperature for 1 h. The aqueous layer was extracted with CH2Cl2 
(3 × 40 mL) and the combined organic extracts were washed with brine (30 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (Et2O) to afford resorcylate 168a (37 mg, 21% yield) as a 
white solid. 
Rf 0.21 (Et2O); mp 208–210 °C (Et2O); [α]D28 +38 (c 0.25, acetone); IR (thin film) 
3015 (br.), 2456, 1938, 1725, 1620, 1582, 1319, 1256 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 11.17 (s, 1H, Ar-OH), 9.21 (s, 1H, Ar-OH), 6.31 (d, J = 2.5 Hz, 1H, Ar-H), 
6.24 (d, J = 2.5 Hz, 1H, , Ar-H), 5.56 (d, J = 1.7 Hz, 1H, C=CH), 5.13 (d, J = 
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16.9 Hz, 1H, CHaHbO), 4.97 (d, J = 16.9 Hz, 1H, CHaHbO), 4.52–4.43 (m, 1H, 
CHOH), 3.69–3.63 (m, 1H, CHOH), 2.68 (m, 1H, CH), 2.63–2.52 (m, 1H, CHa1Hb1), 
2.49 (m, 3H, Ar-CH3), 2.42–2.32 (m, 2H, CHa2Hb2 + CHa3Hb3), 2.27–2.14 (m, 4H, 
CHa1Hb1 + CHa2Hb2 + CHa4Hb4 + CHa5Hb5), 2.10–1.98 (m, 2H, CHa6Hb6 + CH), 1.94–
1.63 (m, 4H, CHa5Hb5 + CHa7Hb7 + CHa4Hb4 + CHa3Hb3), 1.48 (s, 3H, CH3), 1.39 (s, 
1H, CHa7Hb7), 1.30–1.24 (m, 1H, CH), 1.16–1.01 (m, 2H, CHa6Hb6 + CH), 0.97 (s, 
3H, CH3); 13C NMR (100 MHz, CDCl3) δ 203.7, 198.3, 172.3, 171.1, 165.9, 163.3, 
144.6, 122.6, 112.4, 105.4, 101.7, 70.1, 68.1, 60.0, 58.4, 57.1, 48.1, 44.7, 40.1, 35.6, 
34.4, 33.7, 32.6, 32.3, 25.1, 24.0, 23.0, 21.3, 16.0; MS (ESI+) 497 [M+H]+; HRMS 
(ESI+) calcd for C29H37O7 497.2539, found 497.2545. 
 
2-(N-Methylphenylsulfonamido)acetic acid (179a) 
 
Following a literature procedure,45 to a solution of sarcosine (178) (890 mg, 
10.0 mmol, 1.0 eq.) in aqueous NaOH solution (4 M, 4 mL) was added phenylsulfonyl 
chloride (1.23 mL, 1.0 eq.) and the reaction mixture was stirred at room temperature 
for 45 min. The product was precipitated by addition of aqueous HCl solution (6 M) 
and the mixture was cooled to 0 °C. The crystals were collected, washed with cold 
water and dried in vacuo to afford carboxylic acid 179a (1.69 g, 74% yield) as white 
solid. 
mp 138–140 °C (water); IR (thin film) 2770 (br.), 1722, 1450, 1336 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 12.83 (br. s, 1H, CO2H), 7.83–7.76 (m, 2H, 2 × Ar-H), 7.73–
7.66 (m, 1H, Ar-H), 7.66–7.57 (m, 2H, 2 × Ar-H), 3.88 (s, 2H, CH2), 2.78 (s, 3H, N-
CH3); 13C NMR (100 MHz, CDCl3) δ 169.8, 137.9, 132.9, 129.3, 127.0, 50.5, 35.5; 
MS (ESI+) 230 [M+H]+; HRMS (ESI+) calcd for C9H12NO4S 230.0487, found 
230.0492. 
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2-(5-Chloro-N,1,3-trimethyl-1H-pyrazole-4-sulfonamido)acetic acid (179b) 
 
Following a literature procedure,45 to a solution of sarcosine (178) (178 mg, 
2.00 mmol, 1.0 eq.) in aqueous NaOH solution (4 M, 2 mL) was added 5-chloro-1,3-
dimethyl-1H-pyrazole-4-sulfonyl chloride (459 mg, 1.0 eq.) and the reaction mixture 
was stirred at room temperature for 45 min. The product was precipitated by addition 
of aqueous HCl solution (6 M) and the mixture was cooled to 0 °C. The crystals were 
collected, washed with cold water and dried in vacuo to afford carboxylic acid 179b 
(184 mg, 65% yield) as white solid. 
mp 122–124 °C (water); IR (thin film) 2938, 2700 (br.), 2415, 1734, 1506, 1340, 
1172 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.87 (br. s, 1H, CO2H), 3.95 (s, 2H, CH2), 
3.77 (s, 3H, N(Ar)-CH3), 2.83 (s, 3H, N-CH3), 2.28 (s, 3H, Ar-CH3); 13C NMR 
(100 MHz, CDCl3) δ 169.9, 147.4, 128.7, 114.0, 50.3, 36.6, 35.0, 13.6 ; MS (ESI+) 
282, 284 [M+H]+; HRMS (ESI+) calcd for C8H1335ClN3O4S 282.0315, found 
282.0319. 
 
2-(N-Methylphenylsulfonamido)acetyl chloride (180a) 
 
To a solution of carboxylic acid 179a (389 mg, 1.70 mmol, 1.0 eq.) in CH2Cl2 
(3.5 mL) at 0 °C were added (COCl)2 (160 µL, 1.1 eq.) and DMF (1 drop) and the 
reaction mixture was allowed to reach room temperature over 1 h and was stirred for 
2 h until no more gas evolution could be seen. The solvent was evaporated in vacuo to 
afford acid chloride 180a (419 mg, 99% yield) as an orange oil. 1H NMR analysis 
showed sufficient purity and the crude acid chloride was used in the next step without 
further purification. 
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1H NMR (400 MHz, CDCl3) δ 7.84–7.76 (m, 2H, 2 × Ar-H), 7.67–7.59 (m, 1H, Ar-
H), 7.59–7.51 (m, 2H2 × Ar-H), 4.45 (s, 2H, CH2), 2.92 (s, 3H, N-CH3). 
2-(5-Chloro-N,1,3-trimethyl-1H-pyrazole-4-sulfonamido)acetyl chloride (180b) 
 
To a solution of carboxylic acid 179b (184 mg, 0.79 mmol, 1.0 eq.) in CH2Cl2 
(1.6 mL) at 0 °C were added (COCl)2 (75 µL, 1.1 eq.) and DMF (1 drop) and the 
reaction mixture was allowed to reach room temperature over 1 h and was stirred for 
2 h until no more gas evolution could be seen. The solvent was evaporated in vacuo to 
afford acid chloride 180b (236 mg, 99% yield) as a yellow solid. 1H NMR analysis 
showed sufficient purity and the crude acid chloride was used in the next step without 
further purification. 
1H NMR (400 MHz, CDCl3) δ 4.53 (s, 2H, CH2), 3.83 (s, 3H, N(Ar)-CH3), 2.97 (s, 
3H, N-CH3), 2.41 (s, 3H, Ar-CH3). 
 
2-((8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8, 
9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-
oxoethyl methanesulfonate (185)229 
 
To a solution of hydrocortisone (166b) (1.00 g, 2.70 mmol, 1.0 eq.) in CH2Cl2 
(13 mL) at 0 °C were added Et3N (404 µL, 1.1 eq.) and MsCl (224 µL, 1.1 eq.) and 
the reaction mixture was allowed to reach room temperature over 1 h. Water 
(100 mL) was added and the mixture was extracted with CH2Cl2 (3 × 100 mL). The 
combined organic extracts were washed with brine (100 mL), dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography 
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(CH2Cl2 : MeOH, 99 : 1 → 95 : 5) to afford mesylate 185 (910 mg, 77% yield) as a 
white foam. 
Rf 0.53 (CH2Cl2 : MeOH, 95 : 5); [α]D20 +4 (c 1.00, CHCl3); lit229 [α]D20 +150 (c 0.38, 
CHCl3)a; IR (thin film) 3435 (br.), 2925, 1730, 1650, 1346 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 5.66 (d, J = 1.6 Hz, 1H, C=CH), 5.29 (d, J = 18.0 Hz, 1H, CHaHbOMs), 
5.02 (d, J = 18.0 Hz, 1H, CHaHbOMs), 4.50–4.45 (m, 1H, CHOH), 3.22 (s, 3H, 
SO2CH3), 2.84–2.73 (m, 1H, CHa1Hb1), 2.67 (br. s, 1H, OH), 2.56–2.42 (m, 2H, 
CHa2Hb2 + CHa3Hb3), 2.39–2.30 (m, 1H, CHa2Hb2), 2.27–2.14 (m, 2H, CHa3Hb3 + 
CHa4Hb4), 2.13–1.98 (m, 3H, CH + CHa5Hb5 + CHa6Hb6), 1.89–1.78 (m, 2H, CHa1Hb1 
+ CHa7Hb7), 1.77–1.57 (m, 3H, OH + CH + CHa5Hb5), 1.57–1.46 (m, 2H, CHa4Hb4 + 
CHa7Hb7), 1.43 (s, 3H, CH3), 1.17–1.04 (m, 1H, CHa6Hb6), 1.04–0.97 (m, 1H, CH), 
0.94 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3) δ 204.0, 199.9, 172.5, 122.3, 89.8, 
72.4, 68.1, 55.9, 52.0, 47.7, 39.8, 39.3, 39.2, 34.9, 34.8, 33.8, 32.7, 32.0, 31.4, 23.6, 
21.0, 17.2; MS (ESI–) 439 [M+H]–; HRMS (ESI–) calcd for C22H31O7S 439.1791, 
found 439.1802. 
 
(8S,9S,10R,11S,13S,14S,17R)-17-(2-Azidoacetyl)-11,17-dihydroxy-10,13-dime-
thyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-
3(2H)-one (186)230 
 
To a solution of mesylate 185 (881 mg, 2.00 mmol, 1.0 eq.) in DMF (10 mL) was 
added NaN3 (390 mg, 3.0 eq.) and the reaction mixture was stirred at room 
temperature for 3 h. Water (100 mL) was added and the mixture was extracted with 
CH2Cl2 (3 × 100 mL). The combined organic extracts were washed with aqueous LiCl 
solution (5% w/v, 100 mL), brine (100 mL), dried over MgSO4 and concentrated in 
                                                
a Discrepancy not accounted for. 
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vacuo. The residue was purified by flash column chromatography (CH2Cl2 : MeOH, 
99 : 1 → 95 : 5) to afford azide 186 (579 mg, 84% yield) as a white foam. 
Rf 0.35 (CH2Cl2 : MeOH, 95 : 5); [α]D20 +208 (c 1.00, CHCl3); IR (thin film) 3343 
(br.), 2912, 2105, 1647, 1109 cm-1; 1H NMR (500 MHz, DMSO-d6) δ 5.55 (s, 1H, 
C=CH), 5.41 (s, 1H, OH), 4.47 (d, J = 18.7 Hz, 1H, CHaHbN3), 4.31–4.27 (m, 1H, 
OH), 4.27–4.21 (m, 1H, CHOH), 3.93 (d, J = 18.7 Hz, 1H, CHaHbN3), 2.61–2.51 (m, 
1H, CHa1Hb1), 2.47–2.31 (m, 2H, CHa2Hb2 + CHa3Hb3), 2.23–2.12 (m, 2H, CHa2Hb2+ 
CHa3Hb3), 2.12–2.02 (m, 1H, CHa4Hb4), 1.98–1.82 (m, 3H, CH + CHa1Hb1 + CHa5Hb5), 
1.82–1.71 (m, 1H, CHa4Hb4), 1.71–1.58 (m, 2H, CH + CHa6Hb6), 1.56–1.49 (m, 1H, 
CHa5Hb5), 1.49–1.38 (m, 1H, CHa7Hb7), 1.35 (s, 3H, CH3), 1.31–1.18 (m, 1H, 
CHa6Hb6), 1.06–0.90 (m, 1H, CHa7Hb7), 0.89–0.81 (m, 1H, CH), 0.76 (s, 3H, CH3); 
13C NMR (125 MHz, DMSO-d6) δ 207.1, 198.0, 172.2, 121.5, 88.7, 66.4, 55.5, 55.3, 
51.5, 46.5, 39.0, 38.8 34.0, 33.4, 32.9, 32.7, 31.3, 31.1, 23.3, 20.4, 16.9; MS (ESI+) 
388 [M+H]+; HRMS (ESI+) calcd for C21H30N3O4 388.2236, found 388.2243. 
 
(8S,9S,10R,11S,13S,14S,17R)-17-(2-Aminoacetyl)-11,17-dihydroxy-10,13-dime-
thyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]-phenanthren-
3(2H)-one (187)231 
 
Following a literature procedure,164 to a solution of azide 186 (100 mg, 0.26 mmol, 
1.0 eq.) in a mixture of THF (1.2 mL) and water (0.3 mL) were added saturated 
aqueous solution of NH4Cl (55 mg, 4.0 eq.) and zinc dust (34 mg, 2.0 eq.) and the 
reaction mixture was stirred at room temperature for 15 min. Aqueous ammonia 
(0.15 mL) was added and the mixture was stirred for 2 min. AcOEt was added and the 
solution was filtered through cotton wool. The filtrate was concentrated in vacuo and 
purified by flash column chromatography (CH2Cl2 : MeOH/NH3, 99 : 1 → 90 : 10) to 
OHH
H H
HO
O
O
NH2
 
250 
afford amine 187 (50 mg, 53% yield) as an orange oil, which was used directly in the 
next step. 
Rf 0.69 (CH2Cl2 : MeOH/NH3, 90 : 10); IR (thin film) 3372 (br.), 2928, 1654 (br.), 
1386 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.68 (s, 1H, C=CH), 4.46 (br. s, 1H, 
CHOH), 3.94 (d, J = 19.5 Hz, 1H, CHaHbNH2), 3.57 (d, J = 19.5 Hz, 1H, CHaHbNH2), 
2.78–2.65 (m, 1H), 2.59–2.40 (m, 2H), 2.40–2.29 (m, 1H), 2.29–2.12 (m, 3H), 2.02 
(m, 4H), 1.94–1.78 (m, 3H), 1.70 (td, J = 11.3, 7.3 Hz, 2H), 1.55 (s, 3H), 1.43 (s, 3H, 
CH3), 1.20–1.07 (m, 1H), 1.05–0.97 (m, 1H), 0.94 (s, 3H, CH3); MS (ESI+) 362 
[M+H]+; HRMS (ESI+) calcd for C21H32NO4 362.2331, found 362.2323. 
 
N-(2-((8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-10,13-dimethyl-3-oxo-2,3,6, 
7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenan-thren-17-
yl)-2-oxoethyl)-2,4-dimethoxy-6-methylbenzamide (188) 
 
To a solution of 2,4-dimethoxy-6-methylbenzoic acid (167) (27 mg, 0.14 mmol, 
1.0 eq.) in DMF (1 mL) were added DIPEA (82 µL, 3.0 eq.) and HATU (52 mg, 
1.0 eq.) and the reaction mixture was stirred at room temperature for 30 min. A 
solution of amine 187 (50 mg, 1.0 eq.) in DMF (0.3 mL) was added and the mixture 
was stirred at room temperature for 3 h. Aqueous HCl solution (1 M, 20 mL) was 
added and the mixture was extracted with CH2Cl2 (3 × 30 mL). The combined organic 
extracts were washed with aqueous LiCl solution (5% w/v, 20 mL), brine (20 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (CH2Cl2 : MeOH, 99 : 1 → 97 : 3) to afford amide 188 
(54 mg, 73% yield) as a yellow solid. 
Rf 0.27 (CH2Cl2 : MeOH, 95 : 5); mp 90–92 °C (CH2Cl2 : MeOH, 95 : 5); [α]D20 +118 
(c 1.00, CHCl3); IR (thin film) 3403 (br.), 2931, 1648, 1580, 1201 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 6.74 (app. t, J = 4.9 Hz, 1H, NH), 6.33 (d, J = 2.3 Hz, 1H, Ar-
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H), 6.30 (d, J = 2.3 Hz, 1H, Ar-H), 5.67 (s, 1H, C=CH), 4.64 (dd, J = 19.9, 4.6 Hz, 
1H, CHaHbNH), 4.47–4.42 (m, 1H, CHOH), 4.33 (dd, J = 19.9, 5.3 Hz, 1H, 
CHaHbNH), 3.80 (s, 3H, Ar-OCH3), 3.79 (s, 3H, Ar-OCH3), 3.07 (br. s, 1H, OH), 
2.80–2.72 (m, 1H, CHa1Hb1), 2.53–2.40 (m, 2H, CHa2Hb2 + CHa3Hb3), 2.40–2.29 (m, 
4H, Ar-CH3 + CHa3Hb3), 2.29–2.20 (m, 1H, CHa2Hb2), 2.20–1.95 (m, 4H, CH + 
CHa4Hb4 + CHa5Hb5 + CHa6Hb6), 1.89–1.77 (m, 2H, CHa7Hb7 + CHa4Hb4), 1.77–1.66 
(m, 3H, CH + CHa5Hb5 + OH), 1.59–1.49 (m, 1H, CHa1Hb1), 1.49–1.35 (m, 4H, CH3 + 
CHa7Hb7), 1.17–1.04 (m, 1H, CHa6Hb6), 1.04–0.97 (m, 1H, CH), 0.94 (s, 3H, CH3); 
13C NMR (125 MHz, CDCl3) δ 207.8, 199.6, 172.1, 168.2, 161.1, 157.9, 139.4, 122.3, 
118.1, 107.2, 96.1, 89.6, 68.3, 56.0, 55.8, 55.3, 51.9, 47.8, 47.5, 39.9, 39.2, 35.0, 34.1, 
33.8, 32.7, 32.1, 31.4, 23.7, 21.0, 20.3, 17.5; MS (ESI+) 540 [M+H]+; HRMS (ESI+) 
calcd for C31H42NO7 540.2961, found 540.2943. 
 
5-Chloro-N,1,3-trimethyl-1H-pyrazole-4-sulfonamide (196) 
 
To a solution of sulfonic acid 195 (5.00 g, 24.0 mmol, 1.0 eq.) in CH2Cl2 (120 mL) 
were added oxalyl chloride (2.30 mL, 1.1 eq.) and DMF (3 drops, cat.) and the 
reaction mixture was stirred at room temperature for 30 min. The solvent was 
evaporated in vacuo and the residue dissolved in CH2Cl2 (120 mL). Methylamine 
(2.25 M in MeOH, 24.0 mL, 2.0 eq.) was added slowly and the reaction mixture was 
stirred at room temperature for 2 h. Aqueous HCl solution (1 M, 200 mL) was added 
and the mixture was extracted with CH2Cl2 (3 × 100 mL). The combined organic 
extracts were washed with brine (50 mL), dried over MgSO4 and concentrated in 
vacuo to afford sulfonamide 196 (4.81 g, 90% yield) as a white solid. The residue was 
used directly in the next step without further purification, as NMR analysis showed 
sufficient purity. 
Rf 0.17 (PE : AcOEt, 70 : 30); mp 38–40 °C (PE : AcOEt, 70 : 30); IR (thin film) 
3288 (br.), 1502, 1315, 1178, 1114 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.57–4.47 
(m, 1H, NH), 3.82 (s, 3H, N(Ar)-CH3), 2.68 (d, J = 5.4 Hz, 3H, NHCH3), 2.42 (s, 3H, 
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Ar-CH3); 13C NMR (100 MHz, CDCl3) δ 149.0, 129.0, 114.3, 36.5, 28.9, 13.7; MS 
(CI+) 224, 226 [M+H]+; HRMS (CI+) calcd for C6H1135ClN3O2S 224.0261, found 
224.0258. 
 
1-Methoxy-5-methylcyclohexa-1,4-diene (200)232 
 
Following a literature procedure,169 a solution of 3-methoxybenzyl alcohol (199) 
(5.00 g, 36.0 mmol, 1.0 eq.) in methanol (13 mL) was added slowly to a solution of 
sodium (5.00 g, 6.0 eq.) in condensed ammonia (120 mL) at –78 °C and the mixture 
was stirred for 10 min. Solid NH4Cl (5 g) was added portionwise and the mixture was 
allowed to reach room temperature in an open flask over 3 h. The residue was 
partitioned between CH2Cl2 (300 mL) and water (300 mL) and extracted with CH2Cl2 
(2 × 500 mL). The combined organic extracts were washed with brine (300 mL), 
dried over MgSO4 and concentrated in vacuo to afford diene 200 (4.30 g, 96% yield) 
as colourless oil. 
Rf 0.75 (PE : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 5.45–5.38 (m, 1H, 
C=CH), 4.67–4.59 (m, 1H, C=CH), 3.61–3.52 (m, 3H, OCH3), 2.82–2.72 (m, 2H, 
CH2), 2.68–2.56 (m, 2H, CH2), 1.70 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 
152.9, 130.4, 118.7, 90.2, 53.6, 33.1, 26.8, 22.7; MS (ESI+) 125 [M+H]+; HRMS 
(ESI+) calcd for C8H13O 125.0966, found 125.0976. The analytical data are consistent 
with the reported data in the literature.232 
 
(3,4-Dimethoxyphenyl)methanol (203)233 
 
To a solution of 3,4,dimethoxybenzoic acid (202) (10.0 g, 55.0 mmol, 1.0 eq.) in THF 
(73 mL) at 0 °C was added BH3•THF (1 M, 73.0 mL, 1.3 eq.) and the reaction mixture 
was stirred for 30 min. Water (200 mL) and potassium carbonate (5 g) were added 
MeO
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and the mixture was extracted with CH2Cl2 (3 × 300 mL). The combined organic 
extracts were washed with brine (200 mL), dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash column chromatography (PE : AcOEt, 50 : 
50) to afford the alcohol 203 (8.78 g, 95% yield) as a colourless oil.  
Rf 0.55 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 6.93 (d, J = 1.9 Hz, 
1H, Ar-H), 6.90 (dd, J = 8.2, 1.9 Hz, 1H, Ar-H), 6.85 (d, J = 8.2 Hz, 1H, Ar-H), 4.63 
(d, J = 5.8 Hz, 2H, CH2), 3.90 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 1.62 (t, J = 5.8 Hz, 
1H, OH); 13C NMR (100 MHz, CDCl3) δ 148.7, 148.2, 133.5, 119.1, 110.9, 110.3, 
64.6, 55.7, 55.5; MS (EI+) 168 [M]+•; HRMS (EI+) calcd for C9H12O3 168.0786, found 
168.0784. The analytical data are consistent with the reported data in the literature.233 
 
Dimethyl succinate (207)170 
 
Following a literature procedure,170 to a suspension of succinic acid (206) (9.45 g, 
80.0 mmol, 1.0 eq.) in tert-butylmethylether (50 mL) was added concentrated 
sulphuric acid (1.80 g) and the reaction mixture was refluxed for 18 h. Saturated 
aqueous solution of K2CO3 (100 mL) was added and the mixture was extracted with 
CH2Cl2 (3 × 200 mL). The combined organic extracts were washed with brine (100 
mL), dried over MgSO4 and concentrated in vacuo to afford diester 207 (9.20 g, 79% 
yield) as a colourless oil. The residue was used directly in the next step without 
further purification, as NMR analysis showed sufficient purity. 
Rf 0.56 (PE : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 3.70 (s, 6H, 2 × 
CO2CH3), 2.64 (s, 4H, 2 × CH2); 13C NMR (100 MHz, CDCl3) δ 172.6, 51.7, 28.7; 
MS (CI+) 147 [M+H]+; HRMS (CI+) calcd for C6H11O4 147.0657, found 147.0664. 
The analytical data are consistent with the reported data in the literature.170 
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Dimethyl 2,5-dihydroxycyclohexa-1,4-diene-1,4-dicarboxylate (208)171 
 
Following a literature procedure,171 to a stirred solution of sodium hydride (2.90 g, 
2.1 eq.) in DMSO (50 mL) at 5 °C was added dimethyl succinate (207) (5.00 g, 
34.0 mmol, 1.0 eq.) and the reaction mixture was stirred at room temperature for 1.5 h 
and heated at 50 °C for 1 h. The reaction mixture was cooled to 5 °C and aqueous 
HCl solution (1 M, 50 mL) was added slowly. The precipitate was collected, washed 
with water (100 mL) and dried in vacuo to afford diol 208 (3.03 g, 79% yield) as an 
off-white solid. The residue was used directly in the next step without further 
purification, as NMR analysis showed sufficient purity. 
Rf 0.84 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 12.12 (s, 2H, 2 × 
OH), 3.79 (s, 6H, 2 × CO2CH3), 3.18 (s, 4H, 2 × CH2); 13C NMR (100 MHz, CDCl3) 
δ 171.6, 168.5, 93.1, 51.7, 28.4; MS (EI+) 228 [M]+•; HRMS (EI+) calcd for C10H12O6 
228.0634, found 228.0638. The analytical data are consistent with the reported data in 
the literature.171 
 
6-(Bromomethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (210)172 
 
Following a literature procedure,172 to a solution of LiHMDS (1.00 M in hexanes, 
0.77 mL, 1.1 eq.) in THF (1 mL) was added a solution of dioxinone 109 (100 mg, 
0.70 mmol, 1.0 eq.) in THF (1 mL) at –70 °C. After 30 min, the solution was 
transferred via a cannula to a solution of 1,2-dibromotetrachloroethane (252 mg, 
1.1 eq.) in THF (0.8 mL) at –50 °C and the mixture was stirred at –50 °C for 2 h. A 
saturated aqueous solution of NH4Cl (20 mL) was added, the pH was adjusted to pH 
1–2 with aqueous HCl solution (1 M), the aqueous layer was extracted with CH2Cl2 
(3 × 30 mL) and the combined organic extracts were washed with brine (50 mL), 
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dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
column chromatography (PE : AcOEt, 90 : 10) to afford bromo derivative 210 
(94 mg, 61% yield) as a yellow oil.  
Rf 0.65 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 5.53 (s, 1H, C=CH), 
3.88 (s, 2H, CH2Br), 1.72 (s, 6H, C(CH3)2); 13C NMR (100 MHz, CDCl3) δ 164.3, 
160.5, 107.5, 95.7, 26.9, 24.7; MS (EI+) 219, 221 [M]+•; HRMS (EI+) calcd for 
C7H979BrO3 219.9735, found 219.9750. The analytical data are consistent with the 
reported data in the literature.172 
 
5-Chloro-N-((2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)methyl)-N,1,3-trimethyl-1H-
pyrazole-4-sulfonamide (209) 
 
To a solution of bromo derivative 210 (42 mg, 0.19 mmol, 1.0 eq.) and 
N-methylsulfonamide 196 (40 mg, 1.0 eq.) in acetone was added Cs2CO3 (358 mg, 
1.1 eq.) and the reaction mixture was stirred at room temperature for 24 h. An 
aqueous HCl solution (1 M, 10 mL) was added, the aqueous layer was extracted with 
CH2Cl2 (3 × 20 mL) and the combined organic extracts were washed with brine 
(30 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by 
flash column chromatography (Et2O) to afford dioxinone 209 (49 mg, 72% yield) as a 
colourless oil. 
Rf 0.54 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 2946, 1726, 1640, 1177, 730 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 5.48 (s, 1H, C=CH), 3.93 (s, 2H, N-CH2), 3.82 (s, 3H, 
N(Ar)-CH3), 2.85 (s, 3H, N-CH3), 2.40 (s, 3H, Ar-CH3), 1.67 (s, 6H, C(CH3)2); 13C 
NMR (100 MHz, CDCl3) δ 165.7, 160.3, 149.1, 129.4, 114.1, 107.3, 94.5, 50.9, 36.7, 
35.2, 24.9, 14.0; MS (ESI+) 364, 366 [M+H]+; HRMS (ESI+) calcd for 
C13H1935ClN3O5S 364.0734, found 364.0742. 
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Methyl 4-(5-chloro-N,1,3-trimethyl-1H-pyrazole-4-sulfonamido)-3-oxobutanoate 
(191a) 
 
Dioxinone 209 (35 mg, 0.10 mmol, 1.0 eq.) was heated at 110 °C in a sealed tube in a 
mixture of methanol (0.6 mL) and toluene (4.7 mL) for 20 h. The solvent was 
evaporated in vacuo and the residue was purified by flash column chromatography 
(CH2Cl2 : MeOH, 99 : 1) to afford β-ketoester 191a (33 mg, 99% yield) as a 
colourless oil. 
Rf 0.54 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 2954, 1750, 1726 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 4.10 (s, 2H, MeOCOCH2), 3.81 (s, 3H, N(Ar)-CH3), 3.74 (s, 3H, 
OCH3), 3.58 (s, 2H, N-CH2), 2.87 (s, 3H, N-CH3), 2.39 (s, 3H, Ar-CH3); 13C NMR 
(100 MHz, CDCl3) δ 198.1, 167.2, 149.1, 129.5, 113.8, 58.9, 52.5, 45.7, 36.7, 35.9, 
14.0; MS (ESI+) 338, 340 [M+H]+; HRMS (ESI+) calcd for C11H1735ClN3O5S 
338.0577, found 338.0591. 
 
Methyl 4-azido-3-oxobutanoate (191b)234 
 
Following a literature procedure,234 to a solution of ethyl 4-chloroacetoacetate (197) 
(2.00 g, 13.3 mmol, 1.0 eq.) in a mixture of acetone (18 mL) and water (6 mL) was 
added sodium azide (1.00 g, 1.2 eq.) and the mixture was heated at 60 °C for 2 h. The 
solvent was evaporated in vacuo and the residue was partitioned between water 
(100 mL) and AcOEt (200 mL). The aqueous layer was extracted with AcOEt (2 × 
200 mL) and the combined organic extracts were washed with brine (300 mL), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (PE : AcOEt, 80 : 20) to afford azide 191b (1.61 g, 77% yield) as a 
yellow oil. 
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Rf 0.47 (PE : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 4.11 (s, 2H, CH2N3), 
3.76 (s, 3H, OCH3), 3.53 (s, 2H, CH2); 13C NMR (100 MHz, CDCl3) δ 197.2, 166.7, 
57.4, 52.4, 46.0; MS (CI+) 175 [M+NH4]+; HRMS (CI+) calcd for C5H11N4O3 
175.0831, found 175.0822. The analytical data are consistent with the reported data in 
the literature.234 
 
2-Hydroxy-4-methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile (213)166 
 
Following a literature procedure,166 to a solution of methyl acetoacetate (214) (1.16 g, 
10.0 mmol, 1.0 eq.) and cyanoacetamide (190) (0.84 g, 1.0 eq.) in methanol (2.9 mL) 
was added piperidine (0.99 mL, 1.0 eq.) and the reaction mixture was heated at 65 °C 
in a sealed tube for 20 h. The solvent was evaporated in vacuo and the residue was 
dissolved in water (100 mL). The solution was acidified with concentrated HCl 
(20 mL) and the white precipitate was collected and dried in vacuo to afford lactam 
213 (1.24 g, 83% yield) as a white solid. 
mp > 170 °C (decomp.) (water); IR (thin film) 2881 (br.), 2222, 1595, 1539, 1299  
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 11.16 (br. s, 2H, NH + OH), 5.58 (s, 1H, 
C=CH), 2.23 (s, 3H, CH3); 13C NMR (100 MHz, DMSO-d6) δ 161.8, 161.0, 160.5, 
117.1, 92.6, 89.3, 20.7; MS (ESI+) 192 [M+CH3CN+H]+; HRMS (ESI+) calcd for 
C9H10N3O2 192.0773, found 192.0784. 
 
3-Cyano-4-methylpyridine-2,6-diyl diacetate (219a) 
 
To a solution of lactam 213 (50 mg, 0.33 mmol, 1.0 eq.) and pyridine (59 µL, 2.2 eq.) 
in THF (3.3 mL) was added acetic anhydride (69 µL, 2.2 eq.) and DMAP (1 mg, 
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0.1 eq.) and the reaction mixture was stirred at room temperature for 20 h. Water 
(10 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 × 30 mL) and the 
combined organic extracts were washed with brine (50 mL), dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(CH2Cl2 : MeOH, 99 : 1) to afford protected phenol 219a (19 mg, 25% yield) as a 
white solid. 
Rf 0.77 (CH2Cl2 : MeOH, 95 : 5); mp 78–80 °C (CH2Cl2 : MeOH, 95 : 5); IR (thin 
film) 2923, 2235, 1775 (br.), 1603, 1368 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.08 (s, 
1H, Ar-H), 2.62 (s, 3H, Ar-CH3), 2.40 (s, 3H, OCOCH3), 2.34 (s, 3H, OCOCH3); 13C 
NMR (100 MHz, CDCl3) δ 167.6, 167.4, 158.5, 158.4, 158.1, 115.5, 112.8, 102.1, 
21.2, 20.7, 20.6; MS (CI+) 235 [M+H]+; HRMS (CI+) calcd for C11H11N2O4 235.0719, 
found 235.0730. 
 
3-Cyano-4-methylpyridine-2,6-diyl bis(2,2-dimethylpropanoate) (219b) 
 
To a solution of lactam 213 (500 mg, 3.30 mmol, 1.0 eq.) and pyridine (0.86 mL, 
3.2 eq.) in THF (33 mL) was added pivalic anhydride (2.17 mL, 3.2 eq.) and DMAP 
(10 mg, 0.1 eq.) and the reaction mixture was stirred at room temperature for 20 h. 
Water (100 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 × 
200 mL) and the combined organic extracts were washed with brine (300 mL), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash column 
chromatography (CH2Cl2 : MeOH, 99 : 1) to afford protected phenol 219b (168 mg, 
16% yield) as a white solid. 
Rf 0.76 (CH2Cl2 : MeOH, 95 : 5); mp 46–48 °C (CH2Cl2 : MeOH, 99 : 1); IR (thin 
film) 2978, 2238, 1809, 1764, 1604, 1069 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.99 
(s, 1H, Ar-H), 2.59 (s, 3H, Ar-CH3), 1.42 (s, 9H, C(CH3)3), 1.36 (s, 9H, C(CH3)3); 13C 
NMR (100 MHz, CDCl3) δ 175.5, 175.3, 159.2 (2C), 157.5, 115.4, 113.0, 102.0, 39.4 
(2C), 26.9, 26.9, 20.5; MS (ESI+) 319 [M+H]+; HRMS (ESI+) calcd for C17H23N2O4 
319.1658, found 319.1664. 
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6-(tert-Butyldimethylsilyloxy)-3-cyano-4-methylpyridin-2-yl pivalate (221) 
 
To a solution of protected pyridine 219b (200 mg, 0.62 mmol, 1.0 eq.) in CH2Cl2 
(6 mL) was added TBSOTf (156 µL, 1.1 eq.) and the mixture was stirred at room 
temperature. After 15 min, 2,6-lutidine (79 µL, 1.1 eq.) and methanol (28 µL, 1.1 eq.) 
were added and the reaction mixture was stirred for 1 h. Water (10 mL) was added, 
the layers were separated and the aqueous layer was extracted with CH2Cl2 (10 mL). 
The organic extracts were washed with brine (10 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified twice by flash column 
chromatography (PE : AcOEt, 90 : 10 → 95 : 5) to afford the silyl ether 221 (30 mg, 
14% yield) as a white solid. 
Rf 0.62 (pentane : AcOEt, 90 : 10); IR (thin film) 2963, 2933, 2859, 2231, 1770, 
1593, 1416, 1073 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.54 (s, 1H, Ar-H), 2.49 (s, 3H, 
Ar-CH3), 1.34 (s, 9H, COC(CH3)3), 1.02 (s, 9H, Si(CH3)2C(CH3)3), 0.32 (s, 6H, 
Si(CH3)2C(CH3)3); 13C NMR (100 MHz, CDCl3) δ 175.9, 163.4, 159.0, 157.5, 114.6, 
109.5, 96.8, 39.3, 26.8, 25.6, 20.4, 18.3, –4.6; MS (ESI+) 349 [M+H]+; HRMS (ESI+) 
calcd for C18H29N2O3Si 349.1942, found 349.1977. 
 
2,6-Dimethoxy-4-methylnicotinonitrile (219c)173 
 
Following a literature procedure,173 to a suspension of pyridine 213 (200 mg, 
1.33 mmol, 1.0 eq.) in benzene (10 mL) were added silver carbonate (193 mg, 0.7 eq.) 
and methyl iodide (166 µL, 2.0 eq.) and the reaction mixture was heated at 50 °C in 
the dark for 16 h. The mixture was filtered through celite, washed with toluene 
(10 mL) and the solvent was evaporated in vacuo. The crude product was purified by 
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flash column chromatography (CH2Cl2 : MeOH, 99 : 1) to afford bis-methyl ether 
219c (73 mg, 31% yield) as a white solid. 
Rf 0.77 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 6.23 (s, 1H, Ar-H), 
4.02 (s, 3H, Ar-OCH3), 3.95 (s, 3H, Ar-OCH3), 2.42 (s, 3H, Ar-CH3); 13C NMR 
(100 MHz, CDCl3) δ 165.2, 165.2, 155.8, 115.5, 103.3, 88.0, 54.3, 53.9, 20.1; MS 
(CI+) 196 [M+NH4]+; HRMS (CI+) calcd for C9H14N3O2 196.1086, found 196.1091. 
The analytical data are consistent with the data reported in the literature.173  
 
3-Cyano-4-methylpyridine-2,6-diyl bis(trifluoromethanesulfonate) (219d) 
 
Following a literature procedure,177 to a suspension of pyridine 213 (200 mg, 
1.33 mmol, 1.0 eq.) in a mixture of aqueous dipotassium phosphate (30% w/v, 
3.50 mL, 6.0 eq.) and toluene (10 mL) was added dropwise triflic anhydride (538 µL, 
2.4 eq.) at 0 °C and the mixture was stirred for 30 min. The phases were separated and 
the organic layer was evaporated in vacuo. The crude product was purified by flash 
column chromatography (CH2Cl2 : MeOH, 95 : 5) to afford bis-triflate derivative 
219d (283 mg, 46% yield) as a colourless oil. 
Rf 0.88 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 2242, 1607, 1429, 1209, 1126 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H, Ar-H), 2.77 (s, 3H, Ar-CH3); 13C NMR 
(100 MHz, CDCl3) δ 161.9, 154.5, 154.2, 123.2 (q, J = 321 Hz), 123.1 (q, J = 
321 Hz), 116.3, 110.3, 103.2, 21.1; 19F NMR (400 MHz, CDCl3) δ –72.12, –72.22; 
MS (CI+) 431 [M+NH4]+; HRMS (CI+) calcd for C9H8F6N3O6S2 431.9759, found 
431.9764. 
 
(Z)-Methyl 3-aminobut-2-enoate (224)235 
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Following a literature procedure,235 a solution of methyl acetoacetate (214) (500 mg, 
4.30 mmol, 1.0 eq.) in saturated ammonia in methanol (1 mL) was stirred at 0 °C for 
30 min. The solvent was evaporated in vacuo and the residue was dried in vacuo to 
afford enamine 224 (490 mg, 99% yield) as a white solid. 
Rf 0.74 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 7.87 (br. s, 1H, NH), 
4.65 (br. s, 1H, NH), 4.49 (s, 1H, C=CH), 3.60 (s, 3H, CO2CH3), 1.87 (s, 3H, CH3); 
13C NMR (100 MHz, CDCl3) δ 170.5, 159.8, 83.6, 50.0, 22.2; MS (ESI+) 116 
[M+H]+; HRMS (ESI+) calcd for C5H10NO2 116.0712, found 116.0712. The 
analytical data are consistent with the reported data in the literature.235 
 
Methyl 4-hydroxy-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (225)165 
 
Following a literature procedure,165 a solution of enamine 224 (190 mg, 1.60 mmol, 
1.0 eq.) and malonic acid bis(2,4,6-trichlorophenyl)ester (192) (840 mg, 1.1 eq.) in 
diglyme (6 mL) was heated at 100 °C in a sealed tube for 10 h. Et2O (2 mL) was 
added and the precipitate was collected and dried in vacuo to afford lactam 225 
(239 mg, 82% yield) as a beige solid. 
IR (thin film) 2765 (br.), 1655, 1571, 1254, 811 cm-1; 1H NMR (400 MHz, DMSO-d6) 
δ 11.49 (br. s, 1H, OH), 11.06 (br. s, 1H, NH), 5.47 (s, 1H, C=CH), 3.77 (s, 3H, 
OCH3), 2.30 (s, 3H, CH3); 13C NMR (100 MHz, DMSO-d6) δ 167.1, 165.8, 163.0, 
150.6, 102.0, 96.1, 52.0, 18.4; MS (ESI+) 184 [M+H]+; HRMS (ESI+) calcd for 
C8H10NO4 184.0610, found 184.0600. The analytical data are consistent with the 
reported data in the literature.165 
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5-(Methoxycarbonyl)-6-methylpyridine-2,4-diyl bis(2,2-dimethylpropanoate) 
(226) 
 
To a solution of lactam 225 (49 mg, 0.26 mmol, 1.0 eq.) and pyridine (69 µL, 3.2 eq.) 
in THF (5.2 mL) was added pivalic anhydride (174 µL, 3.2 eq.) and DMAP (1 mg, 
0.1 eq.) and the reaction mixture was stirred at room temperature for 20 h. Water 
(10 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 × 20 mL) and the 
combined organic extracts were washed with brine (30 mL), dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash column chromatography 
(CH2Cl2 : MeOH, 99 : 1) to afford protected phenol 226 (63 mg, 69%) as a white 
solid. 
Rf 0.81 (CH2Cl2 : MeOH, 95 : 5); IR (thin film) 2977, 1762, 1732, 1577, 1267, 1076 
cm-1; 1H NMR (400 MHz, CDCl3) δ 6.80 (s, 1H, Ar-H), 3.88 (s, 3H, CO2CH3), 2.58 
(s, 3H, Ar-CH3), 1.36 (s, 9H, C(CH3)3), 1.31 (s, 9H, C(CH3)3); 13C NMR (100 MHz, 
CDCl3) δ 176.1, 175.0, 165.5, 158.7, 158.2, 158.1, 120.3, 107.8, 52.5, 39.3, 39.2, 
27.0, 26.9, 23.2; MS (ESI+) 352 [M+H]+; HRMS (ESI+) calcd for C18H26NO6 
352.1755, found 352.1750. 
 
Methyl 6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (229a)167 
and Ethyl 4-methyl-2,6-dioxo-2,3-dihydropyrimidine-1(6H)-carboxylate (229b) 
       
229a                                   229b 
To a solution of enamine 224 (100 mg, 0.86 mg, 1.0 eq.) in diethyl ether (1.7 mL) at 
0 °C was added ethyl isocyanatoformate (194) (90 µL, 1.0 eq.) and the reaction 
mixture was stirred at 0 °C for 3 h and the temperature was allowed to reach room 
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temperature. The white precipitate was collected and washed with diethyl ether 
(10 mL) and dried in vacuo. 1H NMR analysis showed the presence of two 
regioisomers 228a and 228b (3 : 2). The residue was dissolved in a mixture of water 
(3 mL) and triethylamine (1 mL) and the reaction mixture was heated at 50 °C for 
15 h. The solvent was evaporated in vacuo and the crude product was purified by 
flash column chromatography (CH2Cl2 : MeOH, 95 : 5) to afford pyrimidine 
derivatives 229a (76 mg, 48% yield) and 229b (76 mg, 37% yield) as white solids. 
229a: Rf 0.08 (CH2Cl2 : MeOH, 95 : 5); mp > 190 °C (decomp.) (water); IR (thin 
film) 3166 (br.), 3050, 2826, 1705, 1652, 1592, 1513, 1415 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 11.29 (s, 1H, NH), 11.26 (s, 1H, NH), 3.70 (s, 3H, CO2CH3), 2.17 (s, 3H, 
CH3); 13C NMR (100 MHz, CDCl3) δ 164.8, 160.8, 155.9, 150.0, 104.6, 51.7, 17.4; 
MS (ESI+) 185 [M+H]+; HRMS (ESI+) calcd for C7H9N2O4 185.0562, found 
185.0545. 
 229b: Rf 0.40 (CH2Cl2 : MeOH, 95 : 5); mp 176–178 °C (water); IR (thin film) 
3230 (br.), 3182, 2998, 1783, 1723, 1659, 1422, 1243 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 11.58 (s, 1H, NH), 5.56 (s, 1H, C=CH), 4.35 (q, J = 7.1 Hz, 2H, OCH2CH3), 
2.07 (s, 3H, CH3), 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (100 MHz, CDCl3) δ 
160.6, 154.3, 150.3, 148.8, 97.7, 65.2, 18.4, 13.5; MS (ESI+) 199 [M+H]+; HRMS 
(ESI+) calcd for C8H11N2O4 199.0719, found 199.0711. 
 
 
3.3. Chapter 3 
 
2R,3S)-Diethyl 2-azido-3-hydroxysuccinate (254)236 
 
Thionyl chloride (2.6 mL, 1.5 eq.) was added dropwise over a period of 1 h to a 
solution of (−)-diethyl tartrate (252) (5.0 g, 24.2 mmol, 1.0 eq.) and triethylamine 
(6.8 mL, 2.0 eq.) in CH2Cl2 (120 mL) at −5 °C. The reaction mixture was stirred for 
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1 h and poured into ice water (100 mL). The mixture was separated and the organic 
extracts were dried over MgSO4 and concentrated in vacuo. The crude cyclic sulfite 
253 was dissolved in DMF (240 mL) and sodium azide (3.14 g, 2.0 eq.) was added. 
The reaction mixture was stirred for 2 h and quenched by addition of water (400 mL). 
The mixture was extracted with Et2O (3 × 100 mL) and the combined organic extracts 
were dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash column chromatography (pentane : EtOAc, 80 : 20) to afford azide 254 (3.73 g, 
68% yield) as a colourless oil. 
Rf 0.48 (pentane : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 4.63 (dd, J = 5.4, 
2.8 Hz, 1H, CHOH), 4.42–4.20 (m, 5H, CHOH + 2 × CO2CH2CH3), 3.29 (d, J = 
5.6 Hz, 1H, CHN3), 1.31 (d, J = 7.1 Hz, 3H, CO2CH2CH3), 1.30 (d, J = 7.1 Hz, 3H, 
CO2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 170.8, 166.9, 72.0, 64.4, 62.7, 62.3, 
14.1, 14.0; MS (CI+) 249 [M+NH4]+; HRMS (CI+) calcd for C8H17N4O5 249.1199, 
found 249.1206. The analytical data are consistent with the data reported in the 
literature.236 
 
(S)-2-Azido-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanol (256)236 
 
Sodium borohydride (3.63 g, 6.0 eq.) and lithium chloride (680 mg, 1.0 eq.) were 
added to a solution of diester 254 (3.72 g, 16.0 mmol, 1.0 eq) in EtOH (50 mL) at 
0 °C and the reaction mixture was stirred for 2 h at 0 °C. The pH was adjusted to 4 by 
the addition of aqueous HCl solution (1 M, 100 mL) and concentrated in vacuo. The 
residue was filtered through silica gel (AcOEt : CH2Cl2, 80 : 20). The resulting triol 
255 was dissolved in acetone (35 mL), 2,2-dimethoxypropane (7.90 mL, 4.0 eq.) and 
p-toluenesulfonic acid (305 mg, 0.1 eq.) were added and the reaction mixture was 
heated at reflux for 1 h. The mixture was cooled and a saturated aqueous solution of 
NH4Cl (30 mL) was added. The mixture was stirred for 1 h, the aqueous layer was 
extracted with Et2O (3 × 50 mL) and the combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash column 
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chromatography (pentane : EtOAc, 80 : 20) to afford acetal 256 (1.80 g, 60% yield) as 
a colourless oil. 
Rf 0.51 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 4.20–4.03 (m, 2H, 
CHaHbO(CH3)2 + CHO(CH3)2), 3.93 (dd, J = 8.0, 5.4 Hz, 1H, CHaHbO(CH3)2), 3.87 
(ddd, J = 11.5, 5.7, 3.9 Hz, 1H, CHaHbOH), 3.75–3.65 (m, 1H, CHaHbOH), 3.65–3.57 
(m, 1H, CHN3), 2.04–1.95 (m, 1H, CH2OH), 1.46 (s, 3H, OC(CH3)(CH3)O), 1.36 (s, 
3H, OC(CH3)(CH3)O); 13C NMR (100 MHz, CDCl3) δ 109.8, 75.5, 66.6, 64.6, 62.8, 
26.4, 25.1; MS (CI+) 205 [M+NH4]+; HRMS (CI+) calcd for C7H17N4O3 205.1301, 
found 205.1289. The analytical data are consistent with the data reported in the 
literature.236 
 
(S)-4-((S)-1-Azido-2-(methoxymethoxy)ethyl)-2,2-dimethyl-1,3-dioxolane (246)189 
 
Chloromethyl methyl ether (2.95 mL, 4.0 eq.) was added to a solution of alcohol 256 
(1.80 g, 9.60 mmol, 1.0 eq.) and DIPEA (8.38 mL, 5.0 eq.) in CH2Cl2 (90 mL) at 
0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. The 
mixture was washed with water (100 mL) and the organic extracts were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (CH2Cl2 : MeOH, 99 : 1) to afford MOM ether 246 (1.84 mg, 83% 
yield) as a colourless oil. 
Rf 0.36 (CH2Cl2 : MeOH, 99 : 1); 1H NMR (400 MHz, CDCl3) δ 4.66 (s, 2H, 
OCH2OCH3), 4.13–4.00 (m, 2H, CHaHbO(CH3)2 + CHO(CH3)2), 3.93 (dd, J = 7.8, 
5.1 Hz, 1H, CHaHbO(CH3)2), 3.81–3.75 (m, 1H, CHaHbOMOM), 3.71–3.58 (m, 2H, 
CHaHbOMOM + CHN3), 3.39 (s, 3H, OCH2OCH3), 1.44 (s, 3H, OC(CH3)(CH3)O), 
1.34 (s, 3H, OC(CH3)(CH3)O); 13C NMR (100 MHz, CDCl3) δ 109.8, 96.6, 74.8, 
67.3, 66.6, 63.0, 55.4, 26.5, 25.2; MS (CI+) 249 [M+NH4]+; HRMS (CI+) calcd for 
C9H21N4O4 249.1563, found 249.1557. The analytical data are consistent with the data 
reported in the literature.189 
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9-Bromononan-1-ol (258)237 
 
Hydrobromic acid (15.5 mL, 48% in water, 1.1 eq.) was added to a solution of 
nonane-1,9-diol (257) (20.0 g, 125 mmol, 1.0 eq.) in toluene (250 mL) and the 
reaction mixture was heated at reflux for 16 h employing a Dean-Stark apparatus. The 
mixture was cooled to room temperature and sequentially washed with an aqueous 
HCl solution (1 M, 100 mL), an aqueous NaOH solution (2 M, 100 mL) and brine 
(100 mL). The organic extracts were dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by recrystallisation from petroleum ether to afford 
bromo derivative 258 (21.1 g, 75% yield) as a white solid.  
Rf 0.63 (CH2Cl2 : MeOH, 95 : 5); 1H NMR (400 MHz, CDCl3) δ 3.64 (app. q, J = 
6.1 Hz, 2H, CH2OH), 3.40 (t, J = 6.9 Hz, 2H, CH2Br), 1.93–1.78 (m, 2H, CH2), 1.64–
1.50 (m, 2H, CH2), 1.49–1.28 (m, 10H, 5 × CH2), 1.25 (d, J = 5.3 Hz, 1H, CH2OH); 
13C NMR (100 MHz, CDCl3) δ 63.0, 34.0, 32.8, 32.7, 29.4, 29.3, 28.7, 28.1, 25.7; MS 
(CI+) 240, 242 [M+NH4]+; HRMS (CI+) calcd for C9H23N79BrO 240.0963, found 
240.0969. The analytical data are consistent with the data reported in the literature.237 
 
(9-Bromononyloxy)(tert-butyl)dimethylsilane (250)195 
 
A solution of tert-butyldimethylsilyl chloride (14.7 g, 1.2 eq.) in CH2Cl2 (200 mL) 
was added dropwise over a period of 10 min to a solution of bromide 258 (18.0 g, 
80.0 mmol, 1.0 eq.), DMAP (977 mg, 0.1 eq.) and triethylamine (13.7 mL, 1.2 eq.) in 
CH2Cl2 (50 mL) and the reaction mixture was stirred for 6 h at room temperature. The 
mixture was washed an aqueous HCl solution (1 M, 400 mL), brine (400 mL) and the 
organic extracts were dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (pentane : CH2Cl2, 90 : 10) to 
afford silyl ether 250 (20.5 g, 76% yield) as a colourless oil. 
Rf 0.20 (pentane : CH2Cl2, 90 : 10); 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 
2H, CH2OTBS), 3.41 (t, J = 6.9 Hz, 2H, CH2Br), 1.94–1.79 (m, 2H, CH2), 1.57–1.47 
Br OH
Br OTBS
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(m, 2H, CH2), 1.47–1.38 (m, 2H, CH2), 1.38–1.24 (m, 8H, 4 × CH2), 0.89 (s, 9H, 
SiC(CH3)3), 0.04 (s, 6H, Si(CH3)2); 13C NMR (100 MHz, CDCl3) δ 63.3, 34.0, 32.8 
(2C), 29.4, 29.3, 28.7, 28.2, 26.0, 25.8, 18.4, –5.3; MS (CI+) 337, 339 [M+H]+; 
HRMS (CI+) calcd for C15H3479BrOSi 337.1562, found 337.1569. The analytical data 
are consistent with the data reported in the literature.195 
 
4,4,5,5,5-Pentafluoropentyl 4-methylbenzenesulfonate (260)196 
 
Following a literature procedure,196 p-toluenesulfonyl chloride (1.43 g, 1.2 eq.) and 
Et3N (1.30 mL, 1.5 eq.) were added to a solution of 4,4,5,5,5-pentafluoropentan-1-ol 
(259) (1.11 g, 6.20 mmol, 1.0 eq.) in CH2Cl2 (21 mL) and the reaction mixture was 
stirred at room temperature for 15 h. Water (100 mL) was added and the aqueous 
layer was extracted with CH2Cl2 (2 × 200 mL). The combined organic extracts were 
washed with brine (100 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (pentane : AcOEt, 100 : 0 → 
90 : 10) to afford tosylate 260 (1.23 g, 60% yield) as a colourless oil. 
Rf 0.75 (pentane : AcOEt, 70 : 30); IR (thin film) 1360, 1188, 1174, 982 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.2 Hz, 2H, 2 × Ar-H), 7.37 (d, J = 8.2 Hz, 
2H, 2 × Ar-H), 4.10 (t, J = 5.9 Hz, 2H, OCH2), 2.46 (s, 3H, Ar-CH3), 2.18–2.01 (m, 
2H, CH2CH2CF2CF3), 2.00–1.87 (m, 2H, CH2CH2CF2CF3).; 13C NMR (100 MHz, 
CDCl3) δ 145.2, 132.7, 130.0, 127.8, 118.9 (qt, J = 284, 35 Hz), 115.3 (tq, J = 250, 
38 Hz), 68.6, 27.0 (t, J = 21 Hz), 21.6, 20.4 (t, J = 4 Hz); Mass of the product could 
not been found by HRMS. 
 
2-(4,4,5,5,5-Pentafluoropentyl)isothiouronium 4-methylbenzenesulfonate (244)196 
 
Following a literature procedure,196 thiourea (290 mg, 1.1 eq.) was added to a solution 
of tosylate 260 (1.15 g, 2.50 mmol, 1.0 eq.) in ethanol (14 mL) and the reaction 
TsO CF2CF3
S CF2CF3H2N
NH2+TsO-
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mixture was refluxed for 15 h. The ethanol was evaporated in vacuo, a mixture of 
pentane : Et2O (1 : 1, 20 mL) was added and the mixture was allowed to sit at room 
temperature for 30 min. The resulting precipitate was collected, washed with pentane 
(10 mL) and dried in vacuo to afford thiouronium salt 244 (1.09 g, 79% yield) as a 
white solid. 
mp 75–80 °C (pentane : Et2O, 50 : 50); IR (thin film) 3109 (br.), 1681, 1642, 1190, 
1123 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 4H, C(NH2)2), 7.49 (d, J = 
7.8 Hz, 2H, 2 × Ar-H), 7.13 (d, J = 7.8 Hz, 2H, 2 × Ar-H), 3.23 (t, J = 7.4 Hz, 2H, 
SCH2), 2.44–2.23 (m, 2H, CH2CH2CF2CF3), 2.30 (s, 3H, Ar-CH3), 1.96–1.78 (m, 2H, 
CH2CH2CF2CF3); 13C NMR (100 MHz, DMSO-d6) δ 169.4, 144.9, 138.2, 128.2, 
125.5, 118.8 (qt, J = 285, 37 Hz), 115.8 (tq, J = 250, 37 Hz), 28.8, 28.2 (t, J = 21 Hz), 
20.8, 20.4 (t, J = 3 Hz); MS (ESI+) 237 [M+H]+; HRMS (ESI+) calcd for 237.0485 
C6H10F5N2S, found 237.0490. 
 
(8R,9S,13S,14S,17S)-3-Methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthren-17-ol (261)197 
 
Following a literature procedure,197 to a solution of β-oestradiol (232) (24.9 g, 
91 mmol, 1.0 eq.) in acetonitrile (920 mL) was added potassium carbonate (63.0 g, 
5.0 eq.) and methyl iodide (53.0 mL, 6.0 eq.) and the reaction mixture was heated at 
reflux for 16 h. The mixture was washed with water (500 mL), brine (500 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (pentane : AcOEt, 80 : 20) to afford methyl ether 261 
(24.9 g, 95% yield) as a white solid. 
Rf 0.45 (pentane : AcOEt, 70 : 30); mp 80–82 °C (pentane : AcOEt, 70 : 30); [α]D28 
+10 (c 1.00, CHCl3); IR (thin film) 3460 (br.), 2932, 2847, 1613, 1506, 1252 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.6 Hz, 1H, Ar-H), 6.71 (dd, J = 8.6, 2.8 Hz, 
1H, Ar-H), 6.63 (d, J = 2.8 Hz, 1H, Ar-H), 3.78 (s, 3H, Ar-OCH3), 3.76–3.69 (m, 1H, 
OH
H
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CHOH), 3.52–3.47 (m, 1H, CH), 2.93–2.78 (m, 2H, Ar-CH2), 2.37–2.26 (m, 1H, 
CHa1Hb1), 2.25–2.06 (m, 2H, CH + CHa2Hb2), 1.99–1.91 (m, 1H, CHa3Hb3), 1.91–1.84 
(m, 1H, CHa4Hb4), 1.75–1.65 (m, 1H, CHa5Hb5), 1.57–1.13 (m, 8H, CHa1Hb1 + 
CHa2Hb2 + CHa3Hb3 + CHa4Hb4 + CHa5Hb5 + 2 × CH + CHOH), 0.78 (s, 3H, CCH3); 
13C NMR (100 MHz, CDCl3) δ 157.4, 138.0, 132.6, 126.3, 113.8, 111.5, 81.9, 55.2, 
50.0, 43.9, 43.3, 38.8, 36.7, 30.6, 29.8, 27.2, 26.3, 23.1, 11.0; MS (CI+) 287 [M+H]+; 
HRMS (CI+) calcd for C19H27O2 287.2011, found 287.2023. The analytical data are 
consistent with the data reported in the literature.197 
 
(8R,9S,13S,14S,17S)-3-Methoxy-13-methyl-4,6,7,8,9,11,12,13,14,15,16,17-dodeca-
hydro-1H-cyclopenta[a]phenanthren-17-ol (262)198 
 
A solution of protected phenol 261 (9.4 g, 34 mmol, 1.0 eq.) in isopropanol (30 mL) 
and THF (80 mL) was added to liquid ammonia (500 mL) at –55 °C. The resulting 
suspension was stirred vigorously for 10 min and sodium (9 g, 11.0 eq.) was added in 
small pieces over 10 min. The reaction mixture was allowed to warm up until the 
thick solution could be stirred properly. After 20 min, methanol (80 mL) was added 
slowly and the mixture was allowed to reach room temperature in an open flask. The 
residue was suspended in water (300 mL) and collected by filtration. The resulting 
white solid was dissolved in CH2Cl2 (500 mL) and washed with water (300 mL), 
brine (300 mL), dried over MgSO4 and concentrated in vacuo to afford 
cyclohexadiene 262 (9.45 g, 99% yield) as a white solid. 
Rf 0.47 (pentane : AcOEt, 70 : 30); [α]D28 +31 (c 1.00, CHCl3); IR (thin film) 3381 
(br.), 2916, 2867, 1656, 1448, 1053 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.64 (t, J = 
3.3 Hz, 1H, C=CH), 3.76–3.61 (m, 1H, CHOH), 3.55 (s, 3H, OCH3), 2.98–2.80 (m, 
1H, CHa1Hb1), 2.77–2.45 (m, 3H, CHa1Hb1 + CH2), 2.19–2.00 (m, 2H, CH2), 1.97–
1.79 (m, 3H, CHa2Hb2 + CHa3Hb3 + CHa4Hb4), 1.78–1.55 (m, 3H, CHa5Hb5 + CHa6Hb6 
+ CH), 1.55–1.02 (m, 8H, CHa2Hb2 + CHa3Hb3 + CHa4Hb4 + CHa5Hb5 + CHa6Hb6 + 2 × 
OH
H
H H
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CH + CHOH), 0.76 (s, 3H, CCH3); 13C NMR (100 MHz, CDCl3) δ 152.6, 127.9, 
125.0, 90.6, 81.9, 53.8, 49.9, 45.5, 43.3, 38.9, 37.0, 34.1, 30.6, 30.5, 28.3, 26.7, 25.4, 
23.0, 11.2; MS (CI+) 288 [M]+; HRMS (CI+) calcd for C19H28O2 288.2089, found 
288.2076. 
 
(8R,9S,10R,13S,14S,17S)-17-Hydroxy-13-methyl-6,7,8,9,10,11,12,13,14,15,16,17-
dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (251)199 
 
Following a literature procedure,199 diene 262 (9.45 g, 33.3 mmol, 1.0 eq.) was heated 
in methanol (200 mL) at reflux. Aqueous HCl solution (3 M, 120 mL) was added and 
the reaction mixture was refluxed for 15 min. Water (300 mL) was added and the 
mixture was extracted with CH2Cl2 (3 × 300 mL). The combined organic extracts 
were washed with brine (300 mL), dried over MgSO4 and concentrated in vacuo to 
afford enone 251 (8.59 g, 94% yield) as a white foam. 
Rf 0.11 (pentane : AcOEt, 70 :30 ); [α]D28 +52 (c 1.00, CHCl3); lit: [α]D28 +55 (c 1.00, 
CHCl3);199 IR (thin film) 3405 (br.), 2924, 2864, 1655, 1618, 1055 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 5.83 (s, 1H, C=CH), 3.67 (app. t, J = 8.6 Hz, 1H, CHOH), 2.51–
2.36 (m, 2H, CHa1Hb1 + CHa2Hb2), 2.34–2.19 (m, 3H, CHa3Hb3 + CHa1Hb1 + CHa2Hb2), 
2.16–2.02 (m, 2H, CH + CHa4Hb4), 1.91–1.78 (m, 3H, CHa5Hb5 + CHa6Hb6 + 
CHa7Hb7), 1.70–0.95 (m, 10H, CH2 + 2 × CH + CHa3Hb3 + CHa4Hb4 + CHa5Hb5 + 
CHa6Hb6 + CHa7Hb7 + CHOH), 0.92–0.81 (m, 1H, CH), 0.81 (s, 3H, CCH3); 13C NMR 
(100 MHz, CDCl3) δ 199.9, 166.6, 124.6, 81.7, 49.7, 49.6, 43.0, 42.6, 40.5, 36.5, 
36.4, 35.5, 30.7, 30.4, 26.6, 26.1, 23.2, 11.0; MS (CI+) 275 [M+H]+; HRMS (CI+) 
calcd for C18H27O2 275.2011, found 275.2026. The analytical data are consistent with 
the data reported in the literature.199 
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(8R,9S,10R,13S,14S,17S)-13-Methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate (264)238 
 
To a solution of alcohol 264 (21.0 g, 76.0 mmol, 1.0 eq.) in pyridine (130 mL) was 
acetic anhydride (130 mL) and the reaction mixture was stirred at room temperature 
for 16 h. The reaction mixture was concentrated in vacuo and the residue was purified 
by flash column chromatography (pentane : AcOEt, 80 : 20) to acetate 264 (21.6 g, 
90% yield) as a white solid. 
Rf 0.30 (pentane : AcOEt, 70 : 30); mp 68–70 °C (pentane : AcOEt, 70 : 30); [α]D28 
+37 (c 1.00, CHCl3); IR (thin film) 2935, 2855, 1727, 1676, 1243, 1044 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 5.82 (d, J = 2.0 Hz, 1H, C=CH), 4.61 (app. t, J = 8.5 Hz, 
1H, CHOAc), 2.54–2.36 (m, 2H, CHa1Hb1 + CHa2Hb2), 2.33–2.12 (m, 4H, CHa1Hb1 + 
CHa2Hb2 + CHa3Hb3 + CHa4Hb4), 2.15–2.08 (m, 1H, CH), 2.04 (s, 3H, COCH3), 1.90–
1.74 (m, 3H, CHa5Hb5 + CHa6Hb6 + CHa7Hb7), 1.72–1.61 (m, 1H, CHa8Hb8), 1.59–1.46 
(m, 2H, CHa3Hb3 + CHa4Hb4), 1.43–1.31 (m, 2H, CHa8Hb8 + CH), 1.29–1.18 (m, 2H, 
CHa5Hb5 + CHa6Hb6), 1.18–1.01 (m, 2H, CHa7Hb7 + CH), 0.91–0.79 (m, 1H, CH), 0.85 
(s, 3H, CCH3); 13C NMR (100 MHz, CDCl3) δ 199.8, 171.1, 166.3, 124.6, 82.5, 49.5, 
49.4, 42.6, 42.5, 40.2, 36.6, 36.5, 35.4, 30.6, 27.4, 26.6, 26.0, 23.3, 21.1, 12.0; MS 
(ESI+) 317 [M+H]+; HRMS (ESI+) calcd for C20H28O3 317.2117, found 317.2123. 
 
(8R,9S,10R,13S,14S,17S)-13-Methyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-
1H-cyclopenta[a]phenanthrene-3,17-diyl diacetate (263)238 
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Following a literature procedure,238 enone 264 (16.6 g, 52.5 mmol, 1.0 eq.) was 
dissolved in pyridine (10 mL) and Ac2O (19 mL) and AcCl (70 mL) was added 
slowly. The reaction mixture was refluxed for 5 h and the solvent was evaporated in 
vacuo. The residue was dissolved in CH2Cl2 (800 mL), washed with water (300 mL), 
brine (300 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (CH2Cl2) to afford acetate 263 (16.1 g, 86% 
yield) as a white solid. 
Rf 0.37 (CH2Cl2); mp 148–150 °C (acetone); lit: mp 165°C (acetone); [α]D28 –139 
(c 1.00, CHCl3); IR (thin film) 2916, 2880, 2818, 1756, 1729, 1205 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 5.76 (s, 1H, C=CH), 5.47 (s, 1H, C=CH), 4.62 (app. t, J = 8.4 
Hz, 1H, CHOAc), 2.52–2.39 (m, 1H, CHa1Hb1), 2.23–2.08 (m, 4H, CH2 + CHa2Hb2 + 
CHa1Hb1), 2.13 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 1.95–1.83 (m, 2H, CH + 
CHa3Hb3), 1.83–1.04 (m, 10H, 2 × CH + 3 × CH2 + CHa2Hb2 + CHa3Hb3), 1.02–0.88 
(m, 1H, CH), 0.82 (s, 3H, CCH3); 13C NMR (100 MHz, CDCl3) δ 171.2, 169.2, 148.7, 
134.6, 123.7, 117.6, 82.8, 50.3, 43.6, 42.6, 40.6, 36.7, 36.6, 30.9, 28.0, 27.5, 27.2, 
26.3, 23.3, 21.2, 21.1, 11.9; MS (ESI+) 359 [M+H]+; HRMS (ESI+) calcd for 
C22H31O4 359.2222, found 359.2201. The analytical data are consistent with the data 
reported in the literature.238 
 
(8R,9S,10R,13S,14S,17S)-13-Methyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dode-
cahydro-1H-cyclopenta[a]phenanthren-17-yl acetate (249)238 
 
Following a literature procedure,238 acetate 263 (19.8 g, 55 mmol, 1.0 eq.) was 
suspended in a mixture of DMF (212 mL) and water (8 mL) at 0 °C, NBS (10.8 g, 
1.1 eq.) was added and the reaction mixture was stirred at 0 °C for 1 h. To the 
resulting clear solution was added LiBr (9.6 g, 2.0 eq.) and Li2CO3 (16.3 g, 2.0 eq.) 
and the mixture was heated at 110 0 °C for 1 h. Water (800 mL) was added and the 
mixture was extracted with AcOEt (3 × 500 mL). The combined organic extracts were 
OAc
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washed with aqueous HCl solution (1 M, 800 mL), brine (800 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography (pentane : AcOEt, 80 : 20) to afford enone 249 (15.3 g, 89% yield) 
as an off-white solid. 
Rf 0.30 (pentane : AcOEt, 70 : 30); mp 88–90 °C (pentane : AcOEt, 70 : 30); [α]D27 
+36 (c 1.00, CHCl3); IR (thin film) 2971, 2945, 2860, 1729, 1663, 1248 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 6.25–6.12 (m, 2H, 2 × C=CH), 5.77 (d, J = 1.9 Hz, 1H, 
C=CH), 4.65 (app. t, J = 8.4 Hz, 1H, CHOAc), 2.58–2.47 (m, 1H, CHa1Hb1), 2.40–
2.10 (m, 5H, CHa1Hb1 + CHa2Hb2 + CHa3Hb3 + 2 × CH), 2.04 (s, 3H, COCH3), 1.91–
1.74 (m, 3H, CHa4Hb4 + CHa5Hb5 + CHa6Hb6), 1.67–1.41 (m, 3H, CHa2Hb2 + CHa3Hb3 
+ CHa4Hb4), 1.38–1.08 (m, 4H, CHa5Hb5 + CHa6Hb6 + 2 × CH), 0.87 (s, 3H, CCH3); 
13C NMR (100 MHz, CDCl3) δ 200.0, 171.1, 158.7, 141.3, 128.9, 124.4, 82.1, 47.7, 
45.9, 43.4, 41.1, 40.8, 37.7, 36.4, 27.3, 26.9, 25.0, 22.9, 21.1, 11.8; MS (ESI+) 315 
[M+H]+; HRMS (ESI+) calcd for C20H27O3 315.1960, found 315.1947. 
 
(7R,8R,9S,10R,13S,14S,17S)-7-(9-(tert-Butyldimethylsilyloxy)nonyl)-13-methyl-3-
oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenan-
thren-17-yl acetate (248a)192 and (7S,8R,9S,10R,13S,14S,17S)-7-(9-(tert-
Butyldimethylsilyloxy)nonyl)-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenan-thren-17-yl acetate (248b)192 
 
248a 
 
248b 
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Following a literature procedure,192 a solution of alkyl bromide 250 (17.0 g, 4.0 eq.) 
in THF (40 mL) was added to a stirred suspension of magnesium turnings (1.1 g, 
4.1 eq.) in THF (5 mL) and the reaction mixture was refluxed for 4 h. The resulting 
mixture was cooled to –30 °C, and CuI (4.5 g, 2.1 eq.) was added. The mixture was 
stirred vigorously for 15 min and a solution of enone 249 (3.54 g, 11.3 mmol, 1.0 eq.) 
in THF (15 mL) was added dropwise over 15 min. The reaction mixture was stirred 
for an additional 40 min, acetic acid (2. 8 mL) was added and the mixture was 
evaporated in vacuo. The residue was partitioned between water (45 mL) and Et2O 
(75 mL), the phases were separated and the aqueous layer was extracted with Et2O 
(3 × 75 mL). The combined organic extracts were washed with water (300 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (toluene : AcOEt, 95 : 5) to afford the 9 α-enantiomer 248a 
(1.44 g, 23% yield) and β-diastereoisomer 248b (0.92 g, 14% yield) as pale yellow 
oils. 
248a: Rf 0.62 (pentane : AcOEt, 70 : 30); [α]D27 +9 (c 1.00, CHCl3); IR (thin film) 
2924, 2854, 1735, 1671, 1237 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.83 (s, 1H, 
C=CH), 4.62 (app. t, J = 8.5 Hz, 1H, CHOAc), 3.60 (t, J = 6.6 Hz, 2H, CH2OTBS), 
2.58–2.35 (m, 2H), 2.34–2.13 (m, 4H), 2.05 (s, 3H, COCH3), 2.04–1.97 (m, 1H), 
1.92–1.82 (m, 1H), 1.80–1.67 (m, 2H), 1.67–1.44 (m, 7H), 1.44–1.00 (m, 19H), 0.89 
(s, 9H, SiC(CH3)3), 0.85 (s, 3H, CCH3), 0.04 (s, 6H, Si(CH3)2); 13C NMR (100 MHz, 
CDCl3) δ 13C NMR (CDCl3) 199.5, 171.1, 165.0, 126.6, 82.5, 63.3, 45.7, 43.2, 43.1, 
43.0, 42.7, 39.6, 36.8, 36.5, 36.0, 32.8, 29.8, 29.6 (2C), 29.4, 27.5, 27.3, 26.9, 26.8, 
26.0, 25.8, 25.6, 22.7, 21.1, 18.3, 11.9, –5.3; MS (ESI+) 573 [M+H]+; HRMS (ESI+) 
calcd for C35H61O4Si 573.4334, found 573.4331. 
248b: Rf 0.51 (pentane : AcOEt, 70 : 30); [α]D27 +4 (c 1.00, CHCl3); IR (thin film) 
2926, 2855, 1737, 1672, 1244 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.80 (s, 1H, 
C=CH), 4.57 (app. t, J = 8.6 Hz, 1H, CHOAc), 3.59 (t, J = 6.6 Hz, 2H, CH2OTBS), 
2.54–2.45 (m, 1H), 2.45–2.36 (m, 1H), 2.33–2.11 (m, 3H), 2.10–2.02 (m, 2H), 2.04 
(s, 3H, COCH3), 1.94–1.79 (m, 2H), 1.79–1.71 (m, 1H), 1.71–1.40 (m, 7H), 1.40–
1.13 (m, 17H), 1.02–0.93 (m, 1H), 0.89 (s, 9H, SiC(CH3)3), 0.86 (s, 3H, CCH3), 0.04 
(s, 6H, Si(CH3)2); 13C NMR (100 MHz, CDCl3) δ 199.7, 171.2, 167.3, 123.8, 82.3, 
63.3, 50.0, 48.7, 44.4, 43.9, 42.2, 41.1, 40.5, 36.7, 36.7, 35.6, 32.9, 30.0, 29.6 (2C), 
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29.4, 27.6, 27.0, 26.4, 26.3, 26.2, 26.0, 25.8, 21.2, 18.4, 12.4, –5.2; MS (ESI+) 573 
[M+H]+; HRMS (ESI+) calcd for C35H61O4Si 573.4334, found 573.4329. 
 
9-((7R,8R,9S,10R,13S,14S,17S)-17-Acetoxy-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12, 
13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-7-yl)nonyl acetate 
(265)192 
 
Following a literature procedure,192 water (4.8 mL) and acetic anhydride (9 mL) were 
added to a solution of silyl ether 248a (1.77 g, 3.08 mmol, 1.0 eq.) in THF (9 mL) and 
the reaction mixture was heated at 50 °C for 3 h. The mixture was cooled to room 
temperature and concentrated in vacuo. The residue was dissolved in pyridine (9 mL) 
and acetic anhydride (4.5 mL) was added. The reaction mixture was stirred for 14 h 
and concentrated in vacuo. The residue was dissolved in Et2O (500 mL) and washed 
with a saturated aqueous NaHCO3 solution (200 mL). The aqueous phase was 
extracted with further Et2O (2 × 200 mL). The combined organic extracts were 
washed with brine (300 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (pentane : AcOEt, 80 : 20) to 
afford diacetate 265 (1.20 g, 75% yield) as a colourless oil. 
Rf 0.50 (pentane : AcOEt, 70 : 30); [α]D27 +14 (c 1.00, CHCl3); IR (thin film) 2925, 
2854, 1735, 1671, 1234 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.83 (s, 1H, C=CH), 
4.62 (t, J = 8.4 Hz, 1H, , CHOAc), 4.05 (t, J = 6.8 Hz, 2H, CH2OAc), 2.51 (dd, J = 
14.3, 2.5 Hz, 1H), 2.41 (dt, J = 15.7, 4.3 Hz, 1H), 2.33–2.13 (m, 4H), 2.04 (s, 6H, 2 × 
COCH3), 2.03–1.97 (m, 1H), 1.93–1.83 (m, 1H), 1.79–1.67 (m, 2H), 1.67–1.47 (m, 
6H), 1.42–0.94 (m, 22H), 0.85 (s, 3H, CCH3); 13C NMR (100 MHz, CDCl3) δ 199.5, 
171.1, 171.0, 164.9, 126.6, 82.5, 64.6, 45.6, 43.1, 43.0, 43.0, 42.6, 39.6, 36.7, 36.4, 
36.0, 29.8, 29.5, 29.4, 29.2, 28.5, 27.4, 27.3, 26.8, 26.8, 25.8, 25.6, 22.7, 21.1, 21.0, 
11.9; MS (ESI+) 501 [M+H]+; HRMS (ESI+) calcd for C31H49O5 501.3575, found 
501.3569. 
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9-((7R,8S,13S,14S,17S)-17-Acetoxy-3-hydroxy-13-methyl-7,8,12,13,14,15,16,17-
octahydro-6H-cyclopenta[a]phenanthren-7-yl)nonyl acetate (266) 
 
Following a literature procedure,192 CuBr2 (1.04 g, 2.0 eq.) and LiBr (200 mg, 1.0 eq.) 
were added to a suspension of enone 265 (1.16 g, 2.31 mmol, 1.0 eq.) in acetonitrile 
(23 mL) and the reaction mixture was stirred at room temperature for 3 h. The 
mixture was diluted with AcOEt (300 mL) and washed with a saturated aqueous 
NaHCO3 solution (500 mL). The aqueous phase was extracted with further AcOEt 
(2 × 200 mL). The combined organic extracts were washed with brine (300 mL), 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (pentane : AcOEt, 90 : 10 → 80 : 20) to afford phenol 266 
(0.92 g, 81% yield) as a colourless oil. 
Rf 0.52 (pentane : AcOEt, 70 : 30); [α]D26 +16 (c 1.00, CHCl3); IR (thin film) 
3400 (br.), 2924, 2853, 1735, 1712, 1240 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.14 (d, 
J = 8.5 Hz, 1H, Ar-H), 6.63 (dd, J = 8.3, 2.7 Hz, 1H, Ar-H), 6.55 (d, J = 2.5 Hz, 1H, 
Ar-H), 4.94 (br. s, 1H, Ar-OH), 4.70 (t, J = 8.5 Hz, 1H, CHOAc), 4.05 (t, J = 6.8 Hz, 
2H, CH2OAc), 2.86 (dd, J = 16.7, 5.3 Hz, 1H, Ar-CHaHb), 2.71 (app. d, J = 16.7 Hz, 
1H, Ar-CHaHb), 0.94–0.85 (m, 1H), 2.43–2.17 (m, 3H), 2.06 (s, 3H, COCH3), 2.05 (s, 
3H, COCH3), 1.87–1.82 (m, 1H), 1.78–1.69 (m, 1H), 1.69–1.08 (m, 23H), 1.08–0.97 
(m, 1H), 0.83 (s, 3H, CCH3); 13C NMR (100 MHz, CDCl3) δ 171.6, 171.5, 153.7, 
136.9, 131.4, 127.0, 116.1, 112.9, 82.9, 64.8, 46.2, 43.0, 41.7, 37.9, 37.0, 34.6, 29.8, 
29.6, 29.5, 29.4, 29.1, 28.5, 28.0, 27.5, 27.1, 25.8, 25.5, 22.7, 21.2, 21.0, 12.0; MS 
(ESI+) 499 [M+H]+; HRMS (ESI+) calcd for C31H46O5 499.3424, found 499.3438. 
 
(8R,13S,14S,17S)-3-Hydroxyestra-1,3,5(10),9(11)tetraen-17-one (267)239 
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Following a literature procedure,201 DDQ (12 mg, 1.3 eq.) was added to a solution of 
oestrone (144) (8 mg, 0.03 mmol, 1.0 eq.) in methanol (0.6 mL) at 45 °C and the 
reaction mixture was heated at 45 °C for 30 min. The solvent was evaporated in vacuo 
and the residue was dissolved in CH2Cl2 (1 mL), filtered through celite and washed 
with CH2Cl2 (2 mL). The solvent was concentrated in vacuo to afford tertiary 267 
(7 mg, 95% yield) as a colourless gum.  
Rf 0.45 (pentane : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.6 Hz, 
1H), 6.68 (dd, J = 8.6, 2.8 Hz, 1H), 6.60 (d, J = 2.6 Hz, 1H), 6.15 (s, 1H), 3.53 (s, 
1H), 2.99–2.80 (m, 2H), 2.65–2.44 (m, 1H), 2.42–2.22 (m, 4H), 1.77–1.59 (m, 2H), 
1.55–1.39 (m, 1H), 0.96 (s, 3H); MS (ESI+) 269 [M+H]+; HRMS (ESI+) calcd for 
C18H21O2 269.1536, found 269.1541. The analytical data are consistent with the data 
reported in the literature.239 
 
9-((7R,8S,13S,14S,17S)-17-Acetoxy-3-(benzyloxy)-13-methyl-7,8,12,13,14,15,16, 
17-octahydro-6H-cyclopenta[a]phenanthren-7-yl)nonyl acetate (271) 
 
To a solution of phenol 266 (854 mg, 1.71 mmol, 1.0 eq.) in acetone (17 mL) was 
added benzyl bromide (0.41 mL, 2.0 eq.) and Cs2CO3 (1.12 g, 2.0 eq.) and the 
reaction mixure was refluxed for 3 h. Water (200 mL) was added and the mixture was 
extracted with CH2Cl2 (3 × 200 mL). The combined organic extracts were washed 
with brine (200 mL), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by flash column chromatography (pentane : AcOEt, 90 : 10 → 80 : 20) 
to afford benzyl ether 271 (0.73 g, 74% yield) as a colourless oil. 
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Rf 0.63 (pentane : AcOEt, 70 : 30); [α]D23 +25 (c 1.00, CHCl3); IR (thin film) 2921, 
2852, 1736, 1238, 1026 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.47–7.27 (m, 5H, 5 × 
Ph-H), 7.20 (d, J = 8.7 Hz, 1H, Ar-H), 6.78 (dd, J = 8.7, 2.8 Hz, 1H, Ar-H), 6.71 (d, 
J = 2.8 Hz, 1H, Ar-H), 5.02 (s, 2H, PhCH2), 4.70 (dd, J = 9.0, 7.8 Hz, 1H, CHOAc), 
4.05 (t, J = 6.8 Hz, 2H, CH2OAc), 2.89 (dd, J = 16.8, 5.4 Hz, 1H, Ar-CHaHb), 2.75 (d, 
J = 16.8 Hz, 1H, Ar-CHaHb), 2.42–2.27 (m, 2H), 2.27–2.17 (m, 1H), 2.06 (s, 3H, 
OCOCH3), 2.04 (s, 3H, OCOCH3), 1.89–1.81 (m, 1H), 1.80–1.69 (m, 1H), 1.69–1.57 
(m, 3H), 1.57–1.12 (m, 19H), 1.09–0.99 (m, 1H), 0.83 (s, 3H, CCH3); 13C NMR 
(100 MHz, CDCl3) δ 171.2 (2C), 156.8, 137.3, 136.8, 132.1, 128.5, 127.8, 127.5, 
126.9, 115.6, 112.3, 82.8, 69.9, 64.6, 46.2, 43.0, 41.7, 37.9, 37.1, 34.7, 33.2, 29.9, 
29.6, 29.5, 29.2, 28.6, 28.2, 27.5, 27.1, 25.9, 25.6, 22.8, 21.2, 21.0, 12.0; MS (ESI+) 
589 [M+H]+; HRMS (ESI+) calcd for C38H53O5 589.3893, found 589.3868. 
 
(7R,8R,13S,14S,17S)-3-(Benzyloxy)-7-(9-hydroxynonyl)-13-methyl-7,8,9,11,12,13, 
14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol (272) 
 
To a suspension of di-acetate 271 (636 mg, 1.08 mmol, 1.0 eq.) in methanol (40 mL) 
was added NaOH (216 mg, 5.0 eq.) in water (1 mL) and the reaction mixture was 
stirred at room temperature for 7 h. The solvent was evaporated in vacuo and the 
residue was partitioned between CH2Cl2 (200 mL) and aqueous HCl solution (1 M, 
200 mL). The aqueous layer was extracted with CH2Cl2 (2 × 200 mL). The combined 
organic extracts were washed with brine (200 mL), dried over MgSO4 and 
concentrated in vacuo to afford diol 272 (540 mg, 99% yield) as a white foam. The 
crude product was used directly in the next step. 
Rf 0.31 (pentane : AcOEt, 70 : 30); 1H NMR (400 MHz, CDCl3) δ 7.50–7.27 (m, 5H, 
5 × Ph-H), 7.21 (d, J = 8.6 Hz, 1H, Ar-H), 6.79 (dd, J = 8.6, 2.6 Hz, 1H, Ar-H), 6.71 
(d, J = 2.6 Hz, 1H, Ar-H), 5.03 (s, 2H, Ph-CH2), 3.75 (t, J = 8.4 Hz, 1H, CHOH), 3.63 
(app. t, J = 6.6 Hz, 2H, CH2OH), 2.90 (dd, J = 16.7, 5.4 Hz, 1H), 2.75 (d, J = 16.8 Hz, 
OH
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1H), 2.44–2.27 (m, 2H), 2.23–2.07 (m, 1H), 2.01–1.86 (m, 1H, CCH3), 1.85–1.71 (m, 
1H), 1.71–1.11 (m, 24H), 1.11–0.98 (m, 1H), 0.78 (s, 3H); MS (ESI+) 505 [M+H]+; 
HRMS (ESI+) calcd for C34H49O3 505.3682, found 505.3696. 
 
(9-((7R,8R,13S,14S,17S)-3-(Benzyloxy)-17-(tert-butyldimethylsilyloxy)-13-me-
thyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-
nonyloxy)(tert-butyl)dimethylsilane (273) 
 
To a solution of diol 272 (540 mg, 1.07 mmol, 1.0 eq.) in DMF (11 mL) were added 
imidazole (291 mg, 4.0 eq.) and TBSCl (339 mg, 3.0 eq.) and the reaction mixture 
was stirred at room temperature for 32 h. The solution was partitioned between 
CH2Cl2 (300 mL) and water (300 mL), and the aqueous layer was extracted with 
CH2Cl2 (2 × 200 mL). The combined organic extracts were washed with brine 
(300 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (pentane : AcOEt, 90 : 10) to afford di-TBS 
ether 273 (582 mg, 74% yield) as a colourless oil.  
Rf 0.86 (pentane : AcOEt, 70 : 30); [α]D28 +29 (c 1.00, CHCl3); IR (thin film) 2926, 
2855, 1249, 1094, 833 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.46–7.28 (m, 5H, 5 ×  
Ph-H), 7.20 (d, J = 8.6 Hz, 1H, Ar-H), 6.78 (dd, J = 8.5, 2.8 Hz, 1H, Ar-H), 6.70 (d, J 
= 2.7 Hz, 1H, Ar-H), 5.02 (s, 2H, Ph-CH2), 3.66 (app. t, J = 8.2 Hz, 1H, CHOTBS), 
3.59 (t, J = 6.6 Hz, 2H, CH2OTBS), 2.88 (dd, J = 16.9, 5.2 Hz, 1H, Ph-CHaHb), 2.74 
(d, J = 16.7 Hz, 1H, Ph-CHaHb), 1.78–1.69 (m, 1H), 2.41–2.24 (m, 2H), 2.01–1.89 
(m, 1H), 1.89–1.78 (m, 1H), 1.69–1.09 (m, 22H), 1.09–0.96 (m, 1H), 0.89 (s, 18H, 2 
× SiC(CH3)3), 0.74 (s, 3H, CCH3), 0.05 (s, 6H, Si(CH3)2), 0.04 (s, 3H, SiCH3), 0.03 
(s, 3H, SiCH3); 13C NMR (100 MHz, CDCl3) δ 156.7, 137.4, 137.1, 132.5, 128.5, 
127.8, 127.5, 126.9, 115.6, 112.3, 81.9, 69.9, 63.3, 46.1, 43.7, 42.0, 38.1, 37.3, 34.8, 
33.3, 32.9, 30.9, 30.0, 29.7, 29.7, 29.4, 28.3, 27.4, 26.0, 25.9, 25.8, 25.6, 22.8, 18.4, 
OTBS
H
H
BnO OTBS
H
 
280 
18.1, 11.4, –4.5, –4.8, –5.2; MS (ESI+) 733 [M+H]+; HRMS (ESI+) calcd for 
C46H77O3Si2 733.5411, found 733.5424. 
 
(7R,8R,9S,10R,13S,14S,17S)-7-Cyano-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14, 
15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate (278)205 
 
Following a litteraure procedure,205 diethylaluminium cyanide (1.0 M in toluene, 
23 mL, 3.7 eq.) was added to a solution of dienone 249 (1.96 g, 6.20 mmol, 1.0 eq.) in 
THF (100 mL) and the reaction mixture was stirred at room temperature for 1 h. Cold 
aqueous NaOH (0.5 M, 300 mL) was added and the mixture was extracted with 
CH2Cl2 (3 × 300 mL). The combined organic extracts were washed with water 
(300 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (pentane : AcOEt, 50 : 50) to afford 
aliphatic cyanide 278 (1.87 g, 87% yield) as a white foam. 
Rf 0.14 (pentane : AcOEt, 70 : 30); [α]D25 +28 (c 1.00, CHCl3); IR (thin film) 2946, 
2864, 2240, 1728, 1669, 1241 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.97 (s, 1H, 
C=CH), 4.68 (dd, J = 9.1, 7.9 Hz, 1H, CHOAc), 3.04–2.97 (m, 1H, CHCN), 2.75 (dd, 
J = 14.8, 2.3 Hz, 1H, CHaHbCHCN), 2.61–2.43 (m, 2H, CHaHbCHCN + CHa1Hb1), 
2.38–2.20 (m, 3H, CHa1Hb1 + CHa2Hb2 + CHa3Hb3), 2.17–2.06 (m, 1H, CH), 2.05 (s, 
3H, OCOCH3), 2.00–1.93 (m, 1H, CHa4Hb4), 1.87–1.22 (m, 10H, 3 × CH + 2 × CH2 + 
CHa2Hb2 + CHa3Hb3 + CHa4Hb4), 0.87 (s, 3H, CCH3); 13C NMR (100 MHz, CDCl3) δ 
198.6, 170.8, 158.3, 127.8, 118.7, 81.8, 46.8, 44.5, 42.8, 41.9, 41.1, 37.4, 36.4, 35.9, 
31.6, 27.2, 26.3, 25.8, 22.6, 21.0, 12.0; MS (ESI+) 383 [M+MeCN+H]+; HRMS 
(ESI+) calcd for C23H31N2O3 383.2335, found 383.2355. 
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(7R,8R,9S,13S,14S,17S)-7-Cyano-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16, 
17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate (279)205 
 
Following a literature procedure,205 CuBr2 (2.39 g, 2.0 eq.) and LiBr (464 mg, 1.0 eq.) 
were added to a suspension of enone 278 (1.83 g, 5.34 mmol, 1.0 eq.) in acetonitrile 
(53 mL) and the reaction mixture was refluxed for 30 min. The mixture was diluted 
with AcOEt (300 mL) and washed with a saturated aqueous NaHCO3 solution 
(500 mL). The aqueous phase was extracted with further AcOEt (2 × 200 mL). The 
combined organic extracts were washed with water (300 mL), brine (300 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (pentane : AcOEt, 50 : 50) to afford phenol 279 (1.51 g, 87% 
yield) as a white foam. 
Rf 0.70 (AcOEt); [α]D29 +17 (c 1.00, CHCl3); IR (thin film) 3374 (br.), 2940, 2244, 
1735, 1245 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 8.4 Hz, 1H, Ar-H), 6.69 
(dd, J = 8.4, 2.7 Hz, 1H, Ar-H), 6.56 (d, J = 2.7 Hz, 1H, Ar-H), 4.82–4.68 (m, 2H, 
CHOAc + Ar-OH), 3.20–3.04 (m, 3H, CH + Ar-CH2), 2.70–2.60 (m, 1H, CH), 2.47–
2.35 (m, 1H, CHa1Hb1), 2.35–2.21 (m, 1H, CHa2Hb2), 2.06 (s, 3H, COCH3), 1.94–1.84 
(m, 1H, CHa3Hb3), 1.84–1.74 (m, 1H, CHa4Hb4), 1.74–1.32 (m, 6H, 2 × CH + CHa1Hb1 
+ CHa2Hb2 + CHa3Hb3 + CHa4Hb4), 0.84 (s, 3H, CCH3); 13C NMR (100 MHz, CDCl3) 
δ 171.4, 154.1, 132.7, 130.0, 127.2, 120.2, 115.3, 114.2, 82.2, 47.0, 43.2, 39.4, 39.2, 
36.3, 32.6, 28.5, 27.4, 26.2, 22.6, 21.1, 12.0; The mass of the product could not be 
found by HRMS. 
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(7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-de-
cahydro-6H-cyclopenta[a]phenanthrene-7-carbaldehyde (280)205 
 
Following a literature procedure,205 a solution of DIBAL-H (1.0 M in toluene, 
11.2 mL, 3.0 eq.) was added to a solution of cyanide 279 (1.27 g, 3.74 mmol, 1.0 eq.) 
in toluene (37 mL) and the reaction mixture was stirred vigorously at room 
temperature for 3 h. Methanol (7 mL) and aqueous HCl solution (2 M, 11 mL) were 
added slowly and the mixture was stirred at room temperature for 30 min. The 
mixture was partitioned between AcOEt (200 mL) and water (200 mL) and extracted 
with AcOEt (2 × 300 mL). The combined organic extracts were washed with water 
(300 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (pentane : AcOEt, 50 : 50) to afford 
aldehyde 280 (779 mg, 70% yield) as a white foam. 
Rf 0.52 (AcOEt); [α]D29 +20 (c 1.00, MeOH); IR (thin film) 3242 (br.), 2931, 1705, 
1226, 1011 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.86 (d, J = 2.0 Hz, 1H, CHO), 7.18 
(d, J = 8.5 Hz, 1H, Ar-H), 6.76–6.55 (m, 2H, 2 × Ar-H), 5.33 (br. s, 1H, Ar-OH), 3.81 
(app. t, J = 8.3 Hz, 1H, CHOH), 3.17 (d, J = 17.3 Hz, 1H, Ar-CHaHb), 3.00 (dd, J = 
17.3, 6.2 Hz, 1H, Ar-CHaHb), 2.80–2.70 (m, 1H, CH), 2.50–2.33 (m, 2H, CH + 
CHa1Hb1), 2.28–2.15 (m, 1H, CHa2Hb2), 2.02–1.83 (m, 3H, CH + CHa3Hb3 + CHa4Hb4), 
1.79–1.43 (m, 4H, CHa1Hb1 + CHa2Hb2 + CHa3Hb3 + CHa4Hb4), 1.39–1.24 (m, 1H, 
CH), 1.17 (br. s, 1H, CHOH), 0.82 (s, 3H, CCH3); 13C NMR (125 MHz, CDCl3) δ 
204.7, 153.9, 135.3, 131.4, 127.2, 115.5, 113.7, 81.7, 46.9, 46.4, 43.8, 41.2, 39.7, 
36.6, 30.5, 30.2, 27.4, 23.0, 10.6; MS (ESI+) 301 [M+H]+; HRMS (ESI+) calcd for 
C19H25O3 301.1798, found 301.1799. 
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(7R,8R,9S,13S,14S,17S)-7-Formyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahy-
dro-6H-cyclopenta[a]phenanthrene-3,17-diyl diacetate (281)205 
 
Following a literature procedure,205 acetic anhydride (2 mL) was added to a solution 
of diol 280 (200 mg, 0.67 mmol, 1.0 eq.) in pyridine (4 mL) and the reaction mixture 
was stirred at room temperature for 18 h. Water (40 mL) was added, the mixture was 
acidified with concentrated HCl (4 mL) until pH 1 and extracted with AcOEt 
(300 mL). The combined organic extracts were washed with aqueous HCl solution 
(1 M, 200 mL), water (200 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash column chromatography (pentane : AcOEt, 70 : 
30) to afford diacetate 281 (208 mg, 81% yield) as a white foam. 
Rf 0.35 (pentane : AcOEt, 70 : 30); [α]D27 +28 (c 1.00, CHCl3); IR (thin film) 2931, 
1760, 1726, 1204, 1012 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.84 (s, 1H, CHO), 
7.32–7.27 (m, 1H, Ar-H), 6.92–6.85 (m, 2H, 2 × Ar-H), 4.73 (dd, J = 9.1, 7.6 Hz, 1H, 
CHOAc), 3.21 (d, J = 17.2 Hz, 1H, Ar-CHaHb), 3.03 (dd, J = 17.4, 6.4 Hz, 1H, Ar-
CHaHb), 2.79–2.70 (m, 1H, CH), 2.58–2.44 (m, 1H, CH), 2.44–2.31 (m, 1H, 
CHa1Hb1), 2.31–2.24 (m, 1H, CHa2Hb2), 2.28 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 
1.97–1.83 (m, 3H, CHa3Hb3 + CHa4Hb4 + CH), 1.81–1.68 (m, 1H, CH), 1.67–1.33 (m, 
4H, CHa1Hb1 + CHa2Hb2 + CHa3Hb3 + CHa4Hb4), 0.84 (s, 3H, CCH3); 13C NMR 
(125 MHz, CDCl3) δ 204.2, 171.1, 169.7, 148.8, 136.4, 135.3, 127.1, 121.8, 119.4, 
82.3, 46.5, 46.1, 43.3, 40.3, 39.6, 36.6, 29.8, 27.4, 26.9, 23.1, 21.1 (2C), 11.5; MS 
(CI+) 402 [M+NH4]+; HRMS (CI+) calcd for C23H23NO5 402.2280, found 402.2291. 
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(7R,8R,9S,13S,14S,17S)-7-(Hydroxymethyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]phenanthrene-3,17-diyl diacetate (277)205 
 
Following a literature procedure,205 NaBH4 (29 mg, 2.0 eq.) was added to a solution 
of aldehyde 281 (147 mg, 0.38 mmol, 1.0) in EtOH (8 mL) at 0 °C and the reaction 
mixture was stirred at 0 °C for 30 min. Aqueous HCl solution (1 M, 100 mL) was 
added and the mixture was extracted with AcOEt (3 × 200 mL). The combined 
organic extracts were washed with water (200 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography (pentane : AcOEt, 75 : 25) to afford alcohol 277 (129 mg, 89% 
yield) as a white foam. 
Rf 0.18 (pentane : AcOEt, 70 : 30); [α]D27 +32 (c 1.00, CHCl3); IR (thin film) 3447 
(br.), 2935, 1760, 1730, 1206, 1024 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 
8.3 Hz, 1H, Ar-H), 6.89–6.79 (m, 2H, 2 × Ar-H), 4.69 (dd, J = 9.1, 7.7 Hz, 1H, 
CHOAc), 3.75 (dd, J = 10.1, 4.4 Hz, 1H, CHaHbOH), 3.46 (dd, J = 10.1, 4.4 Hz, 1H, 
CHaHbOH), 3.01 (dd, J = 17.2, 1.9 Hz, 1H, Ar-CHaHb), 2.93 (dd, J = 17.2, 5.3 Hz, 
1H, Ar-CHaHb), 2.40–2.17 (m, 3H, CH + CHa1Hb1 + CHa2Hb2), 2.28 (s, 3H, COCH3), 
2.14–2.01 (m, 1H, CH), 2.06 (s, 3H, COCH3), 1.95–1.69 (m, 3H, CH + CHa3Hb3 + 
CHa4Hb4), 1.63–1.26 (m, 6H, CH + CHa1Hb1 + CHa2Hb2 + CHa3Hb3 + CHa4Hb4 + OH), 
0.82 (s, 3H, CCH3); 13C NMR (125 MHz, CDCl3) δ 171.2, 169.8, 148.6, 136.7, 136.5, 
127.1, 122.4, 118.9, 82.5, 60.7, 46.6, 43.2, 40.1, 38.9, 36.9, 35.9, 32.5, 27.5, 27.2, 
22.8, 21.2, 21.1, 11.8; MS (ESI+) 387 [M+H]+; HRMS (ESI+) calcd for C23H31O5 
387.2171, found 387.2184. 
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(7R,8R,9R,13S,14S,17S)-9,7-(Epoximethano)-13-methyl-7,8,9,11,12,13,14,15,16, 
17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diyl diacetate (276) 
 
To a solution of alcohol 277 (87 mg, 0.23 mmol, 1.0 eq.) in carbon disulfide (6 mL) 
was added iodine (63 mg, 1.0 eq.) and lead tetraacetate (409 mg, 4.1 eq.) and the 
reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated 
in vacuo and the residue was dissolved in CH2Cl2 (200 mL), washed with aqueous 
NaS2O3 (10 wt%, 3 × 100 mL), water (100 mL), brine (100 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography (pentane : AcOEt, 70 : 30) to afford benzylic ether 276 (67 mg, 77% 
yield) as a colourless gum. 
Rf 0.43 (pentane : AcOEt, 70 : 30); [α]D30 –31 (c 1.00, CHCl3); IR (thin film) 2936, 
1753, 1730, 1247, 1201 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.34 (d, J = 8.2 Hz, 1H, 
Ar-H), 6.91–6.81 (m, 2H, 2 × Ar-H), 4.67 (dd, J = 9.2, 7.7 Hz, 1H, CHOAc), 4.09 
(ddd, J = 8.6, 5.8, 2.4 Hz, 1H, CHaHbO), 3.61 (d, J = 8.6 Hz, 1H, CHaHbO), 3.13 (d, 
J = 17.1 Hz, 1H, Ar-CHaHb), 2.86 (dd, J = 17.1, 2.4 Hz, 1H, Ar-CHaHb), 2.58–2.37 
(m, 2H, CH + CHa1Hb1), 2.38 (s, 3H, COCH3), 2.30–2.21 (m, 1H, CHa2Hb2), 2.06 (s, 
3H, COCH3), 2.09–2.00 (m, 1H, CHa1Hb1), 2.01–1.93 (m, 1H, CH), 1.81–1.68 (m, 
2H, CHa3Hb3 + CHa4Hb4), 1.65–1.51 (m, 2H, CHa2Hb2 + CHa3Hb3), 1.47–1.37 (m, 2H, 
CH + CHa4Hb4), 0.79 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3) δ 171.1, 169.6, 
149.8, 140.3, 136.2, 124.9, 122.2, 119.0, 82.2, 79.6, 71.1, 46.7, 42.2, 42.0, 38.3, 37.5, 
32.6, 27.6, 26.2, 23.5, 21.1 (2C), 10.6; MS (ESI+) 385 [M+H]+; HRMS (ESI+) calcd 
for C23H29O5 385.2015, found 385.2008. 
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